ESCMID Global 2025 - Programme
Friday, 11 April 2025 Challenges in identification and relevance of slow-growing pathogens
Chairs Kerrie Davies (Leeds, United Kingdom)
Yann Dumont (Nancy, France)
SP1 - Hall 0
08:30 10:30
W0009 08:30 Sampling and culturing anaerobesHugo Cruz (Porto,
Special Session
Portugal)
Antimicrobial Stewardship in Different Scenarios W0010 08:50 I have an anaerobe: what is it and does it
matter?Kathleen Boiten (Groningen, Netherlands)
Chairs Murat Akova (Ankara, Türkiye)
Andre Fuchs (Augsburg, Germany) W0011 09:10 Actinomyces in clinical samples: when is it worth the
Maddalena Giannella (Bologna, Italy) trouble?Eija Inkeri Könönen (Turku, Finland)
Angela Huttner (Geneva, Switzerland) W0012 09:30 Nocardiosis: when to test and how to manage
Benedikt Huttner (Geneva, Switzerland) results?David Lebeaux (Paris, France)
Jose Ramon Pano-Pardo (Zaragoza, Spain)
Co-organised with: ESCMID Study Group for Anaerobic Infections (ESGAI),
Galadriel Pellejero-Sagastizábal (Zaragoza, Spain)
ESCMID Study Group for Clostridioides difficile (ESGCD)
Holger Rohde (Hamburg, Germany)
Oana Sandulescu (Bucharest, Romania)
Jeroen Schouten (Nijmegen, Netherlands)
Valentijn Schweitzer (Utrecht, Netherlands) EW004 08:30 - 10:30 Hall 6
Thomas Tängdén (Uppsala, Sweden)
Suzanne Van Asten (Nijmegen, Netherlands) Educational Session
Dafna Yahav (Ramat-Gan, Israel)
A hard nut to crack in HIV
Chairs Yoav Keynan (Winnipeg, Canada)
Justyna Kowalska (Warsaw, Poland)
Co-organised with: ESCMID Education Subcommittee
EW001 - Hall 2 W0013 08:30 Viral reservoir: what a physician should knowIvailo
08:30 10:30
Alexiev (Sofia, Bulgaria)
Educational Session W0014 08:50 Non-suppressible viraemia during HIV-1 therapy: a
challenge for cliniciansJose Arribas (Madrid, Spain)
Surgical site infections: principles and practice in the era of multidrug
W0015 09:10 Chronic vascular and pulmonary disease and HIV:
resistance
what can we do about it?Susanne Dam Poulsen
Chairs Gabriel Birgand (Nantes, France) (Copenhagen, Denmark)
Efthymia Giannitsioti (Athens, Greece)
W0016 09:30 Opportunistic infections: most common and most
deadlyMilena Stevanovikj (Sopje, North Macedonia,
Republic of)
W0001 08:30 Evolving antimicrobial resistance: do we need a Co-organised with: Euroguidelines in Central and Eastern Europe Network
change in surgical antimicrobial prophylaxis?Camilla Group
Rodrigues (Mumbai, India)
W0002 08:50 Role of decolonisation and bowel decontamination in
regions of overwhelming multidrug EW005 - Hall 8
08:30 10:30
resistancePrasannakumar Palanikumar (Vellore,
India) Educational Session
W0003 09:10 Screening for MDR GNR coloniSation: is there
Diagnostic parasitology in the XXIst century: is microscopy “+” still useful?
evidence for prophylaxisElisabeth Presterl (Vienna,
Austria) Chairs Miriam José Álvarez-Martínez (Barcelona, Spain)
Caroline Rönnberg (Stockholm, Sweden)
W0004 09:30 Perioperative prophylaxis in special populations in
the era of MDRDivyashree Shanthamurthy (Mumbai,
India)
W0017 08:30 Artificial Intelligence for the diagnosis of parasitic
infectionsBobbi Pritt (Rochester, United States)
EW002
08:30
-
10:30
Hall 3
W0018 08:50 Histopathology of parasitic infectionsRichard
Bradbury (Townsville, Australia)
Educational Session
W0019 09:10 Molecular diagnosis vs. microscopy in the diagnosis
Demystifying pharmacokinetics and population pharmacokinetics: a toolkit of parasitic infectionsSitara Sr Ajjampur (Vellore,
for non-experts India)
Chairs Shampa Das (Liverpool, United Kingdom) W0020 09:30 Paleoparasitology: what diagnostic tools?Ayman El-
João Paulo Telles (Sao Paulo, Brazil) Badry (Cairo, Egypt)
Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)
W0005 08:30 Pharmacokinetics 101: navigating the basics for
optimal dosingLinda Aulin (Leiden, Netherlands) EW006 08:30 - 10:30 Hall 9
W0006 08:50 The ABCs of population pharmacokinetic Educational Session
modelsErwin Dreesen (Leuven, Belgium)
W0007 09:10 Looking into the crystal ball: exploring the fabulous Vaccine hesitancy: from issues to solutions through developing
world of PK-PD simulationsVincent Aranzana-Climent communication skills
(Poitiers, France) Chairs Monia Chemais (Soignies, Belgium)
W0008 09:30 Decoding population pharmacokinetic papers: Petar Velikov (Sofia, Bulgaria)
interpreting, comparing and discussing resultsIris K.
Minichmayr (Vienna, Austria)
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG) W0021 08:30 Vaccine hesitancy and its consequencesNoni
Macdonald (Halifax, Canada)
W0022 08:50 Why are patients and parents hesitant about
EW003 - Hall 5
08:30 10:30 vaccination?Eve Dube (Quebec City, Canada)
Educational Session W0023 09:10 Using social media to deal with vaccine
hesitancyMuge Cevik (St Andrews, United Kingdom)

ESCMID Global 2025 - Programme
W0024 09:30 Strengthening vaccine confidence in patients and Co-organised with: ESCMID Study Group for Implant-associated Infections
parentsTba (ESGIAI), ESCMID Study Group for Mycobacterial Infections (ESGMYC)
Co-organised with: ESCMID Vaccine Study Group (EVASG)
ME012 - Hall 9
11:00 12:00
SP2 - Hall 0
11:00 12:00 Meet-the-Expert
Special Session
How to understand infectious disease risks in changing climates
Principles of systematic reviews (with and without meta-analysis)
Chairs Chiara Iaria (Palermo, Italy)
Miranda Langendam (Amsterdam, Netherlands)
M0035 11:00 Kimberly Fornace (Singapore, Singapore)
Blin Nagavci (Gjakove, Kosovo)
Mical Paul (Haifa, Israel) M0036 11:12 Rachel Lowe (Barcelona, Spain)
Luigia Scudeller (Pavia, Italy)
SP3 - Hall 0
13:30 14:30
Co-organised with: ESCMID Education Subcommittee Special Session
Top five mistakes in Infection prevention and control
ME007 11:00 - 12:00 Hall 2 Chairs Maeve Doyle (Waterford, Ireland)
Barbara Juliane Holzknecht (Copenhagen, Denmark)
Meet-the-Expert David Ong (Zoetermeer, Netherlands)
Arjana Tambic Andrasevic (Zagreb, Croatia)
How to interpret resistance patterns from antibiograms
Co-organised with: ESCMID Education Subcommittee
M0025 11:00 Tommaso Giani (Florence, Italy)
M0026 11:12 Diaz Lorena (Santiago, Chile)
ME013 - Hall 2
13:30 14:30
Meet-the-Expert
ME008 - Hall 3
11:00 12:00
Orthopaedic implant infections: new approaches for improved outcomes
Meet-the-Expert
Children are not just small adults: interactive paediatric cases
M0037 13:30 Marjan Wouthuyzen-Bakker (Groningen,
Netherlands)
M0027 11:00 Julie Toubiana (Paris, France) M0038 13:42 Trisha Peel (Melbourne, Australia)
M0028 11:12 Sanjay Patel (Winchester, United Kingdom) Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG),
ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID
Study Group for Infectious Diseases of the Brain (ESGIB)
ME009 - Hall 5
11:00 12:00
Meet-the-Expert ME014 - Hall 3
13:30 14:30
How to practise WHO Guidelines for the prevention of bloodstream infections Meet-the-Expert
and other intravascular catheter infections
Timing of antimicrobials in sepsis and septic shock - the sooner the better?
M0029 11:00 Kushlani Jayatilleke (Battaramulla, Sri Lanka)
M0030 11:12 Walter Zingg (Zurich, Switzerland) M0039 13:30 Laura Evans (Seattle, United States)
M0040 13:42 Evangelos Giamarellos-Bourboulis (Athens, Greece)
Co-organised with: ESCMID Study Group for Bloodstream Infections,
ME010 11:00 - 12:00 Hall 6 Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Staphylococci
and Staphylococcal Diseases (ESGS)
Meet-the-Expert
Can we stop vertical transmission of syphilis, HIV and hepatitis? Regional
ME015 - Hall 5
experience 13:30 14:30
Meet-the-Expert
PrEP in Europe: Current gaps and solutions
M0031 11:00 Ecaterina Noroc (Chisinau, Moldova, Republic of)
M0032 11:12 Fakhriddin Nizamov (Almaty, Kazakhstan)
Co-organised with: Euroguidelines in Central and Eastern Europe Network
Group, United Nations International Children's Emergency Fund (UNICEF) M0041 13:30 Teymur Noori (Stockholm, Sweden)
M0042 13:42 Milosz Parczewski (Szczecin, Poland)
Co-organised with: European AIDS Clinical Society (EACS)
ME011 - Hall 8
11:00 12:00
Meet-the-Expert
ME016 - Hall 6
13:30 14:30
Biofilm-related nontuberculous mycobacterial infections: ongoing nightmare
Meet-the-Expert
Short regimens for treating drug-susceptible and drug-resistant tuberculosis:
Insights from guidelines
M0033 11:00 Jaime Esteban (Madrid, Spain)
M0034 11:12 Philippe Morand (Paris, France)

ESCMID Global 2025 - Programme
M0043 13:30 Daria Podlekareva (Copenhagen, Denmark)
M0044 13:42 Raquel Duarte (Porto, Portugal)
Co-organised with: European Respiratory Society (ERS) M0053 14:45 Luigia Scudeller (Pavia, Italy)
M0054 14:57 Blin Nagavci (Gjakove, Kosovo)
ME017 - Hall 8 Co-organised with: ESCMID Guidelines Subcommittee
13:30 14:30
Meet-the-Expert
ME022 - Hall 6
14:45 15:45
How to navigate Risk Communication in Public Health
Meet-the-Expert
Multidisciplinary management of bone and joint infections: is there a recipe
M0045 13:30 Christina Rolfheim-Bye (Oslo, Norway) for success?
M0046 13:42 Marius Gilbert (Brussels, Belgium)
Co-organised with: ESCMID Study Group for Public Health Microbiology
(ESGPHM) M0055 14:45 Natividad Benito (Barcelona, Spain)
M0056 14:57 Tiziana Ascione (Naples, Italy)
ME018 - Hall 9 Co-organised with: ESCMID Study Group for Lyme Borreliosis (ESGBOR)
13:30 14:30
Meet-the-Expert
ME023 - Hall 8
14:45 15:45
Do we need antiviral stewardship in immunocompromised hosts? role of cell-
mediated immunity Meet-the-Expert
How to manage and prevent travellers' diarrhoea
M0047 13:30 Michelle Yong (Melbourne, Australia)
M0048 13:42 Genovefa Papanicolaou (New York, United States)
M0057 14:45 Tinja Laaveri (Helsinki, Finland)
M0058 14:57 David Tribble (Bethesda, United States)
SP4 - Hall 0
14:45 15:45
Special Session ME024 14:45 - 15:45 Hall 9
Science Slam - How to Communicate Science with Clarity Meet-the-Expert
Chairs Mary Horgan (Dublin, Ireland)
How to diagnose and treat infectious complications in critically ill patients
Jaroslav Hrabak (Plzen, Czech Republic)
receiving ECMO support
Nina Khanna (Basel, Switzerland)
Preeti Malani (Ann Arbor, United States)
Emily G. Mcdonald (Montreal, Canada)
Joshua Nosanchuk (Bronx, United States)
M0059 14:45 Jordi Riera (Barcelona, Spain)
Jesús Rodríguez-Baño (Seville, Spain)
M0060 14:57 Giacomo Grasselli (Besana In Brianza, Italy)
Co-organised with: European Extracorporeal Life Support Organization
(EuroELSO)
Co-organised with: ESCMID Education Subcommittee
SP5 - Hall 0
ME019 - Hall 2 16:15 18:15
14:45 15:45
Special Session
Meet-the-Expert
Multidisciplinary approach to early sepsis management
Healthcare-associated CNS infections
Chairs Markus Bald (Lüdenscheid, Germany)
Aleksandra Davidovic (Luedenscheid, Germany)
Charalambos Dokos (Lüdenscheid, Germany)
M0049 14:45 Diederik Van De Beek (Amsterdam, Netherlands)
M0050 14:57 Alexandra Mailles (Paris, France)
Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain Co-organised with: ESCMID Education Subcommittee
(ESGIB)
EW025 - Hall 2
16:15 18:15
ME020 - Hall 3
14:45 15:45 Educational Session
Meet-the-Expert
AMR surveillance: current challenges and new perspectives
Translation of gut microbiome data to clinical practice: a guide for clinicians Chair Tomislav Mestrovic (Varazdin, Croatia)
M0051 14:45 Aycan Gundogdu (Kayseri, Türkiye) W0061 16:15 The essentials of GRAM project: data sources,
methodology and challenges in estimating AMR
M0052 14:57 Niranjan Nagarajan (Singapore, Singapore)
burdenAuthia Gray (Washington, United States)
Co-organised with: ESCMID Study Group for Host and Microbiota Interaction
W0062 16:35 Networks for surveillance of AMR in animal
(ESGHAMI)
pathogensLucie Collineau (Lyon, France)
W0063 16:55 Transition to genomic-based methodology for
ME021 - Hall 5 surveillance and outbreak detection to effectively
14:45 15:45 combact AMRCamilla Wiuff Coia (Copenhagen,
Meet-the-Expert Denmark)
W0064 17:15 Implementing and running hospital-wide genomic
How to make sense out of guidelines and scientific evidence surveillance of pathogensAlexander Mellmann

ESCMID Global 2025 - Programme
(Münster, Germany) Chairs Mark G. J. De Boer (Leiden, Netherlands)
Co-organised with: ESCMID Education Subcommittee, ESCMID Study Group Suzanne Van Asten (Nijmegen, Netherlands)
for Antimicrobial Resistance Surveillance (ESGARS), ESCMID Study Group for
Veterinary Microbiology (ESGVM)
W0077 16:15 The impact of diabetes and host-pathogen interaction
and gut microbiomeReinout Van Crevel (Nijmegen,
EW026 16:15 - 18:15 Hall 3 Netherlands)
Educational Session W0078 16:35 Diabetes and invasive fungal infectionsJochem Buil
(Nijmegen, Netherlands)
New insights into antifungal agents and resistance W0079 16:55 Viral infections and diabetes: is there a
Chairs Anuradha Chowdhary (New Delhi, India) connection?Malin Flodström-Tullberg (Stockholm,
Jon Salmanton-Garcia (Cologne, Germany) Sweden)
W0080 17:15 Pathogenesis of diabetic wound infectionTba
W0065 16:15 Emerging resistance in Candida tropicalisSharon
EW030 - Hall 9
Chen (Sydney, Australia) 16:15 18:15
W0066 16:35 Mechanisms of resistance in Candida glabrataDavid Educational Session
Perlin (Nutley, United States)
W0067 16:55 Surveillance of resistance in Aspergillus Primer on infection prevention and control: the crucial support by clinical
speciesMaiken Cavling Arendrup (Copenhagen, microbiology
Denmark) Chairs Nico Tom Mutters (Bonn, Germany)
Margreet C. Vos (Rotterdam, Netherlands)
W0068 17:15 Environmental surveillance for antifungal
resistanceEveline Snelders (Wageningen,
Netherlands)
W0081 16:15 Microbial fundamentals: building blocks of infection
prevention and controlLaurence Armand-Lefevre
EW027 16:15 - 18:15 Hall 5 (Paris, France)
Educational Session W0082 16:35 Optimising environmental sampling in infection
control: rational use of the microbiology
Going Viral! Phage Therapy Clinical rounds laboratoryJohn E. Coia (Esbjerg, Denmark)
Chairs Gregory German (Maple, Canada) W0083 16:55 The crucial role of molecular typing in infection
Ameneh Khatami (Sydney, Australia) controlStefanie Kampmeier (Würzburg, Germany)
W0084 17:15 How can we link diagnostic and antibiotic
stewardship?Constantinos Tsioutis (Nicosia, Cyprus)
W0069 16:15 Clinical cases and lessons from the STAMP Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI),
protocolHolly Sinclair (Nsw, Australia) EUCIC Steering Committee
W0070 16:35 Difficult cases treated with phagesGhady Haidar
(Pittsburgh, United States) Saturday, 12 April 2025
W0071 16:55 Challenging osteoarticular cases treated with
phagesTristan Ferry (Lyon, France)
W0072 17:15 Treating urinary tract infections with phages: dream
or reality?Saima Aslam (San Diego, United States) SY036 - Hall 15
08:30 10:30
Co-organised with: ESCMID Study Group for Non-traditional Antibacterial
Therapy (ESGNTA) 2-hour Symposium
The quality of antibiotics used in the communities of LMICs
EW028 - Hall 6 Chairs Thi Thuy Nga Do (Ha Noi, Vietnam)
16:15 18:15
Christina Obiero (Kilifi, Kenya)
Educational Session
Addressing infection challenges in immunocompromised patients: a case-
based exploration S0105 08:30 The quality of antibiotics and their potential impact on
patient outcome and AMRPaul Newton (Oxford,
Chairs Maddalena Giannella (Bologna, Italy)
United Kingdom)
Asma Nasim (Karachi, Pakistan)
S0106 09:00 Community antibiotic access and use in Sub-Sahara
AfricaSamuel Afari-Asiedu (Kintampo, Ghana)
S0107 09:30 Encountered challenges and reflections on
W0073 16:15 Challenges in managing gastrointestinal infections in
conducting multi-country medicine quality
patients with primary immunodeficiencyEffrossyni
studiesNoudy Sengxeu (Vientiane Capital, Lao
Gkrania-Klotsas (Cambridge, United Kingdom)
People's democratic republic)
W0074 16:35 Respiratory infections in patients receiving CAR-T
S0108 10:00 Confusion in appearance of common used antibiotics
cells or bispecific monoclonal antibodiesGemma
in LMICsHeiman Wertheim (Nijmegen, Netherlands)
Reynolds (Heidelberg, Australia)
W0075 16:55 Mycobacterial infections in patients with HIV
infectionGraeme Ayton Meintjes (Observatory, South SY031 - Hall 6
08:30 10:30
Africa)
W0076 17:15 Breakthrough fungal infections in haematopoietic 2-hour Symposium
cancer and in stem cell transplantationDimitrios P.
Kontoyiannis (Houston, Tx, United States) To screen or not to screen prior to transplant?
Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), Chairs Laura Alicia Barcan (Buenos Aires, Argentina)
International Immunocompromised Host Society (ICHS) Oscar Len (Barcelona, Spain)
EW029 16:15 - 18:15 Hall 8 S0085 08:30 HHV-8 ScreeningAlessandra Mularoni (Palermo,
Italy)
Educational Session
S0086 09:00 TB screening and prevention in endemic
Impact of diabetes on infectious diseases: what should we know? regionsRubina Naqvi (Karachi, Pakistan)

ESCMID Global 2025 - Programme
S0087 09:30 Screening for and prevention of chagas in response to antibiotics in a dual-species intracellular
immunocompromised hostsMarcelo Victor Radisic infection modelF. Van Bambeke* (Brussels, Belgium),
(Buenos Aires, Argentina) G. Wang
S0088 10:00 Screening of lung donors for MolicutesMichael G Ison E0031 In vitro investigations of ceftazidime-avibactam and
(Derwood (MD), United States) fosfomycin against carbapenemase-producing
Enterobacterales clinical isolatesM. Martens*
(Hamburg, Germany), F.M. Docobo-Perez, C. Sauco
EF003 - Arena 1 Carballo, J. Rodriguez-Baño, S. Marchand, L.
08:30 09:30
Keomany, I. Portillo-Calderon, M. Gianella, S.
ePoster Flash Session Ambretti, B. Secci, S.G. Wicha
E0032 In vivo activity and PK of the novel siderophore-
On the frontiers of vaccine driven prevention cephalosporin AR-2126 in a lethal lung infection
Chair Maria Ganczak (Zielona Gora, Poland) model in mice infected with a carbapenem-resistant
Pseudomonas aeruginosa following subcutaneous
administrationW. Wicha* (Bruck An Der Leitha,
Austria), S. Paukner
E0021 Changes in dose interval can impact T cell responses
E0033 Synergistic Potency Unveiled: ￿-Lactam and ￿-
but not antibody levels in individuals receiving the
Lactamase Inhibitor Combination against
modified vaccinia Ankara Mpox vaccineJ. Parsons*
Mycobacterium abscessus with Dual Action of ￿-
(Liverpool, United Kingdom), K. Subramaniam, L.
Lactamase Inhibition and Multi-Target Receptor
Turtle, S. Dobson, L. Goodwin, C. Jones, T. Jones, P.
InactivationE. Shin* (Cleveland, United States), K.M.
Shellman, A. Uriel, S. Jones, A. Otter, S. Laidlaw, M.
Dousa, C.R. Bethel, M. Nantongo, S.M. Holland, E.J.
Carroll
Rubin, J.B. Bulitta, K. Barry, R.A. Bonomo
E0022 A phase 1 study with an innovative approach for an
E0034 Pharmacokinetic/pharmacodynamic evaluation of
HIV-1 prophylactic vaccineP. Garbes* (Newark,
benzoxaborole MRX-5 in mouse pneumonia model
United States), C. Chang, H. Wraight, R. Norton, S.
with Mycobacterium abscessus infectionW. Wang*
Ouyang, S. Shen, H. Gao, D. Montefiori, J. Heptinstall,
(Foster City, United States), S. Liu, B. Rimal, Y. Xu, Q.
S. Sawant, G. Tomaras, J. Zhu, K. Braz Gomes, M.
Dai, G. Lamichhane
Giffear, K. Damjanoska, J. Li
E0035 Pharmacokinetic/pharmacodynamic modelling of
E0023 A Pragmatic Randomized Trial to Evaluate Bivalent
immune response and meropenem activity in
RSV Prefusion F Protein–based Vaccine Effectiveness
immunocompetent and neutropenic mouse lung
for Preventing RSV Hospitalizations in Older Adults
infection modelsR. Saporta* (Uppsala, Sweden), N.
(DAN-RSV): Rationale & Trial DesignM. Lassen*
Tassi, O. Ticha, V. Biordi, A. Ginosyan, I. Loryan, E.I.
(Copenhagen, Denmark), S. Christensen, N.
Nielsen, I. Bekeredjian-Ding, B. Kerscher, L.E. Friberg
Johansen, K. Skaarup, D. Modin, B. Claggett, C.
Larsen, L. Larsen, L. Wiese, M. Dalager-Pedersen, M. E0036 Implementation of a model-based nomogram for
Lindholm, L. Køber, S. Solomon, J. Jensen, C. Martel, amoxicillin precision dosing in patients suspected of
C. Schwarz, E. Gonzalez, M. Skovdal, P. Zhang, B. infective endocarditis: preliminary results of the
Gessner, N. Aliabadi, E. Begier, T. Biering-Sørensen NOMOBA-AMX multicentre studyP. Le Turnier*
(Cayenne, French Guiana), S. Jamard, A. Lorleac'h, C.
E0024 Six-month Immunogenicity of mRNA-1345 RSV
Deschanvres, F. Andry, A. Coste, P. Danneels, T.
Vaccine in Adults Aged ≥60 YearsM. Desai*
Guimard, P. Gicquel, H. Harrabi, N. Issa, J.B. Lainé, R.
(Cambridge, United States), E. Comstock, L. Lan, A.
Lamberet, A. Le Bot, M. Maillet, P. Petitgas, V. Rabier,
Kapoor, F. She, C. Reuter, J. Goswami, F. Priddy, R.
S. Sunder, J.M. Turmel, D. Boutoille, C. Delaunay, M.
Das
Grégoire, A.G. Leroy, M. Wargny, R. Bellouard
E0025 Comparative Immune Responses to Homologous and
E0037 No time to waste: hospital-wide assessment of IV-
Heterologous SARS-CoV-2 Vaccination Using DNA
vial and line residuals and impact on target
and Protein PlatformsS. Prieto Martin Gil* (Madrid,
attainment.D. Vanneste* (Leuven, Belgium), M.
Spain), S. Prieto Martín Gil, M. López Siles, J.A.
Gijsen, W. Zhang, O. Elkayal, V. Caubergs, J. Wauters,
Infantes Lorenzo, E. Lorente, D. Fousteris, B. Cano
S. Desmet, E. Dreesen, I. Spriet
Castaño, A. Tajuelo, D. López, V. Mas Lloret, E. Gato,
A. Pérez, M.J. Mcconnell E0038 Population pharmacokinetic modelling of colistin in
critically-ill patients on sustained low-efficiency
E0026 Quantitative correlates of protection against SARS-
dialysis: implications for dose selectionD. Fuhs*
CoV-2 variants using individual-level reconstructed
(Parkville, Australia), A. Boonyasiri, T. Naorungroj, L.
antibody kineticsT. Russell* (London, United
Wang, J. Wang, R. Ratanarat, J. Li, R. Nation, T.
Kingdom), E.C. Wall, A.J. Kucharski, J. Hellewell, O.
Visanu, C. Landersdorfer
Hague, H. Townsley, J. Gahir, M. Shawe-Taylor, D.
Greenwood, R. Harvey, M.Y. Wu, D.L. Bauer, E.J. Carr
E0027 Effectiveness of the 2023-24 seasonal influenza SY034 - Hall 10
vaccine in UK healthcare workers: results from the 08:30 10:30
SIREN prospective cohort studyL. Mcgeoch* 2-hour Symposium
(London, United Kingdom), S. Foulkes, H. Whitaker, K.
Munro, J. Khawam, D. Sparkes, A. Charlett, C. Brown, Endoscopy: infection risks and mitigation
A. Atti, J. Islam, S. Hopkins, N. Andrews, V. Hall
Chairs Elisabeth Presterl (Vienna, Austria)
E0028 Immunogenicity and safety of second COVID-19 Gordon Ramage (Glasgow, United Kingdom)
booster and Influenza vaccination coadministrationI.
Wagenhäuser* (Würzburg, Germany), J. Reusch, J.
Mees, A. Gabel, N. Petri, M. Krone
E0029 The degree of immunization against the Measles S0097 08:30 Should we be concerned about infection from
virus of the infant population in Sibiu county, contaminated endoscopes?Claire Aumeran
RomaniaS. Cristea* (Sibiu, Romania), C. Grigore (Clermont-Ferrand, France)
S0098 09:00 Prevention of multidrug-resistant infections from
contaminated duodenoscopesMargreet C. Vos
EF004 - Arena 3 (Rotterdam, Netherlands)
08:30 09:30
S0099 09:30 Understanding the causes of medical device
ePoster Flash Session contamination: it is all biofilm!Roberto Rusconi (Milan,
Italy)
Pharmacology from bench to the bedside
S0100 10:00 Does the European medical Device Regulation bring
Chair Alina Karoline Nussbaumer-Pröll (Wien, Österreich, us safer duodenoscopes?Markus Hell (Salzburg,
Austria) Austria)
Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID Study
Group for Nosocomial Infections (ESGNI)
E0030 Enterococcus faecalis impairs Escherichia coli

ESCMID Global 2025 - Programme
OS002 - Hall 11 people living with HIVRaimonda Matulionyte (Vilnius,
08:30 10:30
Lithuania)
2-hour Oral Session S0103 09:30 Integration of HIV and TB care to improve patient
outcome in resource-limited settingsAkaki Abutidze
Translating metagenomics into clinical practice
(Tbilisi, Georgia)
Chairs Benjamin Peter Howden (Parkville (Victoria),
S0104 10:00 How researchers can influence policy and practice in
Australia)
HIV/TB careJens D. Lundgren (Copenhagen,
Paula Mölling (Örebro, Sweden)
Denmark)
Co-organised with: ESCMID Study Group for Mycobacterial Infections
(ESGMYC), Euroguidelines in Central and Eastern Europe Network Group
O0011 Nanopore metagenomic sequencing for rapid
bloodstream infection diagnostics evaluated in a
prospective observational studyH.L. Nielsen* EW041 - Hall 13
08:30 10:30
(Aalborg, Denmark), C. Thygesen, K.K. Søgaard, A.B.
Sørensen, S.M. Karst, A.L. Krarup, M. Albertsen Educational Session
O0012 Interpretative Criteria for Adjudicating Clinical
RSV infections: diagnosis, surveillance and treatment in the advent of
Significance to Next-Generation Sequencing Results
vaccines
from Bronchial-alveolar Lavage and Bronchial
Wash.J. Alexander* (Orlando, United States), A. Chair Monika Redlberger-Fritz (Vienna, Austria)
Charles
O0013 Implementing same-day respiratory metagenomic
diagnostics in paediatric intensive careR. Hammond*
W0126 08:30 Costs of RSV infection, compared to other
(London, United Kingdom), A. Kopec, J. Brown, J.
respiratory virusesBarbara Rath (Besançon, France)
Hatcher, A. Alcolea-Medina, R. Batra, D. Ward, L.B.
Snell, J. Breuer W0127 08:50 Virology and host interactions of RSV
O0014 Detection of pathogenic microorganisms using W0128 09:10 RSV surveillance in the EU/EEA in the vaccine
metagenomic next-generation sequencing in ICU eraEeva Broberg (Solna, Sweden)
patients with ongoing antibiotic therapyT. W0129 09:30 RSV fusion inhibitors and monoclonals: current
Schroeder* (Nuertingen, Germany), M. Eliwi Alsaffan, status and future developmentsPeter Openshaw
A. Dervishi, P. Kawaletz, H. Stäudle (London, United Kingdom)
O0015 Analysis of metagenomic pathogen detection Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV),
compared to conventional diagnostics: clinical usage International Society for Influenza and other Respiratory Viruses (ISIRV)
and relevance for patient outcomesE. Siegel* (Mainz,
Germany), V. Bianco-Wilhelmi, S. Koch, C. Seckert, C.
Hamm, D. Teschner, O. Kriege, D. Grimm, I. EW042 - Hall 14
Sagoschen, D. Schreiner, M. Bodenstein, G. Cakas, S. 08:30 10:30
Hagge, S. Vieira-Silva, T. Sparwasser Educational Session
O0016 Same-day pan-microbial metagenomics for
personalized therapy and pathogen surveillance on Traumatic wound infections: diagnosis and treatment options
the intensive care unit: a single-centre prospective Chairs Amparo Fernández-Rodríguez (Madrid, Spain)
studyL.B. Snell* (London, United Kingdom), A. Veroniek Saegeman (Sint-Niklaas, Belgium)
Alcolea-Medina, G. Humayun, N. Al-Yaakoubi, D.
Ward, C. Alder, V. Patel, F. Vivian, C. Meadows, W.
Duncan, R. Paul, N. Barrett, R. Batra, J. Edgeworth, J.
Whitehorn, G. Nebbia W0130 08:30 Multidrug-resistant infections after trauma in
warzoneShehan Hettiaratchy (Hampton, United
O0017 Evaluation of the diagnostic efficacy of targeted next-
Kingdom)
generation sequencing in the detection of pathogens
in bronchoalveolar lavage fluid from patients with W0131 08:50 Fungal infections during natural disastersAnuradha
lower respiratory tract infections in ICUB. Ran* Chowdhary (New Delhi, India)
(Taiyuan, China), Y. Liu, X. Wu, X. Lin, X. Li, Q. Zhan, C. W0132 09:10 Bacteriophage therapy for multidrug-resistant wound
Wang, L. Huang, T. Zhai, Y. Cai, Y. Song, Q. Zhang, C. infections in traumaTristan Ferry (Lyon, France)
Zhang, J. Hao, L. Jin, Z. Huang
W0133 09:30 Infection of burn woundsNur Benzonana (Istanbul,
O0018 Prognostic and diagnostic value of Next-generation Türkiye)
sequencing in female reproductive tract infection and
Co-organised with: ESCMID Study Group for Forensic and Postmortem
HPV persistenceC. Peng* (Shiyan, China), S. Qi, C.
Microbiology (ESGFOR), ESCMID Study Group for Non-traditional
Jiachang, P. Chunyan, W. Taiquan, X. Xianru, Y.
Antibacterial Therapy (ESGNTA), SEIMC (Sociedad Española Enfermedades
Jianying, Y. Qirong, Z. Pengyuan, L. Jun
Infecciosas Microbiología Clinica), International Society of Antimicrobial
O0019 A promising approach to rapid, non-culture diagnosis Chemotherapy (ISAC)
of invasive fungal infections (IFIs) by targeted next-
generation sequencing (tNGS)M.H. Nguyen*
(Pittsburgh, United States), H. Badrane, B.A. Stevens, SY037 - Hall 16
S. Cheng, G. Guigon, E. Santiago, M. Rambaud, B. 08:30 10:30
Hao, E. Driscoll, W. Maynard, C. Clancy 2-hour Symposium
O0020 Implementation of Clinical Metagenomics in France:
Insights from a Five-Years StudyM. Dutkiewicz* Unveiling the challenges: nosocomial infections in ECMO-supported patients
(Paris, France), T. Ghelfenstein-Ferreira, L. Feghoul, Chairs Antonios Katsounas (Bochum, Germany)
S. Mercier-Delarue, A. Senhaji, A.L. Munier, F. Jordi Riera (Barcelona, Spain)
Caméléna, J. Le Goff, M. Salmona
SY035 - Hall 12 S0109 08:30 Source of infection and pathogensChristian Eckmann
08:30 10:30
(Hannover, Germany)
2-hour Symposium S0110 09:00 Prophylaxis and empiric treatmentGiacomo Grasselli
(Besana In Brianza, Italy)
Barriers to TB/HIV elimination in low- and high-incidence settings
S0111 09:30 Diagnostic criteria and definitionsGraeme Maclaren
Chair Daria Podlekareva (Copenhagen, Denmark)
(Singapore, Singapore)
S0112 10:00 Microbial filmsMarta Hernández-Meneses
(Barcelona, Spain)
S0101 08:30 HIV and TB epidemic: the storm hasn’t subsided Co-organised with: European Extracorporeal Life Support Organization
yetTetiana Koval (Poltava, Ukraine) (EuroELSO)
S0102 09:00 Approaches for latent and active TB screening in

ESCMID Global 2025 - Programme
O0001 Decoding the role of blaCPE-carrying plasmids on
wings: A holistic view using the One Health
EW039 - Hall 2
08:30 10:30 approachS.A. Martínez-Álvarez* (Logrono, Spain),
P. Châtre, T. Cardona-Cabrera, P. François, U.
Educational Session
Höfle, M. Zarazaga, J.Y. Madec, M. Haenni, C.
Are urinary tract infections still the same? Torres
Chairs Suzanne Geerlings (Amsterdam, Netherlands) O0002 A novel isolation room model leveraging culture-
Agnes Maria Sonnevend (Pécs, Hungary) independent Hi-C metagenomics for tracking
antimicrobial resistance transmission between
patients and hospital environmental reservoirsV.
Koh* (Singapore, Singapore), R. Cabrera, J. Chua,
W0118 08:30 Update on paediatric UTI Michael Buettcher (Luzern, J.S. Lee, N.S.B. Haidi Fitri, Z.X. Tan, X. Huan, N.M.
Switzerland) Thevasagayam, T.K.B. Lee, K. Marimuthu, O.T. Ng
W0119 08:50 Diagnosis and treatment of UTI in the era of O0003 Deciphering the pathogenic potentials and
antimicrobial resistanceJennifer Kranz (Aachen, epidemiological identities of Staphylococcus
Germany) pseudintermedius colonizing companion dogs in
Sao PauloI.B. Moses* (Sao Paulo, Brazil), L. Sartori,
W0120 09:10 Can UTI be prevented?Chris Harding (Newcastle
D.A. Henriques, M.M. Marini, F.M. Lima, R.X.
Upon Tyne, United Kingdom)
Espinosa, I. Orlandino Da Silva, F.F. Santos, L.
W0121 09:30 Fungal and parasitic infections of the urinary Gonzaga, A.T. Ribeiro De Vasconcelos, A.C. Gales
tractGladys Mbwanji (Mwanza, Tanzania, United
O0004 Recent progress towards integrated surveillance of
republic of)
antimicrobial resistance in FranceL. Collineau*
(Lyon, France), S. Bareille, G. Birgand, L. Lacmago,
B. Lange, O. Lemenand, C. Chauvin
EW040
08:30
-
10:30
Hall 3
O0005 Exploring the plasmidome of 3rd generation
Educational Session cephalosporin-resistant Enterobacterales in wild
birds: Insights into horizontal gene transfer and
OPAT: from aged wine to new vintage AMR disseminationB. Timmer* (Debrecen,
Hungary), L. Miló, B. Koleszár, C. Freytag, Á. Lovas-
Chairs Birgit Koch (Rotterdam, Netherlands)
Kiss, L. Laczkó, G. Kardos
Sonia Luque (Barcelona, Spain)
O0006 Emergence of mobile colistin resistance in
Klebsiella at human-animal-environment interface
in BangladeshS. Rahman* (Oxford, United
W0122 08:30 OPAT: principles, practice and checklistsCharlotte Kingdom), A. Pondit, J. Parkhill, S. Saha, S.M.R.
Quintens (Leuven, Belgium) Islam, P.I. Disha, S.A. Nasreen, M.A.K. Azad, T.
W0123 08:50 COPAT: complex outpatient parenteral antimicrobial Walsh, R. Farzana
therapy Ronald Andrew Seaton (Glasgow, United O0007 Unveiling the invisible: antimicrobial resistance
Kingdom) genes and pathogenic microbial diversity in sewage
W0124 09:10 Antimicrobial stability and other challenges for OPAT of North India's largest industrial hub, A
practice? Mark Gilchrist (London, United Kingdom) metagenomic perspectiveI. Singh* (Chandigarh,
India), R. Sharma, A. Arora, B. Mohan, N. Taneja
W0125 09:30 New OPAT safety and efficacy data to guide
practiceMatthew Rawlins (Murdoch, Australia) O0008 Culturomics as a tool for ONE HEALTH approach:
Unveiling the role of unknown microorganisms as
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG),
antibiotic resistance carriers in wastewater
Society of Infectious Diseases Pharmacists (SIDP)
samplesE. Ouranou* (Heraklion, Greece), A.
Psaroulaki, D. Chochlakis, M. Malliarou, K.
Tryfinopoulou, A. Ntoula, E. Intze, I. Lagouvardos
EW038
08:30
-
11:30
Hall 4
O0009 One Health intervention impacts on antibiotic
Educational Session resistance in Denmark, England and Senegal: A
mathematical model comparisonG. Knight*
EUCAST Educational Workshop (London, United Kingdom), R. Booton, J.V.
Robotham, K. Aluzaite, D. Belay, J. Guitian, M.
Chairs Marlene Amara (Le Chesnay Cedex, France)
Dione, E. Emes
Alasdair P. Macgowan (Bristol, United Kingdom)
O0010 Clinically important sequence types and resistance
genes in Enterobacteriaceae from coastal
environments and gullsV. Silva* (Lisbon, Portugal),
W0113 08:30 EUCAST updateSören G. Gatermann (Bochum, M. Quintelas, M. Caniça, R. Rivière, P. Poeta, G.
Germany) Igrejas
W0114 08:50 Setting clinical breakpoints, assessing
evidenceAnouk Edwina Muller (The Hague,
Netherlands) SY032 08:30 - 10:30 Hall 7
W0115 09:10 Benzylpenicillin susceptibility testing of S. 2-hour Symposium
pneumoniae by disk diffusionGunnar Kahlmeter
(Tävelsås, Sweden) New insights into Candida pathogenesis
W0116 09:30 What to do when there are no breakpointsBarbara Chairs Aleksandra Barac (Belgrade, Serbia)
Juliane Holzknecht (Copenhagen, Denmark) Joshua Nosanchuk (Bronx, United States)
W0117 09:50 Detection of resistance mechanismsChristian Giske
(Stockholm, Sweden)
Co-organised with: EUCAST Steering Committee
S0089 08:30 Insights into the evolution of Candida under
antifungal pressureAttila Gacser (Szeged, Hungary)
S0090 09:00 How do Candida extracellular vesicles modify
OS001 - Hall 5
08:30 10:30 virulence during disease?Leonardo Nimrichter (Rio
De Janeiro, Brazil)
2-hour Oral Session
S0091 09:30 The commensal to pathogen transition: kind to
One Health means resistance everywhere killerIlse D. Jacobsen (Jena, Germany)
Chairs Alessandra Carattoli (Rome, Italy) S0092 10:00 Fungal-bacterial interactions: who wins?Rebecca Hall
Prasannakumar Palanikumar (Vellore, India) (Canterbury, United Kingdom)

ESCMID Global 2025 - Programme
SY033 - Hall 8 E0047 Economic and health gains associated with the
08:30 10:30
adoption of the 2-hour phenotypic antimicrobial
2-hour Symposium susceptibility testing in patients with bloodstream
infection in EuropeC. Pina-Vaz* (Oporto, Portugal), F.
Single-cell approaches to dissect cellular phenotypic heterogeneity of Aragão, C. Palos, C. Mimoso, I. Neves, M.J. Janeiro,
bacterial pathogen populations. J.A. Paiva
Chairs Christian Stephan Lentz (Tromsø, Norway)
Annelies Zinkernagel (Zurich, Switzerland)
EF006 - Arena 4
09:30 10:30
ePoster Flash Session
S0093 08:30 Adaptive evolution and phenotypic heterogeneity of
bacterial pathogens during infectionsChristoph Ernst Emerging developments in antifungal pharmacology
(Cologne, Germany) Chair Roger Brüggemann (Nijmegen, Netherlands)
S0094 09:00 Single-cell imaging and heterogeneity in antimicrobial
resistanceStefano Pagliara (Exeter, United Kingdom)
S0095 09:30 Single-cell RNAseq and heterogeneity in bacterial E0048 NATURE-US: the natural history of antifungal failure
transcriptionAnna Kuchina (Seattle, United States) in invasive candidiasisL. Ostrosky-Zeichner*
S0096 10:00 Dissecting the function of individual bacteria in their (Houston, United States), P.G. Pappas, M.H. Miceli,
spatial contextKnut Drescher (Basel, Switzerland) A. Spec, C.Z. Grimes, F. Lewis, M. Mammadova, E.
McKie, M. Middle, M. Kordalewska, D.S. Perlin, D.P.
Kontoyiannis, O.A. Cornely, J. Vazquez, D. Angulo
SY043 09:30 - 10:30 Hall 1 E0049 The antidepressant vortioxetine enhances
resistance toward multiple azolesS. Rizzo* (Rome,
1-hour Symposium Italy), M. Cacaci, V. Di Pilato, S. Di Bella, U. Albert, B.
Posteraro, M. Sanguinetti, F. Bugli, R. Torelli
Year in infection control
E0050 Enhancing Isavuconazole Pharmacokinetics: A
Chairs Nico Tom Mutters (Bonn, Germany) Comprehensive Population (PPK) Model from Three
Ermira Tartari (Msida, Malta) Phase 3 Trials and Covariate ExplorationA. Desai*
(Northbrook, United States), L. Kovanda
E0051 Identification of efflux inhibitors for Candida
S0134 09:30 Andrew James Stewardson (Melbourne, Victoria, albicans through a drug repurposing strategyD.
Australia) Marques* (Lisbon, Portugal), S. Santos Costa, L.
Rodrigues
S0135 10:00 Kalisvar Marimuthu (Singapore, Singapore)
E0052 Clinical outcomes of micafungin 100 mg vs. 150 mg
daily for the treatment of Candida auris fungemiaJ.
EF005 - Arena 2 Hou* (Chicago, Il, United States), Y. Wang, R.
09:30 10:30 Burgos, L. Danziger, E. Drwiega
ePoster Flash Session E0053 Resolution of clinical signs in adults with invasive
candidiasis and/or candidaemia treated with
It's all in the blood rezafungin or caspofungin: ReSTORE and STRIVE
Chair Colin R. Mackenzie (Neuss, Germany) trial pooled analysisG.R. Thompson* (Davis,
California, United States), A. Soriano, M. Bassetti,
P.M. Honore, J. Vazquez, S. Dickerson, O.A. Cornely
E0054 Ibrexafungerp is effective in treatment of patients
E0039 Limited delayed incubation of blood culture bottles
with candidiasis, including candidaemia, caused by
has limited effect on yield and time-to-positivityL.
Candida auris: a multicentre, open-label study
Hardy* (Antwerp, Belgium), A.S. Heroes, E.
(CARES)M.H. Miceli* (Ann Arbor, United States),
Genbrugge, B. Gleeson, C. Ferreyra, T. Vermoesen, E.
T.F. Patterson, D. Juneja, G.R. Thompson Ill, P.
Corsmit, B. De Smet
Vergidis, A. Spec, T.J. Walsh, D. Angulo, J. Breedt,
E0040 Unnecessary clinical interventions due to blood N. Yaddanapudi, R.S. Siebert, E. McKie, F. Lewis, M.
culture contamination in a large Canadian hospital Middle, M. Hoenigl
networkC. Hall* (Hamilton, Canada), C. Fuller, S.
E0055 High-dose isavuconazole therapy is well-tolerated
Ramondino, C. Main
and significantly improves survival in a fruit fly
E0041 Utility of sigmoidal growth curve when no organisms model of invasive mucormycosisS. Wurster*
are seen on Gram stain in positive blood culturesD. (Houston, United States), N.D. Albert, N.P.
Crilly* (London, United Kingdom), A. Bapat, J. Wiederhold, R.E. Lewis, D.P. Kontoyiannis
Youngs, G. Maloney, E. Drakes
E0056 Pharmacokinetics, pharmacodynamics, safety, and
E0042 Clinical microbiology laboratory consultancy to efficacy of innovative dosing schedules of liposomal
optimize blood culture workflow: Analysis of resultsC. amphotericin B for treatment of experimental
Magri* (Rome, Italy), C. Magrì, G. Menchinelli, D. invasive pulmonary aspergillosis in persistently
Squitieri, B. Fiori, M. Cacaci, B. Posteraro, G. De neutropenic rabbitsR. Petraitiene* (New York,
Angelis, M. Sanguinetti United States), E. Naing, A. Garcia, V. Zigmantaite,
E0043 Comparison of Syndromic Sepsis Panel and Standard R. Grigaleviciute, A. Pockevicius, M. Zimmerman,
Blood Culture Results: Contribution to Patient A.H. Groll, T.J. Walsh, V. Petraitis
ManagementS. Buyukberber* (Ankara, Türkiye), S.
Aydogan, B. Dinc, N. Coplu, S. Turan, S.S. Yakin, H.
Dal, T. Kayan FO050 11:00 - 12:00 Arena 1
E0044 Predicting blood culture positivity using machine
Open Forum
learning with complete blood and differential counts
in a tertiary care hospital of TurkiyeÖ. Türkmen
HIV: a global ethical Conundrum
Recen* (Izmir, Türkiye), M. Kıplapınar, H. Özdemir, S.
Kurutepe, H. Gazi Chair Seif Al-Abri (Muscat, Oman)
E0045 Performance of direct pathogen and ￿-lactamase
detection workflow using MALDI-TOF MS from
positive blood culture specimensK. Kosai* (Nagasaki, F0147 11:00 HIV, from key population to general population: a
Japan), Y. Kawamoto, K. Yanagihara Pandora's BoxSyed Faisal Mahmood (Karachi,
E0046 Waiting for follow-up blood cultures is not always Pakistan)
necessary for diagnosis of central line-associated F0148 11:10 Ethical considerations in preventing mother-to-child
bloodstream infectionsL. Van Balen* (Maastricht, HIV transmission Glory Alexander (Bangalore, India)
Netherlands), R. Koeck
F0149 11:20 HIV drug trials in Africa: ethical concernsShah Reena

ESCMID Global 2025 - Programme
(Nairobi, Kenya) (Hangzhou, China)
F0150 11:30 HIV-related stigma and discrimination in the E0100 Nanopore long-read only genome assembly for public
healthcare settingTeymur Noori (Stockholm, health surveillance of Enterobacterales bloodstream
Sweden) infections and plasmid epidemiology in England: A
Co-organised with: ESCMID Ethics Advisory Committee (EEAC) pilot studyD. Nagy* (Oxford, United Kingdom), N.
Stoesser, S. Lipworth, V. Pennetta, G. Rodger, K.
Hopkins, C. Jones, T. Neksus Study Group, S.
Hopkins, D. Crook, A.S. Walker, J. Robotham, K.L.
EF014 - Arena 2
11:00 12:00 Hopkins, A. Ledda, D. Williams, R. Hope, C.S. Brown
ePoster Flash Session
Infection control and prevention around the World EF015 11:00 - 12:00 Arena 3
Chair Divyashree Shanthamurthy (Mumbai, India)
ePoster Flash Session
Advances in the diagnosis and treatment of skin, bone, and joint infections
E0092 WHO Global Survey on Infection Prevention and Chair Norma Jung (Köln, Germany)
Control Minimum Requirements: Laying the
Foundation for 2030 Global TargetsP. Bischoff*
(Geneva, Switzerland), S. Tomczyk, G. Satta, E.
E0101 Potential benefits of PET-CT in the management of
Tartari, A. Meinen, P. Rogers, L. Cihambanya, C.R.
bone and joint infections in infective endocarditis: a
Ana Paula, I. Hewedy, Z. Li, P. Ramon-Pardo, A. Singh,
B. Allegranzi retrospective analysis from the Mayo ClinicF. Petri*
(Milan, Italy), F. Borgonovo, O.K. Mahmoud, R.
E0093 Healthcare-associated infections in african intensive Igwilo-Alaneme, T. Matsuo, S. El Zein, D. De Simone,
care units: A muliticentre prospective cohort studyB. A. Gori, E. Berbari
Gaye* (Dakar, Senegal), N. Madani, J. Ben Khlil, A.
E0102 Synovial fluid microRNA biomarkers enable
Ben Souissi, B. Seydina Alouine, G.F. Otiobanda, R.M.
accurate diagnosis of periprosthetic joint
Hamidi, M.S. Chaibou, P.A. Leye, L. Oualili, T.
Dendane, K. Abidi, M. Bouaziz, R. Ammar, M. infectionB.J.H. Frank* (Vienna, Austria), T.
Elombila, W. Naija, M. Kahloul, R. Herch, R. Toumi, E. Krammer, J. Pfeiffer-Vogel, T. Nguyen, A.
Ennouri, M. Boussarsar, N. Ben Mrad, A. Soumare, Diendorfer, M. Hackl, J. Hofstaetter
T.M. Diop, N. Brahmi, A. Ben Jazia, H. Ben Ghezala, E0103 Diagnostic accuracy of 16S rDNA PCR, multiplex
A.A. Messadi, H. Fredj, A. Mokline, S. Abdellatif, T. PCR and metagenomic Next-Generation
Badis, L. Messaoud, A. Bouzid, S. Feki, H. Sequencing in periprosthetic joint infections: a
Cheikhrouhou, A. Hachimi, B. Khemlich, F.Y. Bah, A.B. systematic review and meta-analysisF. Olearo*
Faye, L. Ouanes Besbes, Z. Hammouda, M.S. (Hamburg, Germany), S. El Zein, E. Portillo M, A.
Mebazaa, S. Elatrous, S. Ayed, W. Sellami, A. Ben Zapf, H. Rohde, E.F. Berbari, M. Wouthuyzen-Bakker
Amri, M. Ferjani, O. Bouhamed, N. Hajjem, H. Daddy,
E0104 Comparison of microbiology, management and
M. Gagara Mayaou, B. Marou Soumana, B. Diallo, B.
outcome between patients with native and with
Gafsi, F. Ben Salem, E. Milli, B. Idali, T. Merhabene, N.
post-surgical vertebral osteomyelitis: a 7-year
Ben Slimane, F. Kaaniche Medhioub, R. Allala, C.
retrospective studyG. Franceschi* (Modena, Italy),
Kaddour, N. Baffoun, R. Hammami, H. Allouche, H.
M. Pellegrino, M. Del Monte, A. Bedini, L. Benassi,
Ghadhoune, S. Soui, H. Hmouda, R. Ben Dabebiss, A.
A. Soffritti, A. Tili, E. Dema, M. Palmisani, A. Veroni,
Sidibe, N. Diani, N. Benmouhoub, M.S. Ado Zakari, O.
G. Pavesi, M. Cristina
Mamane Nassirou, O. Bachar Loukoumi, A. Ben Fraj,
H. Jaoua, K. Ben Fadhl, T. Abdoulaye, T. Bagouma, H. E0105 Cefiderocol real-life use in bone and joint infection:
Arfaoui, O. Kaabachi, O. Nasri, C. Ben Massoud, M. a retrospective French multicenter studyA. Diarra*
Niandou, M. Nanzir Sanoussi, H. Bassama, A. Jebri, H. (Tourcoing, France), V. Delastours, A. Bleibtreu, H.
Ben Fradj, A. Hafyene, N. Soraa, O. Kechini, A. Felhi, Wille, N. Sayre, N. Rouzic, K. Jaffal, I. Strachinaru, B.
R. Abouqal, Y. Coulibaly Valentin, M. Bermejo, P. Gazeau, A. Baldolli, B.
Lefevre, A. Asquier, J. Courjon, R. Larcher, L.
E0094 Epidemiology of community-acquired versus
Escaut, L. Deconinck, N. Taar, V. Dacquet, T. Ferry,
hospital-acquired sepsis in acute hospitals in Ireland - I. Eberl, M. Degrendel, P. Patoz, P.Y. Tortai, O.
2016-2022.E. Liddy* (Dublin, Ireland), A. Vellinga, D. Robineau, E. Senneville
Amin
E0106 Real-Life Experience with Dalbavancin as
E0095 Epidemiology of Central Line-Associated Suppressive Antibiotic Treatment in orthopaedic
Bloodstream Infections (CLABSIs) in a Network of
implant-related infections.R. Escudero-Sánchez*
Ten Hospitals across Greece: A 30-Month (Madrid, Spain), S. De La Villa Martínez, A. Rico
Surveillance Study – GRIPP-SNF NetworkI. Kopsidas* Nieto, M. Sanchez-Somolinos, M. Tasias Pitarch, M.
(Neo Psychiko, Greece), E. Kourkouni, G.C. Tsopela, Salaver Lletí, M. Correa Ballester, R. Blanez
D. Kousi, A. Moutou, P. Varda, P. Pantelidou, A. Hernández, E. Calabuig Muñoz, M. Montero Alonso,
Karaiiskou, D. Kaitelidou, T. Zaoutis, A. Koutsoukou L. Guio Carrion, J. Gomez Junyent, M.L. Sorli, F.
E0096 Characterisation of plasmids disseminating antibiotic Braojos Sanchez, A. Muñoz Gomez, M.J. Nuñez
resistance in Klebsiella pneumoniae isolates from Oranto, E. Baos Muñoz, R. Manzano Lorenzo, J.
Pretoria, South AfricaT. Govender* (Pretoria, South Perez-Somarribas Moreno, J.M. Barbero Allende,
Africa), A. Moultrie, M. Moodley, J. Featherston, M. M.J. Garcia Pais, F.J. Martínez Marco, A. Galeote
Mohlamonyane, J. Pitout, T. Hamiwe, T. Lentswe, S. Rivas, B. De La Torre Escuredo, J. Cobo
Liknaitzky, K. Salvador-Oke, A. Smith, I. Arshad, M. E0107 Short or Long Antibiotic Regimes in Orthopaedics:
Said, M. Ehlers, M. Kock the SOLARIO multicentre randomised controlled
E0097 Transmission dynamics of carbapenemase- trialM. Dudareva* (Oxford, United Kingdom), M.
producing bacteria between hospital and household Scarborough, M. Mcnally, M. Kumin, C.
settings in BeninK. Sintondji* (Abomey-Calavi, Benin), Scarborough, W. Vach, J. Ferguson
V. Dougnon, B. Legba, B.G. Hougbenou, K. Fabiyi, H. E0108 Clinical and Antibacterial Diversity of
Koudokpon, A. Dalsgaard, Y.M.G. Hounmanou Staphylococcal Phenotypes in Skin and Soft Tissue
E0098 Evaluating the impact of a rapid screening test for Infections: A Resource-Limited Country
carbapenem-resistant organisms in Brazilian Perspective.F. Zeeshan* (Karachi, Pakistan), A.
intensive care units.M. Salomão* (Sao Paulo Sp, Naeem, F. Uddin
Brazil), B. De Almeida Lessa Castro, C. Loredana P. A. E0109 Discrepancy between clinical-radiological diagnosis
M. Bezerra, E. Lino Dos Santos Junior, C. Lee Luna and surgical confirmation in 62 patients undergoing
Fernandes, A. Pereira Funari, S. Bollinger, F. C. Lessa, fasciotomy for suspected necrotizing fasciitis: a 11-
G. Mahon, M. Westercamp, M. Chiarastelli Salomao year retrospective study.F. Romani* (Modena,
E0099 Genomic Insights into the Rapid Rise of Italy), A. Bedini, A. Spadoni, G. Manzini, G.
Pseudomonas aeruginosa ST463: A High-Risk Franceschi, B. Fontana, M. Sarti, C. Mussini
Clone's Adaptive Strategy in ChinaX. Dong*

ESCMID Global 2025 - Programme
EF016 - Arena 4 France), T. Noël, M. Bonnet, A. Duprey, M. Hentzien
11:00 12:00
O0074 Aztreonam, ceftazidime/avibactam, and tigecycline
ePoster Flash Session combination for the management of multi-drug
resistant E.coli on peritonitis in a pediatric liver
Rising threats: antimicrobial resistance in STIs
transplant recipientR. Morales Junior* (Cincinnati,
Chair Marcos Rust (Feldkirch, Austria) United States), V. Juodinis, C. Donini, J. Sampaio
O0075 Early oral antibiotic treatment in patients with post-
neurosurgical brain abscesses caused by
Cutibacterium acnes – a case seriesM. Karolyi*
E0110 Important rise of antibiotic resistance of
(Vienna, Austria), D. Stahl, E. Pawelka, S. Omid, A.
Mycoplasma genitalium, a sexually transmitted
Kuran, M. Naegeli, A. Zoufaly, C. Well, S. Fischoeder,
pathogen, in a French University hospitalF. Doucet
M. Ortler, C. Wenisch
Populaire* (Clamart, France), W. Ben Nejma, C.
Benet, M. Grimaldi, I. Kansau, S. Pozzi-Gaudin, C. O0076 Meropenem-vaborbactam as intrathecal-sparing
Guillet-Caruba, N. Bourgeois-Nicolaos therapy for the treatment of carbapenem-resistant K.
pneumoniae shunt-related ventriculitis: two case
E0111 Molecular characterization of antimicrobial
reports.G. Giuliano* (Siena, Italy), M. Sambo, P.
resistance and genotyping of Mycoplasma
Castellani, S. Benedetti, F. Tarantino, M. Tumbarello
genitalium positive samples of the Lisbon area,
PortugalM. Barros* (Lisbon, Portugal), F. Pereira, L.
Rodrigues
E0112 Antimicrobial Resistance in Mycoplasma
SY047
11:00
-
12:00
Hall 11
genitalium: Surveillance and Management in São 1-hour Symposium
Paulo, BrazilV. Passarelli* (São Paulo, Brazil), F.
Goldemberg, A. Freitas, C. Picone, C. Lazari, G. How long should contact isolation precautions be continued?
Carnevale, M. Thomazella, S. Chamarelli, D.
Chairs Cansu Cimen (Oldenburg, Germany)
Gennari, C. Pedrozo, G. Hughes, S. Costa
Kyriaki Tryfinopoulou (Heraklion, Greece)
E0113 Impact of genotypic substitutions on treatment
failure for Mycoplasma genitalium infectionN.B.
Bana* (Milan, Italy), A. Nava, D. Fanti, C. Vismara, G.
Cavazza, E. Di Gennaro, F. Peracchi, L. Rezzonico, A. S0141 11:00 Contact isolation in patients with MDR organisms:
Mulè, L. Denti, M. Puoti, R. Rossotti Why, when, where?Gabriel Birgand (Nantes, France)
E0114 Macrolide-resistant Mycoplasma genitalium: an S0142 11:30 Is discontinuation of contact precautions associated
emerging threat to public health?J. Ciscar Soriano* with an increase in infections?Daniel Diekema
(València, Spain), J. Ciscar-Soriano, M.D. Gómez- (Harpswell, United States)
Ruiz, A. Valentín-Martín, A. Hernández-Cabezas,
Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI),
J.L. Lopez-Hontangas
EUCIC Steering Committee, Multidisciplinary Joint Committee Infection
E0115 Comparison of carbapenem MIC in wild-type, MDR Control UEMS
and XDR Neisseria gonorrhoeae isolatesJ.
Brousseau* (Paris, France), A. Braille, M. Mainardis,
F. Meunier, M. Mérimèche, F. Caméléna, B. Berçot ME048 - Hall 12
11:00 12:00
E0116 Unsettling surge in antimicrobial resistance
patterns of Neisseria gonorrhoeae - A study from Meet-the-Expert
national reference centre in India.D. Sharma* (Delhi,
India), S. Muralidhar, N. Joshi Cut a long story short: choosing NGS platforms
E0117 Surveillance of Neisseria gonorrhoeae antimicrobial
resistance rate and treatment regimes in Singapore
from 2014 to 2024M. Giovanni* (Singapore,
M0143 11:00 Etienne Ruppe (Paris, France)
Singapore), A.L. Tan, B.K.W. Yeo, M.T.W. Chio, S.S.
Goh, S.T. Koh, Y.E. Tan M0144 11:12 Stefan Green (Chicago, United States)
E0118 Molecular surveillance results of N. gonorrhoeae in
KoreaK.H. Roh* (Goyang, Korea, Republic of), C.
Liu, Y.H. Suh, H. Lee, K. Lee OS011 11:00 - 12:00 Hall 13
1-hour Oral Session
KN044 11:00 - 12:00 Hall 1 Around the lab in 80 ways: a journey through innovative therapeutics
Keynote Lecture Chairs Zuzanna Drulis-Kawa (Wroclaw, Poland)
Helena Zemlickova (Prague, Czech Republic)
Asia: an AMR Hot Zone
Chairs Giulia De Angelis (Rome, Italy)
Robert Leo Skov (Copenhagen, Denmark) O0077 In vivo expression of an mRNA encoded multi-
mechanistic mAb combination against
Staphylococcus aureus and protection in a disease
modelC. Tkaczyk* (Gaithersburg, United States), N.
K0136 11:00 David L. Paterson (Singapore, Singapore)
Michael, P. Mun Mun, T. George, S. Martin, G. Adam,
M. Andal, D. Julie, S. Oleg, B. Elin, Y. Haitao, E. Mark,
L. Ashley, D. Antonio, S. Bret
OS010
11:00
-
12:00
Hall 10
O0078 Hijacking intrinsic resistance in Mycobacterium
1-hour Case Session abscessusG. Phelps* (Memphis, United States), S.
Kurt, A. Jenner, S. Anderson, T. Jayasinghe, E.
Antimicrobial drugs in action Griffith, C. Thompson, L. Yang, B. Wicki, F. Bright, L.
Boeck, V. Loudon, R. Lee, A. Wright, W. Wright, O.
Chairs Katy Jeannot (Besançon, France)
Grant-Chapman, J. Ochoado, D. Conner, B. Troyer, A.
Timothy R. Walsh (Oxford, United Kingdom)
Iverson, J.W. Rosch, B. Schulthess, P. Geeleher, S.
Hobbie, B. Meibohm, A. Obregon-Henao, P. Sander,
R. Lee
O0072 In vivo cefiderocol resistance due to cirA modification O0079 Tripartite bacteriophage-based strategy to combat
during treatmentE. Carretto* (Reggio Emilia, Italy), P. human clinical pathogensP. Kalatzis* (Copenhagen,
Pini, R. Farzana, C. Bedogni, R. Marrollo, P. Nardini, Denmark), R. Ibarra-Chávez, H. Sampson, S.
M. Bardaro, N.C. Facciolongo, S. Mezzadri, T. Walsh Michniewski, A. Shen, M. Ford, B. Petersen, P.
O0073 Long-term outcomes in dalbavancin-treated patients Worning, P. Klement, H.P. Calum, U.M. Singh, A.
with vascular graft infection.A. Specklin* (Reims, Millard, M. Clokie, T. Sicheritz-Pontén

ESCMID Global 2025 - Programme
O0080 Eosin Y and Ceragenin combinations for enhanced Martínez-Simón* (Barcelona, Spain), C. Ribera-Puig,
antimicrobial photodynamic therapyY. Tekintas* M. Bodro, D. Campany, J. Esperalba, I. Los Arcos, P.
(Cigli, Türkiye), P.B. Savage, M. Ucuncu Clèries-Rovira, A. Padullés, N. Sabé Fernández, M.
O0081 Identification of compounds capable of removing Tuset, O. Len
established bacterial biofilmsT. Inzana* (Brookville, O0090 Prediction of BK Polyomavirus nephropathy in kidney
United States), A. Gates, W. Weng, J. Cusumano, Y.J. transplantation by measuring neutralizing responses
Lee, N. Vogelaar in a large cohort of donor and recipientsM. Solis*
(Strasbourg, France), W. Fardi, I. Benotmane, F.
Gallais, S. Caillard, S. Fafi-Kremer
ME049 11:00 - 12:00 Hall 14 O0091 Dengue in solid organ transplant recipientsS.I.
Galian* (Buenos Aires, Argentina), N. Pujato, N.S.
Meet-the-Expert Nolis, R. Del Grosso, P. Lopez, G. Aballay, M. Agustin,
G. Werber
How to perform clinical trials in mycoses?
SY045 - Hall 2
11:00 12:00
M0145 11:00 Monica Slavin (Melbourne, Australia) 1-hour Symposium
M0146 11:12 Nkechi Azie (Barrington, United States)
What happens following TB infection?
Co-organised with: ESCMID Fungal Infection Study Group (EFISG)
Chairs Catherine Ong (Singapore, Singapore)
Sean Wasserman (London, United Kingdom)
OS012 - Hall 15
11:00 12:00
1-hour Oral Session
S0137 11:00 Post-TB disease: burden and treatment
strategiesDeborah Chong (London, United Kingdom)
Climate Impact and One Health Approaches Against Infectious Diseases
S0138 11:30 TB sequelae and fungal infectionHelmut Salzer (Linz,
Chair Chadia Wannous (Paris, France)
Austria)
Co-organised with: ESCMID Study Group for Mycobacterial Infections
(ESGMYC), CPAnet
O0082 Airborne Threats: Pollution, Climate, and Respiratory
Infections in a Pyrenean setting: The Andorran
hospital based respiratory perspectiveC. Royo- YIA - Hall 3
Cebrecos* (Andorra, Andorra), N. Duran Torralbo, D. 11:00 12:00
Vilanova Gonzalez, M. Clusas Antolin, L. Trapero Awards
O0083 Effects of climate change on Aedes aegypti
abundance and dengue transmissionL. Geng* Young Investigator Award Session
(Singapore, Singapore)
O0084 Impact of climate variables on Crimean-Congo
hemorrhagic fever in Iran, Iraq, Kazakhstan, and
RussiaM. Fereidouni* (Jahrom, Iran, Islamic Republic A001 11:00 Deciphering the pathogenic traits and
of), D. Bisanzio, I. Lizinfeld, N. Pshenichnaya, G. epidemiological identities of Staphylococcus
Abuova, M.R. Shirzadi, H. Abdulghafoor Khaleel, R. pseudintermedius: an emerging and underestimated
Alhilfi, M. Keshtkar-Jahromi zoonotic pathogenIkechukwu Benjamin Moses
(Abakaliki, Nigeria)
O0085 Successful public health and one health response to a
high pathogenicity avian influenza outbreak in poultry A002 11:12 Drugs for Vector-borne Infections: Facts and
farms in Victoria, Australia: implications for future FibrillationsXin Hui Chan (Oxford, United Kingdom)
planningE. Athan* (Geelong, Australia), A. Hussain, K. A003 11:24 Duke criteria for the diagnosis of infective
Blaney, L. Cardamone, N. Clarke, M. Hayes, M. endocarditis in clinical practice: are we there yet?
Muleme, B. Mcnamara, E. Jalil, S. Holwill, C.K. Lim, H. Matthaios Papadimitriou Olivgeris (Sion, Switzerland)
O'brien, E. Layton, A. Fidao, S. Salmon, R. Kinnear
A004 11:36 Finding a place for observational studies in infectious
O0086 Turning disease surveillance into reality: Using diseases researchAnthony Bai (Kingston, Canada)
metagenomic sequencing with piggery
A005 11:48 Clearing fungal fog in viral storms: deciphering
wastewaterM. Muralidhar* (St Lucia, Australia), L.
influenza- and COVID-19-associated pulmonary
Omaleki, M.N. Naseem, J.R.B. Mesa, C. Turni
aspergillosisSimon Feys (Leuven, Belgium)
OS013 11:00 - 12:00 Hall 16 SY046 11:00 - 12:00 Hall 5
1-hour Oral Session 1-hour Symposium
Viral challenges in organ transplantation New frontiers in bacterial pathogenesis
Chairs Ghady Haidar (Pittsburgh, United States) Chairs Silvio Daniel Brugger (Zurich, Switzerland)
Cristiana Oprea (Bucharest, Romania) Abdou Hachani (Melbourne, Australia)
O0087 Evaluation of an individualized CMV prevention S0139 11:00 Bacterial infections and cellular immunityCharlotte
strategy guided by post-transplant CMV-specific cell- Odendall (London, United Kingdom)
mediated immunity in intermediate-risk kidney
transplant recipientsI. Rodríguez-Goncer* (Madrid, S0140 11:20 Immuno-metabolism in bacterial diseasesTania Wong
Spain), J.M. Caso, M. Fernández-Ruiz, E. González, N. (New York, United States)
Polanco, N. Redondo, T. Ruiz-Merlo, R. San-Juan,
L.M. Allende, E. Paz-Artal, A. Andrés, F. López-
Medrano, J.M. Aguado, I. Rodríguez-Góncer OS007 11:00 - 12:00 Hall 6
O0088 Real-world Use of Letermovir Prophylaxis for
1-hour Oral Session
Cytomegalovirus (CMV) Prevention in Non-kidney
Transplant RecipientsA. Mughrabi* (Rochester,
New developements in prophylaxis and treatment of COVID-19
Minnesota, United States), B. Bisono-Garcia, S.
Chesdachai, N. Ranganath, R. Razonable Chairs Gülsen Özkaya Sahin (Lund, Sweden)
Snjezana Zidovec Lepej (Zagreb, Croatia)
O0089 Real-world administration of maribavir beyond the
eight weeks established in the clinical trialD.

ESCMID Global 2025 - Programme
O0057 Ensitrelvir for the prevention of COVID-19 among Corbacho-Loarte, S. De La Fuente-Herranz, J. Cobo
household contacts: key subgroup analyses of a Soriano, J. Urbano, M. Martín Martín, J.A. Pérez-
randomized, double-blinded, placebo controlled Molina
post-exposure prophylaxis study, SCORPIO-PEPF. O0069 Two cases of septic osteoarthritis of Cutibacterium
Hayden* (Virginia, United States), N. Ohmagari, acnes detected by 16S rRNA gene sequencing in
T.W. Clark, M. Shinkai, A.F. Luetkemeyer, P. Sax, immunocompetent adolescentsH. Okuno* (Osaka,
W.P. Hanage, K.A. Gebo, H. Ikematsu, K. Izumikawa, Japan), K. Shiota, K. Amo
C.C. Butler, A. Fukushi, S. Kezbor, H. Sakaguchi, S.
O0070 A UK case of Melioidosis with osteomyelitis two years
Lacey, G. Ichihashi, T. Uehara
after geographical exposureC. Darlow* (Liverpool,
O0058 Efficacy of nirmatrelvir/ritonavir on overall COVID- United Kingdom), L. Swithenbank, R. Taggart, V.
19 related symptoms in immunocompromised adult Owen, N. Wong, S. Woolley, W.D. Harrison, L.
participants from the EPIC-IC trialR. Mokgokong* Ratcliffe, J. Lewis
(Tadworth, United Kingdom), P. Cislo, E. Tudone, E. O0071 When Infection Masquerades as Malignancy: A Case
Weinstein, J.C. Cappelleri of Disseminated Mycobacterium fortuitum complex
O0059 COVID-19 patients benefitting from remdesivir for infection with Mixed Osteoblastic and Osteolytic
improved survival: a neural network-based Lesions and Lymphadenopathy in Anti-IFN-￿
approach.T.F. Aiello* (Barcelona, Spain), C. Teijón- Immunodeficiency SyndromeN. Hiranburana*
Lumbreras, C. Garcia-Vidal, M. Chumbita, M. (Bangkok, Thailand), S. Khahakaew, K.
Rosario, A. Mateu Subirà, O. Peyrony, P. Monzó- Meesilpavikkai, M. Satja, G. Suwanpimolkul
Gallo, A. Gallardo-Pizarro, A. Martinez-Urrea, R.
Méndez, E. Calbo, M. Ballestero-Tellez, G. Cuesta-
Chasco, M. Marcos, A. Soriano LB001 - Hall 9
11:00 12:00
O0060 Efficacy and safety of sotrovimab vs oral antivirals
in omicron waves: a retrospective analysisC. 1-hour Oral Session
Cacace* (Napoli, Italy), A. Russo, M. Pisaturo, P. Advances in vaccine effectiveness for viral respiratory infections
Grimaldi, F. Ambrisi, G. Granata, F.G. Numis, N.
Chair Jean Paul Stahl (Corenc, France)
Coppola
O0061 Pharmacokinetics and immunogenicity of AZD7442
(Tixagevimab/Cilgavimab) in hospitalised COVID-19
patients: results from the DisCoVeRy trialC. L0001 Immunogenicity of JN.1- and KP.2-encoding mRNA
Massonnaud* (Paris, France), M. Hites, N. Peiffer- COVID-19 vaccines against JN.1 SARS-CoV-2
Smadja, T.H.L. Han, G. Carcelain, F. Mentré, F. Ader sublineages in adult participantsA. Figueroa*
(Cambridge, United States), D. Edwards, K. Johnson,
D. Motefiori, B. Girard, S. Hack, X. Cao, E. De Windt
OS008 - Hall 7 L0002 JN.1-adapted vaccine effectiveness against COVID-19
11:00 12:00
hospitalisation in Europe: a test-negative case-control
1-hour Oral Session study using id.DRIVEH.R. Volkman* (New York,
United States), L. De Munter, J.L. Nguyen, T.M.P.
Advancing Malaria Research: From Molecular Insights to Clinical Challenges Tran, C. Marques, E. Mesfun-Kap, L. Choi, L. Drikite,
Chairs Kamruddin Ahmed (Kota Kinabalu, Malaysia) S. Valluri, J.V. Hernandez-Villena, J. Yang, I. Casas, E.
Giri Shan Rajahram (Kota Kinabalu, Malaysia) Martro, B. Gruner, G. Icardi, A. Mira-Iglesias, C.M.
Oñoro López, O. Pares-Badell, A. Orrico-Sanchez, S.
Otero-Romero, A. Riva, A. Torres, F. Martinon Torres,
L. Jodar, J.M. Mclaughlin, K. Bollaerts
O0062 Influence of second blood meals on Plasmodium
L0003 Real-world effectiveness of 20-valent pneumococcal
vivax development and infectivity in mosquitoesS.
conjugate vaccine among adults ≥65 years of age in
Bantuchai* (Bangkok, Thailand), W. Nguitragool, J.
the United StatesA. Miles* (New York, United States),
Sattabongkot, C. Kumpitak
J.T. Vietri, S. Rosenstock, H. Li, J. Vojicic, L.R. Grant,
O0064 Severe imported Plasmodium falciparum malaria with A. Randall, B.D. Gessner, P. Balmer, A. Cane, P.
hyperparasitaemia: evaluation of predictors for Peyrani
critical diseaseT. Lingscheid* (Berlin, Germany), J.
L0004 Safety and immunogenicity of the MERS vaccine,
Jochum, P. Tober-Lau, J. Schöllgen, T. Zoller, L.E.
ChAdOx1 MERS, in older adults with and without prior
Sander, M. Ramharter, F. Kurth
ChAdOx1 exposureD. Jenkin* (Oxford, United
O0065 The current status of Plasmodium falciparum Kingdom), E. Sheehan, R. Huq, T. Lambe, S. Gilbert,
chloroquine resistance transporter gene (K76T) and A.M. Collins, M.N. Ramasamy, A. Mujati, R. Kenneil,
Plasmodium falciparum multi-drug resistance gene 1 N. Marchevsky, I. Haeusler, E. Vannaxay, N. Ebrahimi,
(N86Y) in CameroonM. Fru* (Buea, Cameroon) S. Batawi, F. Cappuccini, R. White, L.S. Ortega, O.
O0066 SOFA score vs WHO severity criteria to guide Mazur, H.T. Belhadef, B. Stoilova, D. Pulido-Gomez, H.
antimalarial treatment - 10 years of imported malaria Zhang, K. Conlin, M. Voysey, A. Hyder-Wright, L.
cases in a UK tertiary centre reviewed.E. Savory* Mclellan, O. Hamilton, V. Simpson, J. Court, N.
(Cambridge, United Kingdom), M. Routledge, B. Murphy, M. Farrar, P. Saunderson
Warne, E. Moore, D. Sparkes L0005 Vaccination in pregnancy with RSVpreF elicits IgG,
IgA and total secretory antibody responses in milk of
lactating individualsJ. Atwell* (New York, United
OS009 - Hall 8 States), R. Powell, X. Yang, C. Decarlo, A. Fox, R. Fan,
11:00 12:00
S. Uppal, J. Deese, M. Vichnin, E. Gonzalez, B.
1-hour Case Session Gessner
Osteoarticular uninvited guests
Chairs Tiziana Ascione (Naples, Italy) SY051 13:30 - 14:30 Hall 1
Jaime Esteban (Madrid, Spain)
1-hour Symposium
Year in infectious diseases
O0067 Antibiotic-refractory oligoarthritis in an adolescent Chairs Nur Benzonana (Istanbul, Türkiye)
caused by Borrelia bavariensis in CroatiaN. Krajcar* Evelina Tacconelli (Verona, Italy)
(Zagreb, Croatia), L. Stemberger Marić, M. Vrdoljak
Pažur, S. Roglić, R. Beck, G. Tešović
O0068 Progression of vertebral echinococcosis despite
radiotherapy treatmentM. González-Sanz* (Madrid, S0151 13:30 Yoav Keynan (Winnipeg, Canada)
Spain), O. Martín, A. Romero-Alegría, M. Belhassen, S0152 14:00 Elisa Cordero Matia (Seville, Spain)
S. Chamorro Tojeiro, D. Gayoso Cantero, F. Norman,
B. Monge Maillo, C. Crespillo-Andújar, M.D.

ESCMID Global 2025 - Programme
SY053 - Hall 16 hematopoietic cell transplant (HCT) recipients
13:30 14:30
receiving meropenem (MER) or
1-hour Symposium piperacillin/tazobactam (P/T)E. Dubberke* (Saint
Louis, United States), M. Schroeder, H. Sappington,
Developing guidelines with AI tools: are they ready for prime time? G. Lampen, K. Reske, T. Hink, V. Joachimstaler, E.
Chairs Miranda Langendam (Amsterdam, Netherlands) Jeremy, M. Keller, A. Bristol, C. Le, S. Connelly, M.
Blin Nagavci (Gjakove, Kosovo) Moenk, V. Wacher, M. Kaleko, J. Kuti, M. Olsen
E0146 Standardized gastrointestinal cytomegalovirus
(CMV) tissue quantitative-nucleic-acid testing
(QNAT) compared to immunohistochemistry in
S0155 13:30 The PROs and CONs of using AI tools for developing allogeneic hematopoietic cell transplant (HCT)
guidelinesHolger Schuenemann (Milano, Italy) recipientsS. De Aragón De La Cruz* (Basel,
S0156 14:00 AI in action: validated tools for speeding up your Switzerland), C.S. Walti, N. Khanna, K. Leuzinger,
systematic reviews and how to use themSara J.P. Halter, H.H. Hirsch, K. Nägele, J. Passweg, J.
Fernandez (Oslo, Norway) Vosbeck
Co-organised with: ESCMID Guidelines Subcommittee E0147 Real-life experience with maribavir for the
treatment of cytomegalovirus infection in
hematological patients.J. Boan Perez* (Madrid,
SY052 - Hall 2 Spain), J.M. Sánchez-Pina, C. Aizpurúa, I.
13:30 14:30 Rodríguez-Goncer, F. López-Medrano, R. San-Juan,
1-hour Symposium M. Fernández-Ruiz, E. Aparicio, M. Lizasoaín, J.M.
Caro-Teller, J. Martínez, M. Calbacho, J.M. Aguado
Exploring children's role in infection spread
Chairs Angelika Berger
Sanjay Patel (Winchester, United Kingdom) EF022 13:30 - 14:30 Arena 2
ePoster Flash Session
S0153 13:30 Are children really super-spreaders of respiratory Syndromic testing is still coming of age
viruses?Emmanuel André (Leuven, Belgium) Chair Tommaso Giani (Florence, Italy)
S0154 14:00 Should schools be closed at the start of the next
pandemic?Vittoria Colizza (Paris, France)
Co-organised with: European Society of Paedriatic Infectious Diseases E0148 Bacterial infections of the central nervous system:
(ESPID) addressing the diagnostic gap in non- community-
acquired meningitisG. Menchinelli* (Rome, Italy), M.
Cacaci, D. Squitieri, B. Fiori, T. D'inzeo, G. De Angelis,
EF021 - Arena 1 B. Posteraro, M. Sanguinetti
13:30 14:30
E0149 Epidemiological surveillance of central nervous
ePoster Flash Session
system infections through a rapid syndromic testing
platformM. Rey* (Barcelona, Spain), L. Pau, C.
Infections in hemato-oncological hosts: from bacterial to viral
Miravet, A. Molins, G. Hansen, M. Juanola-Falgarona
Chair Genovefa Papanicolaou (New York, United States)
E0150 Impact of Syndromic Panel Implementation on
Meningitis/Encephalitis Diagnosis, Antimicrobial Use,
Costs, and Hospital Stay in a Regional Australian
E0139 Vancomycin-resistant Enterococcus faecium HospitalS. Subedi* (Brisbane, Australia), P. Harris, D.
bloodstream infection in patients with Paterson
hematological malignancy and stem cell transplant: E0151 Performance evaluation of the NxTAG® GPP Panel
a case-control studyJ. Fung* (Vancouver, Canada), for the detection of gastrointestinal pathogens by
K. Aldhaheri, C. Nishi, J. Lau, A. Mah, A. Wright, R. comparison with current routine methods in Nantes
Stubbins, M. Charles, S. Belga University Hospital.S. Gibaud* (Nantes, France), L.
E0140 Bacteremia secondary to urinary tract infection in Castain, S. Hartuis, C. Hervochon, B.M. Imbert, P.
oncology patients: risk factors and impact of Lepape, S. Corvec
multidrug-resistant Gram-negative bacilli.I. Grafia* E0152 Correct discrimination of Monkeypox virus clades by
(Barcelona, Spain), A. Moll, S.J. Santillá, C. Rodrigo, fast syndromic testingS. Reister* (Hilden, Germany),
E. Lillo, M. Garcia De Herreros, N. López, A. Soriano, L. Peñarrubia, M. Juanola-Falgarona, G. Pueyo, S.
M. Espasa, D. Marco, S. Fernández, J. Marco- Jiménez-Guzmán, R. Diaz-Hernández, E. Padilla-
Hernández, C. Zamora, J. Padrosa, L. Llavata, M. Cámara, J. Michel, A. Puyskens, F. Van Deursen, D.
Viladot, A. Tuca, P. Puerta-Alcalde Lueerssen
E0141 Rectal carriage of multidrug-resistant organisms E0153 Managing a Mycoplasma pneumoniae Outbreak:
and subsequent bloodstream infections in Impact of Syndromic Panels on Antimicrobial
hematologic patients undergoing hematopoietic Prescriptions in Pediatric EmergenciesL. Brusca*
stem cell transplantation or chimeric antigen (Barcelona, Spain), L. Brusca-Vidao, M. Pallarés-
receptor T-cell therapyC. Charalampidis* (Athens, Borrás, G. Santillana-Cernuda, M. Ballestero-Tellez,
Greece), I. Konstantellos, P. Kazakou, K. Gkirkas, I. A. Boronat, J. Perez
Lazana, C. Chatzidimitriou, A. Zormpa, E.
E0154 Performance of BIOFIRE® FILMARRAY® Pneumonia
Mastrostamati, I. Grigoropoulos, D. Kavatha, S.
plus in general population, solid organ transplant
Tsiodras, P. Tsirigotis, K. Thomas
recipients and patients with hematologic
E0143 The RUSTIC Study: Respiratory Virus Infection in a malignancies – Interim analysisR. Riccardi* (Bologna,
Contemporary Longitudinal Cohort of Patients with Italy), M. Rinaldi, G. Ceccarelli, C. Campoli, C. Tondi,
Haematological MalignancyB. Teh* (Melbourne, M. Casarini, B. Miani, G. Nigrisoli, S. Ambretti, P.
Australia), V.G. Hall, A. Liu, K.Y. Yong, Z. Andrews, Viale, M. Giannella
P. Kinsella, N. Laundy, J. Wolfe, L. Cooley, M.K.
E0155 Impact of the molecular rapid diagnostic panel
Yong, M.A. Slavin
testing in adjustment of antimicrobial therapy in
E0144 Viral respiratory infections in patients with febrile neutropenic patients with bacteremiaS.
hematological diseases over 10 years: epidemiology Chantharasut* (Bangkok, Thailand), M.
and impact on disease severityP. Bono* (Milan, Chayakulkeeree, W. Kamolvit, A. Jitmuang, I.
Italy), A. Parisi, E. Tagliaferri, R. Ungaro, G. Saporiti, Thaipisuttikul
F. Cavallaro, G. Bozzi, M.C. Goldaniga, G. Galli, N.
E0156 BacteREVEAL: Analytical performance and
Hejazifar, C. Biassoni, G. Giacomel, A. Valzano, M.R.
contribution of BioFire® BCID2 and Vitek®
Sciumè, N. Fracchiolla, A. Bandera, F. Passamonti,
REVEALTM in intensive care patients with Gram-
A. Callegaro, C. Alteri
negative bloodstream infectionsC. Roger* (Nimes,
E0145 Safety and tolerability of SYN-004 in allogeneic
France), L. Oudiane, M. Benyahia, F. Salipante, A.

ESCMID Global 2025 - Programme
Dubois, L. Muller, J.P. Lavigne, A. Pantel
E0166 Gfa, a novel integron-born fosfomycin resistance
mechanismN. Kieffer* (Madrid, Spain), L. Ortiz-
Miravalles, A. Hipolito, J.A. Escudero
EF023 - Arena 3
13:30 14:30
E0167 Regulons of RamA, RarA and SoxS mediated
ePoster Flash Session tigecycline resistance and oxidative stress among in
vitro tigecycline resistant evolution trajectory of
Effective microbiology for the management of sepsis Klebsiella pneumoniae.X. Wang* (Beijing, China), J.
Chair Maurizio Sanguinetti (Rome, Italy) Kuai, Y. Zhao
E0168 Assessing the impact of altered penicillin binding
proteins on susceptibility to novel antimicrobials
among clinical isolates of carbapenemase-producing
E0157 Molecular epidemiology of Klebsiella bloodstream Escherichia colC. Tellapragada* (Stockholm,
infection-causing isolates across England using Sweden), P. Jonsson, C. Giske
Nanopore longread-only sequencing: An interim
E0170 Enterococcus faecalis penicillin-binding protein-4
analysis of the NEKSUS studyD. Nagy* (Oxford,
sequence differences based on penicillin minimum
United Kingdom), N. Stoesser, S. Lipworth, V.
inhibitory concentrationO. Funk* (Brooklyn, United
Pennetta, K. Hopkins, G. Rodger, R. Moran, C. Jones,
States), A. Kozlenkov, C. Toro Chacon, J. Azzouzi, S.
T. Neksus Study Group, S. Hopkins, D. Crook, A.S.
Brown, J. Cusumano
Walker, J. Robotham, K.L. Hopkins, A. Ledda, D.
Williams, R. Hope, C.S. Brown E0171 Uncommon genomic rearrangements drive
vancomycin resistance in vanB-positive
E0158 Investigating seasonality of antibiotic resistance
Enterococcus faeciumK. Xanthopoulou* (Cologne,
associated with E. coli and Klebsiella pneumoniae
Germany), J. Mellüh, R. Arazo Del Pino, L.
bloodstream infectionsS. Lipworth* (Oxford, United
Casselmann, V. Persy, T. Burgwinkel, E. Gieraths, L.
Kingdom), L. Gorman, A. Dowsey, K. Pouwels, K.
Maus, A. Klimka, P.G. Higgins
Sanderson, C. Beck, R. Hope, C. Brown, K. Turner
E0172 Heteroresistance in Enterococcus faecalis:
E0159 Sensitivity of a host-protein test for microbiologically
prevalence and mechanistic insights across clinically
confirmed bacterial infectionsR. Navon* (Tirat
relevant antibioticsS. Heidarian* (Uppsala, Sweden),
Carmel, Israel), E. Reiner, O. Shaham, A. Neuberger,
S. Lohsen, A. Guliaev, K. Hjort, S. Satola, D. I.
S. Shiber, S. Halabi, A. Epstein, T. Zalut, S. Motov, T.P.
Andersson
Aufderheide
E0173 Side effects of rifampicin resistance: transcriptome
E0160 Comparative genomics of Klebsiella pneumoniae
modulation by rpoB mutations in Staphylococcus
from gut colonisation and bloodstream infections
aureusM. Roch* (Geneva, Switzerland), R. Sierra, C.
reveal novel genetic associationsM. Hetland*
Colomer Winter, F. Bezrukov, O. Panasenko, A.
(Stavanger, Norway), K.L. Wyres, H.B. Cooper, A.
Guisolon, U. Von Ah, M. Villanueva, P. Redder, K.
Correia, M.A. Winkler, A. Fostervold, N. Raffelsberger,
Kline, J. Prados, W.L. Kelley
A. Sundsfjord, Ø. Samuelsen, K.E. Holt, I.H. Löhr
E0174 Novel continuous experimental evolution
E0161 Conventional microbiology vs. conventional
methodology revealing rapid resistance development
microbiology + nucleic acid-based multiplex real-time
and cross-resistanceT. Echelmeyer* (Greifswald,
polymerase chain reaction (MPCR) test kit in septic
Germany), M. Ellmann, S.E. Heiden, M. Schwabe, H.
shock: results of a matched cohort studyG. Sanlidag
Fickenscher, G. Maschkowitz, D. Nurjadi, R.
Isbilen* (Izmir, Türkiye), G. Şanlıdağ İşbi̇len, B. Akkul,
Podschun, K. Schaufler, E. Eger
C. Tol, D. Akyol Seyhan, H. Sipahi, Ş. Aydemir, F. Çilli,
B. Arda, O.R. Sipahi
E0162 Contribution of Escherichia coli microbiological
OS018 - Hall 11
factors to the presentation as sepsis/septic shock in 13:30 14:30
patients with bacteraemia: a matched case-control 1-hour Oral Session
studyN. Maldonado* (Seville, Spain), I. López-
Hernández, L.E. López-Cortes, P.M. Martínez Pérez- Battling the Spore: C. difficile epidemiology and management
Crespo, A. García-Montaner, M. Alcade-Rico, A.
Chairs Nicolas Benech (Lyon, France)
Sousa-Dominguez, A. Jover-Sáenz, J. Goikoetxea, Á.
Fidelma Fitzpatrick (Dublin, Ireland)
Pulido-Navazo, C. Labayru Echeverría, A.I. Aller-
García, L. Boix-Palop, A. Del Arco-Jiménez, A.
Smithson-Amat, J.M. Sánchez-Calvo, C. Natera-
Kindelán, J.M. Reguera Iglesias, C. Armiñanzas-
O0124 Molecular epidemiology and antimicrobial resistome
Castillo, F. Galán-Sánchez, A. Bahamonde, I. Gea-
of Clostridioides difficile from private and public
Lázaro, J. Fernández-Suárez, I. Pérez-Camacho, T.
healthcare settings in three provinces in South
Marrodán-Ciordia, B. Becerril-Carral, Á. Pascual-
AfricaH. Shirinda* (Pretoria, South Africa), A.M.
Hernández, J. Rodríguez-Baño
Smith, B. Prinsloo, M. Kock, M. Moodley, M. Said, M.
E0163 Simplified and rapid bacterial identification with Ehlers
antimicrobial resistance detection in bacteremia by
O0125 Screening for Clostridioides difficile colonization at
on-chip multiplexed LAMP.C. Treille* (Saclay,
admission and during hospitalizationN. Khanafer*
France), K. Perez-Toralla, H. Boutal, X. Garcia
(Lyon, France), S. Bennia, G. Martin-Gaujard, L.
Velasquez, L. Pommies, S. Simon, H. Volland
Juillard, T. Rimmelé, L. Argaud, P. Cassier, O. Martin,
E0164 Community-onset bloodstream infection among P. Vanhems
people with opioid use disorders: A twenty-year
O0126 Revolutionizing CDI treatment: Are shorter antibiotic
population-based cohort study in Queensland,
regimens the futureM. Duricek* (Prague, Czech
Australia.K. Laupland* (Herston, Australia), A.
Republic), J. Benes, K. Halmova
Stewart, F. Edwards, P. Harris, S. Coulter
O0127 Extended-pulsed fidaxomicin versus conventional
E0165 Microbiological diagnosis tools for primary and
dosing in patients at high risk of recurrence of
secondary abdominal aortic infections requiring
Clostridioides difficile infectionE. Rubio-Martín*
surgeryS. Soueges* (Lyon, France), A. Blanco, A.
(Seville, Spain), R. Escudero-Sánchez, Á. Gutiérrez
Souche, C. Triffault-Fillit, M. Arsicot, M. Wan, N. Della-
Liarte, A. Ibañez Zurriaga, C. Saez Bejar, B. Díaz
Schiava, U. Huvelle, A. Millon, F. Valour
Pollán, C. Marcelo Calvo, G. Ruiz Carrasco, G. Pérez
Caballero, A.M. Rodríguez Benavente, S. De La Villa,
J.D. Ruiz-Mesa, L.F. Caballero Martínez, I. Márquez
EF024 13:30 - 14:30 Arena 4 Gómez, E. Calabuig, M. Tasias, R. Blanes, M.Á. López
Zúñiga, J. Rodríguez Granger, P. Merino Amador, A.
ePoster Flash Session Salinas, D. Rodríguez-Pardo, M. Villamarín Merlo, G.
Maestro De La Calle, J. Mateo Flores, J.B. Pérez
A never-ending evolution of antimicrobial resistance
Gilaberte, R.M. Martínez Álvarez, F. Martínez García,
Chair Antonio Oliver (Palma De Mallorca, Spain) N. Cobos-Trigueros, J. Llenas-García, M. Solivella-
Rodríguez, L. Ramos Merino, B. Castelo López, M.M.

ESCMID Global 2025 - Programme
Montero, D. Echeverría-Esnal, J. López-Contreras, P. O0136 Utilizing a weighted-incidence syndromic
Duch Llorach, M.R. Oltra-Sempere, C. Pinto-Pla, Í. antibiogram to evaluate antimicrobial therapies and
Pineda, J.L. Del Pozo, J. Rodríguez-Baño, A. Halperin, resistance trends in community-acquired infections
A. Muriel García, S. Moreno Guillén, J. Cobo in a community teaching hospitalV. Huang*
O0128 Gut phageome profiling in Clostridioides difficile (Glendale, United States), T. Pham, A. Vogler, H.
infection and faecal microbiota transplantationC. Chhen, C. Vandenberg
Chen* (Lausanne, Switzerland), T. Pillonel, J. Schaer, O0137 Capturing days of therapy per days of service as a
G. Greub, G. Resch, B. Guery, C. Bertelli, T. Galpérine stewardship tool to identify outliers in prescribing
broad-spectrum antimicrobials in the hospital
settingA. Hopkins* (Livingston, United States), A.
OS019 - Hall 12 Farkas, S. Tamirisa, G. Severance, A. Yassin, E. Jaime
13:30 14:30
O0138 Timing of Novel ￿-Lactams vs. Alternatives in
1-hour Oral Session Hospitalized Patients with Gram-Negative Infections:
Line of Therapy (LoT) Analysis Preliminary findingsE.
Microbiome Dynamics and Health: From Pathogenesis to Therapeutic Yucel* (Rahway, United States), J. Min, Y. Wang, M.
Potential Vendetti, Y. Emre, R.K. Shields
Chairs Mauricio Farfan (Santiago, Chile)
Eija Inkeri Könönen (Turku, Finland)
ME054 - Hall 3
13:30 14:30
Meet-the-Expert
O0129 Multi-omics integrated analysis revealed the key role
of Fusobacterium periodonticum in colorectal How antimicrobial tolerance impacts polymicrobial biofilm-associated
tumorigenesis by decanoic acid promoting neutrophil infections
chemotaxis.X. Chu* (Beijing, China), Q. Yang
O0130 Exploring the respiratory microbiome in COPD
patients: The role of Haemophilus spp. in disease
pathogenesisP. Camps-Massa* (Barcelona, Spain), L. M0157 13:30 Hans Steenackers (Leuven, Belgium)
Saiz-Escobedo, J. Guerrero, E. Cuevas, D. Guevara- M0158 13:42 Brian Conlon (Chapel Hill, United States)
Nuñez, F. Tubau, J. Burgos, M. Lopez, A. González-
Díaz, C. Ardanuy, M. Dominguez, S. Santos, S. Martí
O0131 Using the in vitro MiGut system to simulate the OS017 - Hall 5
13:30 14:30
ulcerative colitis microbiome and post-antibiotic
recovery supported by a pre-defined consortium of 1-hour Case Session
microbesI. Moura* (Leeds, United Kingdom), W.
Davis Birch, N. Beauchemin, M. Vulic, K. Bentley, P. Bad bacteria
Culmer, M. Mayol, C. Ford, M. Henn, E. Halvorsen, M.
Chairs Maristela P. Freire (Sao Paulo, Brazil)
Wilcox, N. Kapur, A. Buckley
Siegbert Rieg (Freiburg, Germany)
O0132 Functional characterization of the Brazilian Yanomami
microbiome along an urbanization gradient: Insights
into the impacts of Westernization on human
healthM. Thorp* (Gent, Belgium), C. Callewaert, B. De O0119 Vancomycin Dependent Enterococci: An evolutionary
Pessemier, D. Good, E. Allen-Vercoe, L. Paulino, L. dead end or the ultimate evolution of a superbugR.
Vereecke Gupta (bagga)* (London, Canada), R. Gupta, A.
Cabrera, A. Kanyua, F. Almutawa, J. Delport, K.
O0133 Colonization resistance of the intestinal microbiota to
Kavanoor Sridhar
multidrug-resistant bacteria?K. Villageois-Tran*
(Bobigny, France), C. Emavivie, H. Skerdi, E.N. Saad, O0120 Whipple's disease: one of medicine's great
M. Julie, E. Ruppé imitatorsS. Kesavan* (Nottingham, United Kingdom),
F. Heard, S. Kesevan, E. Hart, V. Fleming, C. Santos,
R. Thomson
ME055 - Hall 14 O0121 Phage Therapy as a Rescue Treatment for Recurrent
13:30 14:30
Pseudomonas aeruginosa Bentall InfectionV.
Meet-the-Expert Eiferman* (Paris, France), P.A. Vion, B. Rached, C.
Granger, N. Hammoudi, A. Bleibtreu
Long acting injectables to treat and prevent infections: an example from HIV
O0122 A clinical case of Legionella longbeachae pneumonia
field
featuring unique epidemiological features in a major
italian hospitalS. Guerriero* (Rome, Italy), M. La
Sorda, F. De Maio, S. Cardinali, M. Di Donato, P. Del
Vecchio, C. Tarli, M. Fantoni, R. Murri, M. Sanguinetti,
M0159 13:30 Monica Gandhi (Salt Lake City, United States)
C. Torti
M0160 13:42 Pedro Cahn (Buenos Aires, Argentina)
O0123 Francisella tularensis – First autochthonous case in
the UKG. Vanstone* (Truro, United Kingdom), A.
Belfield, L. Vincent, V. Perks, D. Wadham, B. Marques
OS020 13:30 - 14:30 Hall 15 Silva, A. Evans, O. Lloyd, N.C. Gordon, C. Arumugam,
A. Ainarozidou
1-hour Oral Session
How to evaluate AMS programs
ME061 - Hall 3
14:45 15:45
Chairs Esther Calbo (Terrassa, Spain)
Sabiha Essack (Durban, South Africa) Meet-the-Expert
How to use large language models and machine learning for improving One
Health
O0134 Preference-based instrumental variables for
estimating the causal effects of antibiotic prescribing
decisions in common infections: Assessing potential
validity using CPRD dataN. Nguyen* (Oxford, United M0170 14:45 Javier Fernández (Oviedo, Spain)
Kingdom), K. Pouwels, J.V. Robotham, S. Yu, S.
Wordsworth M0171 14:57 Nicolas Radomski (Teramo, Italy)
O0135 Novel antibiotic spectrum metrics to quantify the Co-organised with: ESCMID Food- and Water-borne Infections Study Group
impact of antimicrobial stewardship: a multicentre (EFWISG), ESCMID Study Group for Epidemiological Markers (ESGEM),
studyB. Moshy* (London, United Kingdom), R. Portuguese Society of Microbiology (SPM)
Llewellyn, R. Lester, G. Pollara, T. Samuels, J. Sarah,
B. Gemma, I. Balakrishnan

ESCMID Global 2025 - Programme
FO063 - Arena 1 E0204 Clinical characteristics and outcome of Herpes
14:45 15:45
simplex virus type 1 and varicella zoster virus
Open Forum encephalitis: A prospective population-based
cohort studyL. Duerlund* (Aarhus, Denmark), L.
Science communication in a noisy world: podcasting and social media in Larsen, M. Storgaard, H. Mens, L. Weise, M.P.G.
ID/CM Jepsen, B.R. Hansen, H.R. Von Lüttichau, C.Ø.
Chair Emily G. Mcdonald (Montreal, Canada) Andersen, H. Nielsen, J. Bodilsen
E0205 Arbovirus associated neurological disease in adults
and children in Brazil: a multicentre case-control
studyS. Lant* (Liverpool, United Kingdom), R.
F0174 14:45 The ID:IOTS guide to creating a successful CM/ID Mehta, M.L. Brito Ferreira, C. Soares, R. Medialdea
podcast"Callum Mutch (Edinburgh, United Kingdom) Carrera, M. Tulius, P. Brasil, C. Miguelote, A.
F0175 14:55 Using social media for CM/ID educationScott Jake Henriques Souza, M. Ellul, M. Griffiths, M.M. Jardim
(Oakland, United States) Rodrigues, R. Braga, L. Pamplona, C. Spitz, F.
Militao, A. Rosala Hallas, G. Burnside, R. Vivancos,
F0176 15:05 Podcasting and social media for antimicrobial
S. Leonhard, L. Rodrigues De Mendonça-Vieira, B.
stewardship and pharmacyErin Mccreary
Jacobs, C. Brito, P. Sequiera, D. Brown, L. Turtle, R.
(Pittsburgh, United States)
Franca, A. Bispo, T. Solomon
Co-organised with: CMI Communications Board of Editors
E0206 Challenges in managing Central nervous system
infections: Battling the Unknown Enemy, West Nile
virus vs unknown etiologyC. Marin* (Bucharest,
EF029 14:45 - 15:45 Arena 2 Romania), A. Paun, E. Nedu, S. Tetradov, S. Lazar,
M. Nica, G. Tardei, I.A. Condurache, S.A. Florescu,
ePoster Flash Session
S.M. Ruta, C.P. Popescu
Vaccination uptake-challenges and opportunities E0207 Spatial and temporal profiling of the immune
responses induced by Japanese encephalitis virus
Chair Joanne M. Langley (Halifax, Canada)
in a mouse modelZ. Ou* (Shenzhen, China), Z.
Wang, Q. Chen, X. He, P. Ren, J. Li, G. Cheng
E0208 Intrathecal immunoglobulin synthesis in tick-borne
E0195 Electronic nudges to increase influenza vaccination encephalitisS. Grygorczuk* (Bialystok, Poland), P.
uptake among patients with heart failure: insights Czupryna, D. Martonik, J. Dunaj-Małyszko, J.
from 3 nationwide randomized trials enrolling >2 Adamczuk, A. Parfieniuk-Kowerda, J. Osada, A.
million patientsN.D. Johansen* (Hellerup, Denmark), Moniuszko-Malinowska
M. Vaduganathan, A.S. Bhatt, D. Modin, B.L. Claggett,
E0209 B and T cell responses to Tick-borne Encephalitis
K.H. Janstrup, C.S. Larsen, L. Larsen, L. Wiese, M.
VirusN. Mayola Danes* (Stockholm, Sweden), R.
Dalager-Pedersen, E.L. Dueger, S. Samson, M.M.
Varnaitė, N. Mayola Danés, K. Blom, H.G. Ljunggren,
Loiacono, R.C. Harris, L. Køber, S.D. Solomon, P.
S. Gredmark-Russ
Sivapalan, J.U.S. Jensen, T. Biering-Sørensen
E0210 Enterovirus infections in pediatric central nervous
E0196 Psychological Predictors of Influenza Vaccination
system (CNS) diseases: molecular epidemiology
Intent Among Healthcare Workers in BulgariaP.
and neuroimaging insightsD. Sharma* (Chandigarh,
Velikov* (Sofia, Bulgaria), V. Rangelova, Y. Axentieva,
India), R. Pathania, P. Bhattacharya, M. Gautam, A.
Y. Tcholakov, V. Borisova-Nenov￿, D. Ivanov, A.
Bansal, S. Vyas, A. Ghosh, K. Goyal, M. P Singh
Zasheva, A. Hori
E0211 Neuroimaging findings and their correlation with
E0197 Determinants of COVID-19 vaccine uptake in patients
autopsy findings: Prospective study on Rabies
with hematologic malignancies: a nationwide cohort
encephalitisM. Mohata* (New Delhi, India), V. Suri,
studyQ. Hofsink* (Amsterdam, Netherlands), T.
P. Singh, G.K. Mohi, A. Bhalla, R. Mohindra, R.K.
Osmenaj, B.I. Lissenberg-Witte, S. Hahné, J.
Soni, K. Gupta
Heijmans, I.S. Nijhof, A. Goorhuis, M.D. Hazenberg,
C.E. Rutten, S. Haggenburg, P. Den Tex, A. E0212 Toxoplasma gondii IgG Screening and Central
Dinmohamed, J. Kemmeren, H. De Melker, S. Van Nervous System Complications among People with
Den Hof HIV in the Combination Antiretroviral Therapy EraT.
Ou* (New Taipei City, Taiwan, China), T.Y. Tsai, S.H.
E0199 Inequality in vaccine uptake among children in
Huang, T.Y. Wu, W.D. Liu, H.Y. Sun, K.Y. Lin, C.C.
Denmark in the national childhood vaccination
Hung
programmeA.C.M. Breschel* (Copenhagen,
Denmark), A.V. Søndergaard, S.K. Nørgaard, B.
Søborg, P.H. Andersend
E0200 Prevalence and associated factors of parental refusal
EF031
14:45
-
15:45
Arena 4
rates for routine immunisation: A cross-sectional ePoster Flash Session
study in Peshawar, Khyber Pakhtunkhwa, Pakistan-
2024M. Hakim* (Hayat Abad Peshawar Kp Pakistan, AMS around the world: know your data!
Pakistan)
Chair Eoghan De Barra (Dublin, Ireland)
E0201 Shingles Prevalence, Vaccine Awareness, and
Acceptance in People Living with HIVD. Yaman*
(Izmir, Türkiye), D. Akdağ, M. Taşbakan, H. Pullukçu,
D. Gökengin E0213 Duration of antibiotic treatment for respiratory tract
infections in primary care.C. Llor* (Barcelona, Spain),
E0202 Tick-borne encephalitis vaccine uptake,
M.P. Hansen, J. Lykkegaard, J.K. Olsen, B.H.
effectiveness, and impact in Sweden, 2018−2022A.
Lindberg, I.K. Rebnord, R. Radzeviciene, L.
Palmborg* (Stockholm, Sweden), F. Angulo, P.
Jaruseviciene, P.T. Lundgren, P. Bruno, A. Kowalczyk,
Zhang, A. Pilz, J. Stark, M. Jennifer, L. Jodar
C. Lionis
E0203 Monkeypox (mpox) vaccination willingness and
E0214 Antibiotic prescribing for common acute infections in
determinants among people living with HIV (PLWH) in
Pakistan - an analysis using IQVIA prescriber
turkeyC. Boşnak* (Altındağ, Türkiye), T.K. Şahin, E.
healthcare surveysN. Nguyen* (Oxford, United
Erul, M.Ç. Sönmezer, A.Ç. Inkaya, S. Ünal
Kingdom), K. Pouwels, M. Sharland, S. Mangla, A.
Cook, M. Thorn, P. Stephens
EF030 - Arena 3 E0215 Antibiotic prescribing for common acute infections in
14:45 15:45 Egypt - an analysis using IQVIA prescriber healthcare
ePoster Flash Session surveysN. Nguyen* (Oxford, United Kingdom), S.
Mangla, A. Cook, M. Thorn, P. Stephens, K. Pouwels,
Viruses crossing the blood-brain barrier M. Sharland
E0216 Population based analysis of the impact of Japan's
AMR national action plan and the COVID-19
pandemic on antimicrobial prescriptionR. Koizumi*

ESCMID Global 2025 - Programme
(Tokyo, Japan), S. Tsuzuki, Y. Asai, K. Aoyagi, N. 1-hour Oral Session
Ohmagari
Staphylococcus aureus: colonisation, virulence, and persistence
E0217 Quality of antibiotic prescribing in Portuguese
hospitals: a snapshot of the first National Chair Stefano Giulieri (Melbourne, Australia)
Antimicrobial Prescribing Survey.C. Palos* (Lisbon,
Portugal), C. Ierano, R. James, J.A. Paiva, K. Thursky,
P. Sousa
O0185 The nasal microbiome redefines and predicts
E0218 Evaluating the impact on 28-day mortality of different
Staphylococcus aureus nasal colonisation statusD.
empiric AWaRe antibiotic treatment strategies for
Aggarwal* (London, United Kingdom), K.L. Bellis, B.
hospital-acquired infections across different hospital
Blane, M.C. De Goffau, J. Wagner, D.Y.K. Ng, K.E.
settings.C. Lim* (Oxford, United Kingdom), K.B.
Raven, P. Naydenova, S. Kaptoge, R. Henry, C. Perry,
Pouwels, D. Limmathurotsakul, Q. Gu, D.E. Eyre, A.S.
M.R. Walker, C. Churcher, S. Girgis, C.R. De Sousa, L.
Walker, M. Sharland, B.S. Cooper
Sarkane, J. Brennan, S. Duthie, E. Johnson, M.
E0219 Update on WHO's Global antibiotic use surveillance Juhasz, S. Irvine, A. Mcmahon, A. Van Tonder, E. Di
system (GLASS-AMU)B. Huttner* (Geneva, Angelantonio, A. Butterworth, J.A. Geoghegan, J.
Switzerland), A. Muller, M. Escher, V. Ivanoska, D. Danesh, J. Parkhill, S.J. Peacock, E. Harrison
Tong
O0186 Development of a Staphylococcus aureus human
E0220 Harmonisation trajectory of Global-Point Prevalence nasal colonisation modelA. Hachani* (Melbourne,
Survey (Global-PPS) and WHO-PPSA. Versporten* Australia), B. Tran, E. Cho, R. Guérillot, B. Howden, T.
(Antwerp, Belgium), A. Muller, M. Escher, I. Pauwels, Stinear, E. Vincan
D. Tong, A. Boven, V. Ivanovska, B. Huttner, E. Vlieghe
O0187 Selection-free, virulence gene promoter-controlled
E0221 Implementation of prospective audit and feedback CRISPR interference system for in vivo pathogenesis
strategy in intensive care units: Analysis of study of Staphylococcus aureus - A proof of
antimicrobial prescription patterns in a Guatemalan conceptR. Miah* (Tromsø, Norway), M. Johannessen,
tertiary care hospitalN. Sandoval* (Guatemala, M. Kjos, C. Lentz
Guatemala), G. Ozaeta, G. Reyes, K. Carrascosa
O0188 Placebo-controlled study of competitive exclusion
using Lactococcus lactis to reduce transmission of
LA-MRSA from pigs to humansB. Duim* (Utrecht,
KN056 14:45 - 15:45 Hall 1 Netherlands), A. Vlasblom, A. Rittscher-Fogg, R.
Rattigan, L. Wajda, D. Crespo-Piazuelo, M.
Keynote Lecture Broekhuizen-Stins, L. Portengen, G. Van Eijden, C.
Elend, S. Patel, L. Smit, M. Claesson, P. Lawlor, A.
Defending against dengue: global epidemiology and strategies for prevention
Zomer, J. Wagenaar
and control
O0189 Rifampicin-induced Staphylococcus aureus persister
Chairs Anu Kantele (Helsinki, Finland)
formation is driven by CodY and oxidative stress
Carlos Seas (Lima, Peru)
levelN. Pordone* (Lyon, France), J. Guillemot, K.
Rodriguez, N. Personnic, E. Botelho-Nevers, P.O.
Verhoeven
K0161 14:45 Fernanda Boulos (São Paulo, Brazil)
SY059 - Hall 13
14:45 15:45
OS026 - Hall 11
14:45 15:45 1-hour Symposium
1-hour Oral Session
Value-based syndromic diagnostics in medical microbiology: Pro / Con
debate
Carbapenem resistance Gram-negatives, what's new in treatment?
Chairs Hege Vangstein Aamot (Lørenskog, Norway)
Chair Maria Milagro Montero (Barcelona, Spain)
Eric Claas (Leiden, Netherlands)
O0180 Ceftriaxone sulbactam disodium EDTA
S0166 14:45 Pro: clinical benefit and potential for improved patient
combination(CSE) as a treatment option for
outcomesKirstine K. Søgaard (Aalborg, Denmark)
carbapenem resistant gram negative bacilli - to be
or not to be?Y. Verma* (Hisar, India), K. Narang, D. S0167 15:15 Con: limitations, costs, and possible overuse of
Bandlish, C. Sharma syndromic panelsGilbert Greub (Lausanne,
Switzerland)
O0181 Sulbactam-durlobactam as an effective alternative
option against NDM-producing Escherichia coli Co-organised with: ESCMID Study Group for Genomic and Molecular
including cefiderocol and aztreonam-avibactam- Diagnostics (ESGMD), Société de Pathologie Infectieuse de Langue Française
resistant isolates in SwizterlandC. Le Terrier*
(Fribourg, Switzerland), P. Nordmann, A. Delaval, L.
Poirel SY060 - Hall 14
14:45 15:45
O0182 Optimising Difficult-to-treat Gram-negative
1-hour Symposium
Bacterial Infection Outcomes with Personalised
Fosfomycin-Based Combination Therapy Guided by
We need to talk about toilets…
in vitro Antibiotic Combination TestingT. Lim*
(Singapore, Singapore), J.Q. Teo, J.J.Y. Ho, T.G. Chairs Stephanie J. Dancer (Glasgow, United Kingdom)
Lee, L.J. Sin, K.K.K. Goh, N. Mohamed Yusoff, W. Juliette Severin (Rotterdam, Netherlands)
Lee, N.G.S. Chua, J.S. Chung, A.L.H. Kwa
O0183 Management of infections caused by ST308 New
Dehli metallo-ß-lactamase-producing
S0168 14:45 Infection risks from sanitation engineeringDavey
Pseudomonas aeruginosa with in vitro-guided
Jones (Bangor, United Kingdom)
combination antibiotic therapyJ. Teo* (Singapore,
Singapore), J.H. Toh, H.Y. Chang, S.H. Tan, W. Lee, S0169 15:15 Ventilation in toilets: how can we improve it?Michael
T.P. Lim, Y.E. Tan, S.J. Chung, A.L.H. Kwa Gormley (Edinburgh, United Kingdom)
O0184 In vitro activity of cefepime/enmetazobactam Co-organised with: ESCMID Food- and Water-borne Infections Study Group
against clinical isolates of Enterobacterales in (EFWISG), ESCMID Study Group for Legionella Infections (ESGLI)
Portugal: A multicentre retrospective studyH. Cruz*
(Porto, Portugal), C. Chaves, L. Carneiro
OS028 - Hall 15
14:45 15:45
OS027 - Hall 12 1-hour Oral Session
14:45 15:45

ESCMID Global 2025 - Programme
Unlocking the potential of the human microbiome for clinical diagnostics OS025 - Hall 5
14:45 15:45
Chairs John W. A. Rossen (Groningen, Netherlands)
Maria Vehreschild (Frankfurt Am Main, Germany) 1-hour Oral Session
Bacterial battles: a paediatric perspective on infections and interventions
Chairs Angelika Berger
O0190 Deep learning-enhanced wellness scores: Advancing Julie Toubiana (Paris, France)
gut microbiome-based health predictionsO.
Nalbantoglu* (Kayseri, Türkiye), A. Gundogdu, B.H.
Ermis
O0175 Strong Alignment Between National Standard
O0191 Comparison of Second-Generation and Third-
Treatment Guidelines and WHO AWaRe Book
Generation Sequencing technologies for 16S rRNA
Recommendations for Primary Care Pediatric
amplicon-based gut microbiome analysisE. Rubio
InfectionsD. Dona* (Padova, Italy), D. Donà, G.
García* (Barcelona, Spain), E. Rubio-García, A.
Brigadoi, A. Cantarutti, M. Masetti, G. Autore, S.
Pulgarin, R. López-Aladid, L. Martínez-Priego, N.
Mathur, M. Sharland, S.M.R. Esposito
Palau, A. Mendoza, R. Isanta, A. Montalban, J.L.
Villanueva-Cañas, M.M. Montero, M. Sanduzzi, M. O0176 Correlation between antibiotic consumption and
Reig, C. Casals-Pascual digestive colonization with multidrug-resistant
Enterobacterales in a paediatric haematology
O0192 Donor for fecal microbiota transplantation: a
departmentS. Frigui Ep Oueslati* (Tunis, Tunisia), N.
challenging research.B.S. Orena* (Milan, Italy), M.F.
Fitouri, S. Frigui, Y. Chebbi, I. Fezaa, M. Ouederni, C.
Liporace, A. Maraschini, D. Girelli, D. Pizzotti, E.
Drira, W. Achour
Petrillo, C. Alteri, C. Amoroso, F. Caprioli, A.
Callegaro, L. Cariani O0177 Interleukin-6 as a diagnostic biomarker for sepsis in
neonates, children and pregnant women – a real-
O0193 Antibiotic resistance genes diversity and
world cohort studySean Olann Whelan (Dublin,
antimicrobial effects in the vaginal microbiome during
Ireland)
pregnancyN. Boutouchent* (Rouen, France), S.
Kennedy O0178 Impact of rapid diagnostic stewardship interventions
to reduce blood culture utilization in a pediatric
O0194 Distinct gut microbiota and metabolic profiles in brain
medical centerE. Vaugon* (Los Angeles, United
tumor patients: Bridging microbial insights to CNS
States), C. Costales, T. Barter, L. Posch, E. Orgel, J.
oncologyA. Gundogdu* (Kayseri, Türkiye), O.U.
Dien Bard
Nalbantoglu, M. Ulgen, M.A. Sav, G. Ekinci, H.F.
Kelestimur, U. Ture O0179 Infective endocarditis: A Decade of Experience at a
Tertiary Pediatric Care CentreM. De Luca* (Rome,
Italy), R. Iacobelli, S. Samperi, S. Mercadante, L.
ME062 - Hall 16 Romani, L. Ragni, P. Bruno, G. Brancaccio, F.I. Calò
14:45 15:45
Carducci, P. Bernaschi, A. Rizza, L. Lancella, L. Galletti
Meet-the-Expert
Untangling the web: antimicrobial dose adjustments in renal impairment EW071 - Hall 15
16:15 18:15
Educational Session
M0172 14:45 Claire Roger (Nimes, France) The rare art of writing scientific articles: from conception to submission
M0173 14:57 Isabel Spriet (Leuven, Belgium) Chairs Marlieke De Kraker (Geneva, Switzerland)
Mical Paul (Haifa, Israel)
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG),
ESCMID Study Group for Critically Ill Patients (ESGCIP)
W0205 16:15 Expressing yourself correctly: writing tipsAngela
SY057 14:45 - 15:45 Hall 2 Huttner (Geneva, Switzerland)
W0206 16:35 Constructing your manuscript for an original
1-hour Symposium
articleJesús Rodríguez-Baño (Seville, Spain)
Macrolides in community-acquired pneumonia: therapeutic necessity or path W0207 16:55 The use of artificial intelligence tools for writing
to overuse? articles: what to do and not to doErlangga Yusuf
(Rotterdam, Netherlands)
Chairs Marc J.M. Bonten (Utrecht, Netherlands)
Karin Thursky (Carlton, Australia) W0208 17:15 Selecting the best journal for my manuscriptAndre
Kalil (Omaha, United States)
Co-organised with: CMI Board of Editors
S0162 14:45 Pro: maximising outcomes with evidence-based
useEvangelos Giamarellos-Bourboulis (Athens,
Greece) SY069 16:15 - 18:15 Hall 16
S0163 15:15 Con: the risks of routine (over)useAurélien Dinh 2-hour Symposium
(Garches, France)
Controlled human infection models
Chairs Frederick Hayden (Charlottesville, United States)
SY058 - Hall 4
14:45 15:45 Nikolai Siemens (Greifswald, Germany)
1-hour Symposium
Top papers in transplant ID S0197 16:15 Updates on the dengue human infection
Chairs Nicolas Mueller (Zurich, Switzerland) modelKirsten Lyke (Baltimore, United States)
Alessandra Mularoni (Palermo, Italy) S0198 16:45 CHIM in endemic countriesMelissa Kapulu (Kilifi,
Kenya)
S0199 17:15 Controlled human infection models of parasitic
S0164 14:45 Top 10 papers in infections in SOTPatricia Munoz infectionsMeta Roestenberg (Leiden, Netherlands)
(Madrid, Spain) S0200 17:45 Controlled human infection models of non-typhoidal
S0165 15:15 Top 10 paper in infections in HCT and cellular SalmonellaMalick Gibani (London, United Kingdom)
therapyJoshua Hill (Seattle, United States) Co-organised with: British Infection Association (BIA)

ESCMID Global 2025 - Programme
EF033 - Arena 2 Cook* (Oxford, United Kingdom), F.S. Mohd, M.Y.
16:15 17:15
Ahmad, A. Aliyu, K. Iregbu, C. Achi, T. Walsh, K. Sands
ePoster Flash Session E0247 Efficacy of Octenidine Dihydrochloride Versus
Chlorhexidine Gluconate Solutions in Reducing
Current treatment options for invasive fungal infections
Surgical-Site Infections in Total Hip and Knee
Chair Andreas H. Groll (Münster, Germany) Arthroplasty: A Comparative AnalysisA. Abialevich*
(Beer Sheva, Israel), V. Benkovich, G. Benkovich
E0249 Impact on rates of surgical site infection of requiring
pre-authorization of surgical antibiotic prophylaxis
E0232 The paediatric European Confederation of Clinical
choice and post-operative antibiotic dosesC.M.
Mycology (ECMM) Quality (paed-EQUAL) Score for
Villavicencio* (Taguig, Philippines), M.C. Hufano, R.R.
the management of candidaemia in children and
Gabunada, Z. Alano
neonatesZ.D. Pana* (Nicosia, Cyprus), A.H. Groll, A.
Bal, R. Sprute, F. Carlesse, S. Mellinghoff, S. Butzer,
D. Ludwig-Bettin, K. Mehler, J. Stemler, D. Seidel, A.
Marek, U. Ristau-Schäfer, O. Cornely SY067 16:15 - 18:15 Hall 11
E0233 Prevalence rate, species distribution and antifungal 2-hour Symposium
susceptibility of bloodstream infections caused by
rare yeasts of the Saccharomycetales order STIs: an ongoing crisis
documented in 28 Brazilian medical centersC.
Chairs Dagmar Heuer (Berlin, Germany)
Palamin Buonafine* (São Paulo, Brazil), C.P.
Tomislav Mestrovic (Varazdin, Croatia)
Buonafine, A.E. Dos Santos, L.M. Favarello, R.C.
Cognialli, V.R. Aquino, C.B. Agnelli, A.V. Mendes, T.
Guimaraes, T.C. Sukiennik, F. Carlesse, P.T. Castro,
C.C. Baqueiro, E.C. Francisco, A.L. Colombo
S0189 16:15 STI treatment options are running out due to
E0234 Rezafungin showed high in vitro activity and very AMRMagnus Unemo (Örebro, Sweden)
low resistance rate against a collection of yeasts
S0190 16:45 Genomic surveillance of Neisseria gonorrhoeae
causing fungaemia in patients admitted to a tertiary
strainsPetra Wolffs (Maastricht, Netherlands)
hospital in Madrid from 2014 to 2024J. Guinea*
(Madrid, Spain), P. Escribano, A. Gomez, A. Burillo, S0191 17:15 Evolutionary insights into syphilis and Treponema
P. Muñoz pallidumMathew Beale (Hinxton, United Kingdom)
E0235 Posaconazole Drug-Drug Interaction Potential is S0192 17:45 Challenges in chlamydial STI infectionsCecile Bebear
Similar Across BodyweightR.E. Wrishko* (Rahway, (Bordeaux, France)
United States), P. Kothare, T.J. Bateman, M.G. Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie
Johnson, A. Stoch
E0236 Phase 2, open-label, non-comparative clinical trial
evaluating the safety and efficacy of posaconazole SY068 16:15 - 18:15 Hall 12
in paediatric patients 2 to <18 years old with
invasive aspergillosisH. Kang* (Seoul, Korea, 2-hour Symposium
Republic of), A.C. Arrieta, C. Dhooge, A. Kelemen,
M. Macías-Parra, L. Aranda, Y.V. Dinikina, I. Kassis, Tick-borne encephalitis: contemporary diagnosis and management
S. Cesaro, T. Mackey, A. Shepherd, A.K. Shah, H. Chairs Joanna Maria Zajkowska (Białystok, Poland)
Waskin, M.G. Johnson Dace Zavadska (Riga, Latvia)
E0237 Activity of manogepix against a worldwide
collection of mould isolates from 2023M. Winkler*
(North Liberty, United States), S. Edeker, A. Klauer,
S0193 16:15 Tick-borne encephalitis: immune response and
P. Rhomberg, M. Castanheira
clinical experienceSara Gredmark Russ (Stockholm,
E0239 Candida auris displays an inoculum effect with Sweden)
multiple antifungal drug classesR. Ben-Ami* (Tel
S0194 16:45 TBE immune responses and vaccine
Aviv, Israel), R. Shadhan, A. Novikov, N. Mizrahi
effectivenessKarin Stiasny (Vienna, Austria)
E0240 In vitro olorofim activity against Aspergillus spp
S0195 17:15 NS1 antibodies: diagnostics and screening of
clinical isolates collected as part as two national
seroprevalence of TBE virus infectionGerhard
surveys on azole resistance conducted in Spain
Dobler (Munich, Germany)
(ASPEIN II and III)J. Guinea* (Madrid, Spain), P.
Escribano, J. Moraga, A. Gomez, P. Muñoz S0196 17:45 Treatment for TBE: where do we stand?Daniel
Ruzek (Brno, Czech Republic)
EF034 - Arena 4
16:15 17:15
LB006 - Hall 13
16:15 18:15
ePoster Flash Session
2-hour Oral Session
Surgical site infections: epidemiology, risk factors, and prevention strategies The Trial Run: recent trials on S. aureus bacteraemia management
Chair Trisha Peel (Melbourne, Australia) Chairs Julia Anna Bielicki (London, United Kingdom)
Vance Fowler (Durham, United States)
E0241 Incidence of Surgical Site Infections (SSIs) from the
automated patient-based surveillance system, L0031 16:15 Introduction, Julia Anna Bielicki (London, United
SPICMI, FranceP. Astagneau* (Paris, France), B. Kingdom), Vance Fowler (Durham, United States)
Nkoumazok, N. Benhajkassen, I. Arnaud, D. Verjat-
L0032 16:20 Description of SNAP trial
Trannoy, J. Auraix, K. Lebascle
L0033 16:30 Benzylpenicillin versus (flu)cloxacillin for the
E0242 Beta-lactam versus non-beta-lactam antimicrobial
treatment of penicillin-susceptible Staphylococcus
prophylaxis and its association with the surgical site
aureus bacteraemia: a randomised controlled trial of
infection rate, a nationwide cohort study with 348
the S. aureus network adaptive platform (SNAP)S.
793 patientsS. Largiadèr* (Lucerne, Switzerland), D.
Tong* (Melbourne, Australia), S. Aureus Network
Berthod, A. Widmer, N. Troillet, C. Perdrieu, S.
Adaptive Platform Trial Group
Harbarth, R. Sommerstein
L0034 16:45 Cefazolin versus (flu)cloxacillin for the treatment of
E0245 Cutibacterium species in Neurosurgical Infections:
penicillin-resistant, methicillin-susceptible
Not Such a "Cute" Pathogen After AllJ. Donnelly*
Staphylococcus aureus bacteraemia: a randomised
(Dublin, Ireland), B. Dinesh, S. O'donnell
controlled trial within the S. aureus network adaptive
E0246 The polymicrobial nature of wound infections in an platform (SNAP)J. Davis* (Newcastle, Australia), S.
emergency orthopaedic ward in Northern Nigeria - Aureus Network Adaptive Platform Trial Group
implications for treatment and patient outcomeK.

ESCMID Global 2025 - Programme
L0035 17:00 Cloxacillin versus cefazolin for methicillin-susceptible Bernatoniene, S. Bhowmik, J. Perry, P. Mottram, P.
Staphylococcus aureus bacteraemia (CloCeBa): a Mcnamara, D. Lewis, N. Van Kinnekan, A. Finn
randomised, controlled, non-inferiority trialX. O0230 Targeted metagenomic sequencing of influenza,
Lescure* (Paris, France), F. Vandenesch, X. Duval, S. RSV, and symptomatic respiratory infections from
Tubiana, C. Burdet, N. Saïdani, A. Lemaignien, E. UK healthcare workersM. Knoll* (Hinxton, United
Canoui, L. Surgers, M. Esposito Farese, V. Le Moing, Kingdom), L. Findlater, B. Katie, J. Wagner, T. Diego,
P. Tattevin D. Rajan, S. Frances Field, S. Thurston, A. Wong, B.
L0036 17:15 Trial DiscussionJulia Anna Bielicki (London, United Hyatt, N. Thesin, J. Robinson, R. Yeadon, A. Galvin,
Kingdom) B. Blane, Y.L. Huang, K. Howe, M. Forbes, K.
Figueroa, F. Schwach, S. Stott, A. Marhino, A. Frick-
L0037 17:30 Trial DiscussionVance Fowler (Durham, United
Kretschmer, B. Dave, T. Maddison, S. Hopkins, S.
States)
Foulkes, J. Islam, A. Atti, V. Hall, E. Harrison
L0038 17:45 Open Discussion and Q&A
OS032 - Hall 14
SY064
16:15
-
18:15
Hall 2
16:15 18:15
2-hour Symposium
2-hour Oral Session
PK/PD to avoid emergence of resistance?
Unraveling respiratory viruses, 2025
Chairs Anne-Grete Märtson (Leiden, Netherlands)
Chairs Eeva Broberg (Solna, Sweden) Joseph Meletiadis (Athens, Greece)
Florian Krammer (New York, United States)
S0177 16:15 PK/PD and antibacterial therapyDolors Soy-Muner
O0222 Human metapneumovirus infections in hospitalized (Barcelona, Spain)
adults compared to respiratory syncytial virus and
S0178 16:45 PK/PD and antifungal therapyRoger Brüggemann
influenza infections over ten years in FranceP.
(Nijmegen, Netherlands)
Loubet* (Nimes, France), S. Guitton, R. Simon, L.
Lefrancois, L.B. Luong Nguyen, P. Vanhems, F. S0179 17:15 PK/PD and antiviral therapyJoe Standing (London,
Laine, F. Galtier, X. Duval, B. Lina, M. Valette, G. United Kingdom)
Lagathu, V. Foulogne, N. Houhou-Fidhou, A.S.
S0180 17:45 PK/PD considerations in anthelminthic
L'honneur, F. Carrat, L. Meyer, C. Durier, O. Launay
treatmentJennifer Keiser (Allschwil, Switzerland)
O0223 Unveiling animal susceptibility to influenza viruses
(H1N1(pdm09) and H5N1 HPAIV) using animal-
derived respiratory organoidsF. Tarrés-Freixas* EW070 - Hall 3
16:15 18:15
(Bellaterra, Spain), G. Ceada, N. Navarro, M. Pérez-
Simó, N. Carmona-Vicente, L. Bonillo-Lopez, A. Educational Session
Moreno, C. López, J. Segalés, N. Majó, K.
Kochanowski, J. Vergara-Alert Malaria: when the drugs don’t work Management of treatment failure in non-
O0224 Exploring the impact of acute lung hypoxia on CD8 endemic countries
T cell phenotypes following severe influenza Chairs Laura Nabarro (London, United Kingdom)
infection.B. Huckestein* (Memphis, United States), Caroline Rönnberg (Stockholm, Sweden)
P. Thomas
O0225 Virological characterisation of RSV after Nirsevimab
Breakthrough Infections in a Multicentre
W0201 16:15 Malaria in the non-endemic setting: who to treat as
Observational Real-world Study in FranceS.
an outpatient and how to detect treatment
Fourati* (Créteil, France), A. Reslan, J. Bourret, Y.
failureEmmanuel Bottieau (Antwerp, Belgium)
Rahou, L. Chollet, S. Pillet, P. Tremeaux, N. Candace
Dossou, E. Gault, M. Salmona, B.M. Imbert, A. W0202 16:35 Malaria resistance mutations in the non-endemic
Mirand, S. Larrat, A. Moisan, S. Marot, A. setting: role of genomic surveillanceAnna Rosanas
Schnuriger, N. Veyrenche, I. Engelmann, L. Handala, Urgell (Antwerp, Belgium)
A. Henry, V. Stephan, S. Brichler, V. Avettand- W0203 16:55 How to manage Plasmodium Knowlesi infectionGiri
Fenoel, N. Zemali, C. Lefeuvre, C. Pronier, L. Shan Rajahram (Kota Kinabalu, Malaysia)
Deroche, M.C. Jaffar, L. Mouna, C. François, A.
W0204 17:15 Epidemiology and control of Plasmodium
Regueme, C. Hartard, S. Roger, F. Gallais, A. Ly, C.
KnowlesiKimberly Fornace (Singapore, Singapore)
Rodriguez, G. Dos Santos, J. Buchrieser, O.
Schwartz, J.M. Pawlotsky, F. Lemoine, E. Audureau, Co-organised with: British Infection Association (BIA)
M.A. Rameix-Welti
O0226 Baseline immunity to highly pathogenic avian
influenza viruses in a healthcare worker cohortC. SY065 16:15 - 18:15 Hall 4
Geurts Van Kessel* (Rotterdam, Netherlands), M.
2-hour Symposium
Power, W. Rijnink, L. Gommers, T. Bestebroer, W.
Soochit, W. Tan, B. Verstrepen, S. Bogers, G. Van
Gram-positives, are they still going?
Nierop, R. Sikkema, A. Grifoni, A. Sette, M.
Koopmans, R. Fouchier, M. Richard, R. De Vries, C. Chairs Diederik Bathoorn (Groningen, Netherlands)
Geurtsvankessel Stefania Stefani (Catania, Italy)
O0227 Impact of reinfection on post-acute sequelae of
COVID-19 over multi-organ systemsJ. Tan*
(Singapore, Singapore), J.T. Lim, L.E. Wee, C. S0181 16:15 The vanco chronicles: enterococci's global
Chiew, B. Ong, D. Lye journeyGuido Werner (Wernigerode, Germany)
O0228 Clinical and economic burden of respiratory S0182 16:45 Pitfall in susceptibility testing of Gram-
syncytial virus in adults with acute respiratory positivesHelena Zemlickova (Prague, Czech
infections – a Danish nationwide cohort Republic)
studyStanislava Bratkovic (Copenhagen, Denmark)
S0183 17:15 Drivers for daptomycin and linezolid resistance in
O0229 The burden of respiratory syncytial virus in children Gram-positivesGlen Carter (Melbourne, Australia)
<3 years old presenting to primary, secondary and
S0184 17:45 What is new in treatment against MDR Gram-
tertiary care in England: report from the STOP RSV
positives?Alex Soriano (Barcelona, Spain)
prospective surveillance studyE. Carter* (Liverpool,
United Kingdom), H. Hill, D. Ferreira, A. Collins, C.
Solórzano, L. Mclellan, L. Kerruish, F. Fyles, S.
Drysdale, P. Gonzalez-Dias, G. Duncan, K. Davies, P. SY066 16:15 - 18:15 Hall 5
Crozier, P. Saunderson, R. Kramer, M. Bangert, N.
Vassilouthis, S. Messahel, B. Caroline, S. Brearey, J. 2-hour Symposium

ESCMID Global 2025 - Programme
Biomarker testing to manage respiratory infections in primary care in low
resource settings
Chairs Sonia Lewycka (Hanoi, Vietnam) E0259 Central Nervous System Involvement by
Heiman Wertheim (Nijmegen, Netherlands) Mycobacterium avium Complex in Advanced HIV: A
Rare and Underdiagnosed ChallengeE. Sienra
Iracheta* (Tlalpan, Mexico), M. Aranda Aurelio, A.
Camiro Zuñiga, D.H. Martínez Oliva, A. Llamas Lopez,
S0185 16:15 The Vietnamese experience with CRP testing in the A.P. Rodriguez Zulueta
community settingThi Thuy Nga Do (Ha Noi, Vietnam) E0260 Acute disseminated encephalomyelitis following
S0186 16:45 The Nigerian experience with CRP testing in the bacterial meningoencephalitis – Two Case reports &
community settingAugustine Onwunduba (Awka, Review of LiteratureM. Priyadarshi* (Delhi, India), M.
Nigeria) Salunkhe, A. Mohan, P. Gupta, A. Agarwal, V. Goel, R.
Bhatia
S0187 17:15 CRP testing in diagnosing tuberculosis in Zambia and
South AfricaHelen Ayles (Lusaka, Zambia) E0261 Streptococcus equi Subspecies zooepidemicus
Endocarditis and Meningitis in a 62-Year-Old Patient:
S0188 17:45 The health economics of CRP testing in LMICsYoel
A Case Report and Literature reviewD. Chemello*
Lubell (Bangkok, Thailand)
(Modena, Italy), G. Franceschi, S. Alessandra, B.
Andrea, S. Mario, M. Marianna, M. Cristina
EF035 - Arena 1 E0262 Breaking barriers: meropenem-vaborbactam as a
17:15 18:15
game-changer for KPC central nervous system
ePoster Flash Session infectionsF. Prataviera* (Udine, Italy), S. Giuliano, S.
Flammini, J. Angelini, P.G. Cojutti, C. Tascini
Genomics in pathogen surveillance E0263 Multidrug-Resistant Klebsiella pneumoniae
Chair Vítor Borges (Lisbon, Portugal) Meningitis in the Absence of Intracranial Devices: A
Case ReportM. Chumbita* (Barcelona, Spain), E.
Viñas Esmel, P. Castro, S. Herrera, C. Bastida, A.
Soriano
E0250 Genomic Surveillance of Invasive Group A
E0264 Triple Threat: Sequential Meningitis Infections in an
Streptococcus in Argentina's 2023 Epidemic:
Immunosuppressed Patient with Morganella
Unveiling Hypervirulent emm1 Lineages and Pediatric
morganii, Acinetobacter baumannii, and
emm12 BurdenL. Cipolla* (Buenos Aires, Argentina),
Vancomycin-resistant Enterococcus faeciumY. Çakir
A. Gianecini, T. Poklepovich, C. Giovacchini, M. Prieto
Kiymaz* (Sivas, Türkiye), Y. Çakır Kıymaz, E. Kıymaz,
E0251 Understanding the population structure of Moraxella Z. Bulut, S.A. Büyüktuna, N. Elaldı
catarrhalis using core-genome multilocus sequence
E0265 Invasive pulmonary Arthrographis kalrae infection
typingI. Yassine* (Oxford, United Kingdom), K.A.
with cerebral abscesses in an immunocompromised
Jolley, J.E. Bray, M.J. Jansen Van Rensburg, F. Patel,
childB. Winkel* (Utrecht, Netherlands), J. Jans, M.
A. Sheppard, H.J. Zar, V. Allen, L. Ah Tow, M.C.J.
Luesink, R.J. Nievelstein, F. Hagen, J. Buil, T. Wolfs, T.
Maiden, M.P. Nicol, A.B. Brueggemann
Van Der Bruggen
E0252 Impact of the COVID-19 pandemic on the
E0266 Treatment of herpes simplex encephalitis with the
Streptococcus pyogenes clones causing adult
helicase-primase inhibitor pritelivir in an
invasive infectionsM. Ramirez* (Lisbon, Portugal), A.
immunocompromised patientA. Birkmann*
Friães, J. Vermeiren, R. Mamede, C.R. Bettencourt,
(Wuppertal, Germany), C. Lueck, C. Rautenberg, S.
M.P. Bajanca-Lavado, J. Melo-Cristino, P. Group For
Bonsmann, A. Marini, M. Sumner, T. Schroeder, S.
The Study Of Streptococcal Infections
Voigt
E0253 Unveiling the Hidden Complexity of Providencia:
E0267 A case of influenza A (H1N1) encephalitis: Rare
Genomic Insights into Species Reclassification and
neurological implication in a healthy adultN.K. Midha*
Antibiotic ResistanceX. Dong* (Hangzhou, China)
(Jodhpur, India), S. Bhat K S, S. Tiwari, D.S. Meena, D.
E0254 Genomic description of outbreak of VIM-1 carrying Kumar, G.K. Bohra
Enterobacter in Switzerland suggests plasmid
transmission between sequence typesH. Seth-Smith*
(Zurich, Switzerland), M. Greutmann, C. Beckmann, E. Sunday, 13 April 2025
Gruner, R. Capaul, G. Greub, P.M. Keller, S. Tschudin-
Sutter, L. Berlinger, S.D. Brugger, T. Roloff, O. Nolte,
L. Poirel, P. Nordmann, A. Egli
E0255 Genomic epidemiology of Klebsiella pneumoniae SY075 - Hall 15
bloodstream infections in a german tertiary centre: 08:30 10:30
increased virulence in carbapenem-resistant strainsL. 2-hour Symposium
Knegendorf* (Hannover, Germany), M. Lindenberg,
C. Baier, J. Erdmann, S. Häußler, D. Schlüter Diphtheria: from re-emergence to vaccine strategies
E0256 Phylogenetic mixing and undetected circulation of Chairs Helena Seth-Smith (Zurich, Switzerland)
multiple Candida auris lineages following recognition Julie Toubiana (Paris, France)
of imported cases in ItalyV. Di Pilato* (Genoa, Italy),
E. Willison, L. Calabrese, L. Magnasco, C. Elisa, G.
Daniele Roberto, M. Mikulska, B. Matteo, M. Anna
S0221 08:30 Diphtheria: from clinical picture to medical
E0257 Using Long-Read Sequencing for Core Plasmid
managementRegina Oladokun (Oyo, Nigeria)
Multilocus Sequence Typing to Investigate Plasmid
Relationships Among Bacterial Species in German S0222 09:00 The epidemiology of diphtheria worldwide over the
Hospital WastewaterA.K. Bari* (Groningen, last half-century: more than one comebackAndreas
Netherlands), B. Sinha, J.W.A. Rossen, B.B. Xavier, Hoefer (Solna, Sweden)
T.T. Severs, M.J. Cardoso, M. Savin S0223 09:30 There’s more than one toxigenic Corynebacterium:
E0258 Screening for rectal colonization with multidrug- the current genomics landscape of diphtheria-
resistant pathogens: usage of rapid metagenomic associated strainsSylvain Brisse (Paris, France)
long-read technologyS. Purushothaman* (Zurich, S0224 10:00 Diphtheria vaccination: a reappraisal Gayatri
Switzerland), A.M. Rooney, S. Moser, A. Egli Amirthalingam (London, United Kingdom)
Co-organised with: ESCMID Study Group for Epidemiological Markers
(ESGEM), ESCMID Vaccine Study Group (EVASG)
EF036 - Arena 3
17:15 18:15
ePoster Flash Session
EF039 - Arena 1
08:30 09:30
Heads up! CNS infections
ePoster Flash Session
Chair Jacob Bodilsen (Aalborg, Denmark)

ESCMID Global 2025 - Programme
Novel approaches to antiviral therapy Mawa, J. Friedman, A. Bustinduy
Chair Pinyo Rattanaumpawan (Bangkok, Thailand) E0302 Schistosomiasis detected by Screening of sub-
Saharan African Unaccompanied Minor Refugees in
Berlin between 2023 and 2024G. Equihua Martinez*
(Berlin, Germany), A.K. Lindner, M.C. Moreno-Del
E0288 Obeldesivir exhibits broad anti-RSV activity and a Castillo, J. Hammer, M. Nürnberg, P. Pitzinger, T.
high barrier to resistance in vitro and is efficacious Geppert, F. Mockenhaupt, B. Kampmann, F.
in a non-human primate challenge model of RSV Olgemöller
infectionJ. Pitts* (Foster City, United States), J.L.R.
E0303 NADPH oxidase of the mosquitoes and the
Zamora, S. Manhas, T. Aeschbacher, J. Chan, V.
antioxidant genes repertoire of the bacteria
Cutillas, V. Nair, N. Riola, A. Vijjapurapu, M.
coordinate mosquito-bacteria interaction in midgutB.
Vermillion, S. Eng, C. Richards, D. Han, J. Perry, S.
Song* (Kowloon, Hong-Kong SAR, China), J. Zeb, N.
Chaudhuri, I. Liu, C. Martinez, N. Peinovich, K.H.
Buchon, O. Sparagano, P. Butaye
Sun, A. Cai, R. Martin, J. Moshiri, C. Hedskog, V.
Avadhanula, P. Piedra, K. Stobbelaar, P. Delputte, T. E0304 Molecular detection and sequencing of the genes
Cihlar, S. Fletcher, J. Bilello encoding the predicted enzymes; Amidase, NADH
ubiquinone oxidoreductase, and sodium
E0289 EDP-323, a first-in-class, oral, RSV L-protein
neurotransmitter symporter in Onchocerca
inhibitor reduces disease severity (respiratory
volvulusA. Acheampong* (Sunyani, Ghana), J. Larbi,
mucus production) and accelerates viral clearance
P.C. Kudzordzi, P. Nyarko, K.B. Otabil
in a human viral challenge studyJ. Devincenzo*
(Watertown, United States), A. Ahmad, S. Chen, B. E0305 Tuberculosis outcomes among international migrants
Löndt, A. Mann, J. Mori, A. Catchpole, S. living in Europe compared to the non-migrant
Rottinghaus population: a systematic review and meta-analysisG.
Guido* (Bari, Italy), S. Cotugno, L. Frallonardo, R.
E0290 A Combined In Silico and In Vitro Pipeline for
Papagni, V. Giliberti, F.V. Segala, C. Polizzotto, G. Di
Optimizing Nanobodies Targeting Surface Proteins
Franco, M. Affronti, E. Piccione, G. Gualano, F.
of Pathogens: Applications to SARS-CoV-2, WNV,
Palmieri, M. Barbagallo, N. Veronese, A. Saracino, F.
and Influenza A VirusC.L. Pierri* (Bari, Italy), G.C.M.
Di Gennaro
Perrone, A.L. Francavilla, S. Todisco, M.N. Sgobba,
V. Scaglione, D.I. De Luca, F. Mastropirro, S.
Spadone, L. Guerra, M. Volpicella, A. De Grassi
E0291 Bemnifosbuvir and Remdesivir exhibit potent
EW079
08:30
-
10:30
Hall 11
antiviral activity against tick-borne encephalitis Educational Session
virus in vitroD. Grandgirard* (Bern, Switzerland), S.
Leoni, R. Dijkman, L. Eyer, D. Ruzek, S.L. Leib New guidelines for management of brain infections
E0292 Combinations of antiviral drugs demonstrating Chairs Jacob Bodilsen (Aalborg, Denmark)
synergistic inhibition of multiple respiratory RNA Kartika Maharani (Jakarta, Indonesia)
virusesS. Ellis* (London, United Kingdom), A.I.
Jacobs, M. Woodall, S. Zhang, J.F. Standing, J.
Breuer
E0293 The safety and pharmacokinetics of ABI-5366, a W0237 08:30 Tuberculous meningitis: what can we learn from the
novel, oral, long-acting HSV helicase-primase first global guidelines?Joseph Donovan (Ho Chi Minh
inhibitor: Interim results from a Phase 1a/1b study in City, Vietnam)
healthy participantsA. Gaggar* (South San W0238 08:50 WHO guidelines on bacterial meningitis: change of
Francisco, United States), E. Gane, C. Schwabe, G. clinical practice?Matthijs Brouwer (Amsterdam,
Wang, J. Liu, S. Knox, K. Kitrinos, K. Zomorodi Netherlands)
E0294 Efficacy of ganciclovir against CMV infection is W0239 09:10 ESCMID encephalitis guidelines 2024: what’s
dependent on treatment initiation timeL. new?Tom Solomon (Liverpool, United Kingdom)
Sudarsono* (Leiden, Netherlands), X. Liu, J.G.C.
W0240 09:30 WHO guidelines for cryptococcal meningitis: success
Van Hasselt, A.G. Märtson
stories and barriers to implementationNelesh
E0295 Efficacy of molnupiravir and baloxavir against Govender (Johannesburg, South Africa)
influenza A H1N1 infection in vitro and in vivoD. Liu*
Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain
(Hong Kong, Hong-Kong SAR, China), K.Y. Leung, R.
(ESGIB)
Zhang, Y. Fan, K.H. Chan, F.N.I. Hung
E0296 Human defensin derived peptide showing broad
antiviral activity against human adenovirusesX. SY073 - Hall 12
08:30 10:30
Wang* (Hongkong, China), H. Zhao
2-hour Symposium
EF040 - Arena 3 Proxy indicators: bridging the gap between surveillance and antimicrobial
08:30 09:30
stewardship
ePoster Flash Session Chairs Bhanu Sinha (Groningen, Netherlands)
Annelies Verbon (Bosch En Duin, Netherlands)
New frontiers in parasitic disease and migrant health research
S0213 08:30 A broad spectrum of possibilities: spectrum scores as
E0298 Targeting metabolic bioenergetics: the ‘Achilles' heel' a unifying metricCéline Pulcini (Nancy, France)
of LeishmaniaD. Sarkar* (Kolkata, India)
S0214 09:00 Proxy indicators to estimate appropriateness of
E0299 Leishmaniasis in Southern Alicante (Spain): what is antibiotic prescriptionsDiane Ashiru-Oredope
the new patient profile?M.D. Hernández Rabadán* (London, United Kingdom)
(Orihuela, Spain), C. Bernal Alcaraz, M.B. Martínez
S0215 09:30 How to bridge the gap between surveillance and
López, D. López Parra, J. Llenas García
antimicrobial stewardshipMark G. J. De Boer (Leiden,
E0300 Schistosoma haematobium infection is associated Netherlands)
with oncogenic gene expression in cervical mucosa,
S0216 10:00 Health economics, surveillance and antimicrobial
with enhanced effects following treatmentAnna
stewardshipZhu Nina Jiayue (London, United
Mertelsmann (Zürich, Switzerland)
Kingdom)
E0301 Associations between water and sanitation service,
Co-organised with: Dutch Committee on Antimicrobial Policy, ESCMID
risk of intestinal schistosomiasis, infection intensity,
Education Subcommittee, International Society for Infectious Diseases (ISID)
and liver fibrosis in selected households living near
Lake Albert: a descriptive cross-sectional study?G.
Lam* (London, United Kingdom), D. Dee, A. Edielu, E.
SY074 - Hall 13
Ohuma, V. Anguajibi, E. Webb, A. Wamboko, P. 08:30 10:30

ESCMID Global 2025 - Programme
2-hour Symposium
Difficile to treat: advanced management strategies in difficult to treat CDI
S0225 08:30 New indicators in national monitoring and evaluation
Chairs Frédéric Barbut (Paris, France) of AMR supported by improved data utilisationDirek
Kerrie Davies (Leeds, United Kingdom) Limmathurotsakul (Bangkok, Thailand)
S0226 09:00 Interdisciplinary investigation of the drivers and
burden of AMR in urinary tract infectionsStephen
S0217 08:30 Severe CDI: when standard protocols failHynek Mshana (Mwanza, Tanzania, United republic of)
Bartos (Prague, Czech Republic) S0227 09:30 A clinically-oriented AMR surveillance network: case-
S0218 09:00 Therapies for complicated CDIEmma Bishop (Clayton based surveillance and implementationPaul Turner
Vic, Australia) (Siem Reap, Cambodia)
S0219 09:30 Recurrent CDI: Breaking the cycleAndrea Marino S0228 10:00 National prescribing guidelines based on AMR
(Catania, Italy) surveillance dataVilada Chansamouth (Vientiane, Lao
People's democratic republic)
S0220 10:00 Live biotherapeutic products for Clostridioides
difficile infectionSimon Goldenberg (London, United Co-organised with: CAESAR network, ESCMID Study Group for Antimicrobial
Kingdom) Resistance Surveillance (ESGARS)
Co-organised with: ESCMID Study Group for Clostridioides difficile (ESGCD)
EW077 - Hall 2
08:30 10:30
OS038 08:30 - 10:30 Hall 14 Educational Session
2-hour Oral Session New tools in acute bacterial infections and sepsis: from machine learning to
precision medicine
Making fast for making better: AMR rapid diagnostics
Chairs Benjamin Mcfadden (Perth, Australia)
Chairs Giulia De Angelis (Rome, Italy)
Rita Murri (Rome, Italy)
Onur Karatuna (Växjö, Sweden)
W0229 08:30 Differentiating acute infection, sepsis and sepsis
O0278 Point of care rapid lateral flow antibiotic resistance
mimics in the ED?Lisa Mellhammar (Lund, Sweden)
test to detect carbapenem resistance in lower
respiratory tract infectionsJ. Rogers* (Bedford, W0230 08:50 Machine learning for early recognition of
United Kingdom), A. Gregg, Q. Liu, S. Owen, C. Chen, sepsisKarsten Borgwardt (Martinsried, Germany)
M. Edward, S. Jiang, W. Lu, L. Mynheer, W. Finch W0231 09:10 How to avoid common mistakes in randomised
O0279 Evaluation of a new rapid Lateral flow immunoassay clinical study designYin Mo (Singapore, Singapore)
for the detection of DHA-producing Gram-negative W0232 09:30 Improved clinical trials in community-acquired
bacteriaC. Moguet* (Guipry, France), S. Oueslati, A. pneumonia using precision medicineLennie Derde
Vogel, S. Gelhaye, A. Chalin, H. Volland, T. Naas (Utrecht, Netherlands)
O0280 The NitroSpeed Taniborbactam NP test; easy Co-organised with: ESCMID Scientific Affairs Subcommittee, European
detection of ￿-lactamase sensitivity to Clinical Research Alliance on Infectious Diseases (ECRAID), ESCMID Study
taniborbactamO. Raro* (Fribourg, Switzerland), S. Group for Bloodstream Infections, Endocarditis and Sepsis (ESGBIES),
Herrera-Espejo, M. Bouvier, A. Kerbol, L. Poirel, P. European Sepsis Alliance (ESA), ESCMID Study Group for Antimicro
Nordmann
O0281 Rapid detection of ￿-lactamase-mediated resistance
to aminopenicillins from urines.P. Nordmann* SY072 08:30 - 10:30 Hall 3
(Fribourg, Switzerland), N. Helsens, C. Duployez, L.
Poirel, R. Dessein 2-hour Symposium
O0282 Rapid detection of antibiotic resistance in direct urine
Tackling the emergence of dengue and other Aedes-borne diseases in
samplesM. Bot* (Arnhem, Netherlands), J. Flipse, S.
Europe
Bongers, J. Hoogerwerf, J. Ten Oever, H. Wertheim,
M. Van Meer Chairs Fernanda Boulos (São Paulo, Brazil)
Martin P. Grobusch (Amsterdam, Netherlands)
O0283 Next-Generation Utilizer Dipsticks for direct-from-
sample phenotypic Antibiotic Susceptibility Testing in
UTIsE. Iseri* (Stockholm, Sweden), W. Van Der
Wijngaart, V. Özenci, R. Santini, A. Nakama, O. S0209 08:30 How dengue, chikungunya and zika virus disease
Ekelund, A. Van Belkum became emerging threats to EuropeCeline Gossner
O0284 Screening for ceftriaxone-resistant Neisseria (Solna, Sweden)
gonorrhoeae with the Urogenital and Resistance kit S0210 09:00 Surveillance of dengue in urbanised tropical
(AusDiagnostic)A. Braille* (Paris, France), M. regionsVincent Junxiong Pang (Singapore,
Mainardis, F. Meunier, M. Mathar, M. Mérimèche, B. Singapore)
Condamine, F. Caméléna, B. Berçot
S0211 09:30 Mosquito surveillance and control: opportunities and
O0285 Comparative evaluation of rapid antimicrobial challengesTba
susceptibility testing assays for Gram-negative
S0212 10:00 Tracking autochthonous arboviral infectionLuisa
bacteria from positive blood culturesD. Squitieri*
Barzon (Padua, Italy)
(Rome, Italy), G. Menchinelli, C. Magrì, T. D'inzeo, M.
Cacaci, B. Posteraro, G. De Angelis, M. Sanguinetti Co-organised with: European Centre for Disease Prevention and Control
(ECDC)
O0286 Rapid detection of Carbapenemases directly from
positive blood culture bottle: A tool for early shifting
from empirical to targeted therapyK. Chaudhary*
(New Delhi, India), H. Gautam, P. Batra, S. Mohapatra, EW078 08:30 - 10:30 Hall 4
S. Sood, B. Dhawan, B. Das Kumar
Educational Session
Implementing metagenomics in my lab and mistakes to avoid
SY076 - Hall 16
08:30 10:30 Chairs Hege Vangstein Aamot (Lørenskog, Norway)
2-hour Symposium Claudio Neidhöfer (Bonn, Germany)
AMR Surveillance in low resource countries: insights into clinical and policy
translation
W0233 08:30 Is metagenomics right for my lab?Paula Mölling
Chairs Kwame Ohene Buabeng (Ho, Ghana) (Örebro, Sweden)
H. Rogier Van Doorn (Hanoi, Vietnam)

ESCMID Global 2025 - Programme
W0234 08:50 Understanding the experimental and certification Contemporary diagnostic approaches for fungal infections
aspects of metagenomicsMads Albertsen (Aalborg, Chair Ilse D. Jacobsen (Jena, Germany)
Denmark)
W0235 09:10 Navigating tools, techniques, and procurementBasil
Britto Xavier (Groningen, Netherlands)
E0306 Evaluation of persistence of C. auris colonization in
W0236 09:30 Setting realistic goals and outcomes for
a cohort of patients discharged from a C. auris
metagenomics integrationClaire Bertelli (Lausanne,
endemic areaM. Bavastro* (Genoa, Italy), L.
Switzerland)
Mezzogori, M. Bonaffini, L. Magnasco, F.
Co-organised with: Danish Society for Clinical Microbiology, ESCMID Study Centorrino, V. Di Pilato, E. Willison, F. Portunato,
Group for Genomic and Molecular Diagnostics (ESGMD), Trainee Association D.R. Giacobbe, A. Vena, A. Marchese, M. Mikulska,
of ESCMID (TAE) Steering Committee M. Bassetti
E0307 A pilot study of digital retinal photography (DRP)
and tele-ophthalmology of patients with
OS037 08:30 - 10:30 Hall 5 candidemia.C. Clancy* (Pittsburgh, United States),
C. Hadi, E. Waxman, J.A. Viehman, A. Eller, M.
2-hour Oral Session
O'donnell, F. Silveira, P. Samantha, B. Smith, S.
Padival, V. Nauriyal, M.H.T. Nguyen
Whole genome sequencing: tracking transmission and reservoirs in
outbreaks E0308 Epidemiology and diagnosis of Pneumocystis
pneumonia : a 11 years-surveillance in FranceA.
Chairs Eric Claas (Leiden, Netherlands)
Alanio* (Paris, France), K. Boukris-Sitbon, M.
Paul G. Higgins (Cologne, Germany)
Desnos-Ollivier, D. Garcia-Hermoso, F. Lanternier,
O. Lortholoary
E0309 Chronic pulmonary aspergillosis coexisting with
O0268 From outbreaks to outcomes: Harnessing WGS for pulmonary cystic echinococcosis: a global
IPC in a high-risk paediatric settingN. Storey* systematic reviewA. Adhikari* (Chame, Nepal), F.
(London, United Kingdom), E. Cloutman-Green, J. Bongomin, R. Olum, P. Baral, I. Osaigbovo, W.
Hartley, H. Dunn, B. Brekle, M. Adil, S. Barua, J. Kibone, B. Ekeng, L. Atulinda, S. Katwal, B. Morgan,
Hatcher, J. Brown, J. Breuer N.V. Rhijn, D. Denning
O0269 Why do routine genome-oriented surveillance for E0310 Implementation and performance of a universal
Pseudomonas aeruginosa?A. Rath* (Regensburg, Mucorales PCR assay for diagnosis of
Germany), L. Grancicova, B. Kieninger, A. Caplunik- mucormycosisA. Haas* (Salt Lake City, United
Pratsch, J. Fritsch, A. Eichner, W. Schneider-Brachert States), K. Hanson
O0270 TreeTime estimation depicts transmission dynamics E0311 Blood cultures (BCs) contain populations of
of clinical and environmental Pseudomonas genetically diverse Candida strains that may differ
aeruginosa from common reservoirs in healthcare in antifungal resistance and toleranceC. Clancy*
environment through whole genome sequencing (Pittsburgh, United States), S. Cheng, H. Badrane,
(WGS)Ö. Yetis* (London, United Kingdom), Ö. Yetiş, B. Hao, G. Fleres, E. Driscoll, D. Chris, E. Josh, M.H.
F. Dyrkell, S. Ali, P. Wilson Nguyen
O0271 Understanding Serratia transmission during a E0312 Clinical validation of a urinary antigen test as an aid
neonatal ICU outbreak: A combined genotyping and to diagnose invasive aspergillosis in hematology
risk factor analysisK. Jaakkola* (Lyon, France), C. patientsY. Vanbiervliet* (Leuven, Belgium), R. Aerts,
Dananché, A. Fischer, J.C. Picaud, P. Cassier, M. T. Mercier, E. Boon, G. Gysembert, E. Houben, K.
Colomb-Cotinat, S. Haÿs, J.P. Rasigade Lagrou, J. Maertens
O0272 Genomic Insights into the Regional Transmission of E0313 Genomic epidemiology of Greek Candida auris
KPC-Producing Bacteria: Clonal and Non-Clonal clinical isolatesM. Siopi* (Athens, Greece), B.
Plasmid SharingC. Shankar* (Ann Arbor, United Spruijtenburg, I. Anagnostakis, C. Anthoulaki, A.
States), A.M. Pirani, D.B. Narayanan, B. Brennan, S. Argyropoulou, S. Varveraki, C. Vossou, A. Votsi, P.
Mcnamara, A. Miles-Jay, A. Bahr, E.S. Snitkin Giannopoulou, K. Gartzonika, M. Damala, I.
Daskalakis, I. Dendrinos, V. Dimitriou, E. Dimitroulia,
O0273 Genome-oriented analysis of the first outbreaks
L.P. Drosopoulou, O. Zarkotou, L. Zachariadou, V.
involving the novel Serratia sarumanii at a neonatal
Ippa, A. Kampas, P. Karagiannidou, S. Karabela, A.
unitA. Rath* (Regensburg, Germany), B. Kieninger,
Katsaka, A. Katsiaflaka, E. Kafkoula, M. Kimouli, I.
L.J. Klages, A. Eichner, A. Keller-Wackerbauer, S.M.
Lamprou, O. Legga, V. Mamali, M. Martsoukou, G.
Wellmann, A. Ambrosch, J. Fritsch, A. Caplunik-
Mouratis, C. Mparka, T. Biniari, A. Xanthaki, E.
Pratsch, M. Kabesch, J. Kalinowski, W. Schneider-
Oikonomopoulou, M. Orfanidou, F. Paliogianni, E.
Brachert
Palla, A. Pantazatou, K. Panteli, E. Papadogeorgaki,
O0274 Evaluating the Utility of Whole-Genome Sequencing M. Papadogianni, K. Papaefstathiou, P.
to Optimise Infection Prevention and Control in a Papanikolaou, J. Papaparaskevas, G. Parvouleskou,
Hospital Setting: Findings from the GENOTIPE E. Perivolioti, S. Pournaras, C. Silleli, T. Skalidis, E.
StudyJ. Price* (Brighton, United Kingdom), I. Sey, A. Souki, A. Spiliopoulou, C. Stergiou, S. Tsiplakou, P.
Yeoh, D. Wlazly, A. Davies, O. Makanjuola, J. Leach, S. Tsolakidou, N. Charalampaki, E. Chinou, G.S.
Mookerjee, M. Krutikov Christodoulatos, G. Chronopoulou, E. Chrysou, E.
O0275 Outbreak of Carbapenem-Resistant Acinetobacter Meijer, A. Tsakris, J. Meletiadis, G. Vrioni
seifertii in a Neonatal Intensive Care Unit: Genomic
Characterization and Surveillance.D. Pereira* (Porto
Alegre, Brazil), P. Barth, L. Konkewicz, W. Latosinski, EF042 - Arena 4
09:30 10:30
G. De Oliveira, L. Lutz, M. Mott, C. Constante, C.
Wilhelm, L. Antochevis, R. Paiva, K. Tragnago, A. ePoster Flash Session
Barth, A. Martins
Prosthetic and device-associated infections
O0276 Unveiling the Clonal Dynamics and transmission
mechanism of Carbapenem-Resistant Klebsiella Chair Marjan Wouthuyzen-Bakker (Groningen,
pneumoniae in the ICU environmentX. Han* Netherlands)
(Hangzhou, China), J. Zhou, Y. Jiang, Y. Yu
O0277 Survey of Infection Prevention staff perception of
WGS integration into routine IPC practiceD. Ling*
E0315 Case series of gluteal Apophysomycosis post
(Melbourne, Australia), B. Baral, V. Madigan
intramuscular injectionR. Sivasankaran* (Vellore,
India), R. Bandyopadhyay
E0316 MIGRATING mesh - an unusual cause of pyogenic
EF041 - Arena 2
09:30 10:30 liver abscessM. Caris* (Leiden, Netherlands), J.
ePoster Flash Session Rutgers, A. Inderson, S.M. Arend, L.M.F. Kuijpers
E0317 Ceftaroline salvage monotherapy: successful

ESCMID Global 2025 - Programme
treatment of a cerebrospinal fluid drain infection Co-organised with: ESCMID Education Subcommittee, ESCMID Professional
caused by a multidrug-resistant Staphylococcus Affairs Subcommittee, UEMS Section of Medical Microbiology, UEMS Section
epidermidis strainM.D. Di Trapani* (Bozen, Italy), T. of Infectious Diseases
Kamal Eldin, G. Spoladore, D. Drusiani, B. Ladinser, R.
Aschbacher
E0318 Timeline of early infections post porcine EF049 11:00 - 12:00 Arena 2
xenothymokidney transplantH. Neumann* (New
York, United States), M. Ringer, R. Alpizar-Rivas, J. ePoster Flash Session
Stern, F. Zervou, V. Halpern-Cohen, J. Hogan, A.
Griesemer, R. Montgomery, S. Williams, S. Mehta Sometimes it's hard to be a woman
E0319 Invasive Non-tuberculous mycobacteria Infection in Chair Debora Konopnicki (Brussels, Belgium)
children undergoing Cardiac Surgery at the
specialized Cardiology Hospital of PeshawarM.
Khan* (Peshawar, Pakistan)
E0354 Interleukins 17 and 18: Key players in Cervical
E0320 Use of multiplex PCR assay analysis in patients with Cancer Progression in Indian PopulationP. Gupta*
suspected implant-based breast reconstruction (Bhopal, India), A. Vyas, A. Halder, S. Purwar
infection: a single center experienceA. Pagotto*
E0355 Risk evaluation of iatrogenic transmission of Human
(Udine, Italy), G.G. Caputo, A. Scarabosio, A. Sartor,
Papillomavirus (HPV) during gynaecological
A. Colombo, P.C. Parodi, C. Tascini
proceduresB. Casini* (Pisa, Italy), F. Chiovelli, Y.
E0321 PET CT controls and Dalbavancin therapeutic drug Ferchichi, E. Esposito, M. Basile, G. Del Bravo, A.
monitoring can help guiding Dalbavancin treatment Giannini, T. Simoncini
duration of complicated cardiovascular infectionsC.
E0357 Rubella screening in pregnancy – Slovakian one-
Kujat* (Kiel, Germany), M. Jüptner, D. Pape, J. Frank,
center retrospective analysis around COVID-19
A.T.D. Thiem, B. Panholzer, B. Steinborn, S. Ewering,
pandemicZ. Paraličová* (Kosice, Slovakia), D.
A. Friedrichs
Javorská
E0322 A complex case of pelvic bone infection caused by
E0358 The impact of maternal influenza infection and
carbapenem-resistant Acinetobacter baumanii
vaccination during pregnancy on birth outcomesB.
successfully treated with eravacyclineM. Zagarrigo*
Goundappa* (Pittsburgh, United States), X. Zhang,
(Bologna, Italy), S. Tedeschi, M. De Paolis, G. Fornaro,
B. Gk, H.E.A. D'agostino, H. Liu, A.M. Rick
A. Pozzi, E. Zamparini, P. Viale
E0359 Use of valaciclovir therapy during pregnancy for the
E0323 Oritavancin in a patient with recurrent endocarditis by
prevention of congenital cytomegalovirus infection:
Enterococcus faecalis: a new therapeutic option?M.
a monocentric experienceG. Lorenzetti* (Rome,
Bongiovanni* (Lugano, Switzerland), B. Barda, E.
Italy), S. Garattini, L. Romani, M. Di Giuseppe, M. De
Bernasconi
Luca, L. Cursi, S. Bernardi, S. Chiurchiù, S.
Mercadante, C. Tripiciano, A. Krzysztofiak, C.
Vassallo, I. Fabietti, L. Caforio, L. Lancella, F.I. Calò
KN080 09:30 - 10:30 Hall 1 Carducci
Keynote Lecture E0360 Multi-systemic long-term sequelae following SARS-
CoV-2 Omicron infection in pregnancy: a
Infections after solid organ transplantation: past, present and future population-based cohort studyY.Y. Tan*
(Singapore, Singapore), E.X.H. Loy, A.T. Tay, J.T.
Chairs Nina Khanna (Basel, Switzerland)
Lim, C.J. Chiew, D.C.B. Lye, L.E. Wee
Priscilla Rupali (Vellore, India)
E0361 The Impact of OAS1 rs4766664 and OAS3
rs10735079 Polymorphisms on the Clinical Course
of COVID-19 in Pregnant WomenS. Kirik Yilmaz*
K0241 09:30 Jay Fishman (Boston, United States) (Konya, Türkiye), S. Kırık Yılmaz, S. Sumer, N. Demir
Aktug, O. Ural, E. Ozdemir Marzioglu, O. Secilmis, T.
Cora
SY082 11:00 - 12:00 Hall 6 E0362 Sex-stratified analysis of T cell activation,
exhaustion, proliferation and HIV reservoir among
1-hour Symposium PLWHL. Santinelli* (Rome, Italy), M. Andreotti, L.
Maddaloni, Z. Michelini, G. Bugani, F. Romano, E.
How to address anti-science in our community? Gentili Cacciola, G. Antonelli, C.M. Mastroianni, C.
Chairs Tuba Dal (Ankara, Türkiye) Scagnolari, G. D'ettorre
Tyra Grove Krause (Copenhagen, Denmark)
EF050 - Arena 3
11:00 12:00
S0243 11:00 The rise of anti-science: lessons for the future ePoster Flash Session
scientistMarion Koopmans (Rotterdam, Netherlands)
S0244 11:30 Open science for public trustLisa Hansen (Ottawa, Expanding MALDI-TOF applications
Canada) Chair Belen Rodriguez-Sanchez (Madrid, Spain)
FO090 - Arena 1
11:00 12:00
E0363 Application of MALDI-TOF Mass Spectrometry and
Open Forum Machine Learning for the Detection of Vancomycin-
Resistant Enterococcus faeciumM. Sánchez Cueto*
European CM/ID exam: going forward (Madrid, Spain), M. Sánchez-Cueto, M. Blázquez-
Sánchez, M. Marín, E. Cercenado, P. Muñoz, B.
Chair Siri Goepel (Tuebingen, Germany)
Rodríguez-Sánchez, D. Rodríguez-Temporal
E0364 Early detection of ampicillin susceptibility in
Enterococcus faecium with MALDI-TOF MS and
F0259 11:00 View from medical microbiologyMaeve Doyle machine learningT. Pichl* (Munich, Germany), L.
(Waterford, Ireland) Miranda, N. Wantia, K. Borgwardt, J. Sattler
F0260 11:10 view from infectious diseasesEoghan De Barra E0365 Rapid antifungal resistance prediction based on
(Dublin, Ireland) MALDI TOF mass spectrometryD. Duroux* (Zurich,
F0261 11:20 view from trainees (TAE)Christian Kraef Switzerland), Y. Yang, J. Sattler, A. Egli
(Copenhagen, Denmark) E0366 Rapid prediction of fluconazole resistance by
F0262 11:30 European exam - how to prepare?Annelies Verbon machine-learning analysis of Candida parapsilosis
(Bosch En Duin, Netherlands) MALDI-TOF mass profilesC. Magri* (Rome, Italy), C.
Magrì, V. Ivagnes, M. Sanguinetti, E. De Carolis

ESCMID Global 2025 - Programme
E0367 Optimizing pretreatment for MALDI-TOF MS: The new frontiers in antimicrobial stewardship
Evaluating the dispersion method for filamentous Chairs Jose Ramon Pano-Pardo (Zaragoza, Spain)
fungal identificationR. Huang* (Shenzhen, China), Y. Jeroen Schouten (Nijmegen, Netherlands)
Li, Y. He, T. Ma, F. Lu
E0368 Rapid detection of colistin resistance in
Acinetobacter baumannii by a MALDI-TOF MS-based
assayE. Kırbaş* (Van, Türkiye), I.D. Nix, K. Sparbier, K0242 11:00 Karin Thursky (Carlton, Australia)
O. Drews, B. Oberheitmann, M. Kostrzewa, G.
Hasçelik, B. Sancak
SY084 - Hall 10
E0369 Discrimination of clinical Pseudomonas strains at the 11:00 12:00
species level using a large-scale genomically
1-hour Symposium
predicted protein mass database with MALDI-MSK.
Teramoto* (Kyoto, Japan), Y. Sekiguchi, L. Sellami,
Sleeping sickness and Chagas: a tale of the two trypanosomes
M. Tohya, T. Kirikae
Chairs Hanne Brekke (Oslo, Norway)
E0370 Automatic differentiation of Clostridioides difficile
Irene Losada Galvan (Barcelona, Spain)
ribotypes using MALDI-TOF MS and web-based
classification modelsM. Blazquez Sanchez* (Madrid,
Spain), M.C. Blazquez-Sanchez, J.M. Moreno, A.
Guerrero-López, G.P. Mark, V. Gómez-Verdejo, P. S0247 11:00 Human African Trypanosomiasis: recent diagnostic
Muñoz, M. Marín, L. Alcalá, D. Rodriguez-Temporal, and medical practicesJean-Mathieu Bart (Conakry,
B. Rodriguez-Sanchez Guinea)
E0371 Identification of sepsis-causing bacteria using S0248 11:30 American Trypanosomiasis: Diagnosis, screening and
shotgun proteomicsL. Meekes* (Rotterdam, managementTba
Netherlands), D. Rustad, C. Güzel, T.K. Jenssen, H.
Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP)
Hauge, C. Klaassen, M. Bexkens, N. Strepis, T. Luider,
W. Goessens
OS047 - Hall 11
11:00 12:00
EF051 - Arena 4
11:00 12:00 1-hour Oral Session
ePoster Flash Session
Clinical studies in UTI
The enemy of my enemy: From jumbo phages to cocktails for difficult to treat Chairs Iva Butic (Zagreb, Croatia)
infections Paul Christoffer Lindemann (Bergen, Norway)
Chair Paul G. Higgins (Cologne, Germany)
O0344 Short versus long antibiotic treatment for
pyelonephritis and complicated UTIs: an updated
E0372 Anti-K2 recombinant phage depolymerases as anti-
systematic review and meta-analysis of RCTsI.
virulence agents against hypervirulent Klebsiella
Zahavi* (Haifa, Israel), D. Kunwar, J. Olchowski, H.
pneumoniaeM. Roch* (Geneva, Switzerland), R.
Dallasheh, M. Paul
Sierra, D. Andrey
O0345 Antibiotic treatment duration of complicated urinary
E0373 Jumbo Klebsiella bacteriophage demonstrates
tract infection patients in Europe: results from the
efficient multidrug-resistant Klebsiella pneumoniae
Ecraid POS-cUTI studyC. Kats* (Utrecht,
killing and significant clinical potentialY. Liu*
Netherlands), J.M. Bravo-Ferrer, T.T. Doesschate,
(Singapore, Singapore), Y. Zhong, S. Thong, L.H.A.
P.D. Van Der Linden, P. Martinez, O. Awwad, E. Rubio,
Kwa
P. Clevenbergh, A. Barac, A. Cano, E. Merino, P.
E0374 A new phage cocktail targeting at Klebsiella Andrade, L. Jacquin, B. Koprivica, R. Espindola, P.
pneumoniaeX. Yin* (Chengdu, China), Y. Feng, H. Muñoz, T. Lafon, M. Mendris, J. Van Laethem, D.
Luo, Z. Zong Viglino, A. Ternhag, J. Rupp, A. Hernandez-Torres, D.
E0375 Bacteriophages against pulmonary infection and Chadwick, B. Carevic, M. Bonten, E. Tacconelli, J.
colonization of the gut by multidrug-resistant Rodríguez-Baño
Klebsiella pneumoniae in murine modelsA.M. Örmälä- O0346 Prevalence and impact of multidrug resistance in a
Tiznado* (Stockholm, Sweden), S. Patpatia, J. cohort of patients admitted to emergency
Bengoechea, C. Frantzen, A. Garcia Navarro, C. Giske department for urinary tract infections: the UTILITY
E0376 A novel broad-spectrum phage cocktail effictive for study, a prospective multicentre studyL. Onorato*
carbapenem resistant Acinetobacter baumannii of (Naples, Italy), E. Allegorico, M. Macera, C. Monari, B.
capsular type 104/2/7 in vitroL. Wei* (Chengdu, Migliaccio, F.G. Numis, C. Nasta, M.T. Florio, R.
China), Y. Feng, Z. Zong Sciorio, G. Guiotto, M. Giordano, R. Raucci, F. Dello
Vicario, R. Nasti, A. Voza, N. Coppola
E0377 Proteomic and Genomic Characterization of a Novel
Bacteriophage of a New Genus Infecting O0347 Weekly sequential antibioprophylaxis for UTI in
Pseudomonas aeruginosaS. Unlu* (Ankara, Türkiye), neurogenic bladderR. Calin* (Paris, France), C.
A. Uskudar Guclu Chesnel, C. Hentzen, M. Teng, F. Le Breton, V. Phe, F.
Adda, C. Palacios, G. Amarenco, G. Pialoux
E0378 Phages as innovative adjuvants of antibiotics therapy
against S. aureus and P. aeruginosa in the context of O0348 Evidence for the duration of antibiotic therapy for
Cystic FibrosisA. Glorieux* (Brussels, Belgium), S. De chronic bacterial prostatitis: a systematic reviewL.
Soir, M. Merabishvili, J.P. Pirnay, D. De Vos, F. Van Cordes* (Geneva, Switzerland), A. Huttner, R. Calin,
Bambeke K. Gupta, M. Lafaurie, M. Lambregts, V. Lavergne, B.
Trautner
E0379 Evaluation of bacteriophages against Staphylococcus
aureus strains isolated from orthopaedic infectionsS.
Patpatia* (Helsinki, Finland), A. Camporeale, S.
Kiljunen, C. Giske, A.M. Örmälä-Tiznado OS048 11:00 - 12:00 Hall 12
E0380 Anti-Staphylococcus aureus phages: assessing the 1-hour Oral Session
risk of bacterial resistance emergence through
selective pressureM. Degreze* (Lyon, France), M. Complexities of infections in solid organ transplantation
Medina, F. Laumay, L. Blazère, E. Helluin, F. Laurent,
Chair Silvia Corcione (Turin, Italy)
C. Kolenda
KN081 11:00 - 12:00 Hall 1 O0349 Solid Organ Transplants from donors with positive
blood cultures: watch out for carbapenem-resistant
Keynote Lecture EnterobacteralesA. Cona* (Palermo, Italy), C.

ESCMID Global 2025 - Programme
Curatolo, P. Giordani, F. D'andrea, M. Campanella, E. SY087 - Hall 16
11:00 12:00
Conoscenti, S. Caruso, G. Mulè, D. Lo Porto, F.
Monaco, F. Cardinale, G. Di Martino, D. Di Carlo, N. 1-hour Symposium
Coppola, A. Mularoni
Innovating antimicrobial drug discovery and host-pathogen interaction
O0350 Risk factors for carbapenem-resistant
studies using chemical biology
Enterobacteriaceae infection after orthotopic liver
transplant in a large cohort of pre-transplant CRE Chair Laurent Poirel (Fribourg, Switzerland)
carriersM. Rinaldi* (Bologna, Italy), B. Miani, M.
Freire, E. Girão, D. Yahav, M. Valerio, L.M. Parra, L.
Alagna, E. Franceschini, P. Burra, A. Mularoni, M.
Halpern, L. Camargo, R. Romagnoli, E. Graziano, N. S0253 11:00 Bacterial PROTACs: Do proteolysis-targeting
Caroccia, M. Di Chiara, P. Viale, M. Giannella degraders represent a viable strategy for new
antimicrobials?Morreale Francesca Ester (London,
O0351 Serologic follow up of solid organ transplant
United Kingdom)
recipients who receive organs from syphilis
seropositive donors.O. Fernandez Garcia* S0254 11:30 Activity-based protein profiling of bacterial
(Edmonton, Canada), D. You, J. Gratrix, A. Singh, K. pathogens: new enzymes and their functions at the
Doucette host-microbe interfaceChristian Stephan Lentz
(Tromsø, Norway)
O0352 Prophylaxis strategies and risk of cytomegalovirus in
solid organ transplant recipientsA. Dahl* (KøbenhaVn
V, Denmark), M. Koller, O.J. Manuel, K.S. Moestrup,
ME088 - Hall 2
J. Reekie, E. Tusch, C.G. Crone, M. Perch, F. 11:00 12:00
Gustafsson, S.S. Sorensen, N. Schultz, K. Schønning,
Meet-the-Expert
J. Lundgren, N. Mueller, M. Helleberg
O0353 Burden of non-microbiologically confirmed infections Global AMR Policy after UNGA: what do we do now!
in solid organ transplant recipientsM. Zou* (Basel,
Switzerland), M. Koller, O.J. Manuel, N. Mueller, K.
Boggian, C. Hirzel, C. Garzoni, N. Khanna, C. Van
Delden, D. Neofytos M0255 11:00 Gisela Robles Aguilar (Oxford, United Kingdom)
M0256 11:12 Mike Sharland (London, United Kingdom)
SY085 - Hall 13
11:00 12:00
1-hour Symposium OS043 11:00 - 12:00 Hall 3
1-hour Oral Session
Diagnosing the undiagnosed fraction: the final step towards viral hepatitis
elimination
Navigating disinfection challenges: resistance, outbreaks, and efficacy
Chairs Mojca Maticic (Ljubljana, Slovenia)
Chairs Hillary A. Craddock (Dublin, Ireland)
Snjezana Zidovec Lepej (Zagreb, Croatia)
Stephanie J. Dancer (Glasgow, United Kingdom)
S0249 11:00 Role of reflex testing strategies in identifying patients
O0324 Prolonged disinfectant exposure impacts the
with chronic viral hepatitisOana Sandulescu
antimicrobial resistance of healthcare-associated
(Bucharest, Romania)
microorganisms: a systematic reviewÂ.R. Fernandes*
S0250 11:30 Management and elimination of hepatitis in hard-to- (Porto, Portugal), A. Gonçalves Rodrigues, L.
reach personsSuda Tekin (Istanbul, Türkiye) Cobrado
Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), O0325 Sink-associated outbreak of verona integron-
Romanian Society for Infectious Diseases and HIV/AIDS encoded metallo-??-lactamase-producing
carbapenem-resistant Pseudomonas aeruginosa in a
Dutch intensive care unitM. Van Den Bos Kromhout*
SY086 - Hall 14 (Zwolle, Netherlands), S. Debast, M. Van Den Bos-
11:00 12:00
Kromhout, S. De Vries-Van Rossum, S. Abma-Blatter,
1-hour Symposium B. Immeker, K. Zuur, M. Hijmering, J.W.A. Rossen
O0326 Carbapenemase-producing Enterobacterales
Impact on including a measure of viability in molecular diagnostic tests
outbreak control by replacement of toilets or long-
Chairs Fusun Can (Istanbul, Türkiye) term disinfection? A real-life experience.A.L.
Denise O'sullivan (Teddington, United Kingdom) Engsbro* (Slagelse, Denmark), K.H. Hansen, M.F.J.
Larsen, N. Kling, H.T. Larsen, R. Kjølsen, B. Hansen,
L.K. Vejrum, A.L. Laugesen, M. Kemp
S0251 11:00 Viability markers in support of development of O0327 Tolerance of Klebsiella pneumoniae biofilms to
Chlamydia screening recommendationsPetra Wolffs disinfection with peracetic acidM. Arvand* (Berlin,
(Maastricht, Netherlands) Germany), A.M. Richter, D. Csertö, K. Konrat
S0252 11:30 Measuring viability to improve the correlation of AMR O0328 Bringing balance to the formulation: disinfection
markers and clinical outcomes in Neisseria efficacy and material compatibilityJ. Jennings*
gonorrhoeaeTatum Mortimer (Athens, United States) (Halifax, United Kingdom), T. Langford, H.
Mansbridge, E. Fraser, I. Poles, J. Clarke
Co-organised with: ESCMID Study Group for Mycoplasma and Chlamydia
Infections (ESGMAC)
LB002 - Hall 4
11:00 12:00
ME089 11:00 - 12:00 Hall 15 1-hour Oral Session
Meet-the-Expert Investigation of intriguing outbreaks
How to teach Medical Mycology
L0006 Molecular surveillance of artemisinin and
sulfadoxine-pyrimethamine resistance in Plasmodium
M0257 11:00 Katrien Lagrou (Leuven, Belgium) falciparum isolates from Uganda: results of ERASE
studyM. L'episcopia* (Rome, Italy), F.V. Segala, J.
M0258 11:12 Mihai Mares (Iasi, Romania)
Ictho, R. Papagni, I. Obua, E. De Vita, N. Olang, R.
Co-organised with: European Confederation of Medical Mycology (ECMM) Novara, V. Totaro, L. Olal, G. Patti, C. Bignom, C.
Agaro, G. Dall'oglio, B. Ngole, S. Okori, P. Lochoro, G.

ESCMID Global 2025 - Programme
Putoto, F. Di Gennaro, C. Severini, A. Saracino Kingdom), H. Alhosni, F. Alahdab
L0007 Investigation of an international pseudo-outbreak O0335 Gamified Intervention to Enhance Antimicrobial
involving Paraburkholderia fungorum blood culture Stewardship: Improving Knowledge and Practices on
contaminationJ. Moran-Gilad* (Jerusalem, Israel), the Rational Use of Antimicrobials Among Medicines
J.L. Dale, A. Michael-Gayego, A. Gross, V. Temper, S. and Therapeutics Committee Members ???S.
Lim, C. Lees, K. Knowles, J. Strahilevitz, Y. Oster, D. Mahadevaiah* (Mysore, India), C. Es, K. Anil, Y.
Grupel, D. Reshef, B.A. Smith, B. Warren, E.L. Maheshwarappa, S.S. Sc, S. Srinivas, V. Swamy Gs,
Palavecino, P. Snippes Vagnone K. Gautam
L0008 Evolving cluster of severe infective endocarditis with O0336 Healthcare providers' perspectives on antibiotic use
non-toxigenic C. diphtheriae amongst people and resistance in pregnancy, childbirth, and children
experiencing homelessness and substance misuse in under five years of age across four levels of hospitals
the UKR. Cordery* (London, United Kingdom), T. in Lao PDR, 2024S. Vantava* (Vientiane Capital, Lao
Patel, T. Anwar, N. Utjesanovic, A. Aryee, E. People's democratic republic), K. Thilakoun, D.
Mavrogiorgou, N. Karogiannis, D.J. Litt, J. D'aeth, C. Sypaseuth, C. Khamla, I. Bounxou, P. Vanpheng, B.
Primus, S. Das, K. Paranthaman, G. Amirthalingham Phetsamone, S. Bangthong, K. Sengchanh, S.
Latsamy, S. Vanphanom, L. Annick, S. Somphou
L0009 AI-driven live cough rate tracking for public health
surveillanceM. Kågebäck* (Göteborg, Sweden), E. O0337 High gender gap in female labour force participation
Carlsson and reduced gender inequality linked to high
antibiotic consumption: Evidence from a global
analysisD. Samria* (Bangalore, India), D. Batheja, A.
OS044 - Hall 5 Nandi
11:00 12:00
O0338 Gender gaps in knowledge of antibiotics and
1-hour Case Session antimicrobial resistance: Evidence from IndiaD.
Batheja* (Delhi, India), S.R. Umenthala, S. Goel, D.
Unusual presentations of unusual parasites Samria, R. Bhagawati, B. Deepshikha
Chairs Emmanuel Bottieau (Antwerp, Belgium)
Marcelo Victor Radisic (Buenos Aires, Argentina)
OS046 - Hall 9
11:00 12:00
1-hour Oral Session
O0329 Atypical neonatal cutaneous myiasis: a diagnostic
challenge mimicking pustular rash in a resource- Vaccines and prophylaxis against respiratory viral infections
limited settingD. Ekwem Amarachi* (Gulu, Uganda),
Chairs Ana Atti (London, United Kingdom)
E. Namara, E. Ssenuni, A. Amuge, V. Omona, R. Okidi,
Sophie Schneitler (Homburg, Germany)
R. Olum
O0330 An itchy awakening due to Dermanyssus infestationJ.
Sevestre* (Marseille, France), A.Z. Diarra, J.P. Dales,
J.M. Bérenegr, S. Ranque O0339 Public health impact of universal prophylaxis with
nirsevimab for prevention of infant hospitalizations
O0331 Uterine Myiasis: A Rare Case of External
due to respiratory syncytial virus. Full 2023-24
Genitourinary MyiasisR.L. Johnson* (Birmingham,
season analysis of the NIRSE-GAL study
United States), J.C.F. Nakazaki, P. Legua
(www.nirsegal.es/en)F. Martinón-Torres* (Santiago
O0332 Neurognathostomiasis Presenting with Cerebral De Compsotela, Spain), N. Mallah, J. Pardo-Seco, O.
Venous Sinus Thrombosis: A case report of rare Pérez-Martínez, M.I. Santiago-Pérez, M.T. Otero-
clinical manifestation.C. Norsungnern* (Bangkok, Barrós, N. Suárez-Gaiche, R. Kramer, J. Jing, L.
Thailand), J. Vinichanan, L. Paitoonpong Platero-Alonso, R.M. Alvárez-Gil, O.M. Ces-Ozores, V.
O0333 If at first, you don't succeed… Treatment-resistant Nartallo-Penas, S. Mirás-Carballal, M. Piñeiro-Sotelo,
Fascioliasis: case reportW. Garr* (Leeds, United J.M. González-Pérez, C. Rodríguez-Tenreiro-Sánchez,
Kingdom), K. Woods, L. Nabarro I. Rivero-Calle, Á. Manzanares-Casteleiro
O0340 Relative effectiveness of high-dose versus standard-
dose quadrivalent influenza vaccine against
SY083 11:00 - 12:00 Hall 7 hospitalizations and mortality according to Charlson
Comorbidity Index: A post-hoc analysis of the
1-hour Symposium DANFLU-1 randomized trialK. Feldballe Bernholm*
(Copenhagen, Denmark), N. Dyrby Johansen, C.
Lyme neuroborreliosis: challenges in diagnosis and treatment Espersen, D. Modin, K. Hyldekær Janstrup, J. Nealon,
Chairs Alexandra Mailles (Paris, France) S. Samson, M.M. Loiacono, R. Harris, C. Schade
Joanna Maria Zajkowska (Białystok, Poland) Larsen, A.M. Reimer Jensen, N.E. Landler, S. Tellerup
Nielsen, L. Russell, T. Skovsgaard Itenov, B.L.
Claggett, S.D. Solomon, M.J. Landray, G.H. Gislason,
L. Køber, P. Sivapalan, J.U. Stæhr Jensen, T. Biering-
S0245 11:00 Challenges in diagnosis of Lyme neuroborreliosisRick Sørensen
Dersch (Freiburg, Germany)
O0341 Relative vaccine efficacy of a SARS-CoV-2 spike
S0246 11:30 Challenges in treatment of Lyme receptor-binding and N-terminal domain COVID-19
neuroborreliosisAnne Marit Solheim (Kristiansand, vaccine versus mRNA-1273: subgroup analysesC.
Norway) Grassi* (Cambridge, United States), S. Chalkias, P.
Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain Dennis, D. Petersen, K. Radhakrishnan, L. Vaughan, R.
(ESGIB), ESCMID Study Group for Lyme Borreliosis (ESGBOR) Handforth, N. Vicic, A. Rossi, R. Wahid, D. Edwards, J.
Feng, W. Deng, H. Zhou, E. De Windt, V. Urdaneta, B.
Girard, S. Faust, S. Walsh, C. Cosgrove, R. Das
OS045 - Hall 8 O0342 Effectiveness of RSV vaccine in lung transplant
11:00 12:00
recipients: neutralizing antibody response against
1-hour Oral Session reference and seasonal strainsN. Shirin* (Ramat Gan,
Israel), L. Levy, D. Yahav, M. Benzimra, Y. Bezalel, T.
Social behavioural dynamics of antibiotic use and AMR Hoffman, T. Sinai, M. Jurkowicz, O. Deri, N. Matalon,
Chairs Sonia Lewycka (Hanoi, Vietnam) M. Saute, Y. Lustig, E. Nachum, M. Peled, I. Nemet, M.
Filippo Medioli (Milan, Italy) Mandelboim
O0343 Novavax investigational COVID-19 Influenza
Combination nanoparticle vaccine phase 2 study
safety evaluationC. Bennett* (Gaithersburg, United
O0334 Investigating the Knowledge, Attitudes, and Practices
States), V. Shinde, S. Neal, J.S. Plested, T. Vincent, M.
around Antimicrobial Resistance and Stewardship
Zhu, S. Cloney-Clark, Z. Cai, B. Riviers, A. Ahmed, F.
Among Syrian Healthcare Professionals: A Cross-
Mahkhou, A.M. Marchese, I. Cho, L. Fries, W. Woo
Sectional SurveyA. Abbara* (London, United

ESCMID Global 2025 - Programme
EF054 - Arena 3
13:30 14:30
SY093 13:30 - 14:30 Hall 11 ePoster Flash Session
1-hour Symposium Beware the sink! Pathogen reservoirs in drains and waste water
Immunosenescence and immune response to vaccination Chair Stephan Juergen Harbarth (Geneva, Switzerland)
Chairs Petar Velikov (Sofia, Bulgaria)
Dafna Yahav (Ramat-Gan, Israel)
E0391 Genomic Epidemiology to Investigate Healthcare
Environment as Reservoir for Carbapenem-
Resistant Organisms in an Academic Hospital in
S0267 13:30 How immunosenescence impacts vaccine
Miami, Florida.A. Jimenez* (Miami, United States),
responseAndrea Cossarizza (Modena, Italy)
S. Hawken, S. Arenas, K. Mokoban, D. Pronty, O.
S0268 14:00 Strategies to tackle immunosenescence and improve Martinez, J. Colson, A. Richardson, T. Ferreira, B.
immune response to vaccination in the elderlyInna Shukla
Ovsyannikova (Rochester, United States)
E0392 Two clusters of carbapenemase-producing
Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), Enterobacterales linked to hospital wastewater
ESCMID Vaccine Study Group (EVASG) drainage in utility rooms – an outbreak
investigationI. Vock* (Basel, Switzerland), G.
Capoferri, P. Urwyler, P. Domene, D. Roy, S. Kuster,
EW096 - Hall 15 N. Gürtler, B. Ivan, P.M. Keller, S. Tschudin-Sutter
13:30 15:30
E0393 Assessing the burden of carbapenemase and
Educational Session colistin antimicrobial resistance genes in hospital
wastewaterE. Au* (Calgary, Canada), N. Acosta, B.
Tools for successful development as a medical educator
Waddell, J. Lee, K. Du, R.B. Weyant, B. Dalton, M.
Chairs Giorgia Caruana (Sion, Switzerland) Bautista, J. Mccalder, R. Clark, J. Pitout, J. Kim, B.
Yoav Keynan (Winnipeg, Canada) Missaghi, O. Larios, J. Vayalumkal, J. Leal, E.
Rennert-May, J. Kanji, P. Westlund, B. Lee, X.L.
Pang, K. Frankowski, C. O'grady, J.M. Conly, C.R.
Hubert, M. Parkins
W0273 13:30 Developing your educator professional identityTodd
E0394 Hospital wastewater as a reservoir for
Cassese (Bronx, United States)
carbapenemase-producing organismsA.
W0274 13:50 What do IPC doctors need to learn to be Anantharajah* (Brussels, Belgium), C. Altintas, T.
preparedSimone Scheithauer (Göttingen, Germany) Lavalleye, A. Delaunoy, I. Meyts, E. Dumitreasa, A.
W0275 14:10 Communities of practice: successful experience of a Bennert, C. Schirvel, A. Verroken, H. Rodriguez-
transformative collaboration and roadmapErin Villalobos
Bonura (Portland, United States) E0396 Reversing and controlling microbial proliferation in
W0276 14:30 The critical need for ongoing innovations in medical the water system of a high-risk hospital ward after
educationClémentine Schilte (Paris, France) extended closure and reconstructionD. Chaput*
(Glasgow, United Kingdom), K. Clarkson, L.
Co-organised with: Infectious Diseases Society of America (IDSA), ESCMID
Bagrade, A. Marek, D. Kelly, D. Watson, A. Leanord,
Professional Affairs Subcommittee, Trainee Association of ESCMID (TAE)
T. Steele
Steering Committee, British Infection Association (BIA), Young Leader Circle
of the American Society of Microbiology E0397 Whole-genome sequencing as part of the tracking
and managing Carbapenemase producing
Enterobacterales transmission in an acute hospital
FO097 - Arena 1 settingD. Coffey* (Cork, Ireland), R. Waldron, D.
13:30 14:30 Neshev, M. Cormican, C. Clarke, L. Hayes
Open Forum E0398 Is there a solution for hospital acquired infections
due to the aquatic reservoir in the near patient
Essential diagnostics in Low-Resource Settings: why are we still talking? environment?H. Zayyad* (Poriya, Israel), R. Khouri,
Chair Truls Michael Leegaard (Lørenskog, Norway) N. Saleh, A. Peretz
E0399 Reducing Antimicrobial Resistance (AMR) across
the One Health Landscape: Diverse Perspectives on
AMR risks and their mitigation in sinks, drains, and
F0277 13:30 Training skilled personnel in LMIC and brain drain: is
wastewaterH.A. Craddock* (Dublin, Ireland), A.
the solution the problem?Sipho Kenneth Dlamini
Kearney, F. Fitzpatrick, C. Finn, M.T. Pryce, D.
(Observatory, South Africa)
Fitzgerald-Hughes
F0278 13:40 Leveraging surveillance networks to strengthen basic
bacteriologyDissou Affolabi (Cotonou, Benin)
F0279 13:50 Clinical bacteriology laboratories in low-resource EF055 - Arena 4
13:30 14:30
settings: considerations for sustainabilityMakeda
Semret (Montreal, Canada) ePoster Flash Session
Co-organised with: ESCMID Professional Affairs Subcommittee, Dutch
The cutting edge in tuberculosis
Society for Medical Microbiology (NVMM), ESCMID Parity
Commission,Federation of European Microbiological Societies (FEMS), Chair Graeme Ayton Meintjes (Observatory, South Africa)
ESCMID Study Group for Antimicrobial stewardship (ESGAP), Société belge
d'Infectiolo
E0400 Personalised risk predictions for incident TB and
preventive treatment uptake.R. Rose-Key* (London,
FO098 - Arena 2
13:30 14:30 United Kingdom), R. Gupta, M. Noursadeghi
Open Forum E0401 Programmatic migrant screening for tuberculosis
identifies a spectrum of clinical phenotypes and
Best of ID Week outcomes: cohort data from a national migrant
screening programmeM. Gohar* (Leicester, United
Chair Tina Tan (Chicago, United States)
Kingdom), C. Martin, A. Ayobami, H. Patel, M. Patel,
L. Ahyow, B. Srini, G. Rishi, P. Mark, S. Nilesh, C.
Trevithick, K. Pierun, M. Wiselka, L. Gray, I.
F0280 , Seth Cohen (Seattle, United States), Erin Mccreary Abubakar, R. Baggaley, A. Cooper, P. Haldar, M.
(Pittsburgh, United States), Ilan Youngster (Beer Pareek
Yaakov, Israel) E0402 An investigation into the relationship between
human and animal Mycobacterium bovis isolates

ESCMID Global 2025 - Programme
using whole genome analysis.M. Mansfield* LB003 - Hall 13
13:30 14:30
(Dublin, Ireland), E. Roycroft, S. Mok, P. Flanagan,
M. Mc Elroy, B. Byrne, H. Cameron, D. Farrell, S.V. 1-hour Oral Session
Gordon, J. Wagener, M.M. Fitzgibbon, T.R. Rogers
New solutions for difficult-to-treat infection
E0403 Distinguishing relapse from reinfection in
tuberculosis patients from LithuaniaL.
Vasiliauskaite* (Vilnius, Lithuania), L. Vasiliauskaitė,
A. Zinola, F. Di Marco, V.E. Davidavičienė, B. L0011 Antimicrobial CRISPR-Cas9-based treatment against
Nakčerienė, A. Vaitulionytė, D.M. Cirillo, T. antibiotic resistant extraintestinal pathogenic E. coli
Kačergius (ExPEC) ST131C. Morros-Bernaus* (Penryn, United
E0404 Rapid Resistance Profiling of Mycobacterium Kingdom), J. Westley, E. R. Wyrsch, S. P. Djordjevic,
tuberculosis from Clinical Specimens using A. F.C. Leonard, D. Sünderhauf, S. Van Houte
Targeted Next-Generation Sequencing: A Pilot L0012 Ultra-narrow spectrum antibiotic against multi-drug
Validation StudyP. Chheda* (Mumbai, India), S. resistant gonococci with novel mode of actionN.
Shivaprakash, T. Dama, G. Thandassery Nguyen* (Vienna, Austria), N. Nhung, A.K. Mix
E0405 Inflammation precedes early respiratory worsening L0013 Multivalent OMV-based vaccine against Klebsiella
in HIV-negative tuberculosis patients during pneumoniaeB. Cano Castaño* (Madrid, Spain), B.
antituberculosis treatmentA. Van Laarhoven* Cano-Castaño, A. Tajuelo Moreno-Palancas, S. Prieto
(Nijmegen, Netherlands), L. Kurver, E. Klein Martin-Gil, D. Fousteris, L. Del Pozo Acebo, F.
Teeselink, A. Lemson, C. Bosteels, N. Carpaij, J. Van Docando Sánchez, E. Gato, A. Pérez, M.J. Mcconnell
Ingen, E. Ardiansyah, C. Van Arkel, R. Vullinghs, C.
L0014 Epidermicin NI01, a first-in-class peptide antibiotic
Magis Escurra, W. Hoefsloot, R. Van Crevel
candidate, has potent efficacy in a robust MRSA
E0406 Impact of fluoroquinolone resistance on the cost- wound infection model and low allergic reaction
effectiveness of empiric treatment for multidrug- or liabilitiesM. Upton* (Plymouth, United Kingdom), G.
rifampicin-resistant tuberculosisC. Kim* (London, Barker, V. Bennett, I. Fotheringham, S. Baxter, H.
United Kingdom), S. Sweeney, H. Sohn, G.M. Knight, Curry
C.F. Mcquaid
L0015 Minimum inhibitory concentrations of quabodepistat
E0407 A longitudinal study on the evolution of drug in Mycobacterium tuberculosis clinical isolates from
resistance during tuberculosis treatmentE. Danso* patients with drug-susceptible pulmonary
(Accra, Ghana), P. Asare, P. Tetteh, A. Tetteh, A.A. tuberculosisI. Kontsevaya* (Munich, Germany), Y.
Boadu, S. Osei-Wusu, A. Asante-Poku, Y. Klinogo, A. Hayashi, D. Towle, N. Hariguchi, Y. Liu, S. Takuva
Sylverken, J. Afriyie-Mensah, A. Adjei, D. Yeboah-
Manu
E0408 Phase 1, randomized, double-blind, parallel-group, SY094 - Hall 14
13:30 14:30
dose-escalation safety and tolerability of PLGA
encapsulated first line antitubercular drugs 1-hour Symposium
nanoparticles in healthy volunteersA.K. Pandey*
(Chandigarh, India), N. Shafiq, S. Malhotra, C. Farm to fork: food-borne antimicrobial resistance
Mothsara, G. Khuller, J. Verma, L. Verma Chairs Beatriz Guerra Román (Parma, Spain)
Joel Mossong (Luxembourg, Luxembourg)
SEL - Hall 1
13:30 15:30
Special Session S0269 13:30 Foodborne risk in meat and fishery products and
impact on AMRAnders Dalsgaard (Frederiksberg C,
Selective Pressure Denmark)
Chairs Jacob Moran-Gilad (Beer Sheva, Israel) S0270 14:00 Control challenges associated with food-borne
Joshua Nosanchuk (Bronx, United States) multidrug resistanceLuisa Maria Vieira Peixe (Porto,
Jose Ramon Pano-Pardo (Zaragoza, Spain) Portugal)
Jesús Rodríguez-Baño (Seville, Spain) Co-organised with: ESCMID Food- and Water-borne Infections Study Group
Anja Šterbenc (Ljubljana, Slovenia) (EFWISG)
Suzanne Van Asten (Nijmegen, Netherlands)
David Van Duin (Chapel Hill, Nc, United States)
ME095 - Hall 16
13:30 14:30
Meet-the-Expert
JS1 - Hall 12 Local antimicrobials for deep infections
13:30 14:30
Journal Session
Late-breaker research from CMI and CMI Communications
M0271 13:30 Karolina Akinosoglou (Patra, Greece)
M0272 13:42 Pierre Tattevin (Rennes, France)
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG),
J001 13:30 Measuring the impact of hospitalization for infectious ESCMID Study Group for Implant-associated Infections (ESGIAI), ESCMID
diseases on the quality of life of older patients in four Study Group for Infectious Diseases of the Brain (ESGIB)
European countries: the AEQUI longitudinal matched
cohort study (2020–2023)Gaetan Gavazzi (Grenoble,
France) OS052 - Hall 2
13:30 14:30
J002 13:45 Long-term outcomes of passive immunotherapy for
COVID-19: a pooled analysis of a large multinational 1-hour Oral Session
platform randomized clinical trialThomas Holland
(Durham, United States) AI in infectious diseases: the lab and beyond
J003 14:00 The long-term sustainability of a pharmacist-led Chair Miranda Langendam (Amsterdam, Netherlands)
antimicrobial stewardship penicillin allergy
delabelling ward round: A prospective cohort
studyElise Mitri (Heidelberg, Australia)
O0381 Accurate strain typing of key bacterial pathogens
J004 14:15 Efficacy and safety of mechanical thrombectomy in through artificial intelligence analysis of MALDI-TOF
acute ischemic stroke secondary to infective mass spectraN. Macesic* (Melbourne, Australia),
endocarditisTba H.A. Nguyen, A. Peleg, J. Song, J.A. Wisniewski, D.L.
Dowe

ESCMID Global 2025 - Programme
O0382 CarbaDetector: An Artificial Intelligence-Driven
Prediction Model for Detecting Carbapenemase-
S0265 13:30 Sex impacts incidence, management, and outcome in
Producing Enterobacterales Using Disk-DiffusionL.K.
bacteraemiaAnnette Westgeest (Leiden,
Muhsal* (Oldenburg, Germany), C. Cimen, J. Sattler,
Netherlands)
O. Nolte, L. Dortet, R. Bonnin, A. Egli, A. Hamprecht
S0266 14:00 The complex interplay between gender and
O0383 AI-Driven Early Infectious Disease Detection in Dutch
sepsisInes Lakbar (Montpellier, France)
Primary Care: leveraging Bidirectional Encoder
Representations from Transformers (BERT) and Early Co-organised with: ESCMID Study Group for Bloodstream Infections,
Recognition using Neural Information Encoding Endocarditis and Sepsis (ESGBIES)
(ERNIE)G. Danoe* (Groningen, Netherlands), M.
Homburg, M.Y. Berger, T. Olde Hartman, A. Voss, A.
Hamprecht, M. Brilman, L.L. Peters, M.S. Berends ME101 14:45 - 15:45 Hall 14
O0384 Predicting potentially infection-related findings in
Meet-the-Expert
structured radiology reportsJ. Xu* (Oxford, United
Kingdom), J.B. Delbrouck, J. Wei, A.S. Walker, C.P.
How to master conflict management and negotiation in healthcare
Langlotz, D. Eyre
O0385 Application of Artificial Intelligence in Assisting X-ray
Diagnosis of Pediatric Pulmonary InfectionsH. Zhang*
(Shanghai, China), X. Xu, J. Ai M0285 14:45 Esther Calbo (Terrassa, Spain)
M0286 14:57 Jan A.J.W. Kluytmans (Utrecht, Netherlands)
OS053 - Hall 3
13:30 14:30
1-hour Oral Session FO102 14:45 - 15:45 Arena 1
Open Forum
Immune evasion and intracellular survival strategies
Chairs Juliane Bubeck Wardenburg (St. Louis, United States) Navigating the future of pandemics across One Health
Giovanni Delogu (Rome, Italy)
Chair Xavier Lescure (Paris, France)
O0386 Capsule-Dependent Modulation of Cell Death
F0287 14:45 Status of the One Health Joint Plan of Action by the
Pathways and Immune Evasion in Acinetobacter
QuadripartiteChadia Wannous (Paris, France)
baumanniiH. Wang* (Beijing, China), C. Jiang
F0288 14:55 National surveillance responsibilities under the
O0387 Intracellular lifestyle of Acinetobacter baumannii:
updated international health regulationsTba
Role of phospholipase A2 and transcriptional factor
EB (TFEB)Y. Smani* (Seville, Spain), C. Atalaya Rey, I. F0289 15:05 Long-term consequences of emerging viral
Molina Panadero, A. Lora González, A. Hmadcha diseasesAlfonso J. Rodriguez-Morales (Pereira,
Colombia)
O0388 The role of peg344 of hypervirulent Klebsiella
pneumoniae on suppressing autophagy responses of Co-organised with: ESCMID Emerging Infections Subcommittee, ESCMID
macrophagesZ.E. Kuloğlu* (Istanbul, Türkiye), Ö. Study Group for Public Health Microbiology (ESGPHM), Trainee Association
Albayrak, D. Güllü, G. Ekinci, F. Can of ESCMID (TAE) Steering Committee, Brazilian Society of Infectious Diseases
(SBI), Latin American Society for Travel Medicine
O0389 c-Myc Inhibits Macrophage Antimycobacterial
Response in Mycobacterium tuberculosis InfectionC.
Dollé* (Zurich, Switzerland), E. Sarti, R.
Wolfensberger, K. Kusjeko, S. Bredl, R.A. Speck, M. EF059 14:45 - 15:45 Arena 2
Greter, J.H. Rueschoff, D. Mai, A. Diercks, P. Sander,
ePoster Flash Session
G.S. Olson, J. Nemeth
O0390 Targeting neutrophil extracellular traps (NETs) Bacterial infections in the post pandemic era
prevents tuberculosis immunopathologyJ.
Chair Özlem Kurt Azap (Ankara, Türkiye)
Kutschenreuter* (London, United Kingdom), D.
Kirwan, R. Cusman, K.H. Skolimowska, R.H. Gilman,
J.S. Friedland, D.L.W. Chong
E0424 Genomic epidemiology of invasive meningococcal
disease in Scotland: The impact of the COVID-19
SY091 13:30 - 14:30 Hall 4 pandemicN. Ahmad* (London, United Kingdom), C.
Rodrigues, A. Smith, C. Cameron, L. Macdonald, R.
1-hour Symposium Ure, M. Maiden
Emerging infectious diseases: staying informed and prepared in a globalised E0425 Targeted probe-capture culture-independent
world sequencing identifies emergence of Macrolide-
Resistant Bordetella pertussis in AustraliaW. Fong*
Chairs Nitin Gupta (Manipal, India) (Westmead, Australia), R. Rockett, K. Tam, T. Nguyen,
Pikka Jokelainen (Copenhagen, Denmark) E. Sim, C. Suster, J. Agius, S. Chandra, A. Watt, D.
Speers, M. Graham, T. Tran, C. Lim, M. Wehrhahn, A.
Ginn, D. Gray, J. Robson, L. Papanicolas, I. Gardner,
A. Howard-Jones, A. Outhred, K. Kennedy, L. Cooley,
S0263 13:30 Lessons learnt from previous outbreaksTba
Q. Wang, N. Jeoffreys, S. Chen, K. Basile, T.
S0264 14:00 Disease X: preparedness for the next pandemicYee Golubchik, J. Kok, V. Sintchenko
Sin Leo (Singapore, Singapore)
E0426 Invasive pneumococcal disease in Spanish adults.
Co-organised with: ESCMID Emerging Infections Subcommittee, Deutsche Multicenter analysis of serotypes and lineages in the
Gesellschaft für Infektiologie, Deutsche Gesellschaft für Tropenmedizin, post-pandemic period.R. España Bonilla* (Barcelona,
Reisemedizin und Globale Gesundheit e.V. Spain), R. España-Bonilla, A. González-Díaz, J.M.
Marímón, A. Manzanal, E. Cercenado, S. De La Villa,
B. Viñado, M. Bernat-Sole, M. Campos-Ruiz, M.D.
SY092 - Hall 5 Quesada, A. Casabella, M.L. Machado, R. Tejero, M.Á.
13:30 14:30
Galán, S. Calvo-Silveria, D. Berbel, J. Yuste, S. Martí,
1-hour Symposium J. Càmara, C. Ardanuy
E0427 Group A streptococcal infections in Germany from
Sex differences in management and outcome of patients with serious
2017 to 2024: a post-pandemic rebound above
bacterial infections
expected numbers?A. Von Laer* (Berlin, Germany), J.
Chairs Michele Bartoletti (Milan, Italy) Mutevelli, A. Dörre, S. Haller, M. Feig, S. Buda, A.
Merel Lambregts (Leiden, Netherlands) Hoffmann, I. Noll

ESCMID Global 2025 - Programme
E0428 Invasive group A streptococcus infections is often Gold, R. Lovinsky, M. Muller, K. Ostrowska, D.
preceeded by seasonal influenza.J. Westin* Ricciuto, D. Richardson, C. Vermeiren, K. Hassan, M.
(Gothenburg, Sweden), M. Nygren, U. Snygg-Martin, Lefebvre, A.X. Li, N. Malik, M. Pejkovska, A. Sultana,
L. Gustavsson, N. Sundell T. Vikulova, C. Kandel, Z. Zhong
E0429 Impact of the COVID-19 Pandemic on Tuberculosis E0441 Antimicrobial resistance in Streptococcus
Transmission RatesA. Cannas* (Rome, Italy), V. pneumoniae in the Netherlands: an 11-year trend
Antonelli, A. Navarra, O. Butera, A. Mazzarelli, C. Nisii, analysis of surveillance dataI. Nauta* (Bilthoven,
E. Girardi, C. Fontana Netherlands), W. Altorf-Van Der Kuil, D.W.
E0430 Treatment outcomes of bedaquiline-based longer Notermans, A.F. Schoffelen
oral regimens in Indian children above 5-years of
ageD. Gandhi* (Mumbai, India), I. Shah, R. Ansari, H.
Warse, S. Kalawadia, T. Yangchen, D. Shah, V. Puri, S. EF061 14:45 - 15:45 Arena 4
Mattoo, M. Bodhanwala
ePoster Flash Session
E0431 Incidence of Invasive Escherichia coli Disease in the
Northwestern United States (2002–2022): Insights Infections in the immunocompromised: a multifaceted overview
from Electronic Health RecordsM. Blum* (Leuven,
Belgium), C. Onwuchekwa, M.A. Schmidt, J. Chair Effrossyni Gkrania-Klotsas (Cambridge, United
Poolman, T. Verstraeten, J. Geurtsen Kingdom)
E0432 A prospective controlled cross-sectional study
demonstrates significantly higher IgG seroprevalence
of leptospirosis among Munich's Eisbach river E0442 Impact of Donor Colonization or Infection, or
surfersF. Voit* (München, Germany), D. Schult- preservation fluid contamination with Multiresistant
Hannemann, M.H. Richter, L. Wagner, J. Ostermaier, Bacteria and Fungi in Solid Organ Transplantation.
K. Stollberg, E. Luge, P. Bahn, M. Lee, J. Ten-Pas, J. Multicenter registry of ArgentinaL. Barcan* (Buenos
Erber, M. Kosch, M. Mayr, C.D. Spinner, J. Schneider Aires, Argentina), A. Smud, P. Giorgio, R. Gago, N.
Pujato, M. Martinez, S. Villamandos, C. Niveyro, N.
Lasserre
EF060 14:45 - 15:45 Arena 3 E0443 Analysis of viral load kinetics and risk factors for
Epstein-Barr virus DNAemia and Post-transplant
ePoster Flash Session
lymphoproliferative disorders in pediatric liver
transplant recipients - a single centre experienceB.
AMR in the community
Kasztelewicz* (Warsaw, Poland), K. Skrok, I.
Chair Camilla Wiuff Coia (Copenhagen, Denmark) Jankowska, P. Kaliciński, K. Dzierżanowksa-Fangrat
E0444 Impact of pre-transplant infection on post-transplant
morbidity and graft survival in liver transplant
E0433 Socio-demographic factors associated with recipients: a prospective cohort studyL. Mani-
community-acquired extended spectrum ￿- Perren* (Bern, Switzerland), S.F. Perrodin, A.
lactamase producing E. coli urinary tract infections at Berzigotti, V. Banz, C. Hirzel, L.N. Walti
intermunicipal level in FranceM. Prime* (Nantes, E0445 Risks of live-attenuated vaccines in children with
France), O. Lemenand, S. Thibaut, T. Coeffic, B. primary immunodeficiencyS. Frigui Ep Oueslati*
Perrot, J. Caillon, D. Boutoille, E. Batard, G. Birgand (Tunis, Tunisia), S. Ben Jaafar, S. Frigui, Y. Chebbi, M.
E0434 Prolonged community outbreak of OXA-48- Ouederni, W. Achour
producing Escherichia coli linked to a food premises: E0446 Chagas reactivation/ transmission in kidney
Lower Hutt, New Zealand, 2018-2022C. Thornley* transplantation.M. Radisic* (Buenos Aires,
(Lower Hutt, New Zealand), M. Kelly, M. Bloomfield, Argentina), N. Pujato, M.C. Lopez-Albizu, R. Del
A. Nesdale, R. White Grosso
E0435 Low rates of macrolide resistance found in E0447 Clinical presentation and treatment of tuberculosis in
Mycoplasma pneumoniae cases in AustraliaR. solid organ transplant recipients: a multicentric
Rockett* (Westmead, Australia), J. Kok, K.G. Tam, T. retrospective analysisJ. Moltó* (Barcelona, Spain), I.
Golubchik, C. Suster, W. Fong, V. Sivalingam, M.C. Los-Arcos, D. Ruiz Cabrera, L. López González, M.
Wehrhahn, A. Ginn, J. Robson, I. Gardner, L. Fayos Pérez, R. Rodríquez-Alvarez, M. Murga De La
Papanicolas, K. Kennedy, M. Graham, T. Tran, D. Fuente, V. Pomar, E. García Vázquez, T. Tórtola, J.
Speers, L. Cooley, J. Harbidge, S. Campbell, K. Basile, Espinosa, O. Len, A. Sánchez-Montalva
V. Sintchenko, S.C.A. Chen
E0448 Clinical presentation, risk factors and outcome of
E0436 Epidemiology of antibiotic resistance associated with non-tuberculous mycobacteria infection in
E. coli/Klebsiella pneumoniae bloodstream infections hematopoietic stem-cell transplant recipients: a
in England 2012-2023S. Lipworth* (Oxford, United multinational case-control studyM. Fernandez Ruiz*
Kingdom), L. Gorman, A. Dowsey, K. Pouwels, K. (Madrid, Spain), M. Fernández-Ruiz, J.T. Silva, P.L.
Sanderson, C. Beck, R. Hope, C. Brown, T. Katy Carver, S. Rutjanawech, L.F. Aranha-Camargo, R.
E0437 The effect of long-term fluoroquinolone prophylaxis Fernandes, S. Belga, A. Alghamdi, N.J. Mueller, S.
Burkhard, N.M. Theodoropoulos, D.F. Postma, P.J.
on carriage of antimicrobial resistant organisms in
Van Duijn, F. Arnaiz De Las Revillas, C. Pérez Del
children.C. Brand* (Cape Town, South Africa), R.
Molino-Bernal, J. Hand, A. Lowe, M. Bodro, E. Vanino,
Ocloo, D. Wilck, P. Dube, A. Hesseling, J. Seddon, A.
A. Fernández-Cruz, A. Ramos-Martínez, M.J. Makek,
Demers, M. Newton-Foot, A. Whitelaw
R. Bou Mjahed, O. Manuel, N. Kamar, A. Calvo-Cano,
E0438 Risk factors and prevalence of AntiMicrobial L. Rueda-Carrasco, P. Muñoz, A. Álvarez-Uría, S.
Resistant microbes In the English Community Pérez-Recio, N. Sabé, R. Rodríguez-Álvarez, A.
(AMRIC)D. Lecky* (Gloucester, United Kingdom), Z. Mularoni, E. Vidal, J. Alonso-Titos, T. Del Rosal, A.Y.
Aiken, M. Joyce, A. Hawker, N. Zhu, L. Eastwood, S. Classen, C. Mejía-Chew, F. López-Medrano
Leaver, K. Hopkins, R. Hope, S. Eccles, S. Neilson, M.
E0449 Impact of bronchoalveolar lavage results on clinical
Neilson, G. Edwards, S. Hopkins, C. Brown
decision-making among immunocompromised,
E0439 Risk factors for antimicrobial resistance in community critically ill patients.C. Fanelli* (Sassari, Italy), R.
commensal Staphylococcus aureus isolates, a sub- Mondaca, R. Colima, D. Prado, R.R. Abud, S. Morales,
analysis of the AMRIC project.M. Joyce* M.M. Vera, E. Kattan
(Manchester, United Kingdom), Z. Aiken, N. Zhu, A.
E0450 Campylobacter spp. bloodstream infections:
Hawker, L. Eastwood, S. Leaver, K.L. Hopkins, R.
preliminary results from a multicenter differential
Hope, S. Eccles, S. Neilson, M. Neilson, G. Edwards,
clinical analysis in immunocompromised and
S. Hopkins, C. Brown, D.M. Lecky
immunocompetent patients.M. Paniagua-García*
E0440 Prevalence and risk factors for antimicrobial (Seville, Spain), J.M. Bernal-Aznar, S. Herrera-
resistance in invasive pneumococcal disease in Espejo1, S. Salto-Alejandre, A. Valiente, M.C.
southern Ontario in the late post PCV13 era (2014- Domínguez, M.Á. López-Zúñiga, F. Cobo, L. Alsina-
2023)A. Mcgeer* (Toronto, Canada), A. Shigayeva, A. Manrique De Lara, C. Marti-Castellote, M. Monsonis-
Golden, I. Martin, G. Zhanel, H. Adam, K. Barker, W.

ESCMID Global 2025 - Programme
Cabed, V. García-López, A. Polo, J. Laporte-Amargos, Barr virus in acute-on-chronic liver failure – cause or
G. López De Egea, M.Á. Galán-Ladero, E. Ruiz De consequence?J. Sonnenberg* (Muenster, Germany),
Gopegui-Bordes, G. Sena-Corrales, J.A. Girón, F. K. Thiyagarajah, E. Görgülü, P. Lembeck, M. Glitscher,
Galán, M. Chávez-Caballero, M.O. Mohamed- F. Uschner, M. Brol, W. Gu, R. Schierwagen, S. Klein,
Balghata, S. Winderickx, J.M. García De Lomas, F.J. M. Schulz, T. Wiedemann, J. Reißing, J. Söhne, N.
Martinez-Marcos, M. Giannella, M. Garzaro, M. Kraus, M. Praktinjo, J. Fischer, H.P. Erasmus, J.
Fernández, M. Freire, M.L. Pedro-Botet Montoya, S. Vasseur, S. Zeuzem, H. Storf, C. Welsch, J. Trebicka,
López Cardenas, E. Cendejas, A.V. Halperin Benito, A. S. Ciesek, J. Chang, T. Bruns, E. Hildt, K.H. Peiffer
Romero Palacios, M. Navarro, C.A. Alonso, A.
O0411 Delta in Denmark: current prevalence of hepatitis
Gimeno-Gascón, S. Jiménez Jorge, J. Pachón, M.E.
delta virus infectionH. Watson* (Lyon, France), P.
Pachón-Ibáñez, E. Cordero-Matía
Jepsen, H. Vilstrup, H. Krarup
O0412 RatHEV as an aetiological agent of acute hepatitis in
Europe: results from the ESGHV-RHEV StudyA.
SY100 - Hall 12
14:45 15:45 Rivero-Juarez* (Córdoba, Spain), M. Casares, B.
Becerril, Á. Dencs, G. Gherlan, J. Caballero, L. Rios-
1-hour Symposium
Muñoz, A.B. Pérez, A. Fuentes, C. Freyre, F. Franco-
The challenge of a healthy microbiota in neonates Álvarez De Luna, I. Viciana, M.D.C. Domínguez, M.
Altindis, G. Özkaya, A. Rivero, A. Rivero-Juárez
Chairs Maria Vehreschild (Frankfurt Am Main, Germany)
Walter Zingg (Zurich, Switzerland) O0413 Understanding the incidence and risk factors of low-
level viremia in chronic hepatitis B: A propensity-
matched comparison of tenofovir and entecavirI.
Hasanoglu* (Ankara, Türkiye), R. Guner, E. Zerdali, A.
S0283 14:45 Infant gut microbiome developmentDebby Bogaert Batirel, Y. Onlen, E. Parlak, B. Kurtaran, S. Tosun, I.
(Edinburgh, United Kingdom) Yilmaz Nakir, O. Gunal, N. Eser, H. Yaqoobi, O. Tabki,
T. Turunc, U. Balci, S. Komur, E.E. Tutuncu, L.N.
S0284 15:15 Metagenomic signatures and antibiotic disruption of
Altunal, N.D. Sari, D.S. Yildiz, H.D. Ozkaya, I.E. Yildiz,
the gut microbiome in neonatesGautam Dantas (Saint
S. Kaya, O. Karabay, S. Alkan, F. Tabak
Louis, United States)
Co-organised with: ESCMID Study Group for Nosocomial Infections (ESGNI),
European Society of Paedriatic Infectious Diseases (ESPID) OS057 - Hall 3
14:45 15:45
1-hour Oral Session
OS058 - Hall 16
14:45 15:45
Precision Medecine: from models to patient care
1-hour Case Session
Chairs Anouk Edwina Muller (The Hague, Netherlands)
Sebastian Wicha (Hamburg, Germany)
In the field with fungi
Chairs Beatriz L. Gomez (Bogota, Colombia)
Leonardo Nimrichter (Rio De Janeiro, Brazil)
O0414 Pharmacokinetics and pharmacodynamics of BPaLM,
BPaLC and BPaL regimens for treatment of RR-TBF.
Kloprogge* (London, United Kingdom), B.T.
O0419 Fosmanogepix expanded access in patients with Nyang'wa, I. Motta, R. Moodliar, V. Solodovnikova, S.
Fusarium infectionsS. Dadwal* (Duarte, United Rajaram, M. Rasool, Z. Huang, C. Berry, G. Davies, D.
States), A. Baluch, J. Dickter, J.R. Newman, M.H. Moore
Nguyen, R. Weihe, H. Schlamm, L. Ostrosky-Zeichner
O0415 Physiologically Based Pharmacokinetic Modeling for
O0420 Voriconazole's hidden toll: unveiling periostitis in a Nemonoxacin in Predicting the Respiratory System
heart transplant recipient and a hematologic Pharmacokinetic Profile: Based on Comprehensive
patient.G. Motoa* (Boston, United States), A. Preclinical and Clinical DataY. Chen* (Shanghai,
Woolley, N. Issa China), J. Zhao, J. Zhang
O0421 Unveiling the Uncommon: Managing Geotrichum O0416 Context-specific genome-scale metabolic modelling
candidum in Pancreatic NecrosisL. Kriegl* (Graz, reveals metabolic alterations in multidrug-resistant
Austria), C. Geiger, I. Zollner-Schwetz, T. Valentin, H. Klebsiella pneumoniae in response to polymyxin
Schlager, G. Zollner, K. Dichtl, R. Krause B/zidovudine combinationJ. Zhao* (Melbourne,
O0422 Detection of siderophores as a superior non-invasive Australia), Y.W. Lin, J. Tao, Y. Zhu, T. Velkov, J. Li
diagnostic tool in unravelling mixed fungal O0417 Agent-based model predictions of polymyxin B
infectionsV. Havlicek* (Prague, Czech Republic), R. activity on Acinetobacter baumanniiH. Soeorg*
Dobias, M. Navrátil, R. Patil, D. Luptakova, D.A. (London, United Kingdom), Y. Yuan, J. Readman, J.F.
Stevens Standing
O0423 Efficacy of novel antifungal therapies in refractory O0418 Monthly dalbavancin dosing for suppressive therapy:
Candida and Aspergillus infections: insights from a case series and pharmacokinetic estimation
compassionate use and clinical trialsS. Sedik* (Graz, analysisC. Volk* (Madison, United States), W. Kufel,
Austria), R. Krause, C. Zurl, I. Zollner-Schwetz, M. P. Hutson, R. Mahapatra, W. Rose
Linhofer, C. Hoegenauer, G. Gorkiewicz, M. Hoenigl,
J. Prattes
SY099 - Hall 4
14:45 15:45
OS056 14:45 - 15:45 Hall 2 1-hour Symposium
1-hour Oral Session How innovations of AMR and HAI surveillance systems help the clinical
practice
Emerging trends in viral hepatitis across Europe
Chairs Pascal Astagneau (Paris, France)
Chairs Federico Garcia (Granada, Spain) Mandy Wootton (Cardiff, United Kingdom)
Neven Papic (Zagreb, Croatia)
S0281 14:45 The EUCAST system in surveillance of AMRSören G.
O0409 One of the largest outbreak of hepatitis A in the 21st Gatermann (Bochum, Germany)
century in EuropeI. Hockickova* (Košice, Slovakia), I. S0282 15:15 Insights into developments in the surveillance of
Hockicková, J. Hockicko, D. Javorská, Š. Zamba, A. HAIsDiamantis Plachouras (Solna, Sweden)
Vasiľová, M. Ševčík, A. Cehelská, D. Hudáčková, P.
Co-organised with: EUCAST Steering Committee, EUCIC Steering
Kristian
Committee, European Centre for Disease Prevention and Control (ECDC)
O0410 Higher prevalence of Cytomegalovirus and Epstein–

ESCMID Global 2025 - Programme
E0475 Broad spectrum coverage of serine ￿-lactamase and
high in vitro potency against KPC- and OXA-48-like-
Movie Session 15:00 - 18:30 Hall 5 producing Enterobacterales of meropenem in
combination with the novel diazabyciccloctane ￿-
Special Session
lactamase inhibitor ANT3310L. Sánchez-Peña* (A
Behind the scenes: Contagion Coruña, Spain), S. Rodríguez-Pallares, T. Blanco-
Chairs William Hanage (Boston, United States) Martín, L. González-Pinto, M. Outeda-García, P. Aja-
Luigia Scudeller (Pavia, Italy) Macaya, I. López-Hernández, J.C. Vázquez-Ucha, G.
Bou, A. Beceiro, J. Arca-Suárez
E0476 Antibacterial potential of D-limonene and diallyl
disulfide and their interaction with gentamicin against
multidrug-resistant Pseudomonas aeruginosa in rat
pneumonia modelY. Almuhanna* (Shaqra, Saudi
SY107 - Hall 15
16:15 17:15 Arabia), M. Asad
1-hour Symposium E0477 In vivo pharmacokinetic/pharmacodynamic targets
of a novel macrolide antibiotic nafithromycin,
Communicating (your) ID science for policy and societal impact determined in neutropenic murine lung infection
model of Streptococcus pneumoniaeA. Muller* (The
Chairs Leonard Leibovici (Petah-Tiqva, Israel)
Hague, Netherlands), R. Chavan, S. Takalkar, V. Zope,
Ines Steffens (Solna, Sweden)
K. Umarkar, P. Tayde, M. Tellis, S. Bhagwat, M. Patel,
B. Veeraraghavan
E0478 NiPharmins: novel low resistance-inducing
S0297 16:15 Communicating to policy makers and for societal antimicrobials with antibiofilm activity against
impactBalázs Babarczy (Budapest, Hungary) Staphylococcus aureusA. Nunes* (Lisbon, Portugal),
S0298 16:45 Influencing behaviour through the media and a B. Alves, J.P. Carrilho, N.R. Candeias
multichannel communications strategyCharlotte
Hutchinson (London, United Kingdom)
EF066 - Arena 2
Co-organised with: CMI Board of Editors 16:15 17:15
ePoster Flash Session
EW109 16:15 - 18:15 Hall 2 Modelling infectious disease burden and impact of vaccination
Educational Session Chair David Fisman (Toronto, Canada)
Infections in cancer patients: tips for daily practice
Chairs José Molina Gil-Bermejo (Seville, Spain) E0480 Evaluating the Impact of Re-vaccination on
Stefan Schwartz (Berlin, Germany) Pneumococcal Disease in Individuals Previously
Vaccinated with PPSV23 in Germany: Comparative
ApproachO. Sharomi* (Mt Carmel, United States), S.
Oluwaseun, M. De Lepper, S. Mihm, T.C. Reuter, C.
W0301 16:15 Tailoring pharmacologic prophylaxis in patients with
Solleder, G. Meleleo, T. Malik, K. Bakker, R. Oidtman
non-haematologic cancer: from viruses to fungiJanne
Vehreschild (Frankfurt, Germany) E0481 Modeling the public health impact of a 21-valent PCV
in the Canadian adult populationO. Sharomi*
W0302 16:35 Pneumonitis or pneumonia? A practical approach to
(Rahway, United States), R. Oidtman, M.C. Meilleur,
lung infiltrates in patients with solid tumoursTba
S. Weinrich, K. Bakker
W0303 16:55 The diagnostic dilemmas and treatment challenges of
E0482 Estimating the health and economic burden of
mycobacteria in cancer patientsŞiran Keske
pneumococcal diseases attributable to PCV21 (V116)
(Istanbul, Türkiye)
vs. PCV20 or PPSV23 serotypes among adults in
W0304 17:15 HTLV-1 and T-cell lymphoma - predict & preventLucy NorwayZ. Yi* (Rahway, United States), A.A. Tajik, S.T.
Cook (London, United Kingdom) Klitkou, E. Tsoumani, K. Owusu-Edusei
Co-organised with: ESCMID Study Group for Respiratory Viruses (ESGREV), E0483 Shifting from risk-based to age-based approach for
International Immunocompromised Host Society (ICHS) pneumococcal vaccination in adults in France: a
comprehensive evaluationO. Sharomi* (Mt Carmel,
United States), S. Oluwaseun, M. Breau-Brunel, F.
EF065 - Arena 1 Gaëlle, B. Lionel, C. Jérémy, M. Giulio, N. Robert, O.
16:15 17:15
Rachel, M. Tufail, B. Kevin
ePoster Flash Session
E0484 The socio-economic value of adult respiratory
immunisation programmes in the United Kingdom –
The Antibiotic bakery: Novel compounds in the pipeline
Are we measuring what matters to society?C.
Chair Susanne Haeussler (Braunschweig, Germany) Harrison* (Tadworth, United Kingdom), T. Hu, J.
Yang, J. Vietri, D. Mendes, S. Chowdhury, C.
Theakston, S. Brassel, L. Steuten
E0485 Improving Danish all-cause mortality monitoring by
E0471 In vitro activity and in vivo proof-of-efficacy of
nowcasting weekly deathsA. Kalnæs* (Copenhagen,
epimutilin derivatives AR-7732, AR-7731, AR-9842
Denmark), J. Nielsen, L. Vestergaard, S. Nørgaard
and AR-10058 against AMR bacterial pathogensS.
Paukner* (Vienna, Austria), W.W. Wicha E0486 Modelling to identify an optimal ring vaccination
strategy to mitigate a smallpox outbreakV.
E0472 SC5005 and DHA: A Novel, Rapid-Acting
Costantino* (Sydney, Australia), M. Kunasekaran, T.
Combination Therapy for Biofilm Eradication in
Leroyd, K. Yeo, R.C. Macintyre
Catheter-Associated InfectionsY. Hui Hui* (Taipei,
Taiwan, China), H.H. Yeo, H.N. Huang, Y.T. Huang, E0487 The impact of introducing meningococcal C/ACWY
Y.S. Lu, H.C. Chiu booster vaccination among adolescents in Germany:
a dynamic transmission modelling studyF. Günther*
E0473 In vitro potency of ceftibuten with xeruborbactam
(Berlin, Germany), U. Reinacher, S. Chisholm, M.
against ￿-lactamase-producing isolates of
Griskaitis, M. Höhle, S. Scholz, V. Schönfeld, O.
Enterobacterales (ENT) from the SENTRY global
Wichmann, T. Harder, F.G. Sandmann
surveillance programmeO. Lomovskaya* (San Diego,
California, United States), M. Castanheira, J. Lindley E0488 Potential public health impacts of gonorrhoea
vaccination programmes under declining incidences:
E0474 Effect of novel antimicrobial peptides SET-M33L and
a modelling analysisL. Geng* (Singapore, Singapore)
SET-M33L-PEG on Pseudomonas aeruginosa biofilm
formation.A. Fontanot* (Rotterdam, Netherlands), W.
Unger, J. Hays, P. Croughs, A. De Bruijn, C. Falciani,
A. Pini, R. Ecker, I. Ellinger EF067 16:15 - 17:15 Arena 3

ESCMID Global 2025 - Programme
ePoster Flash Session Gelormini
E0502 Global, regional, and national temporal trends in
Blood parasitology at its best
mortality for carbapenem-resistant bacteria from
Chair Miriam José Álvarez-Martínez (Barcelona, Spain) 1990 to 2021: An age-period-cohort analysisC.
Zhihui* (Shanghai, China), Z. Mingchen, W. Jing, Y.
Xiangru, J. Jialin, Z. Wenhong
E0503 Global Trends and Impact of Antimicrobial Resistance
E0489 Unexepected P.malariae diagnosis in Italian woman
in Paediatric Populations: An Analysis Using WHO
with no history of travel to endemic areasA. Busni*
AWaRe Classification and Priority PathogensJoseph
(Milan, Italy), L. Tartaglione, S. Torri, A. Longhi, E.M.
Harwell (North Melbourne, Australia)
Zavaroni, F. Crippa, C.S. Vismara
E0504 Antibiotic resistance profile and comparative
E0490 A blue-hued mystery: Primaquine-induced
evaluation of WHO AWaRe Guidelines at the
methemoglobinemia in mixed infection with
Emergency's Children's Surgical Hospital in UgandaL.
Plasmodium vivax and Plasmodium falciparumU.A.
Barcellini* (Milan, Italy), F. Riccaboni, V. Fabiano, F.
Zainulabid* (Pahang, Malaysia), X.K. Cheong, P.
Forlanini, A. Banfi, E. Crivellaro, A. La Mendola, A.
Periyasamy, A.F. Mohd Salleh, N. Ghazali, N.W.
Mohammed Zain, G.V. Zuccotti, L. Folgori, L.
Hassan, K. Sangaran, A. Mohd Yasin, Z.M. Idris
Napolitano
E0491 Trick or Treat? An unrelenting malaria caseC.
E0505 Initiatives in antimicrobial resistance surveillance:
Uhomoibhi* (Dublin, Ireland), E. De Barra, C. Leddy,
Using automated bacteraemia surveillance for
A. Brown
hospital-wide multidrug resistance monitoringF.D.
E0492 "64% Parasitaemia in Falciparum Malaria: Ruether* (Berlin, Germany), L.A. Peña Diaz, M.
Challenges in Managing Severe Infection and Behnke, C. Geffers, S.J.S. Aghdassi
Delayed Haemolysis"F. Murphy* (Dublin, Ireland), A.
E0506 Global and regional prevalence of antimicrobial
Albadi, P. Coakley, C. Mcnally
resistance in GLASS target bacterial pathogens for
E0493 Benznidazole treatment in Chagas Disease: a case bloodstream, urinary tract and gastrointestinal
series in Luigi Sacco Hospital, Milan (Italy)F. Sabaini* infections: a systematic review of the global literature
(Milan, Italy), A. Giacomelli, M. Beltrami, L.R. (2019-2024)B. Caddey* (Calgary, Canada), G.
Galimberti, S. Antinori Lazarus, S. Bertagnolio, D.B. Nobrega, R.L. Hamers,
E0494 The Challenge of Managing Visceral Leishmaniasis in A. Dean, V.K. Wangsaputra, F. Febrina, J.M. Conly,
Immunocompromised PatientsS. Vita* (Rome, Italy), H.W. Barkema, E. Van Kleef, O. Tosas-Auguet
A. D'abramo, A. Corpolongo, M.V. Tomassi, F.
Faraglia, T. Ascoli Bartoli, A. Mariano, A. Vulcano, G.
Maffongelli, E. Nicastri KN103 - Hall 1
16:15 17:15
E0495 Diagnosis and management of visceral leishmaniasis
Keynote Lecture
in children in France : a national retrospective studyJ.
De Larminat* (Paris, France), N. Dahane, N. Argy, M.
Tuberculosis: where are we now and where should we be
Rifai, O. Haas Ferrua, C. Pomares, N. Rasandisona
Ravonjena, D. Dupont, J.P. Lemoine, T. Cesar, O. Chairs Jon S. Friedland (London, United Kingdom)
Pineau, P. Picherit Steinbrucker, S. Azohana, S. Delia Goletti (Rome, Italy)
Guilmon-Crepon, I. Allouche, C. Ravel, A. Faye
E0496 Chronic cutaneous leishmaniasis following visceral
leishmaniasis in a pediatric patient: a rare report of
K0290 16:15 Guy Thwaites (Ho Chi Minh City, Vietnam)
extensive facial involvementA. Mohta* (Bikaner,
India)
E0497 Therapeutic challenges in the management of OS063 - Hall 11
16:15 17:15
Disseminated leishmaniasis in a patient with HIV co-
infectionN. T R* (Jodhpur, India), T. Kanagiri, S. 1-hour Oral Session
Angirekula, N. Kaur, Y. Khatod, D. Kumar, A. Purohit,
G.K. Bohra Improving blood culture diagnostics: rethinking the basics
Chairs Direk Limmathurotsakul (Bangkok, Thailand)
Pilar Retamar Gentil (Seville, Spain)
EF068 - Arena 4
16:15 17:15
ePoster Flash Session
O0461 Blood culture volume, guideline adherence and
A global perspective on antimicrobial resistance surveillance pathogen yield of 35,433 paediatric blood cultures in
Chair Mirfin Mpundu (Lusaka, Zambia) GermanyJ. Forster* (Würzburg, Germany), A.L. Sieg,
V. Rücker, H. Haefner, T. Bähr, S. Rössler, J. Held, V.
Le Saout – Chapot, M. Hogardt, B. Spielberger, E.A.
Idelevich, M. Christner, S. Zimmermann, S.
E0498 Global, regional and country-level prevalence of Schneitler, M. Mauritz, C.S. Stingu, M. Gerlach, U.
antimicrobial resistance in human bacterial infections Von Both, S. Schoeler, L. Marr, J. Zens, E. Komini, M.
under surveillance in WHO's Global Antimicrobial Krone
Resistance and Use Surveillance System (GLASS)E.
O0462 Changing the paradigm: are two sets of blood
Van Kleef* (Geneva, Switzerland), O. Tosas Auguet,
cultures always needed?R. Rosa* (Miami, United
S. Tolba, S. Eremin, D. Marcano, K.B. Pouwels, B.S.
States), J. Somani, K. Manzanillo, H. Dinh, G. Rosello,
Cooper, A.S. Dean, S. Bertagnolio
L. Abbo
E0499 Comparative analysis of antimicrobial resistance
O0463 Evaluating clinical and economic empact of reducing
(AMR) burden across european countriesA. Dörre*
blood culture incubation timings: Time to shift the
(Berlin, Germany), A. Meinen, S. Haller, G. Robles
paradigm?R. Gupta (bagga)* (London, Canada), R.
Aguilar, T. Meštrović, M. Nahgavi, T. Eckmanns
Gupta, J. Delport, T. Mazzulli
E0500 Setting up a regional AMR surveillance network in the
O0464 Revolutionizing hospital workflows with blood
Netherlands: challenges and opportunitiesC. Van
culture-free ultra-rapid antimicrobial susceptibility
Rossum* (Nijmegen, Netherlands), C. Meijer, P.
testing: A clinical pilot studyS. Kwon* (Seoul, Korea,
Koopman, D. Van Der Vegt, T. De Groot, M. Nabuurs-
Republic of), K. Sunghoon, K. Dong Young, J. Jisung,
Franssen, G. Heeren, M. Heuvelmans, J. Flipse, E.
K. Tae Hyun, K. Junwon, J. Hyelyn, L. Gi Yoon, P. Wan
Bowles, A. Tostmann, C. Van Der Veer, S. Pas
Beom
E0501 Bridging gaps in antimicrobial resistance
O0465 Human in vivo footprints from blood plasma for
surveillance: the CAESAR network's first decadeR.
improved diagnostics in sepsisM. Sonntag*
Janssen* (Bilthoven, Netherlands), S. Woudt, D.
(Stuttgart, Germany), J. Mueller, A. Von Haeseler, Y.
Boudville, C. Ruesen, W. Van Den Reek, J. Monen, O.
Vainshtein, S.O. Decker, T. Brenner, K. Sohn
Karatuna, A. Tambić-Andrašević, D. Lo Fo Wong, M.

ESCMID Global 2025 - Programme
ME108 - Hall 12 SY106 - Hall 14
16:15 17:15 16:15 17:15
Meet-the-Expert 1-hour Symposium
Navigating travel medicine: expert tips for safe international travel Strain dynamics in determining gut microbial colonisation resistance
Chairs Silvio Daniel Brugger (Zurich, Switzerland)
Li Yang Hsu (Singapore, Singapore)
M0299 16:15 Sophie Schneitler (Homburg, Germany)
M0300 16:27 Andreas Neumayr (Basel, Switzerland)
S0295 16:15 Strain dynamics in serious bacterial infections in
infantsDrew Schwartz (Saint Louis, United States)
OS062 - Hall 13 S0296 16:45 Long-term colonisation dynamics of carbapenemase-
16:15 18:15
producing EnterobacteralesNiranjan Nagarajan
2-hour Oral Session (Singapore, Singapore)
Heterogeneity and complexity of sepsis
Chairs Despoina Koulenti (London, United Kingdom) OS064 16:15 - 17:15 Hall 16
Sylvain Meylan (Lausanne, Switzerland)
1-hour Oral Session
Viral immune response - nature or nurture? Exploring the limits of immune
O0451 A consensus immune dysregulation framework for response
sepsis: results of the SUBSPACE consortiumA. Chairs Malin Flodström-Tullberg (Stockholm, Sweden)
Moore* (Emerald Hills, United States), T. Sweeney, Florian Krammer (New York, United States)
A. Rogers, P. Khatri, H. Zheng, A. Ganesan, Y. Hasin-
Brumshtein, M. Maddali, J. Levitt, T. Van Der Poll, B.
Scicluna, E.J. Giamarellos-Bourboulis, A. Kotsaki, I.
Martin-Loeches, A. Garduno, J. Sevransky, D. O0466 Orthopoxvirus-specific antibody dynamics up to
Wright, R. Rothman, M. Atreya, L. Moldawer, P. two years after monkeypoxvirus infection or
Efron, M. Kralovcova, T. Karvunidis, H. Giannini, N. vaccinationC. Van Dijck* (Antwerp, Belgium), N.
Meyer Berens-Riha, L. Zaeck, I. Brosius, R. De Vries, J.
Marien, L. Liesenborghs
O0452 BLOODICU: Bloodstream infections and their
outcomes in ICU patients - Insights from the O0467 DENG-VAC study: preliminary data on
PROSAFE StudyC. Genovese* (Milan, Italy), M. immunogenity and reactogenity of Qdenga vaccine
Offer, G. Tricella, G. Scaglione, E. Palomba, G. versus natural infectionA. D'abramo* (Rome, Italy),
Montrucchio, F. Agostini, F. Dore, G. Monti, B. S. Vita, F. Colavita, E. Cimini, P. De Marco, E. Lalle,
Viaggi, A. Gori, S. Finazzi, M. Colaneri G. Maffongelli, L. Rosa, S. Cammisa, G. Delia, M.
O0453 Deciphering the Dynamics of Klebsiella pneumoniae Fabrizio, N. Emanuele
Colonization and Infection: Genomic Insights and O0468 Long-Lasting Immunity Followed by Natural CCHFV
Microbiome Interactions in ICU PatientsW. Yu* InfectionH. Karakoc* (Trabzon, Türkiye), H.N.
(Beijing, China) Karakoç Parlayan, A. Aslanabadi, D. Yapar, Q.
O0454 Antibiotics with anti-anaerobe activity promote Murphy, G. Kaplan, O. Akdoğan, A. Çelikbaş, A.
enteric pathobionts in ICU patientsS. Taylor* Koroglu, F. Aksoy, E. Karaaslan, A. Abbasi, M.
(Adelaide, Australia), S. Miller, E. Vasil, B. Reddi, Karimi, M. Hojabri, G. Yilmaz, S.M. Ciupe, S.D.
L.A. Chapple, S. Bihari, M. Chapman, G. Rogers, L. Pegan, É. Bergeron, G. Lewis, N. Baykam, M.M.
Sajadi
Papanicolas
O0455 Association between blood culture time to positivity O0469 Why does rabies virus not induce an anti-viral
and 30-day bacteremia mortality differs for immune response : insights from experimental
bacterial groupsM.H. Øvre* (Herlev And Gentofte, models and a human cohortC. Geurts Van Kessel*
Denmark), J.B. Boel, J.G. Holler, S. Skovgaard, D.S. (Rotterdam, Netherlands), C. Embregts, A. Gohar,
Hansen, T.S. Itenov, B.J. Holzknecht B. Verstrepen, J. Aijaz, N. Salahuddin, C.
Geurtsvankessel
O0456 Treatment patterns of patients with
sepsis/SIRS/septic shock treated with O0470 Establishing a human challenge model for human
metapneumovirus: disease characteristics and
ceftolozane/tazobactam – results from SPECTRAE.
Yucel* (Rahway, United States), A. Soriano, F. immune responsesN. Noulin* (London, United
Kingdom), A. Mann, N. Veselinski, J. Mori, B. Löndt,
Thalhammer, S. Kluge, P. Viale, M. Allen, B. Akrich,
J. Levy, H. Yang, S. Kaul K. Bradley, M. Kalinova, S. Ascough, G. Boivin, C.
Chiu, A. Catchpole
O0457 Risk of myocardial infarction and stroke following
bloodstream infection: a population-based self-
controlled case seriesJ. Underwood* (Cardiff,
SY104 - Hall 3
United Kingdom), N. Reeve, V. Best, A. Akbari, H. 16:15 17:15
Ahmed
1-hour Symposium
O0458 Is transthoracic echocardiography required in all
patients with Staphylococcus aureus bacteremia? Targeted vs. standard perioperative prophylaxis in Solid Organ Transplant
Validating the VIRSTA and VIRSTA+ scores to with MDR Gram-negative colonisation
define the population at low risk of endocarditisM. Chairs Elda Righi (London, United Kingdom)
Verdejo Gómez* (Barcelona, Spain), D. Malano- David Van Duin (Chapel Hill, Nc, United States)
Barletta, M.Á. Verdejo, G. Cuervo, C. Pitart, M.
Hernández-Meneses, M. Bodro, S. Herrera, C.
Garcia-Vidal, P. Puerta, A. Del Rio, M. Espasa, J.A.
Martínez, L. Morata, A. Soriano S0291 16:15 Standard prophylaxisMaddalena Giannella (Bologna,
O0459 DNA methylation changes in Sepsis: Potential use Italy)
as biomarkersI. López-Cruz* (Valencia, Spain), J.L. S0292 16:45 Targeted approachesMaristela P. Freire (Sao Paulo,
García-Giménez, L. Piles, M. Madrazo, G. Judit, M. Brazil)
López-Torres, A. Artero
Co-organised with: European Association for the study of the liver (EASL)
O0460 Host response plasma biomarkers and
transcriptomic alterations in critically ill patients
with suspected aspiration pneumoniaS. Doeleman* SY105 - Hall 4
(Amsterdam, Netherlands), D. Susanne, E. Michels, 16:15 17:15
J. Butler, F. Uhel, O. Cremer, T. Van Der Poll 1-hour Symposium

ESCMID Global 2025 - Programme
Novel beta-lactams and beta-lactamase inhibitors: a diagnostic and coinfected with HIV and tuberculosis: a multicentre,
therapeutic approach open-label, randomised trialY. Shen* (Shanghai,
Chairs Robert A. Bonomo (Cleveland, United States) China), X. Le
Arjana Tambic Andrasevic (Zagreb, Croatia) L0022 17:27 Initial vancomycin taper for the prevention of
recurrent Clostridioides difficile infection: the TAPER-
V randomised controlled trialE.G. Mcdonald*
(Montreal, Canada), Y. Chen, B. Coburn, N. Daneman,
S0293 16:15 Novel beta-lactams and beta-lactamase inhibitors: S. Hota, C. Frenette, C.E. Kandel, L. Kong, Y. Longtin,
challenges for laboratory diagnosticsAnna Sramkova V.G. Loo, D. Macfadden, M. Muller, T.S. Steiner, L.
(Pilsen, Czech Republic) Valiquette, T.C. Lee
S0294 16:45 Clinical perspectives of novel beta-lactams and beta- L0023 17:39 Beneficial effects of a clinical metagenomics
lactamase inhibitorsParikshit Prayag (Pune, India) intervention on clinical outcomes, healthcare
Co-organised with: EUCAST Steering Committee economics, and quality of life in patients with
sepsis/septic shock: results of the DigiSep-trialT.
Brenner* (Essen, Germany), A. Skarabis, S.J.
LB004 - Hall 9 Schaller, T. Von Groote, C. Putensen, U. Günther, M.
16:15 18:15 Sauer, S.O. Decker, F. Dusse, M. Weiss, K.
2-hour Oral Session Suchodolski, T.P. Simon, P. Rosenberger, O. Moerer,
M. Unterberg, J.C. Schewe, H. Bracht, S. Hutzl, M.
Trials in severe infections
Feißt, U. Marschall, P. Brandenburg, J. Englisch, P.
Chair Steven Tong (Melbourne, Australia) Stevens, J. Schmidt, M.W. Pletz, J. Brands, A.
Antinoro, L.O. Warner, M.A. Weigand, D.M. Hart, G.
Marx, J. Mossanen, T. Breuer, H. Häberle, K.
Nitzsche, P. Thalmann, J. Brezinski, J. Saam, T.
L0016 16:15 Temocillin versus meropenem for the targeted Schwerhoff, S. Grumaz, M. Steinmann, M. Gaasch, B.
treatment of bacteraemia due to third-generation Pasieka, U. Jaekel, T. Brandenburger, F. Bach, H.
cephalosporin-resistant Enterobacterales (ASTARTÉ): Mutlak, S. Utzolino, M.M. Berger
a randomised, pragmatic trialF. Cogliati Dezza*
(Seville, Spain), L. Barrera Pulido, I. Borreguero L0024 17:51 Shortened antibiotic treatment for 5 days in patients
Borreguero, F. Docobo Peréz, V. Palomo Jiménez, S. hospitalised with community-acquired pneumonia
De La Rosa Riestra, J. Bravo-Ferrer Acosta, M.A. (CAP5): a multicentre randomised controlled
Lopez Zuñiga, F. Cobo, J. Gómez-Junyent, J.P. noninferiority trialS. Bastrup Israelsen* (Hvidovre,
Horcajada, E. Merino, M. Parra, J. Lopéz-Contreras, Denmark), L. Hagens Mygind, F. Al-Zergani, B.
A. Rivera, D. Sousa Regueiro, M. Pampin Garcia, S. Lindegaard, A. Knudsen, S. Tingsgård, L. Thorlacius-
Lopez Cardenas, M.C. Goméz Sanchez, I. Peréz Ussing, I. S Johansen, H. Nielsen, P. Ravn, T. Benfield
Camacho, S.M. Martin Ramos, E. Leon Jimenez, A.I. L0025 18:03 High-dose rifampicin in the treatment of tuberculous
Aller García, M.T. Peréz-Rodríguez, A. Sousa, M.C. meningitis: results of the HARVEST phase III multi-
Fariñas, A.D.L.R.A. Fracisco, L. Gisbert Pérez, J. country randomised clinical trialR. Van Crevel*
Goikoetxea Agirre, A. Cano, F.J. Martínez-Marcos, (Nijmegen, Netherlands), D. Meya, R. Rovina, D.
M.J. García País, R. Escudero Sanchez, S. De La Villa, Boulware, B. Dai, N. Engen, F. Cresswell, K. Naidoo, A.
J.R. Yuste Ara, M.A. Esteban-Moreno, A. Ruiz- Rizal, D. Imran, R. Lessels, L. Tugume, R. Hamers, M.
Sancho, M. Pedrosa Aragón, J. Alba Fernandez, A. Kabahubya, S. Marais, Y. Moosa, N. Bahr, E.
Barrios Blandino, H.H. Vilchez Rueda, R. Álvarez- Svensson, L. Te Brake, R. Aarnoutse
Marín, A. Romero Palacios, A.E. Roura Piloto, E. Nuño
Álvarez, Z.R. Palacios Baena, L. López Cerero, J.
Rodríguez-Baño EF074 - Arena 1
17:30 18:30
L0017 16:27 HRS-8427 versus imipenem-cilastatin for
complicated urinary tract infections: a randomised, ePoster Flash Session
double-blind phase 2 studyM. Ju* (Shanghai, China),
M. Wang, J. Yuan, H. Huang, G. Bi, J. Lyv, X. Lyv, L. New methods for rapid pathogen detection and typing
Xue, H. Yang, D. Fan, H. Wu, X. Wang, J. Xu, X. Li, Q. Chair Sylvain Brisse (Paris, France)
Zhang
L0018 16:39 Efficacy and safety in a Phase 2 study of intravenous
BV100 combined with polymyxin B versus best
E0532 Rapid detection of Shiga toxin-producing Escherichia
available therapy in adult subjects with ventilator-
coli (stx2a and stx2d) in korean diarrheal stool
associated bacterial pneumonia suspected or
samples: a performance evaluationL. Hyeonji* (Seoul,
confirmed to be due to carbapenem resistant
Korea, Republic of), H.J. Lee, H.J. Kim, S.S. Choi, H.J.
Acinetobacter baumanniiG. Dale* (Basel,
Choo, H.J. Huh, E.J. Won
Switzerland), F. Fratzeskaki, I. Tsagkaris, A.
Armaganidis, M. Katsiashvili, D. Kazaishvili, T. E0533 Global prevalence of O-serotypes and antibiotic
Gaphrindashvili, K. Japaridze, E. Mouloudi, M. resistance among extraintestinal pathogenic
Kapanadze, T. Kachibaia, A. Sarkany, E. Zakynthinos, Escherichia coli isolated from older adult patients
P. Delique, M. Davila, L. Husband, P. Timofeev, F. with bacteraemia (2011–2021)J. Geurtsen* (Leiden,
Jung, C. Kemmer Netherlands), M. De Been, O. Go, M. Aitabi, C.
Willame, E. Weerdenburg
L0019 16:51 Neutralising plasma versus placebo for hospitalised
patients with West Nile fever: a double-blind E0534 Strategy for the rapid typing of Salmonella spp using
randomised controlled trialM. Canetti* (Tel Aviv, infrared spectroscopy: a one health perspectiveJ.
Israel), G. Regev-Yochay, N. Barda, Y. Shusterman, E. Jiménez* (Santiago, Chile), D. Fredes, A. Piña, I.
Magiel, N. Baharav, A. Belkin, I. Margalit, V. Mercado, J. Miranda, S. Henríquez, T. González, A.
Indenbaum, E. Tomer, Y. Lustig, Y. Ottolenghi, G. Adell, A. Moreno-Switt, A. Wozniak, P. García
Joseph, H. Yonath, E. Leshem, I. Levy, Y. Peretz, S. E0535 WGS-based surveillance as a paradigm shift in
Amit, L. Miller, M. Misgav, N. Landa, M. Brod, A. outbreak detection, AMR monitoring and source
Wieder-Finesod, N. Maggio, D. Yahav attribution in CampylobacterA. Nunes* (Lisbon,
L0020 17:03 Randomised placebo controlled trial of faecal Portugal), M.L. Lemos, S. Ortiz, I. Santos, S. Ramos,
microbiota transplantation to tackle antimicrobial M. Oleastro
resistance: inducing bacteriophage network E0536 Prevalence of Staphylococcus aureus clonal complex
remodelling and enteric pathogen reductionL.A. 97 amongst BORSA isolates in a large UK hospitalH.
Edwards* (London, United Kingdom), B. Auch, T. Gareth* (Birmingham, United Kingdom)
Portlock, B.H. Mullish, B. Merrick, C. Woodhouse, T.
E0537 The effectiveness of clinical laboratory tools in the
Tranah, J.M. Blanco, L. Meoli, A. Clavé Llavall1, V.T.
surveillance of nontuberculous mycobacterium
Kronsten, A. Zamalloa, V.C. Patel, J.R. Marchesi, I.
isolations within different counties in TaiwanH.W.
Liachko, S. Goldenberg, D.L. Shawcross
Chu* (Taipei, Taiwan, China), T.F. Lee, C.C. Shu, Y.T.
L0021 17:15 Double-dose dolutegravir and lamivudine versus Huang
efavirenz-based antiretroviral therapy for patients
E0538 Rapid detection of oxazolidinone-resistance-related

ESCMID Global 2025 - Programme
mutations in Enterococcus spp. by using High ePoster Flash Session
Resolution Melting-qPCR-typing analysisR.
Musumeci* (Monza, Italy), E. Giordano, M. Martinelli, Knowing me, knowing you: behaviour influencing AMS
M. Oggioni, D. Oggioni, V. Marano, E. Arighi, C. Villa, Chair Elena Carrara (Verona, Italy)
C. Giubbi, G. Mannarà, F. Perdoni, S. Frugoni, P.
Congedo, C.E. Cocuzza
E0539 An automated pipeline to genotype bacteriophages
using third generation sequencingZ. Halász* E0550 Exploring determinants in deciding the optimal
(Debrecen, Hungary), E. Szoták, L. Dr. Laczkó, G. Dr. antimicrobial dose in patients recieving CRRT: a
Kardos mixed method studyT. Yanık Yalçın* (Ankara,
Türkiye), A. Pehlivanlı, İ. Yeşiler, H. Şahintürk, Ö.
E0540 Novel approach for fast, automated strain typing and
Azap, H. Arslan, B. Başgut, P. Zeyneloğlu
source tracking by Fourier-transform infrared
spectroscopyN. Mauder* (Bremen, Germany), M. E0551 Behaviour change vs policy change: Key drivers of
Cordovana, M. Kostrzewa inappropriate antibiotic use among health care
professionals in LMICs – insights from Indian
community settingN. P Mathew* (Manipal, India), U.
B, M. Varma, V. K E, R. Ruiter, G. Thunga, C.
EF075 - Arena 2
17:30 18:30 Mukhopadhyay
ePoster Flash Session E0552 Contextual determinants to antimicrobial
stewardship implementation in 16 hospitals: a four-
Healthcare (workers') safety revisited country analysis in AsiaH. Vu Thi Lan* (Ha Noi,
Chair Daniel Diekema (Harpswell, United States) Vietnam), R. Limato, H.Y. Duong, S. Manandhar, D.
Limmathurotsakul, A. Apisarnthanarak, N.T. Pham,
V.C. Nguyen, R.L. Hamers, E.J. Nelwan, S. Sakinah, A.
Karkey, M.K. Upadhyaya, E. Dodds Ashley, D.
E0541 Preparedness and cooperation throughout the Anderson, H.R. Van Doorn, H. Vu
chain of care during regional-level outbreaks with E0553 SpeakAB, a pilot study to encourage nurses to speak
multidrug resistant organisms: a network analysis up about antibiotic careM. Bos* (Nijmegen,
and interview studyB. Beishuizen* (Bilthoven, Netherlands), J. Schouten, H. Vermeulen, M.
Netherlands), M. Stein, A. Tostmann, C. Rovers, A. Hulscher, C. De Bot
Timen
E0554 Understanding what matters to patients in
E0542 Preparing First-Line health care workers for 'Virus antimicrobial stewardship in hospitals. PERSPEcT
X' through targeted training (FiLi-Vi-X)A. study updateB. Jacob* (Dublin, Ireland), E. De Barra
Mondelaers* (Antwerp, Belgium), Y. Somers, K.
E0555 Determinants of antibiotic prescribing in hospitals
Vanden Driessche, I. Brosius, L. Liesenborghs, C.
from low, middle and high-income countries in AsiaS.
Rovers, L. Zweers, M. Wieland, E. Vlieghe
Chhabra* (Singapore, Singapore), S. Nair, A.
E0543 Analysis of the current situation of hospital Bramley, J.Y. Chee, K. Vignesvaran, R.E.D. See, L.J.
inspection practices by German health authoritiesA. Sun, A.H. Ching, B.S. Cooper, E. Charani, Y. Mo
Schwabe* (Bonn, Germany), J. Dannenberg, A.D.
E0556 Riding "the antimicrobial rollercoaster": The
Wollkopf, F. Droop, S. Engelhart, N.T. Mutters
behavioural and phenomenological science of
E0544 A nationwide survey on the status and antimicrobial use in haemato-oncology.C. Eades*
implementation of infection prevention and control (London, United Kingdom), L. Byrne-Davis, R.
practice on behalf of INSIEME Project (Italian Rautemaa-Richardson, T. Felton
National project for contrast antibiotic resistance a
E0557 Addressing Antimicrobial Resistance: Expert Insights
cooperation between Simit (Italian society of
and Policy Recommendations for Effective
infectious diseases) E (&) Ministry of hEalth)M.
InterventionsB. Madran* (Istanbul, Türkiye), F.
Meschiari* (Modena, Italy), F.V. Segala, E. Ricchizzi,
Almeida, E. Carrara, D. Kofteridis, N. Rocha-Pereira,
A. Gallerani, V. Scaglione, R. Castoldi, F.
G. Pieve, N. Tziolos, İ. Kayı, Ş. Keske, E. Önder, S.
Almerigogna, I. Spalliera, A. Parente, S. Coladonato,
Sakarya
P. Grimaldi, C. Camaioni, M. Abbott, A. Carretta, S.
Audagnotto, A. Pan, C. Fanelli, S. Cicalini, P. Tanzili, E0558 Implementation of hospital antimicrobial stewardship
E. Ponatali, I. Gentile, R.F. Del Vecchio, A. Oliva, A. in Europe using a data-driven behaviour change
Mularoni, M. Lichtner, F. Di Gennaro, A. Marino, R. approach: insights from the drive-AMS EU projectI.
Murri, C. Mussini Pauwels* (Antwerp, Belgium), R. Janssen, E. Iosifidis,
N. Milevska-Kostova, M. Lupşe, J.A. Paiva, E. Roilides,
E0545 High level of measles immunity among Dutch
T. Schoffelen, R. Valinteliene, A. Versporten, E.
healthcare workers with self-reported “unknown”
Vlieghe, J. Schouten
measles immunity status.C. Meijer* (Nijmegen,
Netherlands), J. Leijser, M. Mccall, C. Rovers, E.
Bowles, N. Van Der Geest, A. Tostmann
E0546 Factors associated with positive latent TB screening
EF077
17:30
-
18:30
Arena 4
results in healthcare workers at two tertiary referral ePoster Flash Session
hospitals in IrelandC. Anderson* (Dublin, Ireland),
D. Mcgee, M. Coleman, A. Hehir, L. Dolan, N. Viral aphrodites
Noonan, V. Tormey, C. Bergin, C. Fleming, L.
Chair Rémi Charrel (Marseille, France)
Townsend
E0547 Systematic review of determinants of vaccine
hesitancy among healthcare workersV. Gabellone*
(Lecce, Italy), F. Nuccetelli, R. Prato, E. Gabrielli, P.L. E0559 Potential for international spread of Oropouche
Lopalco virus via commercial air travelM. Torres Portillo*
E0548 Post-pandemic questions on vaccine usage: Two (Toronto, Canada), A. Marwah, M. Kraemer, A.
qualitative analyses of open-ended responses Thomas, K. Khan, I. Bogoch
comparing hypothetical and novel vaccinesP. E0560 Estimating mpox Clade Ib outbreak size in the
Shamsrizi* (Hamburg, Germany), S. Eitze, D. Democratic Republic of the Congo to attenuate
Heinemeier, A. Tänzer, M.A. Jenny surveillance gaps during the early stages of the
E0549 Do healthcare professionals working in acute 2024 outbreakM. Torres Portillo* (English, Canada),
healthcare settings identify infection prevention and A. Marwah, A. Thomas-Bachli, I. Bogoch, K. Khan
control related knowledge deficits?A. Kearney* E0561 Disparate epitope recognition between MPXV-
(Dublin, Ireland), H. Humphreys, D. Fitzgerald infected and Smallpox-vaccinated individualsA.
Hughes Otter* (Salisbury, United Kingdom), S. Jones, B.
Hicks, B. Hallis, C. Rowe
E0562 Diverse residual and late-onset symptoms of severe
EF076 17:30 - 18:30 Arena 3 fever with thrombocytopenia syndrome: insights

ESCMID Global 2025 - Programme
from a multicenter questionnaire study in Western cooperation with ISHAM and ASMR. Sprute*
JapanR.M. Sada* (Osaka, Japan), S. Yamamoto, T. (Cologne, Germany), O.A. Cornely, M. Bassetti, C.
Toyokawa, T. Takahashi, A. Yamanaka, M. Sharon, A. Groll, O. Kurzai, C. Lass-Flörl, L. Ostrosky-
Kawamura, K. Yokota, Y. Fukumori, T. Taniguchi, R. Zeichner, R. Rautemaa-Richardson, G. Revathi, M.E.
Tanizaki, K. Iwata, S. Kutsuna Santolaya, L. White, L.P. Zhu
E0563 Post-Acute Sequelae and Excess Healthcare O0513 Impact of achieving early mycological eradication
Utilization Following Dengue Infection: A with rezafungin on all-cause mortality and ICU length
Population-Based Cohort StudyJ.T. Lim* of stayM. Bassetti* (Genoa, Italy), G.R. Thompson, A.
(Singapore, Singapore), I. Wee, W.Z. Tan Soriano, S. Dickerson, I. Bielicka, O.A. Cornely
E0564 Challenges of dengue in haematological malignancy O0514 An open-label study of ibrexafungerp in patients with
patients: Analysis from the DANGO registry during refractory fungal infections (FURI)O.A. Cornely*
the 2023-2024 outbreak in ArgentinaG.A. Méndez* (Cologne, Germany), B.D. Alexander, P.G. Pappas,
(Posadas, Argentina), J. Salmanton-García, C. T.F. Patterson, M. Hoenigl, M.H. Miceli, P. Vergidis, A.
Niveyro, P.A. Villalba Apestegui, V.I. Martín, L.M. Spec, G.R. Thompson, L. Ostrosky-Zeichner, R.S.
Compañy Kec, M.C. Tomasino, M.D.C. Marull, H.I. Siebert, M. Middle, E. McKie, F. Lewis, D. Angulo
Bernard, C.P.L. Fernández, M.F. Tosin, M.F. O0515 Novel immunotherapy approach using pan-Candida
Hobecker, K.B. Duranona, A.D. Jara, O.A. Cornely
monoclonal antibodies to treat life-threatening
E0565 Key predictors of critical illness and mortality in invasive candidiasis and tackle global AMRY. Zhao*
Crimean-Congo haemorrhagic feverD. Yigci* (Aberdeen, United Kingdom), C.A. Munro, S. Palliyil
(Istanbul, Türkiye), D. Güllü, N. Baykam, A. Kocagül O0516 Relative contribution of pharmacokinetics and
Çelikbaş, D. Yapar, Ö. Akdoğan, K. Özden, R. İnan immune signatures to clinical outcomes in patients
Sarıkaya, İ. Hasanoğlu, H.R. Güner, E. Doğan, F. with HIV-associated cryptococcal meningitis.K. Stott*
Karakeçili, H. Alay, Z. Türe Yüce, E. Eryılmaz Eren, A. (Liverpool, United Kingdom), D. Tembo, C. Kajanga,
Erbay, Ş.E. Gök, Ç. Kader, G. Ünüvar Kalın, A. A. Ahmadu, K.D. Ruwanthi, M. Moyo, D. Lawrence, T.
Yetişgen, M. Özgüler, A. Şenol, Ö. Gündağ, M.
Harrison, J. Jarvis, D. Namakhwa, D. Lalloo, W. Hope,
Çağlar Özer, F. Soyak, B. Tanır, I.D. Alıravcı, G.
H. Mwandumba
Çınar, B. Öztürk, E. Gürbüz, F. Pınarlık, M. Kuşkucu,
Ö. Ergönül
E0566 Kyasanur Forest Disease in 2024: A Retrospective OS071 - Hall 14
17:30 18:30
Cohort Study from a tertiary care centre in South
IndiaP. Venkata Swathi Kiran* (Udupi, India), P.K. 1-hour Oral Session
Tirlangi, N. Gupta, R. Bhat, P. Ravindra, S.K.
Pothumarthy Intestinal parasitic uncovered: epidemiology and treatment success
E0567 Unravelling the aetiology of summer flu-like illness Chairs Kurt Hanevik (Bergen, Norway)
in CzechiaM.F. Kříha* (Ceske Budejovice, Czech Pavla Tůmová (Praha, Czech Republic)
Republic), V. Hönig, J. Kamiš, M. Dvořáková, L.
Tardy, D. Teislerová, A. Chrdle, M. Palus, D. Růžek
O0517 Giardia- Does the treatment work? The experience
SY112 - Hall 1 from a national tertiary referral centreA. Boté
17:30 18:30 Casamitjana* (London, United Kingdom), A. Boté-
1-hour Symposium Casamitjana, S. Eisen, L. Nabarro, N. Longley, G.
Godbole
Year in public health O0518 Giardiasis: Who gets it? Experience from a Central
Chairs Ziad A. Memish (Riyadh, Saudi Arabia) London Teaching Hospital.A. Boté Casamitjana*
Catherine Moore (Cardiff, United Kingdom) (London, United Kingdom), A. Boté-Casamitjana, S.
Eisen, L. Nabarro, N. Longley, G. Godbole
O0519 Assessing the Effect of Antimicrobial Treatment on
the Accuracy of Serial Serum and Urine Testing for
S0309 17:30 Li Yang Hsu (Singapore, Singapore)
Detecting E. histolytica cfDNAP. Datta* (Chandigarh,
S0310 18:00 Rita Oladele (Lagos, Nigeria) India), D. Rattan, A. Duseja, N. Sharma, N. Kalra, S.
Khurana
O0520 Longitudinal observation of Blastocystis sp. and
SY111 17:30 - 18:30 Hall 11 Dientamoeba fragilis in children: a very rare
occurrence in chronic diseases with gut dysbiosisJ.
1-hour Symposium Hurych* (Prague, Czech Republic), J. Havlova, V.
Neuman, K. Litosova, K. Hubackova, L. Hlinakova, M.
PK/PD in drug development: what’s in it for me? Kubat, O. Hradsky, J. Bronsky, K.L. Kolho, P.
Chairs Sandrine Marchand (Poitiers, France) Saavalainen, H. Malcova, D. Cebecauerova, P.
Sebastian Wicha (Hamburg, Germany) Dřevínek, Z. Sumnik, O. Cinek
O0521 High prevalence of the zoonotic Angiostrongylus
cantonensis in rats in SpainJ. Caballero Gómez*
(Córdoba, Spain), T. Fajardo-Alonso, I. García-
S0307 17:30 PK/PD from the EUCAST/regulatory perspective:
Bocanegra, M. Gonzálvez, A. Beato-Benítez, R.
what tools do we need?Joseph Meletiadis (Athens,
Cuadrado-Matías, M.Á. Quevedo, R. Guerra, R.
Greece)
Martínez, A. Rivero-Juárez, J. Martínez, E. Martínez-
S0308 18:00 PK/PD for new anti-TB drugs Elin Svensson (Uppsala, Nevado, P. Soriano, D. Crailsheim, J. Lazpita, A.
Sweden) González, P. Foronda, J. Caballero-Gómez
Co-organised with: ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
OS072 - Hall 15
17:30 18:30
OS070 - Hall 12
17:30 18:30 1-hour Oral Session
1-hour Oral Session
Training models - a new model for training
What’s new in antifungal guidelines and management Chairs Erin Bonura (Portland, United States)
Chairs Sharon Chen (Sydney, Australia) Casandra Bulescu (Bucharest, Romania)
Helmut Salzer (Linz, Austria)
O0522 Can ChatGPT4o help build Objective Structured
O0512 Global guideline for the diagnosis and management Clinical Examination (OSCE) stations in infectious
of candidiasis: an initiative of the ECMM in diseases ?S. Villard* (Paris, France), Y. Guedj, L.

ESCMID Global 2025 - Programme
Khider, L. Maisonobe, J. Mesnier, Y. Nguyen, B. successPaola Maria Cinque (Milan, Italy)
Oules, M. Sanchez, S. Voicu, N. Burnichon, A. Faye, A. S0306 18:00 Dysregulated host responses to infectionMichal
Mageau, T. Mirault, A. Pellat, C.A. Hobson, D. Bouzid, Holub (Praha, Czech Republic)
M. Thy, N. Peiffer-Smadja
O0523 Large language model in real-world clinical infectious
diseases: are we there yet?G. Carra* (Switzerland, OS069 - Hall 4
17:30 18:30
Switzerland), M. Van Singer, A. Cancela Costa, P.A.
Crisinel, L. Cobuccio, F. Desgranges, A. Filali, Y. 1-hour Oral Session
Fougère, T. Galpérine, E. Gauthiez, B. Guery, M.
Jaboyedoff, S. Meylan, A. Munting, E. Kampouri, M. Determining new and revising old breakpoints
Papadimitriou-Olivgeris, M. Plebani, V. Suttels, P.
Chairs Jaroslav Hrabak (Plzen, Czech Republic)
Valladares, M.A. Hartley, J.L. Raisaro, D. Kaufmann,
Erika Matuschek (Växjö, Sweden)
N. Boillat-Blanco
O0524 Artificial Intelligence-Powered Transformation:
Enhancing Public Health Education at Tampere
University Towards Sustainable Development Goal O0507 EUCAST disk diffusion testing of ten additional
3S. Ahmad* (Tampere, Finland) species of anaerobic bacteriaJ. Ahman* (Växjö,
Sweden), J. Åhman, E. Matuschek, B.J. Holzknecht,
O0525 A Survey on Perceived Priorities for the
P.C. Lindemann, H. Marchandin, S. Copsey-Mawer, T.
Implementation of Artificial Intelligence in Developing
Morris, G. Kahlmeter
ESCMID GuidelinesJ. Molina Gil-Bermejo* (Seville,
Spain), J. Molina, J.R. Paño-Pardo, B. Nagavci, M. O0508 Standardised antimicrobial susceptibility testing
Paul, T. Kostyanev, M.W. Langendam, J.P. Stahl, E. protocol for Legionella pneumophila validated across
Tacconelli, S. Tschudin-Sutter, M. Zervos, L. ten European reference laboratories.M. Sewell*
Scudeller (Cardiff, United Kingdom), C. Farley, A.V. Krøvel, M.
Golob, D. Kese, U. Roisin, D. Lindsay, S. Nadarajah, B.
O0526 Expect the unexpected: Longitudinally extensive
Afshar, V. Gaia, S. Paukner, C. Michel, E. Fedoua, J.M.
transverse myelitis in a healthy young adult - a rare
González-Rubio, F. González-Camacho, M. Petzold,
manifestation of tuberculosisS. Angirekula*
M. Scaturro, C. Ginevra, G. Descours, S. Jarraud, L.
(Jodhpur, India), R. Modi, R. Bora, R. Lohiya, S.K.
Jones, O.B. Spiller
Shivtarkar, S. Jagennath, D. Kumar, S. Tiwari, G.K.
Bohra O0509 Antimicrobial susceptibility testing of the
combination of aztreonam and avibactam in
carbapenem-resistant Enterobacterales: a practical
OS073 - Hall 16 evaluation using the CLSI and EUCAST methodsL.
17:30 18:30 Chan* (Kennedy Town, Hong-Kong SAR, China),
1-hour Case Session D.Y.L. Lok, R.C.W. Wong, A.L.H. Lee, I.Y.Y. Cheung,
V.C.Y. Chow
Still going viral O0510 Determination of optimal disk diffusion mass for
Chairs Ursula Hofer (London, United Kingdom) zosurabalpinM. Castanheira* (North Liberty, United
Yee Sin Leo (Singapore, Singapore) States), J. Maher, Y. Edah, A. Trauner
O0511 The clinical significance of aminoglycoside
susceptibility breakpoints modificationO. Henig* (Tel
Aviv, Israel), M. Elbaz, N. Bishouty, Y. Yaakobi, R. Ben-
O0527 Clinical outcomes of adoptive cell therapy for EBV
Ami
reactivation and EBV-PTLD in primary
immunodeficiencies: prophylactic and therapeutic
applications of post-allo-HSCT memory T cell Monday, 14 April 2025
infusions.A. Tessitore* (Trieste, Italy), N. Maximova,
S. Braidotti, M. Granzotto, R. Simeone
O0528 Histopathological proof of herpes simplex
pneumonitis in a patient with severe COVID-19
SY116 - Hall 15
pneumoniaJ. Heylen* (Leuven, Belgium), B. Lopuhaa, 08:30 10:30
L. Maessen, S. Feys, L. Vanderbeke, G. De Vlieger, K.
2-hour Symposium
Lagrou, G. Hermans, M. Peetermans, E. Van
Wijngaerden, P. Meersseman, A. Wilmer, G. De
Climate Change: changing risks and adaptation strategies for a world on the
Hertogh, G. Verjans, J. Von Der Thüsen, J. Van
move
Kampen, J. Wauters
Chairs Rachel Lowe (Barcelona, Spain)
O0529 Transmission of dengue virus from donors to
Giacomo Stroffolini (Lausanne, Switzerland)
recipient after solid organ transplantation. Case
series in Argentina.L. Barcan* (Buenos Aires,
Argentina), S. Villamandos, R. Gago, M. Aguirre, A.
Martinoia, A. Patterer, M. Uranga, C. Sarkis, E. S0323 08:30 Vector-borne diseases in Europe and clinical
Temporiti, N. Pujato, S. Claudia, D. Calfunao, C. consequencesTuba Dal (Ankara, Türkiye)
Nyveyro, M. Martinez, A. Smud, P. Giorgio, L. Barcán
S0324 09:00 Rising temperatures and risks of fungal
O0530 Rash without borders: waning immunity in a travelling diseaseAnuradha Chowdhary (New Delhi, India)
physicianR. Ville Benavides* (Mexico City, Mexico),
S0325 09:30 Strategies for climate prevention and adaptation in a
R. Ville-Benavides, I. Avendaño-Gutiérrez
moving worldKristie Ebi (Seattle, United States)
O0531 A handful of Orf: a case of successful management
S0326 10:00 AMR in climate change-affected countriesEsmita
with cidofovir in a renal transplant recipientA. Kaya*
Charani (London, South Africa)
(Izmir, Türkiye), G.S. İzgi, B. Yaman, Y. Tiftikçioğlu, I.
Karaaslan, M. Taşbakan Co-organised with: ESCMID Study Group for Infections in Travellers and
Migrants (ESGITM)
SY110 - Hall 3
17:30 18:30
EF079 - Arena 1
08:30 09:30
1-hour Symposium
ePoster Flash Session
Immune reconstitution syndrome in infectious diseases: Who. Are. You?
AMS around the world: what we can learn from each other
Chairs Elisa Borghi (Milan, Italy)
Justyna Kowalska (Warsaw, Poland) Chair Benedikt Huttner (Geneva, Switzerland)
S0305 17:30 IRIS in HIV immunocompromised hosts: a failure of E0578 Battlefield Stewardship: Implementing Antimicrobial
Management in the Ukrainian Trauma PathwayH.

ESCMID Global 2025 - Programme
Uren* (Lviv, Ukraine), N. Aliieva, O. Voitovych Velavan
E0579 Evaluating a Tailored Antimicrobial Stewardship E0590 In vitro activity of nitroxoline among Acinetobacter
Strategy to Optimise IV to Oral Conversion: A Pre and baumannii and Stenotrophomonas maltophilia
Post-intervention StudyM. Alyazji* (Abudhabi, United clinical isolatesE. Wohlfarth* (Cologne, Germany),
Arab Emirates), A. Sadeq, J. Shamseddine, Z.O.E. P.G. Higgins, M. Kresken
Babiker, A. Almansoori, M. Alhindasi, A. Abadi, S. E0591 Assessing biocide resistance genes and
Alhebsi, S. Alawlaqi, F. Aljasmi, A. Aitamimi, S. susceptibility to biocides in carbapenem-resistant
Shaabani, A. Alhosani, S. Shawish, R. Ali Acinetobacter baumannii isolates from Thai
E0580 Antimicrobial stewardship program for antibiotic use hospitalsM.R.D. Wiradiputra* (Bangkok, Thailand),
in the community: impact of multidisciplinary local K. Thirapanmethee, P. Khuntayaporn, M.T.
guidelines during the 2023-2024 influenza a H1N1 Chomnawang
season in northern ItalyR. Corsini* (Reggio Emilia, E0592 Epidemiological and Genomic Characteristics of
Italy), P. Pavone, L. Donghi, S. Filippini, A. Valcavi, S. Acinetobacter baumannii in a Hospital in Zhejiang,
Filippi, F. Marchi, F. Violi, A. Gandolfi, E. Casini, M. China: A Study from 2015 to 2020Y. Zhang*
Bardaro, G. Russello, P. Nardini, G. Formoso, G. Dolci, (Hangzhou, China), X. Hua
S. Mezzadri
E0593 Evaluation of the susceptibility of Carbapenem-
E0581 Effectiveness of Clinical Algorithms combined with resistant Acinetobacter baumannii to sulbactam-
Point-of-Care testing to improve Antibiotic
durlobactamJ. Caierão* (Porto Alegre, Brazil), L.
Prescribing practices of physicians in outpatient Silva Dornelles, G. Da Silva Collar, M. Preussler
setting of low middle-income countryS. Qureshi* Mott, A. Luís Barth
(Karachi, Pakistan), S. Ahmed, N. Nasir, F.N. Qamar
E0594 Clonal dissemination of Acinetobacter baumannii
E0582 Antibiotic prescribing behaviour in a public International Clone 2 Carrying ArmA and
Bangladeshi hospital: a snapshot from BALANCE
emergence of OXA-23-NDM1 co-producers in
studyM.S. Kabir* (Dhaka, Bangladesh), R. Farzana, IndiaG. Nagaraj* (Bangalore, India), N. Geetha, S.
S.M.R. Islam, A. Monir, A. Sharmin, J.B. Joyee, F. Varun, K. Ravikumar
Humayra, M. Sultana, M.N. Haque, T.R. Walsh
E0595 Insight into Acinetobacter baumannii's phenotypic
E0583 Tailored response to antimicrobial resistance and genotypic traits in oncological patientsF. Sivori*
emergence: remote-created stewardship program in
(Rome, Italy), I. Cavallo, M. Truglio, G. Fabrizio, M.
a low/middle-income country pediatric hospitalP. Francalancia, F. Fraticelli, E. Abril, E.G. Di Domenico,
Favier* (Valencia, Spain), M.A. Aguilera, G. Rapetti F. Pimpinelli
Salik, M. Quipildor, M.M. Maresca, I.A. Falco
E0584 Weekly interdisciplinary antimicrobial stewardship
rounds at two surgical wards show notable potential EW119 - Hall 11
08:30 10:30
in optimising antimicrobial treatmentM. Krauss*
(Vienna, Austria), C. Labut, G. Brunhofer-Bolzer, G. Educational Session
Laml-Wallner, B. Unterkoefler, M. Andtisch, E.
Presterl, H. Burgmann, B. Willinger, I. Minichmayr, P. This bacterium might harbour AmpC, what should I do?!
Starzengruber, F. Loetsch, H. Lagler
Chairs Sören G. Gatermann (Bochum, Germany)
E0585 Antimicrobial stewardship programmes may improve Pranita Tamma (Ellicott City, United States)
patients' outcome and hospitalization: a sub-analysis
of the CASAS (CArbapenem Sparing Antimicrobial
Stewardship) ProjectM. Bongiovanni* (Lugano,
Switzerland), B. Barda, L. Elzi, P. Bellini, C. Di W0335 08:30 Laboratory identification of AmpC and its impact on
Benedetto, N. Ramponi, M. Mombelli, N. Centemero, /i>in vitro resistanceAna Gales (Sao Paulo, Brazil)
A. Colombo, D. Destefani, M. Bissig, E. Bernasconi W0336 08:50 Divergent levels of AmpC expression in Gram-
E0586 “Prescribing antibiotics is a gamble…”: A mixed- negative pathogensAntonio Oliver (Palma De
methods approach to current practices and Mallorca, Spain)
implementation challenges of antimicrobial W0337 09:10 Rational choice of antimicrobial therapy against
stewardship in a Ugandan tertiary care hospitalL. AmpC-producing pathogensPatrick Harris (Herston,
Jung* (Leipzig, Germany), L. Atikoro, D. Owachi, A. Australia)
Schneider, S. Schönherr, A. Von Braun, C. Kabugo
W0338 09:30 Novel antimicrobials active against AmpC: what RCTs
tell us in support of their use?Amy Mathers
(Charlottesville, United States)
EF080 - Arena 3
08:30 09:30
ePoster Flash Session
SY114 - Hall 13
08:30 10:30
Acinetobacter baumannii, still a strong knight to be knocked
2-hour Symposium
Chair Parikshit Prayag (Pune, India)
Sepsis Global 2025
Chairs Brigitte Lamy (Bobigny, France)
E0587 Evaluation of the Antibacterial Activity of New Willem Joost Wiersinga (Amsterdam, Netherlands)
Dermaseptin Derivatives against Acinetobacter
baumanniiH. Haddad* (Sousse, Tunisia)
E0588 Clonal dissemination of highly resistant S0315 08:30 The ESCMID-ISF Sepsis Award LectureAndrew
Acinetobacter baumannii ST2: Insights from the Moore (Emerald Hills, United States)
BALANCE studyC. Abdellaoui* (Oxford, United
S0316 08:45 The WHO Global Maternal Sepsis StudyCarolina
Kingdom), R. Farzana, M.N. Haque, M. Sultana, A.
Carvalho Ribeiro Do Valle (Sao Paulo, Brazil)
Sharmin, R.I. Rony, T. Ahmed Rifat, Z.T. Chaity, S.
Afroj, S. Parvin, M. Ea De Kraker, S. Harbarth, N. S0317 09:15 Sepsis: year in reviewSylvain Meylan (Lausanne,
Hassoun-Kheir, M. Hamza, G. Jana, S. Jamshaid, R. Switzerland)
Yaseen, G. Fatima, M. Nawaz, S.N.Z. Rizvi, U. S0318 09:45 How to design and implement a Sepsis National
Ibrahim, K. Shafique, A. Naqvi, R. Zahra, B. Hassan, Action Plan (SNAP)Erika Vlieghe (Edegem, Belgium)
E. Carretto, K. Sands, K.J. Hoog, T.R. Walsh
Co-organised with: ESCMID Study Group for Bloodstream Infections,
E0589 Prevalence and genomic characterization of Endocarditis and Sepsis (ESGBIES), International Sepsis Forum (ISF)
Sulbactam-Durlobactam-resistant and
Carbapenem-resistant Acinetobacter baumannii in
ICU Patients in a tertiary hospital in Hanoi, Northern SY115 - Hall 14
VietnamD. Nurjadi* (Luebeck, Germany), S. Boutin, 08:30 10:30
Q.T. Nguyen, A.M.P. Thi, N.M. Truong, T.K.P. 2-hour Symposium
Nguyen, T.S. Bui, V.T. Nguyen, L. Göpel, L. Huber, K.
Kocer, T.K.L. Le, T.T. Tran, T.T. Nguyen, H.S. Le, T.P. Challenges in infection management, prevention and antimicrobial

ESCMID Global 2025 - Programme
stewardship in long-term care facilities S0313 09:30 Crimean Congo Haemorrhagic Fever: Newer insights
Chairs Gaetan Gavazzi (Grenoble, France) into pathogenesis leading to new vaccines and
Giusy Tiseo (Pisa, Italy) therapeuticsAli Mirazimi (Stockholm, Sweden)
S0314 10:00 Venezuelan Equine Encephalitis: Impact of newer
strategies for vector controlCarlos Seas (Lima, Peru)
S0319 08:30 The burden of nosocomial infections in long-term
facilities Virginie Prendki (Genève-Thônex, OS078 - Hall 5
Switzerland) 08:30 10:30
S0320 09:00 Pneumonia in the elderly: management and 2-hour Oral Session
preventionMarcos Restrepo (San Antonio, United
States) Trending topics in tuberculosis
S0321 09:30 Challenges in the clinical diagnosis of infection in the Chairs Delia Goletti (Rome, Italy)
elderlyMaheen Abidi (Denver, United States) Sean Wasserman (London, United Kingdom)
S0322 10:00 Challenges in implementing antimicrobial
stewardship in long-term care facilitiesElena Carrara
(Verona, Italy) O0568 Lineage-specific immune responses to
Co-organised with: ESCMID Study Group for Infections in the Elderly (ESGIE), Mycobacterium tuberculosis: insights into L4 and
ESCMID Study Group for Nosocomial Infections (ESGNI), EUCIC Steering L6 pathogenesisM. Silva* (Porto, Portugal), J.
Committee Couto, M. Cardoso, B. Cá, M. Saraiva
O0569 Deciphering the functional role of distinctive
Mycobacterium tuberculosis peptidoglycan
SY117 08:30 - 10:30 Hall 16 modifications in modulating antibiotic resistance
and the immune responseC. Silveiro* (Lisbon,
2-hour Symposium Portugal), F. Olivença, M. Mandal, D. Pires, E. Anes,
M.J. Catalão
Survival of the parasites: is treatment failure due to antimicrobial resistance?
O0570 Increased innate immune and neutrophil blood
Chairs Hanne Brekke (Oslo, Norway) transcriptomic signatures associate with poor
Jaco J. Verweij (Tilburg, Netherlands) outcome in HIV-1 tuberculous meningitisJ.
Barnacle* (London, United Kingdom), A. Davis, R.J.
Wilkinson, K. Wilkinson, C. Stek, M. Maxebengula,
N. Bangani, G. Kelly, M. Rodriguez-Lopez, R. Lai, S.
S0327 08:30 Nitroimidazole refractory Giardia intestinalis
Wasserman, G. Meintjes, A. O' Garra
infectionPavla Tůmová (Praha, Czech Republic)
O0571 Subpopulations in clinical samples of
S0328 09:00 Treatment failure in scabiesFrancisco Bravo (Lima,
Mycobacterium tuberculosis can give rise to
Peru)
rifampicin resistance and shed light on how
S0329 09:30 Recurrent Enterobius infectionsSarah Eisen (London, resistance is acquiredV. Brunner* (Oxford, United
United Kingdom) Kingdom), P. Fowler
S0330 10:00 Recent advances in the treatment of Visceral O0572 A systematic comparison of automated
Leishmaniasis and PKDLShyam Sundar (Varanasi, Mycobacterium tuberculosis complex whole
India) genome sequencing analysis pipelinesR. Spies* (Ho
Co-organised with: ESCMID Study Group for Clinical Parasitology (ESGCP) Chi Minh City, Vietnam), D. Crook, T. Peto, P.
Fowler, R. Turner, H. Thai, J. Watson, T. Walker
O0573 Lung ultrasound for the detection of pulmonary
EW118 - Hall 2 tuberculosis using expert and AI-guided
08:30 10:30
interpretationVeronique Suttels (Lausanne,
Educational Session Switzerland)
O0574 Nanomotion Technology for Rapid Antimicrobial
How can we infer and track plasmid outbreaks?
Susceptibility Testing of Mycobacterium
Chairs Alessandra Carattoli (Rome, Italy) tuberculosis: Evaluating Novel Benzothiazinone
Jacob Moran-Gilad (Beer Sheva, Israel) Derivatives.A. Vocat* (Lausanne, Switzerland), A.
Luraschi-Eggemann, C. Antoni, G. Cathomen, D.
Cichocka, G. Greub, O. Riabova, V. Makarov, O.
Opota, A. Mendoza, S. Cole, A. Sturm
W0331 08:30 Evolutionary modelling of plasmidsManuel Ares
Arroyo (Paris, France) O0575 Rapid drug susceptibility testing of Mycobacterium
tuberculosis directly from clinical samples using
W0332 08:50 How plasmids shape the emergence of nosocomial
targeted next-generation sequencingE. Rosendal*
pathogensJukka Corander (Oslo, Norway)
(Lisbon, Portugal), J. Isidro, S. Carneiro, R. Macedo
W0333 09:10 Understanding the complexity of plasmid outbreaks
O0576 Enhancing cerebral tuberculosis therapy with an
using bioinformaticsTorsten Seemann (Melbourne
innovative particulate nose-to-Brain drug delivery
(VIC), Australia)
system: Insights from pharmacokinetic and
W0334 09:30 Plasmid transmission at the One Health pharmacodynamic studiesK. Jadhav* (Sas Nagar,
interfaceNicole Stoesser (Oxford, United Kingdom) India), K. Sudhakar Jadhav, A.K. Singh, R.K. Verma
Co-organised with: ESCMID Study Group for Epidemiological Markers O0577 Multi-drug resistant tuberculosis among migrants
(ESGEM), ESCMID Study Group for Veterinary Microbiology (ESGVM) in EuropeS. Hayward* (London, United Kingdom),
K. Rustage, L.B. Nellums, J.S. Friedland, S.
Hargreaves
SY113 - Hall 3
08:30 10:30
2-hour Symposium SY120 - Hall 1
09:30 10:30
Haemorrhagic viral infections 1-hour Symposium
Chairs Önder Ergönül (Istanbul, Türkiye)
Catherine Houlihan (Porton Down, United Kingdom) Year in clinical microbiology
Chairs Fidelma Fitzpatrick (Dublin, Ireland)
Maurizio Sanguinetti (Rome, Italy)
S0311 08:30 Filovirus disease: evolving therapeutic strategiesIan
Crozier (Frederick, United States)
S0312 09:00 Jack in the box: Re-emergence of Kyasanur Forest S0339 09:30 Mario Ramirez (Lisbon, Portugal)
Disease in IndiaKavitha Saravu (Manipal, India) S0340 10:00 Anna Papa-Konidari (Thessaloniki, Greece)

ESCMID Global 2025 - Programme
FO129 - Arena 1
11:00 12:00
EF081 09:30 - 10:30 Arena 2 Open Forum
ePoster Flash Session Predatory journals in CM/ID: from symptoms to cure
Clinical features and outcome of invasive fungal infections Chair Emily G. Mcdonald (Montreal, Canada)
Chair Marcus De Melo Teixeira (Brasília, Brazil)
F0356 11:00 The genesis of predatory journals: symptoms and
root problemsLeonard Leibovici (Petah-Tiqva, Israel)
E0596 Management, outcomes and predictors of mortality
of Cryptococcus infection in patients without HIV: a F0357 11:10 The role of editors and publishers of ‘reputable
multicentre study in 46 hospitals from Australia and journals’: what can they do to stop predatory
New ZealandJ. Coussement* (Melbourne, Australia), journals?Till Bärnighausen (Heidelberg, Germany)
C.H. Heath, M.B. Roberts, R.J. Lane, T. Spelman, O.C. F0358 11:20 The roles of authors and academic institutions:
Smibert, A. Longhitano, C.O. Morrissey, B. Nield, M. towards governance and regulation Luigia Scudeller
Tripathy, J.S. Davis, K.J. Kennedy, S.A. Lynar, L.C. (Pavia, Italy)
Crawford, S.J. Crawford, B.J. Smith, A.P. Gador-
F0359 11:30 Bibliometric literacy in scientific publicationLauren
Whyte, R. Haywood, A.A. Mahony, J.C. Howard, G.B.
Maggio (Chicago, United States)
Walls, G.M. O’kane, M.T. Broom, C.L. Keighley, O.
Bupha-Intr, L. Cooley, J.A. O’hern, J.D. Jackson, A.J. Co-organised with: CMI Communications Board of Editors
Morris, C. Bartolo, A.R. Tramontana, K.C. Grimwade,
V. Au Yeung, R. Chean, E. Woolnough, B.W. Teh, M.A.
Slavin, S.C.A. Chen EF089 - Arena 2
11:00 12:00
E0597 Incidence of invasive fungal infections in hospitalised
ePoster Flash Session
paediatric patients in EnglandA. Warris* (Exeter,
United Kingdom), L. Ferreras-Antolin, G. Kiely, Z. Riaz,
Emerging Infectious Diseases, Zoonoses and Outbreaks
M. Czachorowski, M. Gerino, K.K. Rai, Z. Akhter, J.
Owczarek, C. Castillo, I. Jimenez
E0598 Invasive fungal disease in critically ill patients with
cirrhosis: an autopsy studyL. Maessen* (Leuven, E0640 Seasonality of Influenza and Respiratory Syncytial
Belgium), A. Wilmer, P. Meersseman, J. Wauters, J. Virus related hospital contacts in Denmark (1999-
Heylen, S. Feys, C. Jacobs, H.M. Lauwers, K. Lagrou, 2021)O. Rezahosseini* (Hillerod, Denmark), C.L.
M. Peetermans, G. Hermans, Y. Debaveye, E. Van Burrett, M.F. Eiberg, M.P. Andersen, M.F. Howitz, C.
Wijngaerden, S. Van Der Merwe, G. De Hertogh Roed, J.G. Holler, B. Lindegaard Madsen, D.M.
E0599 Non-Aspergillus mould infections in Australia and Weinberger, T.K. Fischer, C. Torp-Pedersen, Z.B.
New Zealand: a multi-centre study on epidemiology Harboe
and clinical outcomesC.F. Neoh* (Melbourne, E0641 Are we serologically prepared against an avian
Australia), S.C.A. Chen, A.J. Morris, C.H. Heath, S.J. influenza pandemic and could seasonal flu vaccines
Tan, R. Lane, S.Y. Tio, M.B. Roberts, S.Y. Tay, K. help us?I. Sanz-Muñoz* (Valladolid, Spain), J.
Kennedy, S. Van Hal, H. Murray, R. Pickles, A. Sánchez-Martínez, C. Rodriguez-Crespo, I. Arroyo-
Douglas, K. Urbancic, M. Menon, A. Stewart, P. Hernántes, C.S. Concha-Santos, M.L. De Dlego, S.
Simos, N.M. Vaselli, J. Howard, C. Keighley, S. Rojo-Rello, M. Domíguez-Gil, M. Hernández-Pérez, A.
Miyakis, R. Beresford, L. Cooley, O. Smibert, M. Sehu, Martín-Toribio, A. Mostafa, L. Martínez-Sobrido, J.M.
K.Y. Yong, A. Crowe, M. England, O. Robinson, S. Eiros, A. Nogales
Lynar, K. Daveson, C. Halliday, S. Kidd, D.C.M. Kong,
E0642 The UK Imported Fever Service (IFS): National VHF
T. Spelman, L. Worth, M. Slavin
testing 2023-2024A. Belfield* (Salisbury, United
E0600 Leveraging natural language processing (NLP) for Kingdom), A. Thompson, H. Umpleby, B. Hack, S.
early detection of aspergillosis: A retrospective Poole, J. Furneaux, J. Owen, J. Osborne, C. Petridou,
studyL. Nwankwo* (London, United Kingdom), N. T. Brooks, N.C. Gordon, T. Rampling, C. Houlihan, C.E.
Pinnock, A. Shek, C. Hemsley, J. Periselneris, S. Warrel
Schelenz, D. Armstrong-James
E0643 Reemergence of Poliovirus in Pakistan: Challenges
E0601 How often does Mucormycosis (MCM) contribute to and Implications for Global Health SecurityS. Ahmad*
mortality in Hematologic Malignancy (HM) patients? (Tampere, Finland)
Analysis of 103 patients over 20 yearsS. Wurster*
E0644 Preparing an emerging infectious diseases unit for
(Houston, United States), T.M. John, J. Ying, D.P.
high-consequence infectious diseasesA. Silva-Pinto*
Kontoyiannis
(Porto, Portugal), C. Silva, A.S. Santos, M. Teixeira, L.
E0602 Emergence of Wickerhamomyces anomalus invasive Santos
infections in injecting drug usersM. Lefranc*
E0645 Correlation between clinical and wastewater measles
(Bordeaux, France), M. Desnos-Ollivier, P. Baudino, K.
positivity rate in three towns of karachi, pakistanF.
Boukris-Sitbon, C. Plaisant, F. Dalle, F. Lanternier, S.
Naz Qamar* (Karachi, Pakistan), F.N. Qamar, S.
Imbert
Qureshi, M. Larik, F. Kabir, J. Iqbal, K. Begum, J.
E0603 Prevalence and risk-factors for secondary Gauld, S. Kroiss, J. Giles
localizations during candidemia in intensive care unit
E0646 Salmonella serovars in wild European hedgehogs
patients: the French CandidICU multicenter studyJ.P.
(Erinaceus europaeus): an over 12-year monitoring in
Gangneux* (Rennes, France), F. Reizine, J. Henry, L.
the Ferrara Province, ItalyE. Massella* (Piacenza,
Desmedt, C. Camus, V. Coirier, F. Arrive, E. Burban,
Italy), M. Munari, S. Russo, L. Cirasella, C.
G. Eustache, T. Belleville, A. Marc, J. Malherbe, P.
Torreggiani, R. Taddei, A. Luppi, S. Rubini
Bouju, P. Jaubert, O. Lesieur, M. Leclerc, P. Fillâtre, A.
Frérou, R. Prével, A. Cady, F. Morio, M. Pihet, G. E0647 Clinico-epidemiological and Microbiological
Nevez, L. Delhaes, S. Imbert, H. Guegan, J. Investigation of Diphtheria Outbreak in Odisha, India,
Bonhomme, E. Perraud, C. Dupin, D. Du Cheyron, Y. 2024I. Praharaj* (Bhubaneswar, India), S. Panda, S.
Launey, C. Aubron Subhadra, J. Sabat, S. Mallik, S. Xalxo, N. Manisha, S.
Priyadarshini, S. Nayak, N. Ray, S. Mallick, S. Pati
E0604 Population-based longitudinal study over two
decades of Candida and Candida-like species E0648 Seroprevalence of nine causes of acute febrile illness
bloodstream infection reveals gender and species in rural Cambodia and Thailand using a multiplex
differences in mortality, recurrence and resistanceA. assayM. Zhang* (Bangkok, Thailand), R. Tripura, L.
Stewart* (Boston, United States), K. Laupland, F. Dysoley, C. Perrone, E. M. Batty, J. Wongsantichon,
Edwards, S. Koo, S. Hammond, P. Harris, D. Paterson, S. D. Blacksell, S. S. Y. Kang, N. P. J. Day, R. J. Maude,
M. Slavin, S. Chen S. J. Lee, Y. Lubell, T. J. Peto

ESCMID Global 2025 - Programme
EF090 - Arena 3 O0622 Molecular epidemiological characterization of
11:00 12:00
enterotoxigenic and enteroaggregative Escherichia
ePoster Flash Session coli causing traveller's diarrhoea and their
relationship with clinical featuresP. Oliveras Julia*
Addressing the need for speed: advances in point-of-care testing (Barcelona, Spain), P. Oliveras, E. Riera, L. Horvath,
Chair Jennifer Dien Bard (Los Angeles, United States) R.M. Albarracín, M.E. Valls, M.J. Álvarez-Martínez, M.
Alguacil, E. Guiral, M. Espasa, D. Camprubi-Ferrer, J.
Vila
O0623 Bites and bytes – can digital surveillance of travellers'
E0649 Rapid respiratory microbiological POCTs and illness predict outbreaks?N. Hedrich* (Zürich,
antibiotic use in primary care: the RAPID-TEST RCTE. Switzerland), T. Lovey, P. Schlagenhauf
Brown* (Bristol, United Kingdom), A.D. Hay, S. Abbs,
O0624 Travel-associated infections and diseases: a
M. Ridd, S. Granier, A. Lane, P. Muir, J. Taylor, G.
retrospective cross-sectional studyM. Trojanek*
Young, K. Eastwood, H. Dash, L. Bradshaw, R. Clarke,
(Prague, Czech Republic), M. Trojánek, V. Grebenyuk,
M. Lui, E. Bridgeman, R. Brierley, H. Thornton, P.
V. Jegorova, P. Hubacek, A. Briksi, J. Havlova, K.
Mitchell, L. Zhu, L. Yardley, C. Metcalfe
Dundrova, L. Kolarik, I. Zicklerova, L. Richterova, O.
E0650 Evaluation of the prototype BIOFIRE® nasal HR panel Beranek, T. Ernestova, L. Kohout, G. Meseznikov, A.
(nHRP) in children with acute respiratory illness, a Nycova, B. Pisova, R. Šindlerová, M. Tulach, Z.
nasal swab-based rapid hoSt gene expression testG. Uhříková, M. Vidlička, M. Štefan, F. Stejskal
Storch* (Saint Louis, Missouri, United States), M.
Wallendorf, C. Rindlisbacher, J. Jackson, M. Hockin
E0651 Evaluation of the analytical performance of the OS086 - Hall 11
11:00 12:00
Biosynex AMPLIQUICK Fecal Bacteriology kit in the
diagnossis of bacterial intestinal infectionsP. 1-hour Oral Session
Lehours* (Bordeaux, France), Q. Beaufils, L. Benejat,
A. Ducournau, J. Aptel, A. Chevalier, M. Jauvain Marker based diagnostics: forget the pathogen
E0652 Development and Validation of a Novel Rapid Antigen Chairs Virginie Prendki (Genève-Thônex, Switzerland)
Test for Norovirus Detection: A Comparative Suzanne Van Asten (Nijmegen, Netherlands)
Performance AnalysisN. Younes* (Doha, Qatar), G.
Nasrallah
E0653 A Rapid Molecular POCT System for Detection of O0625 A 29-mRNA molecular host response test
Carbapenem-Resistant Enterobacterales (CRE)S.Y. demonstrates enhanced accuracy compared to a
Choi* (Daejeon, Korea, Republic of), C. Lee, H.O. Park protein-based host response test for the diagnosis of
E0654 Validation of an ultra-rapid, point-of-care, antibiotic bacterial and viral infectionsN. Whitfield* (Sunnyvale,
susceptibility testing deviceA. Van Der Linden* United States), C. Lu, O. Liesenfeld
(Eindhoven, Netherlands), Y. Deurloo, N. Doomen, D. O0626 Diagnostic accuracy of a bacterial versus viral host-
Kreft, J. Hays, H. Stapert, A. Van Belkum, S. Shanko protein test for pediatric inpatients with acute
E0655 Development of a frugal multiplexed paper sensor for infectionT. Gottlieb* (Tirat Carmel, Israel), L. Bont, A.
rapid detection of sepsis-causing pathogensC. Klein, M. Stein, M. Mor, I. Srugo, R. Navon, E. Eden,
Singhal* (Faridabad, India), S. Chatterjee, S. Gupta, B.P. Muller
M. Yadav, C. Sharma, S. Pandey, D. Kumar, P. Joshi, O0627 Diagnostic accuracy of combined urine lipocalin 2
J. Jaya, R. Dwivedi, S. Tanwar, S. Sharma, S. Shamsi, and copper test in acute pyelonephritis or cystitisV.
A. Tyagi, N. Kumar, S. Chaudhuri Havlicek* (Prague, Czech Republic), J. Hrbacek, T.
E0656 Multianalyte POCT device for a sample-to-result Pluhacek, J. Houst, A. Palyzova, D. Luptakova, D.A.
detection of nucleic acid and proteinL. Pommiès* (Gif Stevens, J. Novak, R. Dobias, R. Zachoval
Sur Yvette, France), H. Boutal, D. Fras, H. Volland O0628 Diagnostic Performance of Whole-Blood RNA
E0657 A smartphone app for point-of-care quantification of Signatures for Tuberculosis Diagnosis in a Cohort of
lateral flow assaysR. Armiger* (London, United Patients with Non-Tuberculous Mycobacterial Lung
Kingdom), R. Reid, P. Georgiou, A. Holmes, J. Herberg DiseaseP. Escalante* (Rochester, Mn, United States),
B. Piatkowski, B. Pathakumari, V. Van Keulen, N.
Fadra, P. Arias-Sanchez, L. Gutierrez, S. Karnakoti, T.
KN121 - Hall 1 Peikert
11:00 12:00
O0629 Diagnostic utility of MxA and MxA/CRP ratio in
Keynote Lecture differentiating viral and bacterial infections: a
prospective cohort studyO. Beránek* (Prague, Czech
HIV: from needle parks to injectables Republic), R. Prusa, M. Trojánek, O. Beranek, Z.
Chairs Mary Horgan (Dublin, Ireland) Uhříková, J. Illner, P. Lehnert, P. Bukovska, M. Štefan,
Gülsen Özkaya Sahin (Lund, Sweden) V. Jegorova, T. Ernestova, L. Kohout, G. Meseznikov,
A. Nycova, R. Šindlerová, M. Tulach, M. Vidlička, V.
Grebenyuk
K0341 11:00 Huldrych Günthard (Zürich, Switzerland)
PM2 - Hall 12
11:00 12:00
OS085 11:00 - 12:00 Hall 10 Panel Discussion
AMR and vaccines
1-hour Oral Session
Chairs Charlotte Vernhes (Brussels, Belgium)
Planes, Pains, and Pathogens: The Perils of Travel Medicine Ghada Zoubiane (London, United Kingdom)
Chairs Anu Kantele (Helsinki, Finland)
Carlos Seas (Lima, Peru)
L005 11:00 Overview of the current evidence of the impact of
vaccines on AMRAdam Cunningham (Birmingham,
United Kingdom)
O0620 Fever in returning travelers from tropical regions:
what not to miss in an evolving epidemiologyS. L006 11:20 Panel discussion: gaps, needs, and opportunities to
Caronni* (Milan, Italy), M. Pieruzzi, A. Rizzo, A.H. leverage vaccines against AMR, Adam Cunningham
Behring, A. Poloni, A. Giacomelli, F. Salari, S. Grosso, (Birmingham, United Kingdom), Sipho Kenneth
A. Mancon, D. Mileto, S. Antinori Dlamini (Observatory, South Africa), Erin Duffy
(Boston, United States), Mateusz Hasso-Agopsowicz
O0621 Tracing the itch: A spatiotemporal analysis of scabies
(Geneva, Switzerland)
rates and its risk factors using the Global Burden of
Disease dataS. Gupta* (Auckland, New Zealand), S.
Thornley, G. Sundborn, C. Grant

ESCMID Global 2025 - Programme
SY126 - Hall 13 O0636 Viral metagenomics in patients with persistent
11:00 12:00
unexplained neutropenic fever- some clues to the
1-hour Symposium cause of fever?A. Douglas* (Melbourne, Australia),
L. Caly, M.A. Slavin, I. Savic, J. Moselen, A. Aziz, G.
Why is the concept of complicated UTI so complicated? Papadakis, G. Ng, J. Druce, K. Thursky
Chairs Gernot Bonkat (Basel, Switzerland) O0637 Results of Optifil study: 18F-FDG-PET/CT guided
Maeve Doyle (Waterford, Ireland) antifungal stewardship in invasive pulmonary
aspergillosisF. Lanternier* (Paris, France), C.
Maunoury, F. Montravers, F. Marquant, S. Poiree, C.
Elie, C. Robin, A. Thiebaut, F. Ader, F. Suarez, E.
S0350 11:00 The concept of complicated UTI: underlying Blanchard, O. Lortholary
conditions matterSuzanne Geerlings (Amsterdam,
O0638 Long-term immunogenicity and boostability of the
Netherlands)
5-dose pneumococcal vaccination schedule
S0351 11:30 The concept of complicated UTI: the site of infection following allogeneic hematopoietic stem cell
matters mostJesús Rodríguez-Baño (Seville, Spain) transplantation: a prospective cohort studyS.
Co-organised with: ESCMID Education Subcommittee Haggenburg* (Amsterdam, Netherlands), J.
Schnyder, H. Garcia Garrido, M. Schoordijk, A.
Reiners, B. Meek, M. Hazenberg, A. Goorhuis
ME128 - Hall 14 O0639 Humoral and cellular immune response to
11:00 12:00
adjuvanted respiratory syncytial virus vaccine
Meet-the-Expert RSVPreF3 in adults after allogeneic hematopoietic
cell transplantationJ. Lötscher* (Basel,
How to apply organoid models to study infectious disease Switzerland), C.S. Walti, J. Halter, N. Khanna, S.
Heller, S. Schmid, K. Leuzinger
M0354 11:00 Jennifer Rohn (London, United Kingdom) OS082 - Hall 2
11:00 12:00
M0355 11:12 Nathalie Sauvonnet (Paris, France)
1-hour Oral Session
New insights in bloodstream infections and endocarditis
OS087 - Hall 15
11:00 12:00
Chairs Barbara Hasse (Zurich, Switzerland)
1-hour Oral Session José M. Miro (Barcelona, Spain)
Antimicrobial resistance around birth
Chairs Julia Anna Bielicki (London, United Kingdom)
O0605 Different from the start – Sex differences in
Surbhi Malhotra-Kumar (Antwerp, Belgium)
Staphylococcus aureus bacteremia mortalityA.
Westgeest* (Leiden, Netherlands), M. Lambregts, F.
Ruffin, V.G. Fowler, J.T. Thaden
O0630 Prevalence and risk factors of antibiotic resistance O0606 Tracking evolution in action during invasive
genes in breastmilk and neonatal oral cavity of Staphylococcus aureus infections: the BARISTA
preterm mother-infant pairsA. Sharma* (Chandigarh, studyS. Giulieri* (Melbourne, Australia), D. Daniel, M.
India), S. Dutta, M. Biswal, A. Chakraborty, V. Suri, P. Duarte Aguilera, D. Velasquez-Reyes, R. Guérillot, A.
Ray Gador-Whyte, F. James, E. Goodall, P. Fuge-Larsen,
O0631 Effect of maternal peripartum antibiotic exposure on M. Henri, J. Trubiano, M. Leroi, K. Bond, T. Stinear, S.
the microbial diversity, relative abundance of taxa, Tong, J. Kwong, B. Howden
and resistome in breastmilkA. Chakraborty* O0607 Identifying heterogeneity of treatment effect for
(Chandigarh, India), S. Dutta, P. Sikka, D. Puri, A. antibiotic duration in bloodstream infection – an
Kumar, P. Kumar, A. Pal, A. Arora exploratory post-hoc analysis of the BALANCE
O0632 Dynamics of gastrointestinal colonisation by randomized clinical trialS. Ong* (Melbourne,
antibiotic-resistant bacteria in high-risk infants in Australia), R. Pinto, A. Rishu, S. Tong, R. Commons,
Swiss and Greek neonatal intensive care unitsA. J.M. Conly, G. Evans, M. Fralick, C. Kandel, P. Lagacé-
Braspenning* (Antwerp, Belgium), L. Timbermont, L. Wiens, T. Lee, S. Lother, D. Macfadden, J. Marshall, V.
Van Heirstraeten, M. Berkell, A. Cook, E. Sieswerda, Martel-Laferrière, M. Mayette, E. Mcdonald, J. Neary,
C.H. Van Werkhoven, J. Bielicki, S. Malhotra-Kumar J. Prazak, E. Raby, A. Regli, B.A. Rogers, S. Smith, L.
Taggart, H.T. Wang, T. Wuerz, D. Yahav, P. Young,
O0633 Harnessing functional omics to decipher how
R.A. Fowler, N. Daneman
probiotics reduce antibiotic resistance gene carriage
in infants' gutV. Pettersen* (Tromsø, Norway), A. O0608 Bloodstream infection pathogen diversity and clinical
Bargheet, G.H. Bø, C. Klingenberg impact revealed through unbiased whole genome
sequencing: a prospective genomic epidemiology
O0634 Dynamics of gut resistome and mobilome in early life:
studyN. Macesic* (Melbourne, Australia), J. Hawkey,
A meta-analysisV. Pettersen* (Tromsø, Norway), A.
J.A. Wisniewski, A. Peleg
Bargheet, H.T. Noordzij, A.J. Ponsero, C. Jian, K.
Korpela, M. Valles-Colomer, J. Debelius, A. O0609 Risk of infection of intracardiac devices in patients
Kurilshikov with valvular infective endocarditis who carry
cardiovascular implanted electronic devices. Analysis
on a national cohortA. Blanco Arévalo* (Barcelona,
Spain), A. Blanco-Arevalo, E. Calbo, P. Muñoz, D.
OS088 - Hall 16
11:00 12:00 Monzón, M. Valerio, M. Hernandez Meneses, J.M.
1-hour Oral Session Miró, M. Cobo Belastegui, A. De Alarcón, R.
Rodríguez, I. Villanueva Benito, J.C. Lopez-Azor, L.
Advancing diagnostics and preventive measures in hemato-oncological Garcia-Alvarez, L. Boix
patients
Chairs Dina Averbuch (Jerusalem, Israel)
SY122 - Hall 3
Malgorzata Mikulska (Genoa, Italy) 11:00 12:00
1-hour Symposium
Chronic infections in the era of CFTR modulators: what is going on in cystic
O0635 Prediction of bacterial and fungal bloodstream
fibrosis lungs these days?
infections using machine learning in patients
undergoing chemotherapyM. Freire* (Sao Paulo, Chairs Pavel Drevinek (Prague, Czech Republic)
Brazil), A. Villani. Jr, M. P. Freire, F. Lazzar Neto, L.A. Helle Krogh Johansen (Copenhagen, Denmark)
De Padua Covas Lages, M. Salaroli De Oliveira, E.
Abdala, F. L.S. Nunes, A.S. S. Levin

ESCMID Global 2025 - Programme
S0342 11:00 The lung microbiome of people with cystic fibrosis
receiving modulator therapySebastien Boutin SY125 - Hall 7
(Lübeck, Germany) 11:00 12:00
S0343 11:30 Tackling chronic infections in people with cystic 1-hour Symposium
fibrosis receiving modulator therapy: is it still
necessary?Alessandra Bragonzi (Milano, Italy) Cutting edge methods in mycology
Co-organised with: ESCMID Study Group for Biofilms (ESGB), Czech Society Chairs Katrien Lagrou (Leuven, Belgium)
for Medical Microbiology Antonio Vena (Genova, Italy)
SY123
11:00
-
12:00
Hall 4
S0348 11:00 Imaging for diagnosing mycoses: focus on 18F-FDG
PET/CTAna Fernández-Cruz (Majadahonda (Madrid),
1-hour Symposium
Spain)
Infection prevention and control and intensive care: challenges and solutions S0349 11:30 Exploring the intersection of fungal metagenomics
and medical mycologyMarcus De Melo Teixeira
Chairs Antonios Katsounas (Bochum, Germany)
(Brasília, Brazil)
Claire Roger (Nimes, France)
Co-organised with: ESCMID Fungal Infection Study Group (EFISG), ESCMID
Education Subcommittee, Medical Mycology Study Group (GEMICOMED)
within the SEIMC (Spanish Society of Infectious Diseases and Clinical
S0344 11:00 Intensive care unit (ICU) and infection: two sides of a Microbiology), ESCMID Study Group for Critically Ill Patients (ESGCIP),
coinReto Schuepbach (Zurich, Switzerland) Società Italiana per la Terapia Antinfett
S0345 11:20 Ventilator- associated pneumonia (VAP) and ICU
enviroment: how can we improve practices?Despoina
Koulenti (London, United Kingdom) OS084 - Hall 8
11:00 12:00
Co-organised with: ESCMID Study Group for Critically Ill Patients (ESGCIP),
1-hour Case Session
EUCIC Steering Committee
Weird and unusual infections
OS083 - Hall 5 Chairs Murat Akova (Ankara, Türkiye)
11:00 12:00 Muge Cevik (St Andrews, United Kingdom)
1-hour Oral Session
Don't 'rash' it
O0615 Vertical Transmission of Clade Ib monkeypoxvirus
Chairs Heli Harvala (Turku, Finland) during Pregnancy: Clinical and Histopathological
Catherine Moore (Cardiff, United Kingdom) description of 3 casesE. Hasivirwe Vakaniaki*
(Kinshasa, Congo, the Democratic Republic of the),
N.R. Swar Kuispond, H. Yuichiro, S. Tadaki, R. Bulakali
Chirimwami, L. Liesenborghs, P. Mbala-Kingebeni, E.
O0610 Current Prevalence of Parvovirus B 19 Infections:
Bangwen, I. Brosius, T. Wawina-Bokalanga, S. Sabiti
Ankara Bilkent City Hospital Experience 2019-
Nundu
2024B. Dinc* (Ankara, Türkiye), F.G. Aslan, F. Kırca,
A. Toyran, S. Aydoğan, B. Dinç O0616 First case of Oropouche fever in the South of SpainI.
Pérez Hernández* (Málaga, Spain), I.A. Pérez-
O0611 Managing an outbreak of parvovirus B19 infection in
Hernández, E. Basallote Leal, M.A. Sempere Alcocer,
pregnancy: clinical outcomes from a single-centre
B. O´donell Cortés
studyM. Melchio* (Genoa, Italy), E. Ricci, E. Cristina,
E. Di Marco, P. Caligiuri, F. Prefumo, S. Mangini, A. O0617 Wild hippopotamus bite and Aeromonas spp.
Mesini, M. Mariani, C. Russo Artimagnella, C. infection: a treatment challenge. First case report.J.
Saffioti Alza Arcila* (Medellín, Colombia), N.M. Daza Alarcon,
M.V. Montoya Garcia, A. Múnera-Echeverri, F.F.
O0612 The dark side of the „fifth disease” endemic: human
Jiménez Quiroz, J. Alza-Arcila
parvovirus B19 infections transmitted through blood
transfusions in adults with malignant hematological O0618 From the sea to the land: an emerging speciesK.
diseasesB.G. Szabo* (Budapest, Hungary), D. Rodríguez Martínez* (Santo Domingo, Dominican
Korozs, P. Remenyi, J. Sinko Republic), K. Rodríguez, A. Fernández, K. Espaillat, J.
Cruz, X. Rodríguez, T. Flores
O0613 Key learnings from a measles outbreak with
multiple hospital exposures in Ireland, May-July O0619 The first findings of Wohlfahrtiimonas chitiniclastica
2024A.M. Murray* (Dublin, Ireland), G. Larkin, D. and Ignatzschineria species bacteremia in two cases
Hickey with maggot infested wounds in ScandinaviaA.L.
Engsbro* (Slagelse, Denmark), C. Mortensen, R. Jul,
O0614 Measles virus in the context of subacute sclerosing
W. Cebula, A.L. Laugesen, J.T. Møller, M. Kemp
panencephalitis (SSPE)J. Dina* (Caen, France), S.
Medragh, J. Adnet, T. Belveyre, C. Vauloup-Fellous
ME127 - Hall 9
11:00 12:00
SY124 - Hall 6
11:00 12:00 Meet-the-Expert
1-hour Symposium
EUCAST: What's new in susceptibility testing
Antimicrobial prescribing: myths or pearls?
Chairs Massimo Fantoni (Roma, Italy)
Spyros Pournaras (Athens, Greece) M0352 11:00 Erika Matuschek (Växjö, Sweden)
M0353 11:12 Rafael Canton (Madrid, Spain)
Co-organised with: EUCAST Steering Committee
S0346 11:00 Why treat IV when PO is possible?Bradley Spellberg
(Los Angeles, United States)
S0347 11:30 De-escalation of antibiotic therapy to narrow- ME134 - Hall 16
13:30 14:30
spectrum IV drugsFlaminia Olearo (Hamburg,
Germany) Meet-the-Expert
Co-organised with: CMI Communications Board of Editors, ESCMID AMR
The older solid organ transplant recipient: between frailty,
Action Subcommittee, ESCMID Study Group for Antimicrobial stewardship
immunosenescence and infection
(ESGAP), Trainee Association of ESCMID (TAE) Steering Committee, ESCMID
Scientific Affairs Subcommittee

ESCMID Global 2025 - Programme
Bernasconi
M0367 13:30 Maheen Abidi (Denver, United States)
E0669 Assessment of HIV-DNA, immune activation and
M0368 13:42 Alaa Atamna (Petah-Tikva, Israel) senescence biomarkers during injectable
Co-organised with: ESCMID Study Group for Infections in Compromised cabotegravir/rilpivirine treatmentM. Mazzitelli*
Hosts (ESGICH), ESCMID Study Group for Infections in the Elderly (ESGIE) (Padua, Italy), M.R. Petrara, C. Cozzolino, L. Sasset,
D. Leoni, S. Gardin, E. Ruffoni, A. De Rossi, A. Cattelan
E0670 Impact of Cabotegravir plus Rilpivirine Long-Acting
SY131 13:30 - 14:30 Hall 2 on Body Composition: Results from a Prospective
StudyA. De Vito* (Sassari, Italy), A. Marongiu, A.
1-hour Symposium Cano, M. Puci, A. Colpani, A. Mura, M.G. Catte, M.A.
Deledda, S. Uzzau, S. Babudieri, G. Sotgiu, F. Deriu, A.
Vaccines and antimicrobial resistance Spanu, G. Madeddu
Chairs Iva Butic (Zagreb, Croatia) E0671 Real-World Efficacy and Tolerability of Long-Acting
Zitta Barrella Harboe (Hillerød, Denmark) Cabotegravir/Rilpivirine in Older Woman with
Polypharmacy and ComorbiditiesM. Rosas Cancio-
Suárez* (Madrid, Spain), A. Moreno, S. Del Campo
Terrón, M.J. Vivancos, A. G. García De Morales, J.
S0361 13:30 The impact of current and future vaccines on AMR:
Martínez-Sanz, M.D. Corbacho, M. Suárez, C. Cano,
from pneumococcal to COVID-19Mateusz Hasso-
R. Ron, M.J. Cárdenas-Isasi, M. Vélez-Díaz-Pallarés,
Agopsowicz (Geneva, Switzerland)
S. Moreno, M.J. Pérez-Elías
S0362 14:00 Can vaccines against AMR be translated into
E0672 Two-year comparative analysis of lipid profile
policy?William Hausdorff (Washington DC, United
changes between INSTI-based single tablet regimens
States)
in treatment-naïve people living with HIV: real-world
Co-organised with: ESCMID Study Group for Antimicrobial Resistance evidence from South KoreaS.Y. Lim* (Seoul, Korea,
Surveillance (ESGARS), ESCMID Vaccine Study Group (EVASG) Republic of), B. Chin, M.K. Kim, Y. Kim, G. Kim, J.
Bang
E0673 Long-acting antiretroviral therapy in PLWH with prior
EW135 13:30 - 15:30 Hall 3 HBV exposureJ. Mateo Gonzalez* (Valencia, Spain),
J.I. Mateo-Gonzalez, M. Plaza-De-La-Torre, D.
Educational Session
Martinez-Perez, J. Martinez-Andres, V. Abril-Lopez-
De-Medrano, E. Ballester-Belda, M. Garcia-
Transforming your research idea into an appropriate study design
Rodriguez, C. Ricart-Olmos, M. Garcia-Deltoro
Chairs Casandra Bulescu (Bucharest, Romania)
E0674 Protease inhibitors in today's antiretroviral
Mary Horgan (Dublin, Ireland)
landscape: are we tracking resistance?J. Ciscar
Soriano* (València, Spain), J. Ciscar-Soriano, M.D.
Gómez-Ruiz, A. Hernández-Cabezas, A. Valentín-
W0369 13:30 Designing high-quality research studies: Martín, M. Montero-Alonso, J.L. López-Hontangas
methodological skills and knowledgeMical Paul E0675 Effect after Switching from Efavirenz to Rilpivirine on
(Haifa, Israel) Liver Steatosis Among People Living with HIV with
W0370 13:50 How to design and run scientific studies using AI Non-Alcoholic Fatty Liver Disease: A Randomized
agents as research assistantsAlyssa Bilinski Controlled TrialL. Srikham* (Sakon Nakhon,
(Cambridge, United States) Thailand), S. Sriphoosanaphan, O. Putcharoen
W0371 14:10 Designing your first study: how to construct a E0676 Impact of maternal dolutegravir on growth outcomes
workable project when your work environment may of HIV-exposed uninfected children: A prospective
not helpThomas Tängdén (Uppsala, Sweden) studyE. Yoram* (Morongoro, Tanzania, United
republic of), E. Luoga, S. Glanzman, F. Vanobberghen,
W0372 14:30 Bridging early-career professionals with partners and
M. Weisser, E. Dotto, G.J. Mollel, G. Sigalla, E.
seniorsGiorgia Caruana (Sion, Switzerland)
Nyenza, L. Moshi, L. Wilson, J. Okuma, D. Paris
Co-organised with: CMI Board of Editors, CMI Communications Board of
Editors, Trainee Association of ESCMID (TAE) Steering Committee
EF094 - Arena 3
13:30 14:30
FO136 - Arena 1 ePoster Flash Session
13:30 14:30
Open Forum Speed, convenience and performance of virus diagnostic methods
Chair Hans H. Hirsch (Basel, Switzerland)
Diversity in CM and ID: gender gaps and policy traps
Chair Andre Fuchs (Augsburg, Germany)
E0677 Prospective evaluation of a rapid diagnostic test in a
tertiary hospital and prospects for reinforced
F0373 13:30 How to avoid parity traps in ID/CM research?Muge dengue surveillance in Catalonia (Northeastern
Cevik (St Andrews, United Kingdom) Spain)L. Horvath* (Barcelona, Spain), L. Horvath
F0374 13:40 Gender gaps in visibility at scientific Ruiz, J. Navero, M. Navarro, M. Pujada, A. Navarro,
conferencesSarah Delliere (Paris, France) M. Garrido, B. Herrerías, P. Rodríguez, N. Zancada,
B. Escudero-Perez, M.J. Martinez
F0375 13:50 Psychological determinants of empowerment at
individual and societal levelTba E0678 Sequence-Independent Single-Primer Amplification
(SISPA) followed by Next-Generation Sequencing
Co-organised with: ESCMID Education Subcommittee, ESCMID Parity for Diagnosing Viral Respiratory Tract InfectionsP.
Commission Trindade* (Santa Maria, Brazil), B.C. Casarin, T.R. Y
Castro, B.C. Piccoli, V.T. Santos, L.F. Tessele, A.V.
Schwarzbold
EF093
13:30
-
14:30
Arena 2
E0679 Seasonal trends and co-infection dynamics of
respiratory pathogens: insights from a yearlong
ePoster Flash Session
studyZ. Tsinaris* (Thessaloniki, Greece), A. Tychala,
G. Meletis, A. Greco, T. Chatziantoniou, R.
Real world experience with modern HIV treatment: the art of ART
Dimitriadou, C. Chantzi, E. Georgiadou, G. Kagkalou,
O. Vasilaki, P. Mantzana, L. Skoura, E. Protonotariou
E0680 Speed meets reliability in respiratory infections
E0668 Use of long-acting cabotegravir/rilpivirine in HIV- diagnosis with a new nucleic acid extraction
viraemic individuals: a metanalysisM. Bongiovanni* workflowL. Pastor-Bernad* (San Mateo De Gállego,
(Lugano, Switzerland), B. Barda, G. Barilaro, E. Spain), B. Santos Da Silveira, E. Lucia, M.C. Gil-
Rodríguez, H. Alonoso, C. Giménez-Rota

ESCMID Global 2025 - Programme
E0681 Pathobiome characterization and role in disease
severity in children under 5-years with respiratory
infection symptomsL. Terranova* (Milan, Italy), L. OS092 13:30 - 14:30 Hall 14
Corneo, G. Di Pietro, R. Pinzani, M. Bolis, L. Alagna,
1-hour Case Session
M. Caruso, F. Giorgetti, N. Hejazifar, E. Furchì, M.
Carnevale Schianca, P. Bono, C. Tagliabue, F.B.A.
Mycobacterial mayhem
Blasi, A. Callegaro, A. Bandera, S. Bosis, C. Alteri
Chairs Seif Al-Abri (Muscat, Oman)
E0682 Viral viability markers of SARS-CoV-2: A
Linda Aulin (Leiden, Netherlands)
Comparison of cell culture genomic RNA RT-PCR
and subgenomic RNA RT-PCRC. Cuesta Chasco*
(Barcelona, Spain), S. Alex, M. Mª Ángeles, C.C.
Genoveva, A. Francesco, R. Cristina, V. Anna, H.
O0663 Limitations of the Xpert® MTB/RIF assay: A series of
Juan Carlos, F.A. Francesc, R.L. Luis Gerardo, N.
four clinical casesA. Haas* (Salt Lake City, United
Mireia, G. Ignacio, B. Marta, G.V. Carolina
States), A. Ma, J. Pham, P. Verma, U. Malhotra, E.C.
E0683 Diagnostic performance of Hepatitis B virus surface Church, M. Narita, V. Escuyer, S. Shakir
antigens in the Netherlands using type-specific
O0664 Pharmacokinetic analysis of blood and cerebrospinal
external quality assessmentE. Vanhulle* (Bilthoven,
fluid contezolid concentrations in a patient with
Netherlands), M. Simões, H. Ten Bruin, G. Boland, A.
tuberculous meningoencephalitisW. Nie* (Beijing,
Brandenburg, K. Benschop
China), N. Chu
E0684 Low utility of parallel testing by multiplex and
O0665 Is this the first case of Mycobacterium
individual real-time PCR assays for the diagnosis of
stephanolepidis infection in humans?S. Pérez-Recio*
viral meningitis and encephalitis at a large public
(Barcelona, Spain), M.D. Grijota-Camino, A. Lérida, A.
hospital in the United States.A. Cuber* (Los
Bauer, L. Fernández-Delgado, M.J. Luque, N. Sabé
Angeles, United States), S. Butler-Wu
Fernández, F. Alcaide, M. Santin
E0685 Plasma Separation Card as an alternative sampling
O0666 Diagnostic Aspects of a Bacillus Calmette-Guërin
method for quantitative HCV RNA testing with high
Infection Following Intravesical Treatment for Bladder
comparability to EDTA plasmaF. Garcia* (Granada,
CancerK.J. Kim* (Seoul, Korea, Republic of), J.H. Cha,
Spain), A. Fuentes López, A. Rando Segura, R.
S.G. Yoon, M.H. Nam, G.I. Lee, Y. Cho
Carracedo, A. Kessler, A. De Salazar González, S.Z.
Gebreab, E. Molina, N. Parajó, S. Pereira, J. Romero O0667 Mycobacterium abscessus: Is Shorter Antibiotic
Vico, E. Ruiz Escolano, M. Vila, L. Viñuela González, Therapy Combined with Surgery Sufficient?M.J.
A. Carrasco Durán, A. Aguilera, F. García, M. Buti Lopes* (Amadora, Portugal), C. Paulo, D. Trigo, M.
Ferret Caixeiro, M. Alves, R. Macedo, P. Pacheco
KN130 - Hall 1 SY133 - Hall 15
13:30 14:30 13:30 14:30
Keynote Lecture 1-hour Symposium
Infectious disease challenges in an ever-changing environment
Probiotics in infectious diseases: current state-of-play
Chairs Jacob Moran-Gilad (Beer Sheva, Israel)
Chairs Nicolas Benech (Lyon, France)
Annelies Zinkernagel (Zurich, Switzerland)
Silvia Corcione (Turin, Italy)
K0360 13:30 Pamela Rendi Wagner (Stockholm, Sweden)
S0365 13:30 Probiotics in infectious diseases: the perfect
complement to antimicrobial therapies?Lena Biehl
(Cologne, Germany)
PM3
13:30
-
14:30
Hall 12
S0366 14:00 The horizon of next generation probiotics for
Meet-the-Innovators infectious diseasesCormac Gahan (Cork, Ireland)
Future prospects of electronic clinical decision support systems in Co-organised with: ESCMID Study Group for Host and Microbiota Interaction
stewardship programs (ESGHAMI)
OS091 - Hall 5
13:30 14:30
L007 13:30 Opportunities for clinical decision support systems in
infectious disease managementNathan Peiffer- 1-hour Oral Session
Smadja (Paris, France)
Genomic and molecular drivers of bacterial virulence and resistance
L008 14:00 CDSS and AMS programs: the Lumed
exampleValiquette Louis (Sherbrooke, Canada) Chairs Ecaterina Noroc (Chisinau, Moldova, Republic of)
Guido Werner (Wernigerode, Germany)
SY132 - Hall 13
13:30 14:30
O0658 Characterization of the virulence shaping and
1-hour Symposium
adaptability in the methicillin-resistant
Staphylococcus aureus ST9 lineage.Y. Chen*
Predicting antibiotic susceptibility profiles from whole genome sequences:
(Hangzhou, China), L. Sun
state-of-the-art
O0659 Elucidating molecular mechanisms of bacterial
Chairs Werner Ruppitsch (Vienna, Austria)
conjugation: towards an improved understanding of
Balaji Veeraraghavan (Vellore, India)
plasmid evolution and epidemiologyS. David*
(Oxford, United Kingdom), C. Seddon, J. Wong, N.
Ishimoto, S. He, J. Bradshaw, W.W. Low, D.
S0363 13:30 Impact of the WHO’s developed catalogue of Aanensen, G. Frankel, K. Beis
mutations on rapid TB diagnosis and O0660 Clinical carbapenem-resistant Klebsiella pneumoniae
treatmentThomas Schön (Kalmar, Sweden) (CRKP) strains carrying a mutH mutation are
S0364 14:00 Antimicrobial resistance prediction using whole hypermutators that have heightened virulence and
genome sequencingPatricia Simner (Rochester, readily develop ￿-lactam/￿-lactamase resistanceS.
United States) Cheng* (Pittsburgh, United States), C. Clancy, M.H.
Nguyen, B. Hao, G. Liu
Co-organised with: ESCMID Study Group for Antimicrobial Resistance
Surveillance (ESGARS), ESCMID Study Group for Epidemiological Markers O0661 Genomic insights into the new prophages of MDR
(ESGEM), EUCAST Steering Committee Pseudomonas aeruginosa: an example of phage-
host-phage interactionA. Uskudar Guclu* (Ankara,

ESCMID Global 2025 - Programme
Türkiye), S. Unlu (Greifswald, Germany), L. Guardabassi, K. Schaufler,
O0662 Genome-wide association study (GWAS) reveals J.U. Müller, B. Jana, M. Schwabe, Y. Ma, M. Pirolo
importance of vaginal epithelium associated genes in E0717 Resistance profiles of Carbapenemase-producing
case of recurrent vaginitisR. Mändar* (Tartu, Enterobacterales in a large centre in England: are we
Estonia), E. Mutli, K. Koort, A. Salumets, T. Laisk already losing cefiderocol?I. Baltas* (London, United
Kingdom), T. Patel, A.L. Soares
E0718 Impact of cefiderocol therapy on patient survival
EF099 14:45 - 15:45 Arena 1 across different multi-drug resistant Gram-negative
bacilli infections: insights from the SUSANA cohort.N.
ePoster Flash Session Corti* (Monza, Italy), M. Faltoni, L. Mezzadri, E. Ricci,
M. Fois, A. De Vito, A. Bandera, P. Maggi, D. Bavaro,
Infection Prevention in Action: Innovations, Insights, and Global Intervention S. Rusconi, A. Mastroianni, M.A. Carleo, G.
Chair Allison Mcgeer (Toronto, Canada) Cenderello, L. Bisi, G. Madeddu, P. Bonfanti
E0719 Decoding resistance: investigating cefiderocol's
battle against carbapenem-resistant Acinetobacter
baumanniiY.T. Lee* (Taipei, Taiwan, China)
E0706 A Candida auris cgMLST Scheme for Enhanced
Outbreak Surveillance and Global Epidemiological E0720 Long-read sequencing reveals novel genetic factors
TrackingC. Harless* (Silver Spring, United States), J. in cefiderocol resistance in Pseudomonas aeruginosa
Stam, B. Corey, E. Horishny, A. Ong, Y. Kwak, J. ATCC 27853: A stepwise adaptive evolution studyM.
Bennett, P. Mcgann, F. Lebreton Cardoso* (Groningen, Netherlands), B.B. Xavier, B.
Sinha, J. W. A. Rossen, A. Kumar Bari, T. T. Severs
E0707 Machine Learning-Augmented Clinical Scoring
System for Predicting KPC Infections in Healthcare E0721 Activity of cefiderocol against carbapenem-resistant
Crisis ScenariosA. Rearte* (Buenos Aires, Argentina), and molecularly characterized Enterobacterales
F. Herrera, E. Temporiti, J. Smayevski, P. Bonvehi clinical isolates causing infection in hospitals in
Europe and adjacent regionsR. Mendes* (North
E0708 Incident infections with respiratory syncytial virus in a
Liberty, United States), A. Scullin, D. Beekman, Z.
hospital-based healthcare worker cohort, 2023-2024
Kockler, J.M. Maher, H.S. Sader, M. Castanheira
winter seasonC. Savulescu* (Paris, France), M. Rojas,
K. Brolin, A. Uusküla, C. Bergin, C. Fleming, V. E0722 Cefiderocol activity against planktonic and biofilm
Zvirbulis, D. Zavadska, V. Gaio, C.P. Popescu, R.M. forms of ￿-lactamase-producing Pseudomonas
Hrisca, M. Cisneros, M. Latorre-Millán, J. Mcgrath, L. aeruginosa from people with cystic fibrosisG.
Lohur, L. Ferguson, I. Abolina, D. Gravele, A. Fabrizio* (Rome, Italy), M. Truglio, I. Cavallo, F. Sivori,
Machado, S.A. Florescu, S.M. Pohrib, P. Subirats, L. M. Francalancia, R. Riveros Cabral J, S. Petrolo, L.
Clusa Cuesta, J. Sui, C. Kenny, D. Krievins, E.A. Pamparau, M. Comar, D. Compagnino, M.
Barzdina, C. Valadas Henriques, A.G. Kosa, M. Lazar, Trancassini, G. Antonelli, F. Ascenzioni, G. Cimino, F.
C. Muñoz-Almagro, A.M. Milagro, S. Bacci, A. Pimpinelli, E.G. Di Domenico
Nardone E0723 Activity of cefiderocol against clinical isolates of
E0709 Evaluation of the efficiency of reusable terminal filters Pseudomonas aeruginosa collected from five
for showers for nosocomial legionellosis prevention European countries as part of SENTRY antimicrobial
in a French university hospitalN. Khanafer* (Lyon, surveillance program 2020-2023C. Longshaw*
France), A. Regard, L. Beraud, R. Sintes-Tissot, Q. (London, United Kingdom), J. Maher, R. Mendes, H.
Barriot, J.C. Saurin, M. Chuzeville, P. Vanhems, M. Yamashiro, Y. Yamano
Chaboud
E0711 Emerging uncommon non-fermenters and their
decreasing antibiotic susceptibility in patients with EF101 14:45 - 15:45 Arena 3
prolonged hospital stayV. Khillan* (New Delhi, India),
ePoster Flash Session
V.G. Nag P, P. Kale, A. Paul, A. Saran
E0712 Air and surface sampling around mpox Clade 1b in Immunology of bacterial pathogens
hospitals in the UKS. Gould* (Liverpool, United
Kingdom), B. Atkinson, B. Hack, T. Williams, J. Otter,
Y. Ceesay, A. Alsonso, G. Nebbia, S. Blundell, W.
Newsholme, G. O'hara, M.G. Semple, T. Fletcher, J. E0724 Serotype 38 Streptococcus pneumoniae emerges as
Dunning one of the dominant serotypes causing invasive
E0713 Utilization of a healthcare facilities rapid assessment pneumococcal disease in Germany and Poland, but
tool to define infection prevention and control and not in the NetherlandsK. Hajji* (Bilthoven,
Water, Sanitation and Hygiene baseline criterion met Netherlands), I. Wróbel-Pawelczyk, J. Van
during Democratic Republic of Congo mpox outbreak Veldhuizen, K. Maruhn, W. Miellet, M. Rob, A. Steens,
from August to November 2024A. Baller* (Geneva, N. Van Sorge, K. Trzciński, M. Van Der Linden, A.
Switzerland), N.R. Okum, G. Nsambi, K. Kabamba, Skoczyńska, L. Visser
Y.L. Soro, L. Kabego, V. Willet, N. Usman, H. Hamilton E0725 Cross reactivity within pneumococcal serogroups 6
Hurwitz, M. Moon and 15 following adult vaccination with
E0714 The REACT study: Exploring the BSI Potential of KPC, pneumococcal conjugate vaccine V116: a secondary
NDM, VRE, and CRAB rectal colonizationM. Colaneri* analysis of five phase 3 studiesM. Esteves Jaramillo*
(Milano, Italy), P. Giordani, S. Lerta, A. Sangani, V.A. (Rahway, United States), J. Li, H. Platt, W. Hu, W. Xu,
Villano, A. Gori, M. Rettani, S. Milanesi, G. De Nicolao, T. Chapman, K. Nolan, J. Hartzel, U. Buchwald
R. Bruno E0726 Baseline serotype-specific IgG responses to
pneumococcal vaccines in type 2 diabetes:
implications for vaccine strategy in vulnerable
EF100 14:45 - 15:45 Arena 2 populationsS. Mettingal Ramakrishnan* (Bsk 2nd
Stage,Bangalore, India), V. Govindan, M.M. Akhila, N.
ePoster Flash Session Geetha, K.L. Ravikumar
Cefiderocol: an efficient Trojan horse? E0727 Protection against invasive meningococcal disease
and gonorrhoea, 5 years post introduction of a
Chair Anna Sramkova (Pilsen, Czech Republic) 4CMenB immunisation program in infants and
adolescents in South AustraliaH. Marshall* (Adelaide,
Australia), B. Wang, L. Giles, P. Andraweera, M.
Mcmillan, S. Almond, R. Beazley, J. Mitchell, J.
E0715 Acceleration of Emergence of Cefiderocol Resistance
Sisnowski, C. Bell, L. Flood, J. Ward
in Microfluidic Evolution SystemB. Li* (Beijing, China),
S. Shen, Q. Wang, S. Wang, W. Wang, H. Wang E0728 Molecular epidemiology and correlates of protection
among group B Streptococcus from carriage and
E0716 The hidden link between cefiderocol resistance and
disease: assessing vaccine coverage in BrazilT.
increased virulence in Klebsiella pneumoniae:
Pinto* (Rio De Janeiro, Brazil), L. Oliveira, N. Costa, E.
Insights from a TraDIS-based investigationE. Eger*
Bressan, A. Rio Tinto, S. Fracalanzza, L. Teixeira

ESCMID Global 2025 - Programme
E0729 Impact of BCG vaccination on adaptive immune O0698 Shiga toxin-producing Escherichia coli O26 as an
responses to mycobacterial and non-mycobacterial increasingly common cause of haemolytic uraemic
antigens in HIV-exposed, uninfected infants.R. syndrome in England: A fifteen-year analysis of
Namakula* (Bergen, Norway), V. Nankabirwa, S. national enhanced surveillance dataL. Mcgeoch*
Cose, O. Namugga, M.G. Netea, H. Steinsland, H. (London, United Kingdom), O. Quinn, C. Sawyer, A.
Sommerfelt, K. Hanevik Douglas, C. Jenkins, S. Balasegaram
E0730 Immune signature against Klebsiella pneumoniae O0699 Incidence, clinical presentation, and outcomes of
proteins in a mother-baby cohort from Blantyre, Pasteurella infections: a population-based Danish
MalawiE. Heinz* (Glasgow, United Kingdom), J. studyL. Øbo Larsen* (8200, Denmark), L.Ø. Larsen,
Campo, O. Pearse, A. Zuza, A. Teng, J. Pablo, A. H.L. Nielsen, K.K. Søgaard
Oberai, J. Edgar, A. Shandling, K. Kawaza, N. Feasey O0700 Natural history of latent brucellosis and efficacy
E0731 A comprehensive computational mapping of B-cell evaluation of B-spot in active and latent cases: A 12-
epitopes in the Klebsiella pneumoniae porinomeS. month prospective cohort studyH. Wang* (Shanghai,
Prieto Martin Gil* (Madrid, Spain), S. Prieto Martín China), G. Yuan, D. Li, H. Liu, J. Ai, W. Zhang
Gil, E. Gato, A. Pérez, M.J. Mcconnell, A.J. Martín
Galiano
E0732 Chronic infection induces a broadly neutralizing OS098 14:45 - 15:45 Hall 15
antibody response to Elastase B of Pseudomonas
aeruginosaA. Albus* (Cologne, Germany), D. Kolling, 1-hour Case Session
K. Rox, D. Holzmann, K. Mundry, M. Sánchez Agut, C.
Meyer, R. Brock, J. Kutschera, K. Schmitt, J.A. Wilms, Opportunistic infections in the Immunocompromised
L. Ullrich, C. Kreer, M. Meyer-Willerscheidt, M. Hallek, Chairs Aleksandra Barac (Belgrade, Serbia)
E. Rietschel, S. Van Koningsbruggen-Rietschel, F. Olivier Lortholary (Paris, France)
Klein, J. Koehnke, J. Rybniker, A. Simonis
KN137 - Hall 1 O0701 Dog scratch disease? A case of Vibrio vulnificus in a
14:45 15:45 liver transplant patientE. Kim* (Galveston, United
Keynote Lecture States), A. Covington
O0702 Mpox infection among solid organ transplant
Staphylococcus aureus host-microbe interaction: ecology, disease, and recipients: a single center experience at a U.S.
vaccine development Tertiary Care Facility.J. Bini Viotti* (Miami, United
Chairs Werner Ruppitsch (Vienna, Austria) States), J. Bini
Annelies Zinkernagel (Zurich, Switzerland) O0703 Histoplasmosis in Hansen's Disease: Thalidomide for
TNF-alpha Inhibition in ENL with a Risk of
Opportunistic InfectionsK.K. Vaitheeswaran* (Delhi,
India), M. Soneja, N. Bhari, R. M., G. K. V., S. Agarwal,
K0376 14:45 Juliane Bubeck Wardenburg (St. Louis, United States)
R. Kumar, Y. Dharmashaktu
O0704 Nocardiosis in a kidney transplant recipient: pros &
cons of tedizolidM. Pellegrino* (Modena, Italy), V.
ME140 - Hall 11
14:45 15:45 Todisco, S. Generoso, L. Benassi, E. Franceschini, F.
Damiano, G. Donati, C. Mussini, A. Cervo
Meet-the-Expert
O0705 Mycobacterium genavense-Associated IRIS with
Bioinformatic tools from start to finish Macrophage Activation Syndrome: A Case Report
Highlighting Diagnostic ChallengesM. Meroi*
(Verona, Italy), M. Morra, M.E. De Rui, E. Tacconelli, F.
Soldani
M0381 14:45 Vítor Borges (Lisbon, Portugal)
M0382 14:57 Clare Sloggett (Melbourne, Australia)
SY139 - Hall 16
14:45 15:45
1-hour Symposium
ME141 - Hall 13
14:45 15:45
How to manage bacterial meningitis in low resource settings
Meet-the-Expert
Chairs Joseph Donovan (Ho Chi Minh City, Vietnam)
AI use in antimicrobial stewardship Christina Obiero (Kilifi, Kenya)
S0379 14:45 Bacterial meningitis diagnosis and surveillanceDivya
M0383 14:45 Shruti Gohil (Irvine, United States)
Deodhar (Muscat, Oman)
M0384 14:57 Jose Ramon Pano-Pardo (Zaragoza, Spain)
S0380 15:05 Clinical presentation and management of CNS
infectionsKartika Maharani (Jakarta, Indonesia)
OS097 - Hall 14 Co-organised with: ESCMID Study Group for Infectious Diseases of the Brain
14:45 15:45 (ESGIB), ESCMID Study Group for Forensic and Postmortem Microbiology
1-hour Oral Session (ESGFOR), Spanish Society of Forensic Pathologists (SEPAF)
Update on zoonotic and enteric infections
Chairs Steen Ethelberg OS095 14:45 - 15:45 Hall 2
Kavitha Saravu (Manipal, India)
1-hour Oral Session
Community respiratory tract infections: latest trends and approaches
O0696 A large-scale epidemiological study of Chairs Catia Cilloniz (Barcelona, Spain)
Campylobacter employing whole genome analysis Aurélien Dinh (Garches, France)
reveals the evolution of highly virulent and multidrug-
resistant clones in the UK.B. Lopes* (Middlesbrough,
United Kingdom), A.S. Boaitey-Biko
O0686 Mycoplasma pneumoniae increase in 2023/24
O0697 Population dynamics and evolution of multidrug
causes disease in adults in EuropeB.M.M. Streng*
resistant clones of Shigella sonnei in Metropolitan
(Utrecht, Netherlands), C. Prat Aymerich, L. Bont, P.
FranceC. Silva Nodari* (Paris, France), I. Carle, M.
Meyer Sauteur, M. Bonten, A. Van Rossum
Lejay-Collin, L. Philippot, C. Ruckly, L. Fabre, M.
Pardos De La Gandara, F.X. Weill O0687 Serotype distribution of pneumococcal community-

ESCMID Global 2025 - Programme
acquired pneumonia in hospitalized adults in Herrera-Yela
GermanyD. Karssen* (Utrecht, Netherlands), L.
Hessels, G. Barten-Neiner, W. Bauer, S. Franch, T.
Fühner, C. Hassiepen, D.F. Heigener, B. Hullegie, R. SY144 - Hall 14
16:15 17:15
Jahja, K.D. Johnson, J. Kremling, C. Roberts, G.G.U.
Rohde, M. Ruggieri, J. Scheider, D. Stolz, T.D. 1-hour Symposium
Swarthout, T. Weiss, H. Van Werkhoven, M. Bonten,
C. Prat-Aymerich What's the role of infant and maternal immunisation for paediatric RSV
O0688 Community-acquired pneumonia identification from prevention?
electronic health records in the absence of a gold Chairs Joanne M. Langley (Halifax, Canada)
standard: a Bayesian latent class analysisJ. Wei* Peter Openshaw (London, United Kingdom)
(Oxford, United Kingdom), K. Yuan, A. Luk, S. Walker,
D. Eyre
O0689 Causes of death and risk factors for 90-day mortality
S0391 16:15 Pros and cons of passive infant immunisation with
and readmission in community-acquired
mAb before their first RSV seasonFederico Martinón-
pneumonia.F. Al-Zergani* (Hvidovre, Denmark), C.
Torres (Santiago De Compostela, Spain)
Lundetoft Clausen, P. Ravn, M. Sebastian Roldgaard,
L. Kolte, H. Sarac, M. Fally, S. Bastrup Israelsen, T. S0392 16:45 Pros and cons of maternal vaccination in preventing
Benfield severe RSV infections in infants.Anne Vergison
(Luxembourg, Luxembourg)
O0690 Oropharyngeal carriage of gut-derived
Enterobacterales increases RTI risk in long-term aged
care residentsS. Miller* (Adelaide, Australia), F.
EF104 - Arena 1
Zhang, S. Taylor, A. Shoubridge, E. Vasil, R. 16:15 17:15
Woodman, L. Papanicolas, G. Rogers
ePoster Flash Session
Cutting-edge technologies to improve viral diagnostics
SY138 - Hall 4
14:45 15:45 Chair Patricia Alvarez (Rio De Janeiro, Brazil)
1-hour Symposium
Global clones and evolving resistance mechanisms towards newer beta-
E0743 How straightforward is the switch from qPCR to
lactams: Where are we heading?
dPCR in a routine lab setting for quantification of
Chairs Yesim Besli (Istanbul, Türkiye) Varicella-zoster virus in CSF samplesA.
Spyros Pournaras (Athens, Greece) Baumhögger* (Bochum, Germany), T. Bähr, G. Geis,
S. Gatermann
E0744 A novel biosensor for the detection of RSV infectionC.
S0377 14:45 Carbapenemase-producing Enterobacterales: the not Zannella* (Naples, Italy), F. Passeggio, F. Napolitano,
so good, the bad and the ugly.Arjana Tambic A. De Filippis, F. Arcadio, C. Marzano, I. Tavoletta, L.
Andrasevic (Zagreb, Croatia) Zeni, M. Galdiero, G. Portella, N. Cennamo
S0378 15:15 The P. aeruginosa frightening cocktail: high-risk E0745 Insufficient sexual health bloods don't always need
clones, horizontally-acquired resistance and evolving throwing away!S. Hutchings* (Bristol, United
mutational resistomeKaty Jeannot (Besançon, Kingdom), R. Hopes, P. North, W. Stoate, M. Murphy,
France) G. Beckley, J. Gabb
Co-organised with: ESCMID Study Group for Antimicrobial Resistance E0746 A comparison of 4 HAV serology assays: the value of
Surveillance (ESGARS) consensus results as a reference standardT. Chin*
(Ghent, Belgium), E. Padalko
E0747 Advancing herpesvirus diagnostics: clinical
OS096 - Hall 5 evaluation of a high-performance real-time PCR
14:45 15:45
assayH. Alonso-Ezcurra* (Zaragoza, Spain), S. Lucea,
1-hour Oral Session C. Escolar, H. Alonso
E0748 Evaluation of microbiological techniques for the
Trends in antifungal resistance
diagnosis of West Nile Virus in the Virgen del Rocío
Chairs Alexandre Alanio (Paris, France) hospital area (Sevilla, Spain).M. Aznar Fernandez*
Ana Alastruey-Izquierdo (Madrid, Spain) (Seville, Spain), M. Aznar, C. Lozano, L. Merino, M.J.
Pérez, J.L. Garcia, C. Cintora, J.A. Lepe
E0749 Development of Non-Cross-Reactive Monoclonal
O0691 Turning resistance into vulnerability: leveraging Antibodies Against West Nile Virus and Usutu Virus
genetic insights to predict collateral sensitivity and Non-Structural Protein 1 to Improve Early
synergism for effective multidrug therapiesK. DiagnosisM. Ceconi* (Antwerp, Belgium), K. Ariën, P.
Schmidlin* (Tempe, United States), K. Geiler- Delputte
Samerotte E0750 Enhancing Diagnostics and Global Standards through
O0692 Role of the C2585G substitution in the MRR1 gene in the QCMD Viral Metagenomics EQAG. Sutton*
the development of azole resistance in Candida (Glasgow, United Kingdom), D. Montgomery, E.
parapsilosis sensu strictu.I. Franconi* (Pisa, Italy), P. Mcculloch, A. Ricketts
Noemi, A. Tavanti, A. Lupetti, R. Cosmeri, L. Maltinti, E0751 Analysis of HIV-1 drug-resistence in newly diagnosed
M. Falcone subjects using Next Generation SequencingV.
O0693 Fungaemia in a tertiary Madrid hospital from 2007 to Micheli* (Milan, Italy), F. Bracchitta, L. Morelli, A.
2024: changes in species epidemiology, increase in Cavallo, S. Giubileo, A. Tamoni, A. Lombardi, A. Dolci
echinocandin resistance and low patient-to-patient
transmission in recent yearsJ. Guinea* (Madrid,
Spain), P. Escribano, G. Jesús, M. Machado, A. EF105 16:15 - 17:15 Arena 2
Burillo, P. Muñoz
ePoster Flash Session
O0694 A multicentre study for determination of
epidemiological cutoff values for rezafungin and four
New data in non-tuberculous mycobacterial disease
comparators against Candida auris with EUCAST
broth microdilution reference methodologyJ. Chair Lorenzo Guglielmetti (Paris, France)
Meletiadis* (Haidari, Greece), J. Guinea, S. Arikan-
Akdagli, E.F.J. Meijer, J. Meis, M.C. Arendrup
O0695 Decoding Candida auris Resistance in Latin America: E0752 Deciphering genotypic resistance to amikacin in
Candida.app vs. PathogenwatchJ. Acosta España* Mycobacterium abscessus using whole genome
(Quiro, Ecuador), P. Eduarda, J.D. Acosta-España, A. sequencing and a specific pipeline (GenoMAB)C.

ESCMID Global 2025 - Programme
Allam* (Paris, France), S. Agsous, P. Baylac, K. La, E0765 The inappropriate use of antibiotics for blood culture
N. Godron, F. Mougari, Z. Awad, E. Cambau contamination and colonisation by multidrug-
E0753 Pseudomonas aeruginosa rapidly kills resistante microorganisms: the role of counselling on
Mycobacterium abscessus in dual-species biofilms antibiotic prescriptionR.R. Peña-Zalbidea* (Palma
in vitroM. Mcdaniel* (Nijmegen, Netherlands), J. (balearic Islands), Spain), L. Martin, H. Vilchez, L.
Scoffield, J. Van Ingen Periañez, E. Rojo, M. Peñaranda, M. Garcia, M. Riera,
X. Mulet, A. Oliver, J. Murillas
E0754 Distribution of contezolid in different tissues of mice
and human patients infected with Mycobacterium E0766 Factors influencing meropenem prescription
following the 2020 EUCAST « I » definition update : a
abscessusW. Nie* (Beijing, China), N. Chu
multicentric observational study in Belgian
E0755 Exploration of clofazimine and bedaquiline activity hospitalsL. Catteau* (Brussels, Belgium), L. Bonacini
against clinical strains of Mycobacterium abscessus
E0767 Impact of an Antimicrobial Stewardship Mobile
to advance innovative therapeutic strategiesC.
Application on Antimicrobial Prescribing, Length of
Maria* (Madrid, Spain), M. Cano-Fernández, J.
Esteban, P. López-Roa, A. Ruedas-López, J.J. Hospital Stay, and Cost SavingsZ.O.E. Babiker* (Abu
Aguilera-Correa, M.C. Muñoz-Egea Dhabi, United Arab Emirates), L. Bukasa, A. Sadeq, J.
Shamseddine, R. Ali
E0756 Leveraging stem cell technology to identify new
treatment options for nontuberculous E0768 Evaluation of a model-based clinical decision support
system for empirical antimicrobial therapyM.L.
mycobacteriaS. Sarkar* (Parkville, Australia), K.
Strumila, S. Yu, R. Werder, T. Johanssen, A. Hidalgo Mogensen* (Aalborg, Denmark), S.N. Søgaard, L.
Gonzalez, E. Stanley, S. Ranganathan Ward, H. Skjøt-Arkil
E0757 Recovery of Non-Tuberculous Mycobacteria and E0769 A rapid systematic review of criteria to facilitate
Detection of Dominant Circulating Clones in Indoor prompt intravenous-to-oral antimicrobial switch in
Water Samples from GermanyN. Wetzstein* children and young people in England.R. Oettle*
(Frankfurt, Germany), M. Diricks, D. Frank, I. (London, United Kingdom), S. Patel, A. Demirjian, M.
Friesen, S. Niemann, T. Wichelhaus Mcleod, C. Jamieson, G. Damant, K. Hand, D. Ashiru-
Oredope
E0758 Deciphering the Epidemiology of Mycobacterium
chimaera: Genetic Lineages, Environmental
Sources, and Infection Prevention InsightsG.
EA - Hall 1
Lorenzin* (Trento, Italy), M. Sandei, P. Fassan, A. 16:15 17:30
Casadei, C. Scarparo
Awards
E0759 Evaluation of a novel media for susceptibility testing
of Mycobacterium avium-intracellulare complex Excellence Award Lectures
isolatesT. Grams* (Salt Lake City, United States), S. Chairs Jon S. Friedland (London, United Kingdom)
Shakir Robert Leo Skov (Copenhagen, Denmark)
E0760 Emerging cases of Mycobacterium chelonae
endocarditis associated with BioIntegral
bioprosthesesJ. Kikhney* (Berlin, Germany), F.
Pfäfflin, L. Kursawe, K. Sarbandi, I. Friesen, M. A006 16:15 Towards pandemic prevention, moonshot or utopia?
Stegemann, R. Schwarzer, D. Von Schöning, V. Falk, Marion Koopmans (Rotterdam, Netherlands)
A. Moter A007 16:50 Can global warming bring new infectious
diseases?Arturo Casadevall (Baltimore, United
States)
EF106 - Arena 3
16:15 17:15
ePoster Flash Session SY143 - Hall 11
16:15 17:15
The ABC (allergy, bloodstream infections and clinical decision support) in 1-hour Symposium
AMS
Chair Céline Pulcini (Nancy, France) ESCMID guidelines for the vaccination of immunocompromised individuals:
solid organ transplant recipients
Chairs Elisa Cordero Matia (Seville, Spain)
Zitta Barrella Harboe (Hillerød, Denmark)
E0761 Evaluation of the allergy fact checker, a clinical
decision support system to promote non-invasive
delabeling of incorrect penicillin allergy labels: a
mixed-methods studyD. Wets* (Leuven, Belgium), R. S0389 16:15 Vaccination against respiratory pathogensAlbert
Schrijvers, I. Spriet, G. Van De Sijpe, L. Gilissen, C. Vollaard (Bilthoven, Netherlands)
Breynaert, T. Ieven, P. De Munter
S0390 16:45 Other vaccinesOlivier Epaulard (Grenoble, France)
E0762 Penicillin allergy assessment pathway versus usual
Co-organised with: ESCMID Study Group for Infections in Compromised
clinical care for primary care patients with a penicillin
Hosts (ESGICH), ESCMID Vaccine Study Group (EVASG)
allergy record to assess safety, de-labelling and
antibiotic prescribing: The ALABAMA randomised
controlled trial.J. Sandoe* (Leeds, United Kingdom),
EW146 - Hall 13
S. Ahmed, K. Armitage, C. Bates, R. Bestwick, B. 16:15 18:15
Jenny, C. Butler, J. Cook, F. Joanne, U. Galal, P.
Educational Session
Howard, D. Howdon, S. Mort, R. Mujica-Mota, A.
Negut, C. Porter, N. Powell, M. Santillo, R. Sargur, S. How to detect, manage and communicate hospital outbreaks
Savic, S. Tonkin-Crine, M. Wanat, R. West, M. Yang, Chairs Margaret Ip (Shatin, Hong-Kong SAR, China)
L.M. Yu, S. Pavitt Rossitza Vatcheva-Dobrevska (Sofia, Bulgaria)
E0763 Stewardship interventions reduced blood culture
utilization by 40% during BD BACTEC™ Blood
Culture media shortageX. Li* (Toronto, Canada), K.
W0395 16:15 How to detect hospital outbreaksDavid Fisman
Katz, A. Ceentavida, R. Kozak, C. Vermeiren, P.
(Toronto, Canada)
Sheldrake, S. John, A. Belhaj, S. Hsieh, S. Patel, R.
Lovinsky W0396 16:35 How to confirm hospital outbreaks using
genomicsJohn W. A. Rossen (Groningen,
E0764 Prescriptive Impact of Rapid Microbiological
Netherlands)
Diagnostics in Bloodstream Infections Caused by
Escherichia coli, Klebsiella pneumoniae, and W0397 16:55 How to rapidly respond to an ongoing hospital
Staphylococcus aureus (PRIMEKA): A Retrospective outbreakErmira Tartari (Msida, Malta)
Single-Center Cohort Study.F. Salvati* (Rome, Italy), W0398 17:15 How to communicate hospital outbreaks via scientific
F. Giovannenze, G.M. Leanza, M. Chiuchiarelli, A. publicationInes Steffens (Solna, Sweden)
Frater, M.L. Colombo, F. Iannarelli, B. Fiori, T. D'inzeo,
R. Murri, C. Torti

ESCMID Global 2025 - Programme
ME145 - Hall 15 N. Schweintzger, E. Hofer, B. Kohlmaier, V. Švendová,
16:15 17:15
P. Bogovicˇ, J. Zajkowska, L. Krbková, V. Štruncová,
Meet-the-Expert A. Mickiene, D. Kohlfürst, A. Sonnleitner, A. Fořtová,
M. Berankova, M. Pychova, D. Zavadska, N. Sallah, A.
Fungal meningitis: recognition and current status of management Pichler, D. Sedlácek, A. Chrdle, C. Haudum, B.
Obermayer-Pietsch, P. Hoffmann, M. Nöthen, M.L.
Tammesoo, A. Metspalu, P. Husa, K. Stiasny, A.
Binder, A. Berghold, F. Strle, M. Hibberd, W. Zenz
M0393 16:15 Olivier Lortholary (Paris, France) L0027 First detection of tick-borne encephalitis virus in
M0394 16:27 Janis Blair (Phoenix, United States) Belgian ticks, May 2024E. Portell-Buj* (Stockholm,
Sweden), C. Philippe, S. Van Gucht, F. Dufrasne
L0028 Spread of a fusidic acid and methicillin-resistant
JS2 - Hall 16 Staphylococcus aureus clone causing impetigo in
16:15 17:15
EuropeA.R. Larsen* (Copenhagen, Denmark), A.
Journal Session Petersen, L. Roer, K. Vendrik, R. Zwittink, D.
Notermans, N. Yin, M. Perrin, K. Khonyongwa, A.
Late-breaker research from the Lancet group: new interventions for familiar Tristan, B. Youenou, F. Layer-Nicolaou, G. Werner, H.
and new infectious diseases Enger, E.C.H. Eikrem, J. Darenberg, B. Mäkitalo, M.
Chairs Syeda Saleha Hassan (London, United Kingdom) Paulsson, H. Fang, E. Tång Hallbäck, L. Lindholm, K.
Ursula Hofer (London, United Kingdom) Moganeradj, B.J. Holzknecht, H.B. Eriksen, M. Hoppe,
M.D. Bartels, J.A. Samaniego Castruita
L0029 Increase of PVL-positive livestock-associated MRSA
in the Netherlands: a growing concern beyond
J011 16:15 TBA
livestock settingsK. Vendrik* (Bilthoven,
J012 16:30 The spatio-temporal ecology of Oropouche virus: a Netherlands), S. Witteveen, D.W. Notermans, S.C. De
laboratory-based modelling study across Latin Greeff, C.C. Wielders, E. Van Duijkeren, A.S.
AmericaJan Felix Drexler (Berlin, Germany) Schoffelen, A.P. Hendrickx, R.D. Zwittink
J013 16:45 The WHO Bacterial Priority Pathogens List: guiding L0030 H5N1 human infection in the United Kingdom: a One-
research and development, and informing innovative Health approachR. Puleston* (London, United
public health strategies to address antimicrobial Kingdom), N. Hamzaoui, S. Hayward, W. Proto, E.
resistanceHatim Sati (Geneva, Switzerland) Booth, C. Beck, A. Lackenby, K. Spence, M.
J014 17:00 Efficacy, safety, and immunogenicity of the AS01E- Beadsworth, N. Wong, M. Samuel, A. Singanayagam,
adjuvanted respiratory syncytial virus prefusion F K. Hoschler, N. Groves, D. Kumar, O. Olufon, W. Cook,
protein vaccine (RSVPreF3 OA) in older adults over N. Watkins, D. Ready, S. Makki, K. Marston, S. Collins,
three RSV seasons: a randomized trialAlberto Papi C. Arevalo, D. Blackman, L. Guiness, C. Chatt, M.
(Ferrara, Italy) Mcgivern, A. Edwards, A. Banyard, R. Jorquera, K.
Saville, R. Benee, S. Van Helvoort, E. Brown, L.
Co-organised with: The Lancet group
Leighton Mcteague, M. Chand, S. Rokadiya, S.
Hopkins, H.I.M. Team, N. National Response Center
Team
OS102 - Hall 2
16:15 17:15
1-hour Oral Session
SY142 - Hall 4
16:15 18:15
AI tools empowering AMR prediction in WGS and MALDI-TOF
2-hour Symposium
Chairs Oliver Nolte (Zürich, Switzerland)
Patricia Simner (Rochester, United States) Precision genomics to improve infectious diseases management
Chair Jacob Moran-Gilad (Beer Sheva, Israel)
O0733 A scalable machine learning approach to predict
antimicrobial susceptibility from whole genome
S0385 16:15 Human genomics approaches to infection
sequencing dataY. Zhong* (Liverpool, United
immunityFergus Hamilton (Bristol, United Kingdom)
Kingdom), A. Gerada, A. Howard, P. Green, W. Hope
S0386 16:45 Applying bacterial GWAS to uncover new
O0734 Machine Learning-Based Antimicrobial Resistance
mechanisms of antibiotic resistanceMarco Galardini
Prediction of 11 antibiotics for Klebsiella pneumoniae
(Hannover, Germany)
from Clinical NGS DataJ. Xinmiao* (Beijing, China), X.
Jia, J. Zhang, J. Chen, Q. Yang S0387 17:15 Evolution in action: large-scale within-host evolution
analyses of persistent bacterial infectionsStefano
O0735 AI-Powered Real-Time Plasmid Prediction Using
Giulieri (Melbourne, Australia)
Nanopore SequencingE. Sauerborn* (Munich,
Germany), S. Atum, H. Urel, M. Peisker, N. Wantia, E. S0388 17:45 Machine learning in bacterial genomics and
Foster-Nyarko, L. Urban metagenomicsFrancesco Asnicar (Trento, Italy)
O0736 MALDI-TOF Prediction model based on machine
learning algorithm for the detection of ST23 high-
OS103 - Hall 5
virulence K. pneumoniaeL. Dortet* (Le Kremlin- 16:15 17:15
Bicêtre, France), L. Mancera Pascual, M.J. Arroyo
1-hour Oral Session
O0737 Predicting rifampicin resistance in Mycobacterium
tuberculosis complex with a machine learning based Polymicrobial interactions and competition
MALDI-TOF MS approcheY.W. Sun* (Taichung,
Chairs Alessandra Bragonzi (Milano, Italy)
Taiwan, China), P. Huang, B. Tsou, S.C. Chang, C.W.
Kimberly Kline (Genéve, Switzerland)
Lu, C.C. Chen, J. Yu
LB005 - Hall 3 O0738 The Klebsiella pneumoniae type VI secretion system
16:15 17:15
effector Tle4 facilitates adaptation survival by
1-hour Oral Session damaging the cell membrane of competing
Emerging pathogens in humans, animals and vectors bacteriaW. Li* (Shanghai, China), J. Zhang
O0739 Candida albicans promotes TSST-1 production in
Staphylococcus aureus by depleting glucose and
lifting carbon catabolite repressionM. Carriou* (Lyon,
L0026 Genome-wide association study identifies ABCG1 as France), C. Badiou, A. Soulard, K. Chikh, O. Vitalis, A.
a susceptibility locus for tick-borne encephalitisP. Frugier, K. Dufresne, G. Lina
Gampawar* (Graz, Austria), M. Sagmeister, D. Ruzek, O0740 Understanding polymicrobial biofilm dynamics: focus

ESCMID Global 2025 - Programme
on Pseudomonas aeruginosa and its molecular N. Feijoó, R. Garrido, G. Barbosa, B. Zappa, C.
interactionsS. Kansal* (Chandigarh, India), U. Dutta, Weksler, M. Correia, W. Golebiovski
A. Angrup, P. Ray
O0741 Intra- and interspecific antagonism inhibits growth of
Staphyloccous aureus in human nasal microbial EF111 17:30 - 18:30 Arena 2
communitiesL. Brülisauer* (Zurich, Switzerland), M.
Boumasmoud, S. Brugger, A.R. Hall ePoster Flash Session
O0742 Combination therapy against drug resistance Don't blink: STIs are everywhere
biomimetic dual-species biofilm model of
Pseudomonas aeruginosa and Staphylococcus Chair Mathew Beale (Hinxton, United Kingdom)
aureusP. Mojarrad* (Helsinki, Finland), P. Tammela,
T. Laaksonen, Z. Gounani
E0794 Neurosyphillis and Mpox co-infection mimic HIV
encephalitisL. Mejdoubi* (Vienna, Austria), A. Nader,
EF110 17:30 - 18:30 Arena 1 L. Mautner, A. Bahrami, F. Hofer
ePoster Flash Session E0796 An unusal cause of transverse myelitisJ. Koleri*
(Doha, Qatar), M. Samawi, M. Maslamani
Advancing diagnostics and treatment of endocarditis E0798 Ocular Syphilis, an uncommon presentation form of
Chair Benoît Guery (Lausanne, Switzerland) syphilis: two casesR. Kardashi* (Dresden, Germany),
A. Frenz, K. De With
E0799 Case report of a severe skin infection in a young man
on PrEP and DoxyPEPM. Zlámal* (Prague, Czech
E0785 18F-FDG-PET/CT improves source control of extra-
Republic), Z. Bartovská, B. Lacmanová, M. Holub
cardiac complications in infective endocarditisJ.M.
Prins* (Amsterdam, Netherlands), S. Douiyeb, W. E0800 Serowaffling in PrEP Users: The Difficulty of HIV
Van Gameren, D. Buis, T. Van Der Vaart, M. Diagnosis – A Case Report.P. Pillado Alonso*
Boekholdt, J. Selder, D. Robbers-Visser, H. (Badalona, Spain), G. Fernández Rivas, A. Rivero
Verberne, H. Van Werkhoven, K. Sigaloff Calaf, Á. Hernández-Rodríguez, R. Peña, J. Prado, J.
Martínez-Picado
E0786 Comparing Duke criteria updates: Advancing IE
diagnosis in patients with prosthetic intracardiac E0801 Severe disseminated mpox in a patient with
materialsM. Papadimitriou Olivgeris* (Sion, advanced HIV: A case reportM.A. Quadros Flores*
Switzerland), M. Papadimitriou-Olivgeris, B. (Lisbon, Portugal), R. Diogo, F. Gonçalves, T.
Ledergerber, N. Fourré, V. Zimmermann, N. Marques, S. Paulo, F. Cota Medeiros, D. Mendes
Ianculescu, P. Monney, M. Frank, G. Tzimas, G. Pedro
Domenichini, P. Tozzi, M. Kirsch, M. Van Hemelrijck, E0802 Sensorimotor polyneuropathy in a patient affected by
O. Dzemali, J. Epprecht, B. Guery, B. Hasse HIV-1: an atypical presentation of neurosyphilis
E0787 In vivo Dalbavancin efficacy against methicillin- associated to anti-SOX-1 antibodiesA. Lippi* (Siena,
resistant Staphylococcus aureus (MRSA) and high- Italy), L. Ancillotti, M. Fabbiani, L. Migliorini, S.
level aminoglycoside resistant (HLAR) Bartalini, F. Ginanneschi, M. Tumbarello, F. Pippi, C.
Enterococcus faecalis (EFAE) experimental Puttini, F. Montagnani
endocarditis model.C. Garcia De La Maria*
(Barcelona, Spain), C. García De La Mària, M.A.
Cañas, M. Brunet, J. García-González, G. Cuervo, M. EF112 17:30 - 18:30 Arena 3
Espasa, M. Hernandez-Meneses, C. Falces, A.
Perissinotti, B. Vidal, J.M. Tolosana, E. Sandoval, J. ePoster Flash Session
Llopis, A. Moreno, J.M. Miro
Clinical considerations in resistant organisms
E0788 Identification and validation of clinical phenotypes
in Staphylococcus aureus blood stream infection Chair Divya Deodhar (Muscat, Oman)
and their association with mortality (FEN-AUREUS
study)J. Rodríguez-Baño* (Seville, Spain), B.
Gutiérrez-Gutiérrez, B. Gallego, A.J. Kaasch, M.
E0803 Clinical characteristics, therapy and outcome of
Riediger, S. Rieg, M. Trigo, S. Sonsoles, F. Anguita-
bloodstream infections caused by vancomycin-
Santos, Á. Cano, R. Palacios, S. López-Cárdenas,
resistant enterococci: a multicenter clinical
M.T. Pérez-Rodríguez, F.J. Martínez-Marcos, E.
experienceF. Serapide* (Catanzaro, Italy), R.
Merino-Lucas, B. Anaya-Baz, A. Aizcorreta, A. Plata-
Serraino, L. Spadafora, M. Bernardi, G. Brucci, G.
Ciézar, M. Piscaglia, A. Aceituno, E. Ruiz-Gutiérrez,
Cattardico, S. Corcione, I. De Benedetto, M. Del
L. Romero-Calderón, A. Alemán-Rodríguez, E.
Monte, A. Limongelli, D.R. Giacobbe, E. Graziano, M.
Recacha, J. Torre-Cisneros, N. Merchante, Á.
Meschiari, S. Mornese Pinna, M. Peghin, G. Tiseo,
Pascual, L.E. López-Cortés
A. Vena, F. Romeo, G. Sarto, M. Bassetti, G. Biondi-
E0789 Enterococcal Infective Endocarditis: demographics, Zoccai, F.G. De Rosa, M. Falcone, P.A. Grossi, C.
comorbidities, diagnostic evaluation and mortality Mussini, A. Russo
outcomesM. Singh* (London, United Kingdom), C.
E0804 Clinical outcomes of MSSA bacteremia exhibiting
Watkins, H. Bristowe, M. Gunning, J. Galloway, R.
the cefazolin inoculum effect and development of a
Dworakowski, M. Arias
novel diagnostic methodS. Yoshizawa* (Ota-Ku,
E0790 Health related quality of life of patients with Japan), T. Sato, K. Komori, K. Yamada, T.
infective endocarditis – preliminary data of the Yamaguchi, K. Tateda
DERIVE cohortC. Meyer-Schwickerath* (Cologne,
E0805 Third- and fourth-generation cephalosporins for the
Germany), K. Schmidt-Hellerau, J. Camp, K. Last, I.
treatment of infections due to OXA48
Joost, S. Rieg, N. Jung
carbapenemase-producing EnterobacteralesA.
E0791 The optimal management of Enterococcus faecium Blanco Arévalo* (Barcelona, Spain), A. Blanco-
catheter-related bloodstream infections: a gap to Arevalo, E. Sastre-Escolà, J. Camara Mas, F. Tubau
bridgeI. Rancan* (Florence, Italy), M. Rinaldi, F. Quintano, R. Costa, A. Padulles, E. Shaw, C. Gudiol,
Malerba, B. Profiti, L. Ancillotti, M. Tumbarello, P. M. Puig-Asensio
Viale, M. Giannella
E0806 Are meropenem or imipenem-cilastatin effective
E0792 Ceftobiprole alone versus in combination with therapies for patients with invasive ertapenem-
ampicillin against borderline penicillin-resistant, resistant infections?A. Peters* (Santiago, Chile), S.
vancomycin-resistant Enterococcus faecalisO. Fiawoo, L. Diaz, J.R. Martínez, M. Spencer-Sandino,
Funk* (Brooklyn, United States), I. Khan, J. Li, J. L. Rivas, M.P. Riquelme, P. Rojas, L. Rojas, M.L.
Cusumano Rioseco, J. Moreno, R. Araos, P. Garcia, P.D.
E0793 Risk factors for in- hospital mortality in 500 cases of Tamma, J.M. Munita
infective endocarditisC. Lamas* (Rio De Janeiro, E0807 Oral Fosfomycin after Carbapenems as de-
Brazil), G. Pompeo, T. De Almeida, M. De Carvalho, escalating therapy in Complicated Urinary Tract

ESCMID Global 2025 - Programme
Infection: A randomized controlled trialK. OS109 - Hall 16
17:30 18:30
Angkanavisan* (Bankgkok, Thailand), B.
Sakboonyarat, C. Ungthammakhun 1-hour Oral Session
E0808 Oral switch vs. intravenous antibiotics treatment for
Training CM/ID - a global view
serious carbapenem-resistant Enterobacterales and
Pseudomonas aeruginosa infections on hospital Chairs Mihai Mares (Iasi, Romania)
discharge: the next frontier for oral switch?C. Priya Nori (New York, United States)
Arena* (Detroit, United States), A. Abed, R. Kenney,
G. Suleyman, A. Shallal, S. Davis, M. Veve
E0809 Metallo-￿-lactamase colonization and subsequent
O0780 Specialist training in infectious diseases in EuropeJ.
risk of infection: a retrospective study.C. Lee Luna
Salmanton-Garcia* (Cologne, Germany), J.
Fernandes* (Sao Paulo, Brazil), C. Vaiana, C. Amato,
Salmanton-García, A. Guerra Maio, J.P. Stahl, E. De
S. Castelbuono, G. Di Martino, F. Cardinale, F.
Barra, S. Jensen-Fangel, C. Torti, C. Kraef, J.M. Miró,
Monaco, A. Cona, A. Mularoni
A. Verbon, O.A. Cornely, N. Beeching
E0810 Polymyxin including therapy versus colistin
O0781 Infectious Diseases Residency Training over the
including therapy in the therapy of carbapenem-
WorldP. Irkören* (Zeytinburnu/istanbul, Türkiye), P.
resistant Gram-negative infections: A retrospective
Irkoren, C. Cimen, S. Keske, Ö. Ergönül
matched cohort studyM. Mert Vahabi* (Van,
Türkiye), D. Akyol Seyhan, B. Kenanoğlu, Ş. Yeniyol, O0782 Five years of experience with the virtual International
G. Şanlıdağ İşbilen, Ş. Dirik, D. Dağ, B. Özkara, M. Postgraduate Diploma in Infection Prevention and
Ceylan, C. Bulut Avşar, U. Önal, S. Ketentzi, A. Uyan Control from the Infection Control Africa Network.A.
Önal, A. Kaya, O. Acet, D. Kaya, N. Yalcin, G. Tostmann* (Nijmegen, Netherlands), E. Schoeman, B.
Vatansever, C. Tol, Ş. Aydemir, D. Akdağ, H.A. Du Toit Ludick, E. Ruizendaal, Y. Gouws, J. Hopman,
Erdem, T. Yamazhan, H. Sipahi, B. Arda, O.R. Sipahi C. Azzouz, S. Mehtar
E0811 Prognostic factors and role of clinical management O0783 Combatting challenges in laboratory capacity
in carbapenem-resistant Acinetobacter baumannii through an innovative, longitudinal Gram stain
bacteraemia: results from a prospective, training programme for blood culture specimens in
international, multicentre cohort (EURECA)F. Zimbabwe.T. Mwaturura* (Harare, Zimbabwe), D.
Cogliati Dezza* (Seville, Spain), J.M. Bravo-Ferrer Hettle, F. Makoga, A. Mudungwe, B. Sado, K. Kranzer
Acosta, B. Gutiérrez-Gutiérrez, B. Carevic, G. O0784 Benefit of the implementation of Entrustable
Dragovac, G.L. Daikos, M. Akova, L. Raka, A. Professional Activities (EPA) as an assessment tool in
Hristea, P. Viale, E. Shaw, E. Roilides, M. Antonelli, the Laboratory of clinical bacteriology: a study
H. Akalin, A. Komnos, J.M. Reguera, A. Vince, M. focused on the improvement of residents' skills and
Mašanovic, L. Radulović, C. Kirakli, C. Gogos, A. feelings.H. Pailhoriès* (Angers, France), H. Pailhories,
Bartoloni, C. Dan, P. Kapisyzi, M.E. Falagas, A. Vata, C. Zins, R. Chenouard, M. Kempf, M. Eveillard
S. Benea, D. Tomescu, A. Meda Vasiesiu, L.
Bukarica, N. Lukic, A. Cano, V. Pintado, A. Azap, H.
Goosens, M.J.M. Bonten, J. Rodríguez-Baño ME149 - Hall 2
17:30 18:30
Meet-the-Expert
SY147 - Hall 11
17:30 18:30
How to perform molecular surveillance of multidrug resistant bacteria
1-hour Symposium
Avian influenza in mammals: jumps under the radar
Chairs Patricia Antunes (Porto, Portugal) M0403 17:30 Martina Lengerova (Brno, Czech Republic)
Ana Vale (Dublin, Ireland) M0404 17:42 Henrik Hasman (Copenhagen, Denmark)
S0399 17:30 Threat of highly pathogenic avian influenza to non- OS107 17:30 - 18:30 Hall 3
traditional hosts, including humansThijs Kuiken
1-hour Oral Session
(Rotterdam, Netherlands)
S0400 18:00 Recent changes in the epidemiology of avian Novel vaccines in clinical development
influenza in relation to human health risksRon
Chairs Mateusz Hasso-Agopsowicz (Geneva, Switzerland)
Fouchier (Rotterdam, Netherlands)
Hanna M. Nohynek (Helsinki, Finland)
Co-organised with: ESCMID Food- and Water-borne Infections Study Group
(EFWISG), ESCMID Study Group for Veterinary Microbiology (ESGVM),
ESCMID Study Group for Respiratory Viruses (ESGREV), European Scientific
Working group on Influenza (ESWI) O0770 Safety and immunogenicity of a seasonal booster
dose of the 6-valent, OspA-based Lyme borreliosis
vaccine candidate VLA15 in a healthy population aged
SY148 - Hall 15 5-65 yearsM. Messier* (Vienna, France), L. Wagner,
17:30 18:30 R. Hochreiter, J. Larcher-Senn, E. Lamberth, R.
1-hour Symposium Simon, C. Clarkin, J. Stark, S. Eder-Lingelbach
O0771 Safety and immunogenicity of mRNA mpox vaccine
Echinococcosis: neglected but expanding candidate mRNA-1769: Interim analysis results from a
Chairs Daniel Grupel (Jerusalem, Israel) Phase 1/2 TrialH. Hiruy* (Cambridge, United States),
Francesca Tamarozzi (Negrar-Verona, Italy) R. Lazarus, K. Mccafferty, K. Cohen, R. Dhar, T. Rizk,
A. Adeniji, X. Chang, L. Siquel, H. Bennett, B. Leav
O0772 Development of a Rapid-Acting Oral Cholera Vaccine:
Phase I Clinical TrialA. Hannaford* (Boston, United
S0401 17:30 Expansion and diversity of cystic
States), D. Leitner, M. Waldor, L. Baden, M.
echinococcosisPedro Legua (Lima, Peru)
Desjardins, M. Suzuki, L. Carr, D. Slater, H. Levine, H.
S0402 18:00 Management of echinococcosis: evidence, eminence Kaul, J.B. Park Chang, A. Piermatti, N. Puri, B.
and new developmentsBeate Grüner (Ulm, Germany) Piantadosi, J. Harris, S. Piantadosi, A. Sherman, S.
Co-organised with: Österreichische Gesellschaft für Antimikrobielle Walsh
Chemotherapie (ÖGACH), Österreichische Gesellschaft für Hygiene, O0773 Safety and immunogenicity of a Group B
Mikrobiologie und Präventivmedizin (ÖGHMP), Österreichische Gesellschaft Streptococcus vaccine in participants aged 55-75
für Infektionskrankheiten und Tropenmedizin (OEGIT), ESCMID Study Group yearsL. Oostvogels* (Frederiksberg, Denmark), A.
for Infections in Travellers and Migrants (ESGITM) Alhatemi, S. De Gussem, E. Englev, B. Jacobs, B.
Johansson-Lindbom, G. Kitson, G. Waerlop, I. Leroux-
Roels

ESCMID Global 2025 - Programme
O0774 Aggregated summary of immunogenicity and safety
for the chikungunya virus virus-like particle (VLP)
S0417 08:30 Do we need to redefine the concept of febrile
vaccine development programmeL. Tindale*
neutropaenia in the era of immunotherapy?Manuela
(Toronto, Canada), J. Richardson, D. Anderson, J.
Aguilar-Guisado (Seville, Spain)
Mendy, S. Muhammad, T. Loreth, V. Jenkins, P.
Ajiboye, L. Bedell S0418 09:00 Should some patients be empirically treated with
combination therapy?Dina Averbuch (Jerusalem,
Israel)
OS108 - Hall 5 S0419 09:30 Role of new antibiotics in febrile
17:30 18:30
neutropaeniaMalgorzata Mikulska (Genoa, Italy)
1-hour Oral Session
S0420 10:00 Can treatment strategies be personalised using AI or
new diagnostic tools?Carolina Garcia Vidal
Novel approaches to preventing device-related infections
(Barcelona, Spain)
Chairs Natividad Benito (Barcelona, Spain)
Co-organised with: ESCMID Study Group for Infections in Compromised
Preeti Malani (Ann Arbor, United States)
Hosts (ESGICH), European Conference on Infections in Leukemia (ECIL)
O0775 Clinical and microbiological impact of antibiotic- EW156 08:30 - 10:30 Hall 5
impregnated catheters in ventriculoperitoneal shunt
infections in adults.M. Sanz De Mena* (Barcelona, Educational Session
Spain), I. Pelegrín Senent, J. Gómez Junyent, J.
The rules of the game: how to tackle the peer-review and publication process
Poblet Florentin, C. Iglesias, A. Siverio Parés, S.
Gómez Zorrilla, L. Sorlí Redó, M. Montero, J.P. Chairs Christian Kraef (Copenhagen, Denmark)
Horcajada Oana Sandulescu (Bucharest, Romania)
O0776 Reducing drainage-associated meningitis by using an
antiseptic dressing: A randomized controlled trial
AntiRedMenS. Scheithauer* (Goettingen, Germany),
W0429 08:30 Communicating with journals, editors and
O. Moerer, V. Rohde, N. Srivastava, T. Asendorf, K.
reviewersAngela Huttner (Geneva, Switzerland)
Antweiler, D. Mielke, G. Uwe, N. Lennart, S. Friedrich,
A. Beste, N. Kucheryava, M. Baehr W0430 08:50 The Wild West of predatory journalsUrsula Hofer
(London, United Kingdom)
O0777 Efficacy of antimicrobial envelopes in preventing
cardiac implantable electronic device infections – W0431 09:10 Communicating your publications on social mediaNeil
systematic review and meta-analysisA. Mahajan* Stone (London, United Kingdom)
(Melbourne, Australia), C. Robson W0432 09:30 Re-imagining peer reviewAmelia Joseph
O0778 A bundled approach to reducing central line (Nottingham, United Kingdom)
associated blood stream infections (CLABSI) in Co-organised with: Deutsche Gesellschaft für Hygiene und Mikrobiologie,
hemodialysis (HD) patientsJ. Guerrero* CMI Communications Board of Editors, ESCMID Parity Commission, CMI
(Scarborough, Canada), A. Garga, S. Paramalingam, Board of Editors
R. Lovinsky, F. Go
O0779 Increased long-term mortality in patients with
prosthetic joint infection after primary total hip EF114 - Arena 1
08:30 09:30
arthroplasty – a cohort study with 89'709 patientsN.
Imhasly* (Lucerne, Switzerland), A. Widmer, C. ePoster Flash Session
Brand, V. Zdravkovic, A. Spoerri, K. Schmidlin, M.
Wicki, M. Beck, R. Sommerstein Innovations and insights in diagnosing parasitic infections
Chair Pikka Jokelainen (Copenhagen, Denmark)
Tuesday, 15 April 2025
E0822 Evaluation of a multiplex beads assay for the
simultaneous detection of serum antibodies in
neurocysticercosis patients.A. Lopez Alva* (Lima,
SY152 - Hall 12
08:30 10:30 Peru), P.D.S. Nakazaki Aza, L.M. Toribio Salazar, H.H.
Garcia Lescano
2-hour Symposium
E0823 Development and evaluation of real-time loop
Out of the spotlight or out of reach? Vaccination of hard-to-reach groups mediated isothermal amplification assay for rapid
detection of hookworm (Ancylostoma duodenale) in
Chairs Olivier Epaulard (Grenoble, France)
human fecal samplesM. Thakur* (Chandigarh, India),
Justyna Kowalska (Warsaw, Poland)
S. Khurana, A. Mewara, L. Pvm
E0824 Exploring Genotypic Prevalence and Transmission of
Cryptosporidium and Giardia in
S0413 08:30 Ukrainian war refugees and vaccination attitudes: Immunocompromised Patients: A Dual Approach with
experience from PolandMaria Ganczak (Zielona Gora, Modern Molecular Methods: MLST & nested real-
Poland) time HRMP. Rani* (Chandigarh, India), P. Datta, S.L.
S0414 09:00 Vaccination in migrants in Latin America: The Bhasin, P. Malhotra, S.S. Rana, R. Sehgal
challenges of transit through Darien, PanamaAlfonso E0825 Prevalence and diagnostic accuracy of different
J. Rodriguez-Morales (Pereira, Colombia) diagnostic tests for Chagas disease in the
S0415 09:30 Are penitentiary systems ready for introducing Paraguayan ChacoS. Ardiles Ruesjas*
vaccination programmes?Lara Tavoschi (Pisa, Italy) (Saarbruecken, Germany), S. Ardiles-Ruesjas, V.
Lesmo, V. González-Romero, Z. Cubilla, L. Chena, C.
S0416 10:00 HPV and other essential vaccinations for sex
Huber, M.J. Rivas, P. Saldaña, A. Carrascosa, S.
workersDebora Konopnicki (Brussels, Belgium)
Méndez, S. Sanz, S.L. Becker, J. Alonso-Padilla, I.
Co-organised with: ESCMID Vaccine Study Group (EVASG) Losada
E0826 Development and validation of an artificial
intelligence model for detection of gastrointestinal
SY153 08:30 - 10:30 Hall 13 parasites from concentrated wet-mount stool
examinationsM.R. Couturier* (Salt Lake City, Ut,
2-hour Symposium United States), B. Mathison, K.A. Knight, J.R. Potts, F.
Markow, A.E. Wood, K.W. Dixon, J.F. Walker, D.L.
Breaking new ground in febrile neutropaenia management
Bess, W. Hymas
Chairs Murat Akova (Ankara, Türkiye)
E0827 Evaluation of KU-F40 automated microscope for
Stefan Schwartz (Berlin, Germany)
diagnosis of intestinal parasitic infections : will AI

ESCMID Global 2025 - Programme
rescue old-time microscopy ?A. Aupaix* (Hornu, Priscilla Rupali (Vellore, India)
Belgium), L. Filippin, I. Mansoor, M. Chemais, D. Monica Slavin (Melbourne, Australia)
Martiny, V.Y. Miendje Deyi, M. Deffontaine, C.
Deckers, V. Verbelen, J. Brauner
CGR01 Case 1Kruthi Malur Kumaraswamy (Mumbai, India)
E0828 Improving vector surveillance: evaluating a real-time
PCR assay for Leishmania DNA detection in CGR02 Case 2Christopher Wong (Victoria, Australia)
sandfliesH. Alonso-Ezcurra* (Zaragoza, Spain), M.P. CGR03 Case 3Filipa Ferreira (Porto, Portugal)
Peris, I. Ruiz-Arrondo, J.A. Castillo, D. Martínez-
CGR04 Case 4Jia Arng Lee (Zhongzheng Dist, Taipei City,
Durán, S. Delacour, I. Ruiz-Zarzuela, I. De Blas, C.
Taiwan, Taiwan, China)
Cervera-Acedo, J.A. Oteo, F. Collantes, B. Dehesa, H.
Alonso CGR05 Case 5Lorenzo Bertolino (Naples, Italy)
E0829 Assessment of a new immunochromatographic assay CGR06 Case 6Armani Hawes (Baltimore, United States)
for serological diagnosis of amoebic liver abscessR. CGR07 Case 7Sima Sharara (Baltimore, United States)
Fleury* (Besançon, France), M.P. Brenier-Pinchart, P.
Co-organised with: Infectious Diseases Society of America (IDSA)
Tirard-Collet, F. Gabriel, E. Pretot, F. Touafek, A.
Marteau, S. Houze, C. Amiot, T.G. Nguyen, D. Dupont,
A. Moreno-Sabater, F. Grenouillet
E0830 Human piroplasmosis: diagnostic lessons from a
OS113
08:30
-
10:30
Hall 11
national parasitology reference laboratory in South 2-hour Oral Session
Africa.C. Sriruttan-Nel* (Johannesburg, South Africa),
J. Frean Knockin' on Science's Door: New Antimicrobial Solutions
Chairs Sandrine Marchand (Poitiers, France)
Ursula Theuretzbacher (Vienna, Austria)
EF115 - Arena 3
08:30 09:30
ePoster Flash Session
O0812 Chimerbactin: a hybrid antibiotic for persistent
New genomic methods in clinical microbiology Gram-positive infections that overcomes resistance
Chair Natacha Couto (Oxford, United Kingdom) developmentR. Lee* (Memphis, United States), Y.
Zhao, A. Arya, M. Lafleur, R. Conlin, G. Phelps, C.
Dunn, E. Griffith, J. Portelinha, N. Chumbler, V.
Loudon, I. Lister, S. Zia, K. Urish, K. Lewis
E0831 Prediction of antimicrobial minimum inhibitory
O0813 A Novel Klebicin Cocktail to Treat Lung Infection
concentration from Escherichia coli whole genome
Caused by Klebsiella pneumoniaeV.D. Paul*
sequence data using machine learningA. Gerada*
(Bangalore, India), A. Ambady, U. Chopra
(Liverpool, United Kingdom), N. Harper, Y. Zhong, A.
Howard, P.L. Green, W. Hope O0814 Thiophene derivatives: A promising solution against
MDR Gram-negative bacilliY. Smani* (Seville,
E0832 Dynamically Optimized Reference Adaptive Sampling
Spain), I. Molina Panadero, Á. Rey Hidalgo, M.
(DORAS) to streamline bacterial Multi-Locus
Morales-Tenorio, A. García-Rubia, T. Samernate, P.
Sequence TypingA. Ramette* (Bern, Switzerland), L.
Nonejuie, A. Martínez, A. Hmadcha, A. De Alarcón,
Borcard, M.A. Terrazos Miani, S. Gempeler, S.
C. Gil
Neuenschwander
O0815 Molecular insight into non-lytic polyproline peptide
E0833 Prediction of antibiotic resistance in Pseudomonas
disruption of Klebsiella pneumoniae biofilmsR.
aeruginosa, Escherichia coli and Klebsiella
Fleeman* (Orlando, United States), R. Beckman Iv,
pneumoniae from genomic data using machine
B. Victoria, L. Suits, P. Eswara
learning and deep learning approachesE. Denakpo*
(Gif-Sur-Yvette, France), N. Dias, F. Jay, B. Iorga O0816 Reverting cefotaxime resistance in CTX-M-15-
producing Escherichia coli using Targeted-
E0834 Machine learning pipeline accelerates identification
Antibacterial-Plasmids (TAPs): a CRISPR-Cas9
of diagnostic targets for Neisseria gonorrhoeaeA.
approach.N. Roson Calero* (Barcelona, Spain), N.
Verich* (Sydney, Australia), T. Applegate, D. Bauer, P.
Roson-Calero, E. Derollez, P. Rouze, A. Dedieu-
Ramarao-Milne, L. Sng, E. Trembizki, E. Mokany
Berne, S. Bigot, C. Ballesté-Delpierre, J. Vila, P.
E0835 Reliable bacterial genomic genotyping from Oxford Bogaerts, C. Lesterlin
Nanopore Technologies data – the ONT cgMLST
O0817 Structural and functional characterization of
PolisherN. Scherff* (Muenster, Germany), J.
LysSM5: An innovative endolysin from Salmonella
Rothgänger, D. Harmsen
Phage vB_SenA_SM5K. Sharma* (Chandigarh,
E0836 Developing a core genome MLST (cgMLST) for India), H. Kaur, N. Chaudhary, S. Prajapati, B.
Mycoplasma pneumoniaeC. Dixon* (Cardiff, United Mohan, N. Taneja
Kingdom), R. Mamede, M. Ramirez, H. Milton, P.M.
O0818 Rational step-by-step design of a two-phage
Meyer Sauteur, G. Greub, N. Couto, M.L. Beeton
cocktail against a contemporary A. baumannii strain
E0837 Voyager: real-time taxonomic characterization of recovered from a burned patient at CHUV.G.
long-read mixed-species sequencing samples in Resch* (Lausanne, Switzerland), H. De Villiers De La
sorted motif distance spaceS. Branders* (Hamar, Noue, G. Golliard, X. Vuattoux
Norway), M. Grabherr, R. Ahmad
O0819 A novel antibiotic class targeting the enolase of
E0838 VCP: a signature protein-based tool for accurate and Acinetobacter baumanniiI. Molina Panadero*
rapid profiling of human gut viromeJ. Li* (Shenzhen, (Seville, Spain), A. Moreno Rodríguez, Á. Rey
China), F. Yang, L. Xiong, X. Feng, H. Zhong Hidalgo, L. Tomás Gallardo, M. De La Cruz, P.
E0839 Genomic Data-Driven Machine Learning for Sánchez, T. Samernate, A.J. Pérez Pulido, S. Glisic,
Predicting Antimicrobial Resistance in ESCAPEE O. Genilloud, P. Nonejuie, A. Hmadcha, Y. Smani
PathogensA. Skoulakis* (Lamia, Greece), K. O0820 Reviving antibiotic potency: Pharmacological
Daniilidis, S. Digenis, A. Hatzigeorgiou Assessment of JS238 a newly designed potentiator
against P. aeruginosaP. Rasouli* (Brussels,
Belgium), J.M. Brunel, J.H. Lorent, F. Van Bambeke
CGR 08:30 - 10:30 Hall 1 O0821 Advancements in combating tularemia: Novel
therapeutic strategies targeting Francisella
Special Session
tularensisS. Guillier* (Brétigny-Sur-Orge, France),
M. Gâchon, C. Lemoigne, C. Rougeaux, V. Lourde,
Clinical Grand Round
C. Demeure, J. Pizarro Cerda, G. Guichard, G.
Compain, D. Burnouf, O. Gorgé, J. Wagner
Experts Nina Khanna (Basel, Switzerland)
Dimitrios P. Kontoyiannis (Houston, Tx, United States)
Lior Nesher (Beersheba, Israel) SY154 - Hall 14
David L. Paterson (Singapore, Singapore) 08:30 10:30

ESCMID Global 2025 - Programme
2-hour Symposium Netherlands)
S0407 09:30 What are the right bugs – Developing LBPs out of
Using mathematical and epidemiological models to identify the drivers of
FMTsLena Biehl (Cologne, Germany)
AMR
S0408 10:00 What’s up next? – Hot LBP candidatesIlan Youngster
Chairs Marc J.M. Bonten (Utrecht, Netherlands)
(Beer Yaakov, Israel)
Sarah Tschudin Sutter (Basel, Switzerland)
Co-organised with: ESCMID Study Group for Host and Microbiota Interaction
(ESGHAMI), The European Faecal Microbiota Transplantation Network of
academics (EurFMT), European Helicobacter & Microbiota Study Group
S0421 08:30 Quantifying the drivers of antiviral resistance: what (EHMSG)
does it take to prevent resistance evolution?Roger
Kouyos (Zürich, Switzerland)
S0422 09:00 Inferring the determinants of AMR dynamics across SY151 08:30 - 10:30 Hall 4
bacterial pathogensLulla Opatowski (Paris, France)
2-hour Symposium
S0423 09:30 Modelling the evolution of resistanceErida Gjini
(Lisbon, Portugal) News in endocarditis care
S0424 10:00 Assessing the associations of microbiome and socio- Chairs Michele Bartoletti (Milan, Italy)
demographic dynamics on AMRKatariina Pärnänen Pilar Retamar Gentil (Seville, Spain)
(Helsinki, Finland)
EW157 - Hall 15 S0409 08:30 Endocarditis guidelines: what is new?Siegbert Rieg
08:30 10:30
(Freiburg, Germany)
Educational Session S0410 09:00 Oral therapy and outpatient careLaura Escolà-Vergé
(Barcelona, Spain)
Endemic mycoses and mycetoma: underdiagnosed and underreported fungal
diseases S0411 09:30 PK/PD aspects of endocarditis antibiotic
therapyFekade Bruck Sime (Brisbane, Australia)
Chairs Ana Alastruey-Izquierdo (Madrid, Spain)
Rita Oladele (Lagos, Nigeria) S0412 10:00 The Endocarditis Team: there is no way to work
aloneBarbara Hasse (Zurich, Switzerland)
Co-organised with: ESCMID Study Group for Bloodstream Infections,
Endocarditis and Sepsis (ESGBIES), ESCMID Study Group for Antimicrobial
W0433 08:30 Advances and gaps in the diagnosis and treatment of stewardship (ESGAP), Sociedad Espanola de Infecciones Cardiovasculares
histoplasmosisDiego Rodrigues Falci (Porto Alegre, (SEICAV)
Brazil)
W0434 08:50 Paracoccidioidomycosis: an update on diagnostic
challengesBeatriz L. Gomez (Bogota, Colombia) EF116 - Arena 2
09:30 10:30
W0435 09:10 What is new in TalaromycosisBrown Lottie (London,
United Kingdom) ePoster Flash Session
W0436 09:30 Mycetoma: treatment challenges of a unique Sepsis revolutions: from machines to molecules
neglected tropical diseaseBorna Nyaoke-Anoke
Chair Pierluigi Del Vecchio (Roma, Italy)
(Nairobi, Kenya)
EW155 08:30 - 10:30 Hall 2 E0840 Machine learning enabled prediction of blood
stream infection in emergency department
Educational Session
attendees.C. Rosato* (Liverpool, United Kingdom),
S. Aston, A. Velluva, A. Howard, W. Hope
An update on arboviral disease challenges
E0841 Utilizing Automation to Streamline the Blood Culture
Chairs Misa Korva (Ljubljana, Slovenia)
Process: Enhancing Efficiency and Patient
Anna Papa-Konidari (Thessaloniki, Greece)
OutcomesJ. Qin* (Shanghai, China), M. Li, Z. Shen
E0842 Implementation of a bundle for Gram-negative
bloodstream infection: impact on mortality and
W0425 08:30 The global epidemiology of arboviral diseasesChantal MDT/DTT carriageC. Bonazzetti* (Bologna, Italy), A.
B.E.M. Reusken (Bilthoven, Netherlands) Grechi, D. Gibertoni, L. Mangione, F. Todisco, N.
Caroccia, M. Rinaldi, R. Pascale, B. Tazza, A. Toschi,
W0426 08:50 Arboviral diseases transmitted by mosquitoesLuisa
A. Amicucci, C. Campoli, Z. Pasquini, F. Calo', P.
Barzon (Padua, Italy)
Viale, M. Giannella
W0427 09:10 Aboviral diseases transmitted by ticksJoanna Maria
E0843 A matter of time: impact of time to first follow-up
Zajkowska (Białystok, Poland)
blood cultures in patients with candidemia and
W0428 09:30 Arboviral diseases transmitted by sandfliesRémi Staphylococcus aureus bacteremia from a
Charrel (Marseille, France) retrospective cohortP. Valsecchi* (Pavia, Italy), E.
Co-organised with: EURL-PH-VBV, Polish Association of Epidemiologists and Bono, A. Valeretto, S. Resuli, M. Corbella, P.
Infectiologists Cambieri, E. Seminari, R. Bruno
E0844 Characteristics of infections and outcomes in
patients with left ventricular assist devicesN. Sarı*
SY150 08:30 - 10:30 Hall 3 (Ankara, Türkiye), E. Ateş, Ç. Sarıkaş, Ö. Kurt Azap,
Ç. Erol, A. Sezgin
2-hour Symposium
E0845 Nb2(Sn0.7Cu0.3)C MAX phase for anti-Infection
Faecal microbiota transplantation and live biotherapeutic products: scientific therapy via hyperthermia-mediated bacterial
and regulatory challenges metabolic interferenceM. Yang* (Chengdu, China)
Chairs Lindsey Ann Edwards (London, United Kingdom) E0846 Age-Dependent Plasma Lipidomic Alterations and
Ed J. Kuijper (Leiden, Netherlands) Immune Correlations in Sepsis: Insights into
Disease Severity and Biomarker PotentialY. Sun*
(Shanghai, China), K. Lin, L. Wang, J. Ai, J. Zhao, X.
Cheng, Y. Wan, P. Cui, S. Wang, J. Wu, J. Jin
S0405 08:30 How can we recognise and deal with adverse events
E0847 Aberrant integrin activation causes transmigration
of Faecal Microbiota Transplantation?Serena Porcari
defects in S100A9-/- neutrophils during sepsisS.
(Roma, Italy)
Mülder* (Münster, Germany), N. Ludwig, J.
S0406 09:00 What to check? – An attempt at evidence-based
Rossaint, T. Vogl
donor screeningElisabeth Terveer (Leiden,

ESCMID Global 2025 - Programme
E0848 Efficacy of dimercaptosuccinic acid in combination 1-hour Symposium
with imipenem in a murine model of experimental
sepsis due to metallo-ß-lactamase-producing dsDNA virus infections in immunocompromised patients
Pseudomonas aeruginosa.S. Herrera-Espejo* Chairs Lior Nesher (Beersheba, Israel)
(Seville, Spain), M. Bouvier, J. Findlay, L. Ceballos- Michelle Yong (Melbourne, Australia)
Romero, J. Pachón, J.M. Cisneros, M.E. Pachón-
Ibáñez, P. Nordmann
S0448 11:00 Challenges of diagnosis: do we need to treat all
EF117 - Arena 4 patients with detectable dsDNA virus PCR?Hans H.
09:30 10:30
Hirsch (Basel, Switzerland)
ePoster Flash Session
S0449 11:30 The role of CRISPR-Cas9-edited antiviral T cells
against dsDNA virus infectionsTba
C. diff challenges: insights into treatment, monitoring, and infection
prevention
Chair Kerrie Davies (Leeds, United Kingdom) FO167 - Arena 1
11:00 12:00
Open Forum
E0849 Epidemiology, risk factors, and outcomes of Vaccine rollout in low resource settings
nosocomial Clostridioides difficile infections: a cohort
Chair Asma Nasim (Karachi, Pakistan)
study in a tertiary hospital.L. Ruiz Salazar* (Madrid,
Spain), T. Mata Forte
E0850 Long-read or short-read sequencing in Clostridioides
difficile infection surveillance?M. Brajerová* (Prague, F0454 11:00 Typhoid vaccine roll outNginache Nampota
Czech Republic), M. Brajerova, P. Kinross, P. (Baltimore, United States)
Drevinek, M. Krutova
F0455 11:10 Introduction of malaria vaccines to countries in sub-
E0851 “Beyond C. difficile Colitis”: Exploring the Role of Saharan Africa: acceptance and barriersBernhards
Fidaxomicin in preventing concomitant and Ogutu Ragama (Nairobi, Kenya)
secondary bloodstream infections in patients with
F0456 11:20 The story of COVID-19 vaccines in LMICPaul Adepoju
Clostridioides difficile colitis.D.F. Bavaro* (Milan,
(Perton, United Kingdom)
Italy), D. Schumann, A. Cilli, L. Diella, D. Barbanotti, D.
Mondatore, F. Medioli, M. Casana, A. Belati, L. Co-organised with: ESCMID Ethics Advisory Committee (EEAC)
Bussini, V. Cento, R. Epis, M. Bartoletti
E0853 Comparison of bezlotoxumab versus no-
EF123 - Arena 2
bezlotoxumab on recurrence in high-risk patients 11:00 12:00
with Clostridioides difficile infectionC. Arena*
ePoster Flash Session
(Detroit, United States), A. Abed, R. Kenney, A.
Shallal, S. Davis, M. Veve
Advancing antimicrobials: trials and therapies for resistant infections
E0854 Exploring bacterial contributors to C. difficile
Chair Ursula Theuretzbacher (Vienna, Austria)
colonization resistance: comparative effects of
vancomycin and fidaxomicin in humanised miceE.
Montenegro-Borbolla* (Lausanne, Switzerland), L.
Beldi, S. Hapfelmeier, G. Greub, C. Bertelli, B. Guery E0888 11:00 Efficacy of High Dose Tigecycline-Containing
E0855 An optimised vancomycin dosing regimen is effective Regimens for the Combination Treatment of
against C. difficile, reduces gut microbiota impact Carbapenem Resistance Enterobacterales
and prevents recurrent C. difficile infection in a Bacteremia: a propensity score-matched studyV.
human in vitro gut model.J. Freeman* (Leeds, United Vasikasin* (Bangkok, Thailand), W. Nasomsong, P.
Kingdom), C. Normington, E. Clark, K. Bentley, J. Wanloptaree
Altringham, A. Berry, W. Spittle, D. Ewin, A. Kirby, M. E0883 11:06 Evaluation of CRS3123 compared to vancomycin for
Wilcox, K. Davies the treatment of Clostridioides difficile infection
E0856 Cost and resource utilization of fidaxomicin in risk (CDI)J. Bruss* (Pagosa Springs Co, United States),
patients with recurrent or refractory Clostridioides M.A. Degroote, L. Boccumini, W. Ribble, J. Day, C.
difficile infectionM. Engelhard* (Cologne, Germany), Mason, X. Sun, J. Freeman, N. Seema, N. Janjic, T.
I. Alram, S.M. Wingen-Heimann, N. Pfeiffer, J.J. Jarvis, U. Ochsner, M. Wilcox, T. Louie
Vehreschild, M.J.G.T. Vehreschild, S.M. Hopff E0884 11:12 Phase 2/3, open-label, randomized, active-controlled
E0857 Impact of a cohorting intervention on the incidence of clinical trial evaluating the safety and efficacy of
hospital-acquired Clostridioides difficile infection imipenem/cilastatin/relebactam (IMI/REL) in
(CDI): an interrupted time series analysisC.D. paediatric patients with gram-negative bacterial
Moschopoulos* (Athens, Greece), M. Tsakona, S. infectionJ. Bradley* (San Diego, United States), C.T.
Grigoropoulou, P. Kazakou, M. Kostoula, I. Kliani, C. Norice, E. Roilides, A. Shevelev, B. Jurkiewicz, J.A.
Filis, K. Thomas, I. Grigoropoulos, K. Protopapas, E. Piedrahita, S. Koseoglu, I. Masih, P. Nair, K. Young,
Kalogeropoulou, S. Pournaras, N.V. Sipsas, G.L. D.W. Hilbert, G.T. Nieddu, J.A. Huntington, C.J. Bruno
Daikos, F. Kontopidou, A. Papadopoulos, S. Tsiodras, E0885 11:18 A Phase I, Randomized, Double-Blind, Placebo-
D. Kavatha Controlled, Dose Escalation Study to Evaluate the
Safety and Tolerability of Intravenous Ertapenem
(ERT) with Zidebactam (ZID) in Combination (WCK
ME165 - Hall 12 6777) in Healthy Adult SubjectsT. Lodise* (Albany,
11:00 12:00
United States), R. Chavan, A. Patel, R. Yeole, S.
Meet-the-Expert Bhagwat, M. Patel, G. Saviolakis, K. Gu, V. Ghazaryan,
M. Kankam, A. Jaunarajs, E. Hammett, H. Howell, R.A.
How to use citizen science for public health Bonomo
E0886 11:24 Head-to-head: meropenem/vaborbactam versus
ceftazidime/avibactam in ICUs patients with KPC-
producing K. pneumoniae infections – Results from a
M0450 11:00 Anna Noel-Storr (Leamington Spa, United Kingdom)
retrospective multicentre studyA. Marino* (Catania,
M0451 11:12 Jani Sormunen (Turku, Finland) Italy), A.E. Maraolo, M. Mazzitelli, A. Oliva, N.
Co-organised with: European Centre for Disease Prevention and Control Geremia, A. De Vito, C. Gullotta, V. Scaglione, E.
(ECDC) Vania, S. Lo Menzo, P. Navalesi, L. Volpicelli, A. Fiori,
P. Prestifilippo, A. Cattelan, C.M. Mastroianni, G.
Madeddu, B. Cacopardo, G. Nunnari
SY164 - Hall 15 E0887 11:30 Phase 3 study of oral gepotidacin for the treatment of
11:00 12:00
uncomplicated urinary tract infection in Japanese

ESCMID Global 2025 - Programme
female participants (EAGLE-J)Y. Kayama* (Tokyo, E. Sánchez Báscones, E. López González, A.
Japan), S. Yamamoto, K. Fujii, A. Nimura, T. Maenaka, Blanquero-Porras, M. Riesgo Magaña, A. Bernet
M. Ramirez, R. Banerjee, N.E. Scangarella-Oman, S. Sánchez, S. Mormeneo Bayo, I. Prats Sánchez, A.
Mozzicato, S. Ura Bellés-Bellés, M. García González
E0889 11:36 Efficacy of Ceftolozane/Tazobactam vs.
Ceftazidime/Avibactam in the Treatment of
Nosocomial Pneumonia Caused by Pseudomonas EF125 11:00 - 12:00 Arena 4
aeruginosa: a multicentric retrospective study from
the SUSANA cohort.A. Bitti* (Sassari, Italy), A. De ePoster Flash Session
Vito, M. Fois, E. Ricci, A. Bandera, A. Maccaro, S.
Piconi, P. Maggi, G. Cenderello, M. Merli, G.V. De Bugs breaking the blood-brain barrier
Socio, P. Morelli, P. Bonfanti, G. Madeddu Chair Markus Zeitlinger (Vienna, Austria)
E0890 11:42 Experience of dalbavancin use for unlicensed
indications in a UK tertiary infectious diseases
settingC. Darlow* (Liverpool, United Kingdom), J.
E0901 Pharmacologic depletion of meningeal macrophages
Parsons, D. Lucy, N. Wong
worsens disease in a mouse model of meningitisU.
E0891 11:48 Investigator-driven randomised controlled trial of Koedel* (Munich, Germany), S. Dyckhoff-Shen, I.
cefiderocol versus standard therapy for healthcare- Masouris, H.W. Pfister, M. Klein
associated and hospital-acquired gram-negative
E0902 Pgm1 modulates the inflammatory response of
bacterial bloodstream Infections (BSI) : Hierarchical
macrophages in experimental pneumococcal
composite endpoint analysis with DOOR and
meningitisD. Bakker* (Amsterdam, Netherlands), R.
generalised pairwise comparisonsM. Hardy*
Koning, M. Van Roon, V. Jaspers, M. Brouwer, D. Van
(Maroochydore, Australia), D.L. Paterson, M.
De Beek
Chatfield, H. Bin Sulaiman, L. Po-Yu, M. Yilmaz, Z.N.
Salmuna, M.Z. Mazlan, S. Anunnatsiri, R. Sirijatuphat, E0903 Heparin-binding protein in cerebrospinal fluid as a
D. Chotiprasitsakul, D. Lye, J. Somani, S. Kalimuddin, biomarker for bacterial meningitis: a study of
V. Thamlikitkul, Y.T. Lee, Y.T. Lin, W.N.W. Ramli, H.C. diagnostic accuracyS. Olie* (Amsterdam,
Ong, P. Mootsikapun, A. Meesing, C.H. Tseng, T.K. Netherlands), S.L. Staal, A.C. Da Cruz Campos, J.
Yeh, A.M.B. Hashim, P. Puangpatra, A. Aslan, P. Bodilsen, H. Nielsen, D. Van De Beek, M.C. Brouwer
Santanirand, T.T. Chiang, S. Archuleta, Y.F.Z. Chan, E0904 Efficacy Analysis of Intraventricular/Intrathecal
P.Y. Chia, B. Forde, H. Wright, A. Stewart, K. Ramsay, Polymyxin B sulphate Injections in the Treatment of
W.P. Ling, V. Rossi, T. Harris-Brown, P.N.A. Harris Post-neurosurgical CNS Infections in Neurocritical Ill
Patients:a prospective observational studyL. Yang*
(Shanghai, China), J. Song, M. Wang, H. Yuan, Q.
EF124 - Arena 3 Yuan, Z. Du, G. Wu, J. Hu, W. Chen
11:00 12:00
E0905 Ventriculitis characteristics and outcomes (VELCRO):
ePoster Flash Session
an international retrospective cohort studyD. Luque
Paz* (Rennes, France), B. Díaz Pollán, M. Boyer-
Thinking outside the box in urinary tract infection
Besseyre, F. Djanikian, A.L. Munier, F. Cunha, L.
Chair Özlem Kurt Azap (Ankara, Türkiye) Escaut, G. Martin-Blondel, B. Sarton, P. Jaquet, F.
Arrivé, R. Wolf, V. Legros, M. Willig, O.R. Sipahi, L.
Flurin, A. Bianchi, B. Balança, J. Puel, R. Lino, B.
Soyer, T. Leveque, A. Salomon, A. Serris, R. Larcher,
E0892 Targeted NGS: a promising approach for pathogen
F. Bruneel, N. Mongardon, A. Mazeraud, M. Wolff, R.
detection of urinary tract infectionW. Gao* (Beijing,
Sonneville, F. Valour, P. Tattevin
China), P. Li, W. Han, D. Chen, L. Huang, P. Chen, B.
Cheng, Y. Gu, C. Hu, J. Chen, Z. Zhang E0906 Clinical Features and Outcomes of Staphylococcus
aureus Brain AbscessE. Eriksen* (Aalborg, Denmark),
E0893 Turnaround time of just four hours from sample
M. Bijlsma, S. Olie, L. Larsen, M. Storgaard, H. Mens,
collection to informed decision-making for
L. Wiese, M.P.G. Jepsen, B.R. Hansen, H.R. Lüttichau,
complicated urinary tract infections in a urology
H. Nielsen, M. Brouwer, J. Bodilsen
ward, using culture-independent metagenomicsA.B.
Bellankimath* (Hamar, Norway), S. Branders, J. Ali, F. E0907 Epidemiology of Adult Intracranial Bacterial Abscess
Asadi, T.E.B. Johansen, C. Imirzalioglu, T. Hain, F. in the Republic of Ireland (2010-2021)S. Kilgarriff*
Wagenlehner, R. Ahmad (Cork, Ireland), E. Glynn, D. Murray, C. Lim, C. Hickey,
S. O Donnell, B. Dinesh, C. O Connor, A. Doherty
E0894 Identification of Microorganism Types in Urinary
Tract Infections Using Machine Learning and Flow E0908 Corticospinal tract involvement in Neuromelioidosis:
CytometryE. Flores* (Alicante, Spain), I. Gutierrez, R. A Retrospective cohort Study from South India and a
Torrreblanca, A. Blasco, R. Carbonell, M. Lopez- Systematic Review of LiteratureP.K. Tirlangi*
Garrigós (Manipal, India), N. Gupta, V. Muralidhar, C.
Mukhopadhyay
E0895 A New Approach In Diagnosis Of Urinary Tract
InfectionsB. Dinc* (Ankara, Türkiye), F. Kırca, S. E0909 A multicenter prospective study to develop and
Kazcı, Ö. Uslu, N. Çöplü validate clinical prediction models for diagnosis of
scrub typhus and treatment with doxycycline in
E0896 Diagnosis of urinary tract infections: from machine
children with acute encephalitis syndrome in
learning to clinical practiceE. Flores* (Alicante,
southern IndiaT. Damodar* (Bangalore, India), L.
Spain), R. Torrreblanca, I. Gutierrez, R. Carbonell, L.G.
Turtle, R. Kolamunnage-Dona, M. Jose, U. Kinhal, B.
Maite, A. Blasco
Singh, A. L, S. Marate, N. Prabhu, L. A V, F.S. D'souza,
E0897 Strategic testing optimisation practices for urinary S.V. Sajjan, K. Mallesh, R.S. Mani, T. Solomon, V.K.
tract infections (STOP-UTI): findings from LMIC Gowda, R. Vasanthapuram, R. Yadav
hospital settingS. Sarika* (Tamil Nadu, India), B.
Rithik Dharan
E0898 Rapid culture-independent mass spectrometry based KN158 11:00 - 12:00 Hall 1
proteomics methods for improving urinary tract
infection diagnosticsS. El-Ali* (Gothenburg, Sweden), Keynote Lecture
L. Acha Alarcon, G. Alves, Y.K. Yu, R. Karlsson, E.
Moore What genomics brought to the knowledge of tuberculosis, leprosy and buruli
ulcer
E0899 Unraveling the complexity: Corynebacterium
diversity and antimicrobial resistance hub in the Chairs Emmanuelle Cambau (Paris, France)
urinary tract ecosystemE. Cappelli* (Porto, Portugal), Kathryn Holt (London, United Kingdom)
A. Morais, T. Ribeiro, L. Peixe
E0900 Active surveillance in the diagnosis of sexually
transmitted infections: performing PCR in negative K0437 11:00 Stewart T. Cole (Paris, France)
urine culturesA. Castellano Verdasco* (Lleida, Spain),

ESCMID Global 2025 - Programme
SY162 - Hall 11 management by an interdisciplinary annual multi-
11:00 12:00
centred webinarA. Friedrichs* (Kiel, Germany), E.
1-hour Symposium Kramme, T. Koch, J. Jochum, A. Van Der Linde, H.
Gerth, F. Jahn, A. Neubert
Antimicrobial stewardship across the lifespan from paediatrics to geriatrics
Chairs Lucy Catteau (Brussels, Belgium)
Priya Nori (New York, United States) SY159 11:00 - 12:00 Hall 2
1-hour Symposium
S0444 11:00 Antimicrobial Stewardship in paediatrics across Beat the cancer by beating the infections
different settingsTaylor Morrisette (Charleston, Chairs Daniela Maric (Novi Sad, Serbia)
United States) Mojca Maticic (Ljubljana, Slovenia)
S0445 11:30 Stewardship in geriatrics: an exceedingly important
targetDafna Yahav (Ramat-Gan, Israel)
S0438 11:00 Prevention of infection-associated cancer: learning
from each otherCatharina Alberts (Amsterdam,
ME166 - Hall 13
11:00 12:00 Netherlands)
Meet-the-Expert S0439 11:30 Test and treat early to prevent cancer: hepatitis B and
hepatitis CFrancesco Negro (Geneva, Switzerland)
Implementing AI in microbiological diagnostics: practical steps and quality
control
SY160 - Hall 4
11:00 12:00
1-hour Symposium
M0452 11:00 Oliver Nolte (Zürich, Switzerland)
Personalised patient management and infection prevention: Current evidence
M0453 11:12 Jennifer Dien Bard (Los Angeles, United States)
and future perspectives
Co-organised with: ESCMID Study Group for Genomic and Molecular
Chairs Agnes Hajdu (Budapest, Hungary)
Diagnostics (ESGMD), Swiss Society for Microbiology (SSM)
Iris K. Minichmayr (Vienna, Austria)
SY163 - Hall 14
11:00 12:00
S0440 11:00 The dosing perspective: towards individualised
1-hour Symposium treatment strategiesThomas Tängdén (Uppsala,
Sweden)
People-centred approach to strengthening the AMR response at primary care
S0441 11:30 The infection control perspective: advancing patient-
Chairs Benedikt Huttner (Geneva, Switzerland) centred approachesAlessia Savoldi (Verona, Italy)
Mirfin Mpundu (Lusaka, Zambia)
SY161 - Hall 5
11:00 12:00
S0446 11:00 Implementation of WHO’s people-centred
1-hour Symposium
interventionsNienke Van De sanDe Bruinsma
(Geneva, Switzerland)
Emerging fungal diseases in children: Global challenges and approach to
S0447 11:30 Opportunities for strengthening AMR interventions in management
primary healthcareSholpan Kaliyeva (Karaganda City,
Chairs Andreas H. Groll (Münster, Germany)
Kazakhstan)
Adilia Warris (Exeter, United Kingdom)
Co-organised with: World Health Organisation (WHO)
OS122 - Hall 16 S0442 11:00 Emerging fungal infections in immunocompromised
11:00 12:00
and geographically exposed childrenLaura Ferreras-
1-hour Oral Session Antolin (London, United Kingdom)
S0443 11:30 Best available treatments and options for children in
Serious games - a serious business resource-limited settingsFabianne Carlesse (Sao
Chairs Christian Kraef (Copenhagen, Denmark) Paulo, Brazil)
Galadriel Pellejero-Sagastizábal (Zaragoza, Spain) Co-organised with: ESCMID Fungal Infection Study Group (EFISG), German-
Speaking Mycological Society (DMykG)
O0878 The development process, impact and
implementation of an educational VR-module in OS118 11:00 - 12:00 Hall 6
infection prevention and control for medical students
1-hour Oral Session
and healthcare workers in The Netherlands.A.
Tostmann* (Nijmegen, Netherlands), O. Coenen-
Plasmids as a powerful tool of antibiotic resistance spread
Bouwman, B. Schippers, F. Luk, M. Graner, F. Van
Hoek, N. Stikkelbroeck, M. Dronkers Chair Monika Dolejska (Pilsen, Czech Republic)
O0879 Impact of Professional Background on Performance
in ToREIMC: A Gamified Medical Knowledge
PlatformA. Blanco-Di Matteo* (Pamplona, Spain), M. O0858 Co-anchorage of antibiotic resistance genes and
Morante Ruiz, M. Riesgo Magaña, M. Martín García mobile genetic elements on bacterial plasmids
O0880 Serious games and storytelling to enhance boosts horizontal gene transfer across sewage
adolescents' capabilities for decision-making interfacesM. Shafiq* (Shantou, China)
regarding meningococcal vaccination: a monocenter O0859 The emergence of tet(X4) and mcr co-harbored on
studyT. Morris* (Saint-Etienne, France), S. Essalim, K. the same plasmid and its clinical significanceN.
Atroune, V. Ronat, M. Moulin, R. Eichel, E. Botelho- Rakhi* (Oxford, United Kingdom), A. Lankapalli, T.
Nevers, A. Gagneux-Brunon Lanyon-Hogg, P. Niumsup, K. Thomson, K. Sands, T.
O0881 ‘The Sepsis Olympics': Raising awareness of the Walsh
Sepsis 6 care bundle in an Irish Hospital through a O0860 The plasmidome of a global collection of convergent
clinical challenge game.C. Uhomoibhi* (Dublin, K. pneumoniae and its impact on virulenceF.
Ireland), K. Costelloe, J. Harte, N. Power, E. De Barra Lebreton* (Silver Spring, United States), M. Martin,
O0882 Improvement of learners' confidence in antibiotic A.P. Sapre, T. Luo, U. Carolino-Macdonald, E. Mills, B.

ESCMID Global 2025 - Programme
Corey, R. Maybank, A. Ong, Y. Kwak, J. Bennett, T. China), Y.C. Wang
Russo, P. Mc Gann O0872 Platelets drive neutrophil-mediated
O0861 Factors that affect plasmid transfer in multispecies neuroinflammation in tuberculous meningitisK.
biofilmsH.Y. Liu* (Norwich, United Kingdom), M. Skolimowska* (London, United Kingdom), R.
Yasir, E. Trampari, G. Langridge, M. Webber Wilkinson, J.S. Friedland, D. Kirwan, T. Reid, D. De
O0862 Identification of the czc metal efflux operon on a new Swardt, D.L.W. Chong, J. Kutschenreuter, M. Saeed,
plasmid type in a Pseudomonas aeruginosa clinical A. Davis, S. Wasserman, R. Goliath, Q. Kakana, P.
isolate belonging to ST357 O11A. Valcek* (Brussels, Renner, M. Panchoo, C. Stek, R. Johnson, M.
Maxebengula
Belgium), D.I. Costescu Strachinaru, P. Soentjens, A.
Stoefs, C. Van Der Henst
OS121 - Hall 9
11:00 12:00
OS119 - Hall 7
11:00 12:00 1-hour Oral Session
1-hour Case Session
Shaping the future of IPC - digitalisation of surveillance
Looking inside endovascular infections Chairs Diamantis Plachouras (Solna, Sweden)
Chairs Claus Moser (Copenhagen, Denmark) Maaike S.M. Van Mourik (Utrecht, Netherlands)
Matthaios Papadimitriou Olivgeris (Sion, Switzerland)
O0873 11:00 PRAISE hospital-onset bacteraemia and fungaemia
O0863 A Case of Persistent Legionella micdadei Aortitis with algorithm as novel automated surveillance indicator:
Endocarditis: Diagnostic and Therapeutic results from four European university hospitalsS. Van
ChallengesV. Zwart* (Breda, Netherlands), E. Der Werff* (Stockholm, Sweden), S.J.S. Aghdassi, M.
Kayabasi, H. De Groot, R. Bentvelsen Behnke, M.S.M. Van Mourik, G. Catho, M.
Brekelmans, L.A. Peña Diaz, N. Buetti, F.D. Rüther, D.
O0864 Management and Prognosis of Vascular Endograft Dinis Teixeira, D. Sjöholm, P. Nauclér
Infections: Case SeriesN. Scarpulla* (Napoli, Italy), F.
Patauner, L. Bertolino, R. Andini, A.M.C. Peluso, R. O0874 11:12 Transforming hospital-onset bacteremia and
Gallo, E. Durante-Mangoni fungemia data to the OMOP common data modelH.
Düsseldorf* (Vienna, Austria), G. Duftschmid, E.
O0865 Fungal frenzy: handling an uncommon etiology in Presterl
prosthetic valve endocarditisI. Cafarella* (Naples,
O0876 11:24 Dutch Electronic Health Records in primary care: the
Italy), R. Gallo, F. Patauner, F. Luciano, L. Bertolino,
Nivel general practisioners databaseF.F. Stelma*
A.M.C. Peluso, F. Boccia, R. Zampino, E. Durante-
Mangoni (Utrecht, Netherlands), J. Van Summeren, M.
Hooiveld, C. Baliatsas, V. Sankatsing, J. Schmitz, S.
O0866 Successful Use of Oritavancin as Consolidation Van Beusekom
Therapy for Infective Endocarditis Caused by
O0877 11:36 Local signs at catheter insertion sites: Insights from
Enterococcus spp.: Experience from Seven Cases in a
the multicenter DeepCath cohort study with 4,256
Referral CenterF. Frondizi* (Rome, Italy), G.M.
Leanza, F. Catania, F. Sangiorgi, M. Chiuchiarelli, B. picturesN. Buetti* (Geneva, Switzerland), S. Ruckly,
Andriolo, L. Vahedi, B. Liguoro, F. Giovannenze, E. A. Byczko, L. Gallay, A. Nguyen, H. Slimani, J.R. Zahar,
Taddei, G. Scoppettuolo, C. Torti J.F. Timsit
O0867 Clinical Features and Outcomes of Gram-Negative O0875 11:48 Prospective evaluation of a machine learning-based
Bacterial Endocarditis: A Case Series from a real-time multidrug-resistant organism prediction
University HospitalG. Oliva* (Rome, Italy), F. systemV. Vasikasin* (Bangkok, Thailand), W.
Giovannenze, G.M. Leanza, F. Frondizi, M. Nasomsong, A. Holmes, R.L. Peach, K. Bhangananda,
Chiuchiarelli, B. Liguoro, B. Andriolo, E. Taddei, G. A. Myall, C.H. Yoon, D. Changpradub, S. Mookerjee,
Scoppettuolo, C. Torti J. Price, B. Mauricio, T.M. Rawson
OS120 11:00 - 12:00 Hall 8 EF131 13:30 - 14:30 Arena 1
1-hour Oral Session ePoster Flash Session
Exploring Host-Pathogen Interactions and Immune Dynamics in Bacterial The current landscape of carbapenem resistance: from genotype to
Virulence phenotype and virulence determinants
Chairs Giovanni Delogu (Rome, Italy) Chair Amy Mathers (Charlottesville, United States)
Simon Foster (Sheffield, United Kingdom)
E0940 Molecular Insights into the Growing Threat
O0868 Bacteria and host responses in both mice and human Carbapenem-Resistant Hypervirulent Klebsiella
lung organoid model revealed the role of a novel pneumoniae and the Rising Challenge of Ceftazidime-
plasmid pvirhs1 in hypervirulent Carbapenem- Avibactam ResistanceC. Vatansever* (Istanbul,
resistant Klebsiella pneumoniaeY. Zhang* (Shanghai, Türkiye), A. Akpinar, J. Boral, S. Belge, N. Kardan, B.
China), W. Liu, K. Lin, L. Chen, J. Wu, N. Jiang Tanyolaç, G. Shahrokhi, G. Ekinci, E. Ural, B. İşler, Ö.
Ergönül, F. Can
O0869 Presence and role of hypervirulence-associated
markers in Klebsiella pneumoniae groups based on E0941 Global large-scale genomic snapshot on the diversity
of carbapenem-resistant and hypervirulent Klebsiella
LD50 value in mouse septic modelA. Avdeeva*
(Saint-Petersburg, Russian Federation), D. Kandina, pneumoniae strainsR. Elias* (Lisboa, Portugal), T.
E. Podvysotskaia, P. Chulkova, M. Velizhanina, J. Clark, I. Portugal, J. Perdigao
Sopova, V. Lomonosova, V. Galushka, A. E0942 Carbapenem-resistant Enterobacter cloacae
Afinogenova, V. Shapovalova, O. Sulian, I. Ageevets, complex: genetic determinants of resistance and
V. Ageevets, S. Sidorenko molecular epidemiologyD. Pinheiro De Sousa Santos*
O0870 Meta-transcriptomic Insights into Host-Pathogen (Lisbon, Portugal), D. Santos, A. Bruschy-Fonseca, E.
Interactions in Necrotizing Soft Tissue Infections Gonçalves, D. Ranhel, C. Conceição, A. Pedrosa, A.C.
Using Differential AnalysisT. Vashist* (Chandigarh, Silva, A. Duarte, L. Méndez, C. Toscano, J. Melo-
India), N. Rana, D. Nair, A. Angrup, V. Sharma, C. Cristino, C. Caneiras
Tandup, P. Ray, A. Arora E0943 Molecular epidemiology of carbapenemase-
O0871 Unveiling the hidden virulence of Acinetobacter producing Escherichia coli in HungaryA. Hanczvikkel*
baumannii: how the lipooligosaccharide core (Budapest, Hungary), D. Göbhardter, E. Ungvári, N.
modulates immune responses and enhances Derzsy, A. Darab, L. Jánvári, L. Buzgó, L. Holub, K.
interferon-￿ productionY.T. Lee* (Taipei, Taiwan, Papp, K. Kristóf, L. Majoros, K. Kamotsay, M. Käfer, G.

ESCMID Global 2025 - Programme
Jakab, Á. Sonnevend, Á. Tóth EF133 - Arena 3
13:30 14:30
E0944 Genomic multicentre surveillance of VIM-producing
Enterobacterales shows spread driven by bacterial ePoster Flash Session
clones and plasmids in Germany from 2015 to 2021A.
Viral infections in special populations
Wendel* (Cologne, Germany), J. Sattler, B. Bader, J.
Müller, A. Hamprecht, S. Peter Chair Federico Garcia (Granada, Spain)
E0945 Three distinct routes of virulence-resistance
convergence in ST-395 K. pneumoniae from Eastern
Europe over the last decade.A. Sapre* (Silver Spring,
E0958 ORCHESTRA Delphi Consensus: Therapeutic and
United States), E. Nguyen, T. Luo, E. Mills, B. Corey, R.
Diagnostic Management of SARS-CoV-2 Infection in
Maybank, A. Ong, V. Kondratiuk, V. Kovalchuk, M.
Rheumatological PatientsM.G. Caponcello* (Seville,
Metreveli, N. Trapaidze, Y. Kwak, T. Musich, J.
Spain), P. Olivares Navarro, J. Rodríguez Baño, Z.R.
Bennett, P. Mc Gann, M. Martin, F. Lebreton
Palacios Baena, C. Bonazzetti, C. Campoli, A.
E0946 Carbapenemases in Germany in 2024: Report of the Savoldi, E. Gentilotti, G. Marchetti, S. Lo Caputo, L.
German National Reference Centre for Multidrug- Otero-Varela, I. Castrejón, E. Tacconelli
resistant Gram-negative BacteriaN. Pfennigwerth*
E0959 Immunogenicity, reactogenicity and safety of
(Bochum, Germany), S. Möller, J. Eisfeld, F. Pankok,
booster vaccinations with BNT162b2 or full-dose
A. Anders, S. Gatermann
mRNA-1273 in adults ≥75 years (EU-COVAT-1-
E0947 Unravelling divergent genomic modes of AGED) – final reportJ. Stemler* (Cologne,
transmission of Carbapenemase-Producing Germany), L. Yeghiazaryan, C. Stephan, R. Cox, K.
Organisms in a single hospital in Singapore between Greve-Isdahl Mohn, A.J. Carcas-Sansuan, E.
2019 and 2022V. Koh* (Singapore, Singapore), Z.Q. Romero Rodriguez, J. Moltó, I. Vergara
Lim, S.Q.D. Loy, N.M. Thevasagayam, S.R.S. Prakki, Mitxeltorena, T. Welte, B. Zablockienė, M. Akova, U.
P.Y. Hon, X. Huan, Z.L. Kyaw, A.Y. Lin, P. Rao, P.P. De, Bethe, S. Grimm, J. Salmanton-García, J. Jakobs, L.
S. Vasoo, K. Marimuthu, O.T. Ng Tischmann, M. Zarrouk, A. Cüppers, L.M. Biehl, J.
E0948 2011-2017 vs 2018-2024: comparison of carbapenem Grothe, S.C. Mellinghoff, J.A. Nacov, J.M. Neuhann,
non-susceptibility trends among bloodstream R. Sprute, J. Frías-Iniesta, R. Negi, C. Gaillard, G.
Klebsiella pneumoniae, Acinetobacter baumannii and Saini, A. García León, P.W.G. Mallon, C. Lammens,
Pseudomonas aeruginosa isolates from Greek A. Hotterbeekx, L. Katherine, S. Malhotra-Kumar, H.
hospitals: data from the Electronic System for the Goossens, S. Kumar-Singh, F. König, M. Posch, P.
AMR surveillance-WHONET-GreeceM. Polemis* Koehler, O.A. Cornely
(Vari, Greece), A. Vatopoulos, K. Tryfinopoulou E0960 Effectiveness of adjuvanted recombinant zoster
vaccine in adults aged ≥50 years in the United
StatesL. Qian* (Pasadena, United States), L.S. Sy,
EF132 - Arena 2 B.K. Ackerson, E. Rayens, J. Wu, Y. Luo, Y. Cheng,
13:30 14:30
J.H. Ku, L.I. Vega Daily, H.S. Takhar, J. Song, R.A.
ePoster Flash Session Cohen, H. Yun, D. Oraichi, H. Seifert, H.F. Tseng
E0961 Differential SARS-CoV-2 RNAemia features and
Difficult-to-treat cases in the immunocompromised
humoral immune response analysis of acute COVID-
Chair Nicolas Mueller (Zurich, Switzerland) 19 in solid organ transplant recipients and patients
with hematological malignancies.A. Ruiz-Molina*
(Seville, Spain), J. Martín-Escolano, C. Infante-
Domínguez, Z.R. Palacios-Baena, I. Tallón-Ruiz, F.
E0949 A case of IRIS nocardiosisS.K. Dlamini* (Cape Town, Martín-Dominguez, G. Bernal-Blanco, B. Villacorta-
South Africa), P. Namale, P. Arnab Linaza, G. Suárez-Artacho, C. Cepeda-Franco, D.
E0951 Concurrent invasive disseminated Nocardia farcinica Rangel-Sousa, C. Rodríguez-Urbistondo, B.
and Candida infections in a patient undergoing long- Gutiérrez-Gutiérrez, M. Carretero-Ledesma, N.
term glucocorticoid therapy for autoimmune Maldonado, S. Salto-Alejandre, B. Gallego, L.
thrombocytopenia: A case reportN. Zhang* (Bengbu, Merino, J. Rodríguez-Baño, J.M. Cisneros, J.A.
China) Pérez-Simón, E. Cordero, J. Pachón, M. Aguilar-
Guisado, R. Álvarez-Marín, J. Sánchez-Céspedes
E0952 Subcutaneous paeohyphomycosis due to Alternaria
infectoria in an immunosuppressed renal transplant E0962 Prevalence of and risk factors for persisting COVID-
recipient: successful multidisciplinary managementE. 19 in patients with B-cell malignanciesA. Toschi*
Vetsiou* (London, United Kingdom), E. Rudd, S. Rai, (Bologna, Italy), Z. Pasquini, A. Amicucci, N.
K. Ahmed, S. Rao-Merugumala, A. Wasif, C. Shaw, A. Caroccia, M. Di Chiara, F. Simone, B. Casadei, C.
Abdolrasouli, M. Arias Pellegrini, A. D'abramo, P. De Marco, L. Bussini, M.
Ciccone, A. Visentin, G. Caponcello, M. Bartoletti, E.
E0953 Lung nodules in a patient with breast cancer history…
Nicastri, M. Krampera, P.L. Zinzani, J. Rodriguez
Not everything is cancer.E. Muñoa Hernández*
Baño, E. Tacconelli, M. Giannella
(Chiapas, Mexico), E. Muñoa
E0963 Clinical characteristics and predictors of severe
E0954 Treatment of fulminant Clostridioides difficile
outcome among older adults hospitalized with
infection using bacteria-free stool supernatant in
respiratory syncytial virus (RSV) infection– a
adult hematological patients during chemotherapy-
retrospective study from IsraelM. Jurkowicz* (Tel
induced aplasiaB.G. Szabo* (Budapest, Hungary), D.
Aviv, Israel), I. Margalit, I. Harris, D. Mazar, A. Teper,
Korozs, A. Hardi, K. Jeszenszky, P. Remenyi, J. Sinko
I. Royzman, S. Uppal, C. Liang, E. Begier, I. Ganiel,
E0955 Eradication of multidrug resistant Pseudomonas M. Mandelboim, D. Yahav
aeruginosa pneumonia in acute lymphoblastic
E0964 RSV and bronchiolitis associated primary care and
leukemia patient with broad host-range phageP.
emergency department visit rates in children under
Gadea* (Montevideo, Uruguay), J. Puig, M. Gómez, I.
5 years: Estimates for Europe and other high-
Ferrés, A. Galiana, F. Grill, G. Iraola
income countries.F.F. Stelma* (Utrecht,
E0956 An Emerging fungal pathogen in Netherlands), S. Heemskerk, L. Van Heuvel, P.
immunocompromised hosts: A rare case of Spreeuwenberg, L. Bont, J. Van Summeren
subcutaneous abscess caused by Chondrostereum
E0965 Higher incidence of post-transplant EBV infection in
purpureumP. Kitjacharoenchai* (Bangkok, Thailand),
pediatric liver transplant recipients compared to
A. Thammahong, J. Vanichanan
pediatric kidney transplants: a retrospective
E0957 Unveiling a Rare Simultaneous Central Nervous analysis from a tertiary pediatric transplant centerS.
System infection in an Immunocompromised Patient Mercadante* (Rome, Italy), L. Romani, A.
from MexicoE. Sienra Iracheta* (Tlalpan, Mexico), A. Pietrobattista, I. Guzzo, R. Labbadia, A. Cappoli, A.
Magallanes Lopez, J.P. Venzor Castellanos, M.J. Mosca, L. Lancella, M. De Luca
Corredor Nassar, A.P. Rodriguez Zulueta
E0966 Insights from a single center's experience in
hepatitis C treatment across four prisons in
SlovakiaI. Hockickova* (Košice, Slovakia), I.
Hockicková, J. Hockicko, M. Novotný, Z. Paraličová,

ESCMID Global 2025 - Programme
P. Kristian Schrenzel (Geneva, Switzerland)
W0483 14:10 Viruses in VAP and HAP: should we worry about
them?Catia Cilloniz (Barcelona, Spain)
EF134
13:30
-
14:30
Arena 4
W0484 14:30 Optimising antibiotic therapy in VAPPinyo
Rattanaumpawan (Bangkok, Thailand)
ePoster Flash Session
Infection Controller's Daily
SY170 - Hall 13
Chair Cansu Cimen (Oldenburg, Germany) 13:30 15:30
2-hour Symposium
Novel strategies for eliminating the ‘worst films ever’
E0967 Mortality and length of stay associated with
antimicrobial-susceptible and resistant hospital- Chairs Elisa Borghi (Milan, Italy)
onset bloodstream infections at a tertiary referral Markus Zeitlinger (Vienna, Austria)
hospital in Melbourne, AustraliaA. Stewardson*
(Melbourne, Victoria, Australia), S.J. Curtis, S.L.
Lee, B.S. Cooper, J.M. Bell, G.W. Coombs, D. Daley,
A.C. Cheng, D.W. Spelman, A.Y. Peleg S0465 13:30 What answers can biofilm PK/PD modelling
provide?Coen Van Hasselt (Leiden, Netherlands)
E0968 MRSA on the rise in neonatal care departmentsE.
Herkes* (Amsterdam, Netherlands), A. Schoffelen, S0466 14:00 subMIC antibiotic effects to improve biofilm PK/PD
R. Zwittink, J. Kluytmans, D. Notermans parameters – still relevant?Francoise Van Bambeke
(Brussels, Belgium)
E0969 Risk factors for OXA-carbapenemase-producing
Enterobacteriaceae acquisition in Israel: a S0467 14:30 PK/PD-based optimisation of antibiotic treatments to
retrospective case control studyM. Amar* (Haifa, suppress resistance in dynamic biofilm modelsMaria
Israel), R. Najjar-Debbiny, G. Weber, R. Yasin, A. Dolores Macia Romero (Palma De Mallorca, Spain)
Arbel, S. Shehade, I. Greenfeld, O. Salah, P. Shaked- S0468 15:00 Giving antibiotics an upper hand in the treatment of
Mishan, O. Barnett-Griness biofilm infections – antibiotic augmenting
E0970 Experience providing a rapid, reactive nanopore strategiesClaus Moser (Copenhagen, Denmark)
isolate sequencing service for bacterial outbreak Co-organised with: ESCMID Study Group for Biofilms (ESGB), ESCMID
investigation for hospitals in London, UKS. Scientific Affairs Subcommittee
Raharison* (Nice, France), A. Alcolea-Medina, L.B.
Snell, M. Tan, G. Humayun, R. Chang, D. Ward, V.
Enne, V. Patel, C. Alder, L. Sowole, R. Batra, S. SY171 - Hall 14
13:30 15:30
Goldenberg, J. Edgeworth, J. Otter
E0971 Duration of colonization and time to de-isolation in 2-hour Symposium
patients with extended-spectrum beta-lactamase
producing non-Escherichia coli EnterobacteralesJ. Enhancing efficiency and reducing cost in microbiological diagnostics using
Männer* (St.Gallen, Switzerland), V. Steinacher, T. pool testing
Dörr, M. Schlegel, P. Kohler Chairs Mauricio Farfan (Santiago, Chile)
E0972 A tale of three cities: The comparative longitudinal Chiara Minotti (Basel, Switzerland)
epidemiology of vancomycin-resistant
Enterococcus faecium from bloodstream infections
at three tertiary care hospitals in Bavaria,
S0469 13:30 Congenital cytomegalovirus detection by pool testing
GermanyA. Rath* (Regensburg, Germany), B.
in salivaGiannina Izquierdo (Santiago, Chile)
Neumann, V. Rauschenberger, B. Kieninger, A.
Eichner, J. Steinmann, S. Kampmeier, W. Schneider- S0470 14:00 Detection of blood-corne pathogens in asymptomatic
Brachert blood donors by pool testingPatricia Alvarez (Rio De
Janeiro, Brazil)
E0973 Molecular epidemiology and transmission
dynamics of vancomycin-resistant Enterococcus S0471 14:30 Large-scale pooled testing to increase rapid
faecium in Belgian hospitals (2022-2023)S. De molecular diagnostic test coverage for
Koster* (Edegem, Belgium), S. Van Kleef-Van tuberculosisMelissa Sander (Bamenda, Cameroon)
Koeveringe, H. Jansens, S. Vandamme, T. S0472 15:00 Pool testing for screening of bacterial sexually
Demuyser, M. Vanden Driessche, Y. Glupczynski, S. transmitted infectionsTba
Malhotra-Kumar, V. Matheeussen
E0974 Increasing Prevalence of Linezolid-resistant
Enterococci: Outbreak or Overuse?R. Traynor* OS130 - Hall 16
13:30 14:30
(Cork, Ireland), G. Brennan, I. O Callaghan, E. Keily,
E. Skelton, E. Kennedy, B. O Connell, J. Walsh, A. 1-hour Oral Session
Doherty, C. Hickey
Advances in fungal diagnostics
E0975 Continuous 2-year surveillance for airborne fungi at
hospitals in the same city: Impact of season, Chair Sarah Delliere (Paris, France)
construction, a construction accident and HEPA-
filtered/positive pressure roomsM.H. Nguyen*
(Pittsburgh, United States), C. Clancy, Z. Wilkins, Y.
O0935 BAL galactomannan dynamics predict survival in
Cho, B. Hao, E. Driscoll, S. Cheng, A. Sundermann,
critically ill patients with virus-associated pulmonary
A. Ayres, S. Graham
aspergillosisV. Delanote* (Leuven, Belgium), J.
Wauters, S. Feys, J. Heylen, H.M. Lauwers, C. Jacobs,
L. Maessen, Y. Debaveye, P. Frederiks, G. Hermans,
EW174 - Hall 11
13:30 15:30 P. Meersseman, M. Peetermans, E. Van Wijngaerden,
A. Wilmer, K. Lagrou
Educational Session
O0936 Retrospective Assessment of a New
Best practices and emerging strategies in the management of ventilator- and Chemiluminescence Immunoassay for Serum (1, 3)-
healthcare-associated pneumonia ￿-D-Glucan Levels in Patient with Invasive Fungal
InfectionsZ. Zhou* (Tianjin, China), K. Yuan, L. Ye, S.
Chairs Fusun Can (Istanbul, Türkiye)
Liu, A. Huang, Z. Chen, W. Yan, S. Niu, K. Hua, Q.
Jeroen Schouten (Nijmegen, Netherlands)
Wang, G. Zhang, H. Wang, Y. Zhao, G. Li
O0937 Evaluation of a multiplex PCR assay using barcoded
magnetic bead technology for detection of fungal
W0481 13:30 Artificial Intelligence to predict VAPMiia Jansson pathogens in bronchoalveolar lavage fluid: a
(Oulu, Finland) diagnostic aid for invasive fungal infectionsS. Zhang*
W0482 13:50 Metagenomic approach to VAP diagnosisJacques (Baltimore, United States)

ESCMID Global 2025 - Programme
O0938 Combined use of (1,3)-￿-D-glucan and PCR in oral Bicêtre, France)
wash for Pneumocystis jirovecii pneumonia diagnosis S0464 15:00 Tailoring treatment to resistant Gram-negative
in non-HIV populationA. Falcó Roget* (Mataró, bacteria: newer therapeutic approachesJuan P.
Spain), A. Falcó-Roget, A. Albasanz-Puig, A.B. Pérez, Horcajada (Barcelona, Spain)
S. Serradell, A. Guillén, E. Revilla, I. Los-Arcos, O. Len,
I. Ruiz-Camps, M.T. Martín-Gómez Co-organised with: ESCMID Study Group for Antimicrobial Resistance
Surveillance (ESGARS)
O0939 Iron levels in bronchoalveolar lavage fluid of
hematological patients with suspected invasive
pulmonary aspergillosis and their association with 12-
EW173 - Hall 5
week mortality: a retrospective cohort studyH. 13:30 15:30
Lamberink* (Amsterdam, Netherlands), J. Heijmans,
Educational Session
A. Wagemakers, K. Van Dijk
Tropical dermatology: a case-based approach
Chairs Pedro Legua (Lima, Peru)
SY168 - Hall 2
13:30 15:30 Bobbi Pritt (Rochester, United States)
2-hour Symposium
Staphylococcus aureus: its expansion dynamics and interactions with its pals
W0477 13:30 Parasitic diseases: dermatological manifestations in
Chair Barbara C. Kahl (Münster, Germany) the tropicsKirti Sabnis (India)
W0478 13:50 Madura foot and other implantation mycosesM
Ramam (New Delhi, India)
S0457 13:30 S. aureus and its special relationship to S. W0479 14:10 MycobacteriaFrancisco Bravo (Lima, Peru)
epidermidis Andreas Peschel (Tübingen, Germany)
W0480 14:30 Approach to rash in the returning travellerFrank O. D.
S0458 14:00 Computational and in vitro evaluation of probiotic Pettersen (Oslo, Norway)
treatments for nasal S. aureus decolonizationSilvio
Daniel Brugger (Zurich, Switzerland)
S0459 14:30 Clonal population expansion of S. aureus occurs due OS127 13:30 - 14:30 Hall 6
to escape from a finite number of intraphagocyte
nichesSimon Foster (Sheffield, United Kingdom) 1-hour Oral Session
S0460 15:00 How bacteriophages and pathogenicity islands drive
The good, the bad and the itchy: update on STIs
the evolution of S. aureus John Chen (Singapore,
Singapore) Chair Tatum Mortimer (Athens, United States)
Co-organised with: ESCMID Study Group for Staphylococci and
Staphylococcal Diseases (ESGS)
O0920 High frequency of Nichols-like strains of Treponema
pallidum subsp. pallidum circulating in Barcelona,
EW172 - Hall 3 SpainP. Nadal-Baron* (Barcelona, Spain), P. Nadal-
13:30 15:30
Barón, J. Trejo-Zahinos, M. Arando, A. Barberan-
Educational Session Masegosa, M. Bernat-Sole, A. Perez-Ugarte, M.
Valverde Espinal, A. Canals Quintana, J.J. González-
Beyond the gift of life: viral infection during pregnancy López, A. Antón, M. Alberny, O. Mitjà, N. Larrosa, Y.
Chairs Gülsen Özkaya Sahin (Lund, Sweden) Hoyos-Mallecot
Simona Ruta (Bucharest, Romania) O0921 Doxycycline post-exposure prophylaxis (doxy-PEP)
use and outcomes in metropolitan DetroitC. Arena*
(Detroit, United States), N. Everson, R. Kenney, I. Brar,
S. Gudipati, N. Yared, S. Davis, M. Veve
W0473 13:30 Hepatitis B during pregnancy: diagnosis,
management and outcomeTba O0922 The Gonococcus Bacterial Load Measured by the
Cycle Threshold (Ct) in Urinary Samples Correlates
W0474 13:50 RSV and Influenza during pregnancy: management with SymptomatologyG. Beraud* (Orleans, France),
and outcomeMonika Redlberger-Fritz (Vienna, T. Prazuck, L. Barhoum, H. Meyjonnade, J. Effa, L.
Austria) Hocqueloux, A. Seve, J. Guinard, K. Kochbati, E.
W0475 14:10 Prenatal screening and prevention of congenital Carbonelle, C. Guillaume
CMV: shifting concepts and consensus O0923 STI pathogen interactions and viability in men who
guidelineMarianne Leruez-Ville (Paris, France) have sex with men (MSM)E. Rayo* (Zurich,
W0476 14:30 Novel methods of vaccine administration to Switzerland), D. Onorini, C. Leonard, H. Marti, T.
newbornsTba Pesch, B. Hampel, N. Low, N. Borel
Co-organised with: ESCMID Study Group for Viral Hepatitis (ESGVH), O0924 Epidemiology of bacterial genitourinary infections
European Society for Infectious Diseases in Obstetrics and Gynaecology among women with recurrent vulvovaginal
(ESIDOG), Society on Liver Diseases in Africa (SOLDA), Gastroenterology and Candidiasis (RVVC) in Nigeria.S. Fayemiwo* (Ibadan,
Hepatology Association of SubSaharan Africa (GHASSA) Nigeria), L. Novak-Frazer, I. Adewole, R. Rautemaa-
Richardson
SY169 - Hall 4
13:30 15:30
OS129 - Hall 7
13:30 14:30
2-hour Symposium
1-hour Oral Session
Molecular epidemiology, resistance mechanisms and management of Gram-
negative bacteria Biofilm biology and control
Chairs Agnes Maria Sonnevend (Pécs, Hungary) Chairs Margherita Cacaci (Rome, Italy)
Kyriaki Xanthopoulou (Cologne, Germany) Laura Escolà-Vergé (Barcelona, Spain)
S0461 13:30 Globally emerging resistance patterns of O0930 Influence of non-coding small RNA00203 in biofilm
EnterobacteralesSasheela Ponnampalavanar (Kuala cells of Acinetobacter baumannii: Transcriptomic and
Lumpur, Malaysia) phenotypicD. Gebrelibanos* (Hong Kong, China), P.
S0462 14:00 Non-fermenters still important globally: a review of Leung, A.M. Shenkutie, F. Chow
spread and resistanceAnupa Thampy (Vellore, India) O0931 Sub-MIC antibiotic effects on Pseudomonas
aeruginosa biofilm streamer formationA. Di Claudio*
S0463 14:30 Innovative rapid diagnostic methodologies for Gram-
(Pieve Emanuele, Italy), R. Rusconi, E. Secchi, G.
negative pathogensLaurent Dortet (Le Kremlin-
Savorana

ESCMID Global 2025 - Programme
O0932 Regulation of Novel Genes and Their Downstream O0919 Substantial viral diversity in bats and rodents from
Functions in the AI-2-Mediated Quorum Sensing East Africa: insights into conservation,
System of Klebsiella pneumoniaeX. Chu* (Beijing, recombination, and co-circulationD. Wang*
China), Q. Yang (Shenzhen, China)
O0933 Exploring structural differences in biofilms of smooth
and rough Mycobacterium abscessus clinical strains
through confocal laser scanning microscopyC. OS128 13:30 - 14:30 Hall 9
Maria* (Madrid, Spain), M. Cano-Fernández, J.
Esteban, P. López-Roa, A. Ruedas-López, M.C. 1-hour Oral Session
Muñoz-Egea
AI Aiding AMS
O0934 Antibacterial and biofilm eradication of mupirocin-
loaded nano-emulsionsZ. Najmi* (Novara, Italy), A.C. Chairs Marlieke De Kraker (Geneva, Switzerland)
Scalia, A. Cochis, J. De Souza Nunes, J. Alkorta, L. Bhanu Sinha (Groningen, Netherlands)
Rimondini, D. Dupin
O0925 Using natural language processing to understand
OS126 13:30 - 15:30 Hall 8 free-text antibiotic prescriptionsA. Martin*
(Middlesbrough, United Kingdom), L. Christopher
2-hour Oral Session
O0926 Enhancing Antimicrobial Stewardship Through
Emerging viruses, diverse threats Collaboration Between an Intelligent System and
Infectious Disease ExpertsH.M. Wei* (Taichung,
Chairs Luisa Barzon (Padua, Italy)
Taiwan, China), Y.L. Hsu, Y.W. Chang, I.C. Chen, K.P.
Karin Stiasny (Vienna, Austria)
Hwang
O0927 Augmented Intelligence in Infectious Diseases (AI2D)
as an antimicrobial stewardship tool for early
O0910 Epidemiological and clinical features of mpox antibiotic discontinuation in suspected lower
during the clade Ib outbreak in South-Kivu, respiratory tract infectionsJ.L. Lim* (Singapore,
Democratic Republic of the Congo: a prospective Singapore), P.Z.B. Cherng, P.M. Chlebicki, L.S.C. Gan,
cohort studyI. Brosius* (Antwerp, Belgium), E. S.Y. Thien, S.L.S. Tang, L.X.T. Lee, Y.C.D. Yii, P.Y.
Hasivirwe Vakaniaki, S. Sabiti Nundu, L. Zhou, Y. Wang, S.J. Chung, L.H.A. Kwa
Liesenborghs, P. Mbala-Kingebeni, G. Mukari, P.
O0928 Virtual antimicrobial stewardship ward rounds:
Munganga, J.C. Tshomba, E. De Vos, E. Bangwen,
predicting antibiotic course stopping decisions in
Y. Mujula, A. Tsoumanis, C. Van Dijck, A. Alengo, L.
hospitals using machine learningK. Yuan* (Oxford,
Mutimba-Mambo, F. Mweshi Kumbana, J.
United Kingdom), J. Wei, C.H. Yoon, Q. Gu, W. Walker,
Babingwa Muunga, D. Mazambi Mambo, J.
T. Zhu, D. Eyre
Wakilongo Zangilwa, S. Bilembo Kitwanda, S.
Houben, N. Hoff, J.C. Makangara-Cigolo, E. O0929 Prospective evaluation of a machine learning-based
Kinganda-Lusamaki, M. Peeters, A. Rimoin, J. decision support system for intravenous-to-oral
Kindrachuck, N. Low, P. Katoto, E. Bwenge antibiotic switching.W. Bolton* (London, United
Malembaka, J.H. Amuasi, O. Tshiani, R. Kojan, D. Kingdom), R. Wilson, P. Georgiou, A. Holmes, T.M.
Muamba Kambaj, C. Kacita, D. Mukadi-Bamuleka, Rawson, M. Gilchrist
S. Ahuka-Mundeke, K. Vercauteren, T. Wawina-
Bokalanga, J.J. Muyembe-Tamfum
O0911 Tracing the origin, spread and molecular evolution
of Dengue type 1 cases occurred in Northern Italy in
2023G. Romano* (Pavia, Italy), G. Ferrari, A.M.G.
Pitrolo, F. Rovida, A. Piralla, F. Baldanti
O0912 Dengue Country Risk Estimation: Vector Suitability
and Imported Activity 2024.M. Torres Portillo*
(Toronto, Canada), K. Williams, R. Lababidi, A.
Thomas, K. Khan
O0913 Rat HEV in humans in Germany: presence but low
detection rate, a screening study 2022 - 2023L.
Mueller* (Berlin, Germany), M.L. Schmidt, T.
Schwarz, T.D. Best, T. Bleicker, J. Panajotov, J.
Jansen, J. Melchert, T. Mauno, C. Drosten, R.
Johne, V.M. Corman
O0914 Emergence of new enterovirus D68 lineage in
Europe in 2023 associated with distinct amino acid
substitutions in VP1 proteinA. Hirvonen* (Vantaa,
Finland), C.K. Johannesen, P. Simmonds, T.K.
Fischer, H. Harvala, K.S.M. Benschop
O0915 Health-economic impacts of chikungunya
vaccination in 34 countriesJ. Zhou* (Oxford, United
Kingdom), N. Salant, D. Smith, D. Hollingsworth, K.
Pouwels, S. Radoykova, J. Lord, K. French
O0916 Clinical importance of a new tick-borne flaviviridae
virus, Alongshan Virus: retrospective serologic and
molecular study in SwitzerlandF. Tagini* (Lausanne,
Switzerland), O. Opota, A. Eggermann, A. Coste, G.
Greub
O0917 From Trade Routes to Transmission Routes: Risk
Assessment of Japanese Encephalitis Outbreak in
Pakistan under China-Pakistan Economic Corridor
Using One Health ApproachS. Ahmad* (Tampere,
Finland)
O0918 Building a screening protocol for the detection of
Orthobunyavirus oropoucheense infectionG.
Gagliardi* (Milan, Italy), D. Mileto, A. Mancon, L.
Morelli, M. Cutrera, A. Cavallo, A. Rizzo, V. Micheli,
A. Lombardi, A. Dolci

